id,sequence,label,date,quarter,year,speaker,title,text,mystery indicator,VADER sentiment
CI-2021-Q1-2021-05-07,11,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks, Alexis. Good morning, everyone, and thank you for joining us on our call today. But today's we meet our environment remains highly dynamic with COVID-19 continues to affect the world, our industry and our economy. At Cigna, this rapidly changing landscape has only reinforced the tremendous responsibility we have to improve the health, wellbeing and peace of mind of those we serve.",1.3365721,0.949
CI-2021-Q1-2021-05-07,12,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","This remains the primary focus that drives our 70,000 co-workers each and every day. And it's the reason we work to continue to deliver for our customers, clients, patients, partners and our communities, all while delivering strong financial results for you, our shareholders.",2.6062962,0.511
CI-2021-Q1-2021-05-07,13,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","During the first quarter, we delivered adjusted revenue of $41 billion and adjusted EPS of $4.73 per share. We also deployed significant capital to our investors through share repurchase and the payment of a meaningful quarterly dividend, reinforcing the strength of our capital like framework.",0.3000389,0.904
CI-2021-Q1-2021-05-07,14,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Building on our conversation from several weeks ago at our Investor Day, today, I'm going to talk more about how we are continuing to navigate through the current environment to balance and meet the needs of all of our stakeholders, our ability to consistently deliver strong results by executing on a growth framework and the competence we have in achieving our increased outlook by delivering differentiated and sustained growth for the long term.",0.2677808,0.898
CI-2021-Q1-2021-05-07,15,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Then Brian will share more details about our first quarter results and our 2021 outlook. And after that, we'll take your questions. Since we last met at our Investor Day in March, the macro landscape remains fluid. In the U.S. proposed legislation as well as regulation and executive actions to expand extend and further support both public and private programs.",0.6436067,0.84
CI-2021-Q1-2021-05-07,16,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Globally, social and political tensions remain high as COVID-19 with its multiple variants continue to take a toll on a number of countries, such as India, where cases have again dramatically spiked. All these forces are shaping healthcare and influencing the political and economic landscape around the world.",1.8764089,-0.34
CI-2021-Q1-2021-05-07,17,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","At Cigna, we are navigating through this environment by continue to innovate for and support our stakeholders with COVID-19 services, while also executing other strategies to make healthcare more affordable, predictable and simple",0.585309,0.71
CI-2021-Q1-2021-05-07,18,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","For U.S. commercial customers, we're ensuring they get the preventative care they need, including mammographies, colonoscopies, cervical cancer screenings, and childhood immunizations, which today are consistent with pre pandemic levels, reflecting the continued strength of our clinical programs, and proven engagement capabilities.",0.6000777,0.727
CI-2021-Q1-2021-05-07,19,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Within Evernorth, for those customers served by Express Scripts home delivery, we've delivered further improvements in medication adherence for people with diabetes, high cholesterol and high blood pressure. At the same time, we're also supporting the mental wellbeing of our customers. We're doing this through our own best-in-class capabilities where for example, we engage with oncology patients with comorbidities by spending an average of $2,000 on their behavioral health care, we can save an average of $20,000 in avoidable costs.",0.4966965,0.896
CI-2021-Q1-2021-05-07,20,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And we can innovate and leverage our strategic partnerships, including, for example, with Ginger, through Cigna ventures, which provides industry leading on demand 24x7 behavioral health coach and further extending our behavioral health access for the benefit of our customers.",1.8853478,0.691
CI-2021-Q1-2021-05-07,21,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","We're also leveraging data in actionable intelligence to understand the most common long term complications of COVID-19 infection, then building predictive models to determine who is at greatest risk of becoming a COVID law hauler, so we can quickly provide targeted case management and behavioral health services, as well as other resources to help our customers regain their health.",0.609794,0.875
CI-2021-Q1-2021-05-07,22,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","For our clients, we're serving as a trusted partner. by supplying additional physical and behavioral health assistance to aid in the recovery for employees who are infected by COVID-19. We're helping employers build their own communities of immunity by assisting them in launching vaccination clinics. And we're collecting our data and analytics help employers determine when and how it is safe for employees to return to work.",0.8064516,0.772
CI-2021-Q1-2021-05-07,23,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","For provider partners, we're working to guide people to the most effective sites of care and further closing gaps in care with our clinical teams and our virtual capabilities. For coworkers, we're supporting them in this highly disruptive environment by for example, providing $200 incentive for co-workers who choose to become vaccinated for COVID-19 and continuing to offer expanded leave capabilities with our emergency time off program to provide flexibility necessitated by the current conditions.",0.2817723,0.904
CI-2021-Q1-2021-05-07,24,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And finally, for our communities, we're taking steps to address social determinants of health. For example, we all know the alarming statistics on the disproportionate impact COVID-19 has had on communities of color. As part of our safe initiative, we brought additional underground resources to target communities by launching COVID-19 awareness campaigns, distributing PP&E kits, dispatching our health improvement mobile resources to help you administer free flu shots and provide healthy meal, as well as other support.",0.8830159,0.936
CI-2021-Q1-2021-05-07,25,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Similarly, we're leaning in to fight breast cancer with disparities, for example, well, amongst black women remain startling, tough to address this disparity gap, we again went directly into communities. Starting in Tennessee, for example, where we collaborated with local partners to offer mobile mammography vans at churches, and at other local neighborhood locations.",1.0217645,-0.727
CI-2021-Q1-2021-05-07,26,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","At Cigna, balancing the needs of our stakeholders is deeply rooted in our corporate purpose. We constantly challenge ourselves by asking the basic question, what more could we do to help us stay focused on delivering each and every day for the benefit of our customers, our clients, patients and our partners.",1.5410027,0.823
CI-2021-Q1-2021-05-07,27,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Against this backdrop, the strength of our foundation propels us forward and guides our growth. As we share with you at our Investor Day, through our three growth platforms Evernorth, U.S. Medical and International Markets, we are well positioned to leverage the three trends we see shaping healthcare into the future, specifically, pharmacological innovations, the rising demand for coordinated mental and physical health services, and the changing preferences as it relates to access to care models.",2.7975126,0.925
CI-2021-Q1-2021-05-07,28,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And through a proven framework, we're able to drive attractive sustained growth by delivering differentiated value within our portfolio of integrated, coordinated endpoint solutions, continuing to work to partner and innovate, and working to expand our addressable markets.",0.4080839,0.92
CI-2021-Q1-2021-05-07,29,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","As a result, we're off to a strong start in 2021, with strong fundamental execution, and the strategic and capital flexibility to further our momentum into the future. During the first quarter Evernorth continue to build on its differentiated and steady performance it had delivered throughout the pandemic, by evolving the healthcare experience for our customers and clients through continuous innovation, and by building investing, and strengthening our strategic partnerships.",0.7065682,0.93
CI-2021-Q1-2021-05-07,30,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","For example, in January, we further expanded our partnership with Prime Therapeutics by leveraging our home delivery and Accredo Specialty Pharmacy to drive greater value and delivering our promise to make healthcare more affordable. We're also advancing our strategic capabilities with our MDLIVE acquisition which closed last month. This acquisition will expand Evernorth's cares ability to further broaden access, lower cost of care, and strategically positioned us to grow in the rapidly changing access to care environment.",0.4337349,0.952
CI-2021-Q1-2021-05-07,31,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","At the same time, Evernorth pharmacy is also driving affordability improvement. One example is our patient assurance program, which caps the cost of prescriptions for patients with diabetes. During the quarter the number of patients in this program increased by 64%. And the value of patients delivered from this program is on track to more than double what we achieved last year.",3.1049359,0.848
CI-2021-Q1-2021-05-07,32,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Turning to our U.S. medical platform, we see bright spots and growth in our U.S. commercial portfolio. For example, we continue to take share in the Select segment, which includes employers with 51 to 500 employees. As clients continue to value our integrated, align, self funded, medical, pharmacy behavioral and stop-loss programs. And more broadly, we're driving value by bringing differentiated offerings to market fueled by innovations and advancements we are accessing from our Evernorth capabilities, particularly in areas of pharmacy services, and behavioral health.",0.5810338,0.889
CI-2021-Q1-2021-05-07,33,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Through our willingness to strategically partner with innovative companies like Oscar, we're also well positioned to take advantage of market growth opportunities in the small employer market, a market we view is currently being underserved. As a result, we expect to see an uptick in growth in our U.S. Commercial platform during the residual part of this year.",1.1228138,0.947
CI-2021-Q1-2021-05-07,34,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Additionally, one important impact of the pandemic is that businesses have expanded access to support services for the employees, backing is a trusted source of information and providing an extended range of benefits to support whole person health. As more and more employers recognize the critical link between mental and physical health.",1.1422464,0.866
CI-2021-Q1-2021-05-07,35,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","In the wake of COVID-19, more employers are also recognizing the connection between healthy workers, higher productivity and a growing economy. In fact, the National Bureau of Economic Research found that in the U.S., we benefited by $1.5 trillion of value by having employers play a major role in health care. This reinforces the critical role, our U.S. healthcare business plays as an important partner to employers in providing access to quality, affordable care for the benefit of their employees.",0.3093665,0.952
CI-2021-Q1-2021-05-07,36,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Turning to U.S. government business, we're driving strong year-over-year customer growth by continuing to expand our addressable markets. The number of Medicare Advantage customers increased by 11% year-over-year reflecting the ongoing execution of our strategy, as well as our sustained strong star performance.",0.4298484,0.943
CI-2021-Q1-2021-05-07,37,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And the number of customers in our individual and family plan business grew by 17% year over year, driven by our geographic expansion, and the introduction of new plans that provide expanded coverage for maintenance drugs, to further improve affordability for customers with certain chronic conditions.",0.627672,0.649
CI-2021-Q1-2021-05-07,38,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","In our International Markets business, we're focused on actively supporting our co workers, customers and partners around the world who continue to be impacted by COVID-19. For example, in India, our foundation is providing financial support through UNICEF to meet the critical needs on the ground, including additional rapid testing capabilities and expanded access to vaccines.",0.8367664,0.802
CI-2021-Q1-2021-05-07,39,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And we're providing matching gifts from the Cigna foundation to our co-workers who donate to charities in India. Staying true to our mission is not only the right thing to do, it reinforced to our clients, our customers and our patients, our commitment to make a difference in the moments that matter most.",0.6809172,0.827
CI-2021-Q1-2021-05-07,40,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Our purpose driven orientation, together with our strategic flexibility created by our service based model and recapitalize framework that generates significant cash flow from operations, as well as our track record of strong financial performance, where we delivered a 15% adjusted EPS compounded growth rate over the last decade, all give us confidence we will continue to sustainably grow in both the short term and the long term in this dynamic environment.",1.0917217,0.955
CI-2021-Q1-2021-05-07,41,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And now taking into account the strength of our first quarter results, we expect our full year adjusted EPS to be at least $20.20 in 2021. And we remain confident in our ability to deliver our long term targets of average annual adjusted revenue growth of 6% to 8%, average annual adjusted EPS growth of 10% to 13% and continue to play an attractive dividend while delivering cumulative operating cash flow growth of $50 billion through 2025.",0.5592693,0.963
CI-2021-Q1-2021-05-07,42,Remarks,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Now to briefly summarize, we delivered strong first quarter results by executing our growth framework, while harnessing our capital strength to deploy meaningful capital for the benefit of our shareholders, reinvesting in our business, and leveraging our strategic flexibility to continue to innovate and adapt, all of which sets us up for sustained long term success. We remain confident in our ability to continue to grow as we focus our efforts to make healthcare more affordable, predictable and simple each and every day.",0.8542557,0.98
CI-2021-Q1-2021-05-07,44,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"Thanks, David. Good morning, everyone. Today, I'll review key aspects of Cigna's first quarter results, including the ongoing impact of COVID-19 on our business, and I'll discuss their updated outlook for the full year.",0.5824338,0.7
CI-2021-Q1-2021-05-07,45,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"Key consolidated financial highlights for first quarter 2021 include adjusted revenue of $41 billion, adjusted earnings of $1.7 billion after tax and adjusted earnings per share of $4.73. Results in the first quarter reflects strong top line growth with contributions across our businesses. And first quarter earnings came in somewhat ahead of our expectations.",1.6614328,0.836
CI-2021-Q1-2021-05-07,46,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"The favorable first quarter earnings were primarily driven by strong Evernorth performance, favorable net investment income, and favorable prior year medical cost development, partially offset by non-recurring operating expenses. Our results reflect our ability to deliver a dynamic, rapidly evolving environment, including navigating the ongoing impacts of the COVID-19 pandemic.",0.5093229,0.948
CI-2021-Q1-2021-05-07,47,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"Regarding our segments, our first comment on Evernorth. First quarter 2021, adjusted revenues grew to $30.6 billion and adjusted pretax earnings grew to $1.2 billion. Evernorth strong results in the quarter were driven by effective execution of supply chain initiatives, continued strong performance in Accredo, our industry leading specialty pharmacy, and organic growth of our services with deepening partnerships, all while continuing to invest for ongoing growth.",0.5412169,0.931
CI-2021-Q1-2021-05-07,48,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"Our adjusted pharmacy script volume was $393 million during the quarter, a 9% increase over first quarter 2020. Overall, Evernorth continued as positive momentum and delivered another strong quarter financial results. Turning to U.S. medical, we entered the year expecting to see the majority of COVID-19 testing and treatment cost pressure in the U.S. medical segment in the first half of 2021, particularly in the first quarter.",0.3395486,0.791
CI-2021-Q1-2021-05-07,49,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"As we progress throughout the first quarter we saw COVID-19 case counts and hospitalizations declined more rapidly than we originally anticipated. Additionally, as COVID-19 cases decelerated, we saw an increase in non-COVID utilization. Importantly, throughout all of this, we continue to see key components of preventive care, utilize the pre pandemic levels for U.S. commercial customer's taken as a whole and excluding prior year medical cost developments, our first quarter medical care ratio was in line with our expectations.",0.3665358,0.915
CI-2021-Q1-2021-05-07,50,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"With that as context, I'll now comment specifically on first quarter financial results for the U.S. medical segments. First quarter adjusted revenues were $10.4 billion and adjusted pretax earnings were $987 million. Our first quarter U.S. medical earnings were slightly ahead of our expectations, primarily driven by favorable net investment income, and prior year medical cost development, partially offset by non recurring operating expenses.",0.3547596,0.477
CI-2021-Q1-2021-05-07,51,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"Excluding these onetime factors, our us medical earnings were in line with our expectations. Turning to membership we ended the quarter with 16.7 million total medical customers, an increase of 30,000 customers sequentially. As expected, U.S. commercial customer volume declined sequentially due to disenrollment throughout the first quarter, partially offset by new sales in the Select segment. And our U.S. government businesses performed well throughout the annual open enrollment periods.",0.2109912,0.527
CI-2021-Q1-2021-05-07,52,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"Overall results for Cigna's U.S. medical segment reflect strong fundamentals. In our international markets business, first quarter adjusted revenues were $1.6 billion and adjusted pretax earnings were $262 million, reflecting business growth, favorable net investment income and foreign currency movements offset by higher claims costs during the period.",0.860157,0.84
CI-2021-Q1-2021-05-07,53,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"I would also note that a refinements to the accounting for acquisition costs lead to a one-time favorable benefit in the first quarter of 2020 that did not recur in the current period. Corporate and other operations reflect a first quarter adjusted loss of $330 million. These results reflect lower interest expense due to lower levels of outstanding debt offset by the absence of contributions from the group disability and life business, which was invested on December 31, 2020.",0.2100098,0.71
CI-2021-Q1-2021-05-07,54,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"Overall, as a result of strong execution and a dynamic environment, we continue to deliver value for all of our stakeholders and strong financial results across our businesses. Now looking forward to our outlook for full year 2021. As we look to the balance of the year, we expect continued strong execution across our growth platforms. And we expect to make continued meaningful investments in our businesses that are responsive to the forces changing healthcare, positioning us for continued long term growth.",0.0991168,0.972
CI-2021-Q1-2021-05-07,55,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"Taken as a whole, we are raising our prior guidance for full year 2021. We now expect consolidated adjusted revenues of at least $166 billion, representing growth of approximately 7% after adjusting for the divestiture of our group disability and life business. We now expect full year 2021 consolidated adjusted income from operations to be at least $7 billion or at least $20.20 per share.",0.1511286,0.586
CI-2021-Q1-2021-05-07,56,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"Within our outlook, we continue to expect a full year COVID-19 related headwind of approximately $1.25 per share, primarily within our U.S. medical business. And we continue to project an expense ratio in the range of 7.5% to 8%. I'll now discuss our 2021 outlook for our segments. For Evernorth, we now expect full year 2021 adjusted earnings of at least $5.65 billion, which represents year-over-year growth of at least 5%.",0.7679097,0.586
CI-2021-Q1-2021-05-07,57,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"This outlook reflects ongoing investments in our Evernorth portfolio, including investments in care solutions and MDLIVE as we continue to see significant opportunity to bring new innovative solutions to market. For U.S. medical, we continue to expect full year 2021 adjusted earnings of at least $3.8 billion. This outlook reflects focused execution in our businesses, as we expect to drive organic customer growth and deepening of customer relationships.",0.0907753,0.946
CI-2021-Q1-2021-05-07,58,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"We expect direct COVID-19 related testing and treatment to decline throughout the balance of the year, and also anticipate more normalized non-COVID utilization. And with the strength of the U.S. medical first quarter results, we will further accelerate strategic investments to support future growth, thus leaving our full year earnings outlook for U.S. medical unchanged.",0.87684,0.818
CI-2021-Q1-2021-05-07,59,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"Regarding total medical customers, we now expect 2021 growth of at least 350,000 customers. This includes organic growth throughout the remainder of the year in our commercial business, led by the middle market and select segments partially offset by disenrollment in national accounts. We also expect Medicare Advantage customer growth in our target average annual growth range of 10% to 15%. And we expect continue growth in our individual business.",0.3724239,0.919
CI-2021-Q1-2021-05-07,60,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"Turning to medical costs, we continue to expect the 2021 medical care ratio to be in the range of 81% to 82%, reflecting the impacts in 2021 of elevated medical costs, including the impact of direct COVID-19 related costs, and more normalized non-COVID utilization, and the repeal of the health insurance tax effective for 2021. All while we continue to deliver strong clinical quality and overall affordability for our clients and customers.",0.185476,0.863
CI-2021-Q1-2021-05-07,61,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"We also expect continued growth and strong margins in international markets. All-in for full year 2021, we now expect consolidated adjusted income from operations of at least $7 billion, or at least $20.20 per share. Overall, these expected results reflect the differentiated value, strength and strategic positioning of our businesses as we deliver growth, while navigating the impacts associated with COVID-19.",0.0309127,0.936
CI-2021-Q1-2021-05-07,62,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"Now, moving to our 2021 capital management position and outlook, we expect our businesses to continue to drive exceptional cash flow with strong returns on capital, even as we continue reinvesting to support long term growth and innovation. For 2021, we continue to expect at least $7.5 billion of cash flow from operations, reflecting the strong capital efficiency of our well performing businesses.",0.2438665,0.952
CI-2021-Q1-2021-05-07,63,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"During the quarter, we met our previously stated share repurchase expectations and year to date as of May 6, 2021, we have repurchased 14.4 million shares for $3.2 billion. And we now expect full year 2021 weighted average shares of 346 million to 348 million shares. We ended first quarter 2021 with a debt-to-capitalization ratio of 39.9%, in line with our long term target of approximately 40%.",0.3326791,0.778
CI-2021-Q1-2021-05-07,64,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"We had $2.5 billion of cash available to parents at the end of the quarter. And on April 28, we declared a $1 per share dividend payable on June 23 to shareholders of record as of June 8. Our balance sheet and cash flow outlook remains strong, benefiting from our highly efficient service-based orientation that drives strategic flexibility, strong margins, and attractive returns on capital.",0.1197252,0.945
CI-2021-Q1-2021-05-07,65,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"So now to recap. Results in the first quarter reflect strong top line growth with contributions across our businesses. And first quarter earnings came in somewhat ahead of our expectations. These favorable first quarter earnings were primarily driven by strong Evernorth performance, favorable net investment income, and favorable prior year medical costs development, partially offset by non recurring operating expenses.",0.7605496,0.96
CI-2021-Q1-2021-05-07,66,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"Our strong results give us confidence in our increased outlook for full year 2021, all while continuing to support our customers, clients and co workers. As such, we now expect 2021 full year adjusted EPS of at least $20.20 per share, and have continued confidence in our long term growth targets.",0.6035329,0.955
CI-2021-Q1-2021-05-07,67,Remarks,2021-05-07,1,2021,Brian C. Evanko,CFO,"With that, we'll turn it over to the operator for the Q&A portion of the call.",0.0799804,0.0
CI-2021-Q1-2021-05-07,70,Answer,2021-05-07,1,2021,Brian C. Evanko,CFO,"Good morning, Bob. It's Brian. So thanks for the question. And yes, we're really pleased with the strong start to the year in Evernorth, which as I mentioned in my comments, gives us the confidence to increase the full year guidance to at least $5.65 billion of operating income. Quarter-to-quarter there will be some level of variability in the segments. I would encourage you not to overreact to the singular quarter that we had here. But certainly pleased with 13% quarter-over-quarter earnings growth. I would remind you that our Prime Therapeutics partnership launched April 1, 2020. So the base period last year and the first quarter did not have contributions from Prime Therapeutics. So that was a bit of a benefit to this quarter that will not recur to the same degree for the balance of the year. So to your point on the operating income growth appearing to slow to some degree later in the year. That's one contribution that you should -- that they should keep in mind.",0.8783121,0.898
CI-2021-Q1-2021-05-07,71,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Additionally, we continue to invest aggressively in Evernorth to expand and diversify the suite of solutions in that portfolio. So, as you think about Care Solutions, Benefits Management insights, we will make a continued organic and on a targeted basis in organic investments to continue to expand that portfolio, which will increase SG&A in to some degree temper the income growth for the balance of the year. David, anything you want to add to that?",0.5592693,0.904
CI-2021-Q1-2021-05-07,76,Answer,2021-05-07,1,2021,Brian C. Evanko,CFO,"Good morning, Ralph. It's Brian. So maybe let me unpack the U.S. Medical non-recurring items a little bit. This might speak to the core of your question a little bit. As I mentioned in my comments, overall, our U.S. medical earnings in the quarter were above our expectations. But when you remove the effect of the three non-recurring items, we were in line with our expectations. So there's a three non recurring items that I cited, we had some favorability in the quarter and net investment income. We had some favorability in the quarter and prior year medical cost development, and that was offset by non-recurring operating expenses. And so, to the core of your question, the non-recurring operating expenses, you can think of as litigation-oriented matters associated with operations from several years ago.",0.6668302,0.964
CI-2021-Q1-2021-05-07,77,Answer,2021-05-07,1,2021,Brian C. Evanko,CFO,"So these are not related to current time periods. These are unrelated to Anthem. These are matters from several years ago, but they're related to operations. And as a result of that, we chose to book them through SG&A as opposed to considering them as a special item below the line or anything like that. They were appropriate in our eyes to book through SG&A above the line. And in order of magnitude, you can think of that as approximately offsetting the favorable benefit that we had from net investment income in the quarter within U.S. medical. But those are truly non-recurring items since they're related to periods from several years ago and those matters should now be closed.",0.279686,0.735
CI-2021-Q1-2021-05-07,80,Question,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks. Good morning. I want to squeeze in a couple quick questions. First, in terms of medical cost expectations through the year, you give us an update on COVID, but wanted to get an idea of what you're thinking into the back half of the year in terms of -- in terms of utilization pick up, post the vaccine. What you built in versus kind of typical trend. And then, you mentioned, you divested -- plan to divest -- to sell that Texas Medicaid business. Just wanted to see if there's any background there in terms of what drove you to kind of the divest that? And then, kind of updated thoughts on your kind of Medicaid strategy going forward to be helpful? Thanks.",0.9106102,0.955
CI-2021-Q1-2021-05-07,81,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hey, Justin. Good morning. It's David. Let me just frame the medical costs for a moment and then ask Brian to talk a little bit more about our framework and our expectations for the year. And then I'll come back and address the Medicaid divestiture and our Medicaid direction more broadly. First, from a medical cost standpoint, big picture. We're pleased with the start to the year. Big picture broadly speaking, we're pleased to start to the year. And I just want to underscore a couple of components. One, our organization works tirelessly to try to drive elevated utilization of certain services like preventative care services. And importantly, we saw in the first quarter, the use of preventative care services like mammographies, colonoscopies, childhood immunizations, cervical cancer screenings to be at an approximate level of pre-pandemic levels. That's a tremendous result of offsetting what might have been a dampening to utilization.",0.6766421,0.578
CI-2021-Q1-2021-05-07,82,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","The national data we see more broadly is that utilization of those preventative care services is at a more dampened rate, but ours is an elevated or more consistent rate from that standpoint, which is quite important. Secondly, I would just remind you that and I'll tie this back in our Medicaid comment a little later, is that we have a de minimis amount of Medicaid within our portfolio. And our national data suggests to our services businesses, through Evernorth services business that in the first quarter Medicaid medical costs were a bit more dampened year-over-year in the first quarter of 2021. That's not an effect on our portfolio. But we can see that in the services that we're providing. And I'll ask Brian to give you a little bit more color forward looking on the year, then I'll come back and address Medicaid.",1.297707,0.91
CI-2021-Q1-2021-05-07,83,Answer,2021-05-07,1,2021,Brian C. Evanko,CFO,"Yes. Good morning, Justin. So, just a few other comments on the quarter and the balance of the year. Overall, as I mentioned in my comments, the U.S. Medical MCR was in line with our expectations for the first quarter, when you exclude the benefit of PYD , or prior development. When you include the benefit of prior year development, we're actually a little bit favorable on the first quarter. And that was at an elevated level, as we expected, when we stepped into the year. For the balance of the year, we expect that deceleration in COVID-19, testing and treatment costs, we expect an uptick in non-COVID related utilization in quarters two through four, with those factors roughly offsetting one another.",2.5019627,0.893
CI-2021-Q1-2021-05-07,84,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And so, when we constructed our full year outlook of an 81% to 82% medical care ratio, we stress tested a variety of scenarios about -- associate with those two levers and are quite confident in our ability to achieve the full year 81% to 82% medical care ratio for U.S. medical. David, maybe on the Texas Medicaid and our broader Medicaid strategy, over to you sure.",0.8437621,0.991
CI-2021-Q1-2021-05-07,85,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Sure. Justin. We chose to divest of that single site Medicaid operation we had. So number one, it was -- we have one of one. So it was one off within our portfolio that has a de minimis impact on our P&L at the enterprise level. So putting that aside, we determined it was best for that business to be served by an expert or specialist. And we're pleased to effectuate and seek to close a successful transition to Molina. We think that's beneficial to the customers being served than our co-workers in that business. Looking forward, we continue to see Medicaid and government services first and foremost as an attractive growth opportunity within our Evernorth service portfolio. Whether it's Evernorth Pharmacy, Evernorth Care, Evernorth Benefits, Evernorth Intelligence, the opportunity to bring expanded services largely through health plans today in support of Medicaid will be a growing organic part of our portfolio.",0.5915274,0.918
CI-2021-Q1-2021-05-07,86,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Over time, we see opportunities that will manifest themselves state-by-state on state specific service relationships against Evernorth. And then finally, as you recall from our Investor Day conversation, within our M&A priority, we continue to have an expansion of our U.S. government programs as an M&A priority. So we'll be opportunistic from that standpoint, if we see the ability to further strengthen any of our capabilities looking forward. But that divestiture was again, it was a one-off de minimis impact and we deemed that was best in the hands of a specialist. Thanks, Justin.",1.5958026,0.361
CI-2021-Q1-2021-05-07,88,Question,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Yes. Good morning, guys. And thanks for taking the question. I guess, David, I would ask a little bit more color about the MDLIVE acquisition? And how you guys are thinking about care delivery partnerships? And I'd love a little bit of commentary maybe on how the digital formulary is progressing. And if you could maybe talk about if that's going to have meaningful revenue contribution that's in the Evernorth segment?",0.88185,0.963
CI-2021-Q1-2021-05-07,89,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So thanks for the question, George. So specific to MDLIVE, first important to reference the fact that we had a multiyear relationship with MVLIVE both partnering to continue the services, but also through our very successful multiyear Cigna Ventures organization. So, we start from a learned shared experience and even deeper collaboration during the COVID environment. Specific to the asset and the direction, as we discussed in our Investor Day, we see rapid expansion of what we call alternative side of care to be one of the three major trends as we look forward over the next five to 10 years.",2.779246,0.994
CI-2021-Q1-2021-05-07,90,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","This is an important part of those building blocks, and it's an important part of our Evernorth care portfolio of capabilities. We see it as much greater than telemed or even basic virtual care triaging. We see the ability to obviously expand virtual care, primary care, behavioral care. We see the ability to expand that further in terms of longitudinal chronic care programs, polychronic, and ultimately complex care programs and capabilities. So it provides us an accelerant to our strategic direction with a known partner that will now be part of the overall Cigna portfolio. And we're excited. Because net-net, it drives, improved service, improved access, improved affordability with strong clinical outcomes for the benefit of our consumers.",0.9879518,0.974
CI-2021-Q1-2021-05-07,91,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So truly an aggregate win-win in the portfolio. Specific to the digital formulary that innovation continues to be somewhat unique in the marketplace. Our clients really appreciate the approach relative to the digital formulary, helping to essentially curate and apply externally validated expertise to the vast array of digital alternatives that exists in the ecosystem to help, to provide employers more informed decisions for those that may have the greatest outcome and impact for the benefit of the customer. So, I view that as a part of our consultative approach in terms of providing support, and a part of our approach to -- in this case partner and curate additional services on a go forward basis.",1.5308978,0.976
CI-2021-Q1-2021-05-07,92,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Taking in the whole, we see, again, our Evernorth care capabilities as an exciting part of the broader economic growth capabilities, and we see the ability to do that in a complimentary nature with our proven value based care relationships within our Cigna, our portfolio as well. Hope that helps, George.",1.2879907,0.625
CI-2021-Q1-2021-05-07,94,Question,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hi, everybody. I'm going to just ask about the selling season, both for Medical and for Evernorth on the PBM side. I know last year, there was some discussion about potentially people being delayed, different people had different views as to how much of that activity actually happened. I wondered what you've seen in terms of RFP activity on both sides of the business, anything to discuss in terms of new and innovative ways that Cigna is going to market in those two sides of your business? And any discussion about early wins, losses?",0.9479207,0.795
CI-2021-Q1-2021-05-07,95,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","A.J. Good morning, it's David. So relative to the selling season, looking to 2022, your question goes at the commercial side, as well as the services side of the business. First, on the commercial side of the portfolio, at this stage of the year, we're typically looking at the national accounts environment. And remind you that we define national accounts in -- for our U.S. commercial portfolio a little bit more narrowly than some in the market. So it's commercial employers, 5,000 or more employees who are multi-state in nature. As we look to 2022, right now, we see an environment where the RFP volume, so the opportunity to pursue new business is up somewhat. I think order of magnitude 10%.",0.8410416,0.878
CI-2021-Q1-2021-05-07,96,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And we see the portion of our book of business that's out to bid is being up marginally less than that 10% number. So that's a little bit of framing. We have some early traction, some early wins, that exists in our portfolio. And as we sit here at this stage of the environment, we're optimistic that we'll have a very good commercial outlook in aggregate for our portfolio as we look to 2020. I'll bridge with a trend comment and then I'll come to the Evernorthportfolio. Clearly affordability remains a top decision criteria for commercial employers,. There's no doubt about that. We spent ample time on that at our Investor Day, and it remains a top strategic imperative.",1.1064905,0.979
CI-2021-Q1-2021-05-07,97,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Further, beyond that is the flexibility necessary, and then the innovation required to truly integrate or coordinate mental and physical health programs, and then expand and coordinate access to care in a less fragmented way through alternative site of care framework, et cetera. So we see the trends being well lined up to our direction. As relates to within Evernorth and specific to your question within pharmacy services. As you recall, we have now multiple years of very attractive growth under our belts as a combined organization. And we're pleased with that. As we look to 2022, we have an environment where to date our employer renewal process is manifesting itself quite strongly. And our health plan renewal process is manifesting itself rather strongly beyond the two known losses that we previously discussed, relative to the health plan business.",0.7788574,0.718
CI-2021-Q1-2021-05-07,102,Answer,2021-05-07,1,2021,Brian C. Evanko,CFO,"Good morning, Kevin. It's Brian. So, a few thoughts on your question. I appreciate the framing of it. Broadly in the quarter, as I said earlier, the MCR for U.S. Medical was in line with our expectations when you include the federal benefit from prior year development. Now the components within were a little bit different than we anticipated. So to your point, the COVID-19 testing and treatment burden on our book was a little bit lower than we anticipated for the quarter. However, non COVID utilization was a little bit higher than we anticipated coming into the quarter. So net effect of those two factors led to the U.S. Medical MCR, being back in line with where we expected it to be.",0.4553484,0.586
CI-2021-Q1-2021-05-07,106,Question,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks very much for taking my question. I just wanted to go back, David, and ask a question around the comments that you made around MDLIVE. Specifically, you talked about expanding primary care and longitudinal care. You talked earlier about your relationship with Ginger around mental health. So, my question here is really twofold. First, where do you see the opportunities with MDLIVE around lowering overall medical costs for Cigna? Second, do you believe that you need to buy or continue to build out something around behavioral health? And then thirdly, can you just give us an idea of how many Cigna Lives actually use MDLIVE today?",1.3151963,0.991
CI-2021-Q1-2021-05-07,107,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Lisa, thanks. Appreciate the ongoing interest in the space for sure. So number one, bigger picture framing, I appreciate that you brought MDLIVE, Ginger together, for example. We don't -- we do not believe that this is a one-and-done type activity. So, we don't believe that a corporation secures itself a virtual care asset. And then this were for the alternative delivery space. This is a fluid environment. It's a dynamic environment, and it's an environment that has massive promise relative to bringing the expanded access, coordination of services, and improve overall value coming back to the affordability. Our organic capabilities are strong, the MDLIVE asset advances that massively. But as Brian noted in his prior comments, as well, we continue to invest in the space. So I want you to view that we view it as a dynamic and fluid space and we very much like our positioning.",0.9234357,0.987
CI-2021-Q1-2021-05-07,108,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Two is, just like in the -- what we'll call it the traditional care delivery space, the coordination of physical and mental health is mission critical. Just because it's in a virtual care environment, doesn't mean that the coordination of the leverage opportunity there is not -- is critical. And in fact, the virtual capabilities allow us to take fragmentation out of the system more aggressively and more comprehensively. To your affordability comment, unequivocally, we see an ability to further improve affordability through alternative site of care and through our virtual capabilities. You may recall from Investor Day, we identified alternative site of care or site of care leverage as a meaningful opportunity to further deflect or improve overall affordability. And an example maybe, we see already in a virtual care delivery, less use of unnecessary or redundant diagnostic services. That's a tangible illustration of a improvement in affordability.",0.8010105,0.974
CI-2021-Q1-2021-05-07,112,Question,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hi, thanks. Good morning. Here with Eric Percher as well. Can you speak to the progress in both the individual exchanges? I think I heard 17% number as well as the small group markets. I'm specifically interested in membership growth. And when you think you have enough information around medical costs and sort of utilization of new product, et cetera to better understand sort of profit trajectories here, this year?",0.8573649,0.961
CI-2021-Q1-2021-05-07,113,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hey, Josh, good morning. It's David. Let me just start and frame the growth trajectory. And then ask Brian to will provide a little bit of additional color, relative to our insights on the performance. First, we're very pleased. We're very pleased with the sustained performance starting with the individual exchanges. Just as you recall, we entered the exchanges in the first year, and we've sustained engagement in the exchanges since its inception. We've innovated within the exchanges. We've delivered a proven model. And now we're in an expansion mode relative to additional geographies, in large part with our collaborative accountable care and aligned value based relationships from the healthcare delivery system.",0.9568597,0.791
CI-2021-Q1-2021-05-07,114,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And we're pleased with the results, both the base results in individual exchange, as well as thus far our early look at the additional enrollment we're seeing because the expanded SEP. I'll ask Brian just give you a little color relative to that dimension. As relates to the small employer marketplace. As you know, we, Cigna historically have not played in the small employer marketplace. What we've focused above 51 lives or above 100 lives depending on the regulation more broadly. We have continued to view it as an underserved market, a market that has had more traditional or rigidly designed programs, less innovation and less flexibility, and less leverage of more modern specialty and clinical services.",0.7193937,0.969
CI-2021-Q1-2021-05-07,115,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And our determination was, it was best to pursue that market in partnership, leveraging our partnership DNA. And we've entered that market successfully with our partnership with Oscar. We're really early in that journey, some positive indicators for sure, we're really in the journey. Our early indicators are positive, though, that has us accelerating our geographies. And in collaboration with Oscar, and again back to in partnership with our healthcare delivery partners. So, Brian, maybe just a little color in terms of what we view the SEP process looking like and the economics within the individual exchange?",1.2502915,0.84
CI-2021-Q1-2021-05-07,119,Question,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hi. Thanks, and good morning, everyone. Question just first, if it be helpful, maybe you could break down just on the $1 billion raise revenue guidance. How you would sort of break that down between each of the three segments? And then also, interested just in sort of what you're seeing in aggregate right now around the debate around inflation, and not just think about medical inflation, but obviously, Cigna has a lot of insights into just general inflation dynamics across all of your businesses. So, interested in terms of what you're seeing in the first quarter as relates to whether you're actually seeing inflation rising and, and how you're thinking about the outlook for that over the course of the year? Thanks.",1.4531675,0.757
CI-2021-Q1-2021-05-07,120,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Scott, good morning. It's David. I'm going to ask Brian, just to give you a little color on our really strong sustained revenue performance. And then I'll come back and seek to address your inflation question.",0.9623008,0.956
CI-2021-Q1-2021-05-07,121,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, Scott. So really pleased with the Q1 performance on revenue as well as the full year increase in our guidance of at least $166 billion. You should think of the majority of that increase coming from the Evernorth segment. But importantly, we're also seeing strength within U.S. Medical. So we think of most of it from Evernorth and a bit of an uptick in U.S. Medical as well. David, back to you on the inflation question.",0.9661873,0.103
CI-2021-Q1-2021-05-07,122,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Sure. Scott, on the inflation question, I'm going to come out with two ways. First, through the core visibility of our business and then more broadly for those we serve. Thus far within our business, we do not see a large trajectory change relative to what I would call cost of goods sold inflationary pressure. There's always some, makes no doubt about it. There is always some. But through ongoing innovation, ongoing productivity, ongoing value based collaboration, broadly speaking, I would not call a large sea change from that standpoint.",1.1737272,0.854
CI-2021-Q1-2021-05-07,123,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Beyond that, in the broader economy, whether we look at it through a U.S. lens or pockets of markets outside the United States, there's clearly a warming up. There's an indisputable warming up of the economy. And there's a clearly warming up of inflationary indicators, but none of which have triggered across a threshold to suggest any one industry safe for some unique outliers, any kind of orange going to red threshold levels of inflation, but the robustness of the economy and some of the underlying cost drivers in some sub sectors are slowly beginning to elevate.",1.6851924,0.318
CI-2021-Q1-2021-05-07,127,Question,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Thank you. Let me ask the question about Medicare Advantage in the outlook. How do you think it's going to work with rates? I know that I'm asking about 2023. And I know that's a light year away. But my question really is Medicare Advantage benefited from the lower expenses in 2020? I'm wondering how you think that's going to roll through the rate calculation. Because right now, CMS has 2020, down 8% per capita, and then increasing about 11% in this year and the next year. And so I guess my question is, do you think that kind of trajectory is likely for medical costs? And then, if you can comment on how you think that might work into the 2023 rate?",1.220754,0.864
CI-2021-Q1-2021-05-07,128,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Matthew, a pretty complex, Rubik's cube would put on the table. Thoughtful, but nonetheless complex. I think a you -- as I think your question and [Indiscernible] question. If we look at the 2020 to 2021 environment, clearly, the posture of CMS recognize the COVID dislocation, recognize that dislocation, for examples, implication on risk adjusters sought to in their own methodology, seek to provide some offset to that relative to their rate setting environment, as well as their guidance relative to delivery system reimbursement, and set themselves up for what I would say is a pretty fluid and complex environment over the ensuing couple of years ahead.",0.8686358,0.954
CI-2021-Q1-2021-05-07,129,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So, I would expect the next couple years cycle to be a little non-traditional from that standpoint, given the need to adjust the various moving parts that result in a net rate setting environment. History would tell us that the result of all of the above, plus or minus a point or two largely gets the program to a balanced sustainable outcome. And looking forward, I would expect that because the Medicare Advantage program continues to deliver outstanding value, as you know, for seniors, hence the tremendous support from a senior standpoint, as well as overall clinical quality and affordability of which through the bonus programs and the reimbursement programs the federal government's budget actually benefits from.",0.3964244,-0.826
CI-2021-Q1-2021-05-07,130,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So I would expect it to be able to be balanced for that, but a little bit more lumpy than it has been in the past. And I think this year's risk adjuster through ups will be really mission critical in terms of how CMS sees the industry, recapturing a little bit more of the information that they deem necessary to get the risk adjusters and then they'll factor that into the forward looking 2023 rate environment. Stay tuned for more.",2.4053634,0.527
CI-2021-Q1-2021-05-07,133,Question,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Yes. Hi. Good morning. Thank you for taking my question. One for David. You talked about sort of the return of some of the diagnostic procedures did now are in line with for pandemic. Are you clearly, acuity is a big uncertainty for the rest of the year? But now that you starting to have this data as individuals are starting to come back for preventive care testing. Are you seeing any changes in acuity? That's one. And then my second question goes back to M&A and investments, clearly, a very big focus and part of your growth strategy. So what metric do you use when you evaluate a buy versus a partner or a build decision?",0.7069569,0.942
CI-2021-Q1-2021-05-07,134,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Ricky, good morning, It's David. We're going to take both of your questions. And your first question. To be very clear, we have seen consistent, strong utilization of preventative care services. And notably, what I called out is, for example, in the first quarter of 2021, broadly speaking, preventative care services inclusive of mammographies, colonoscopies, childhood immunizations, cervical cancer screening, plus or minus in the commercial portfolio business, approximate pre pandemic levels. We think that's a very good thing. I mean, underscore. It's a very good thing and something that our team has worked tirelessly to try to effectuate elevating those levels.",0.6886902,0.671
CI-2021-Q1-2021-05-07,135,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","We see that performance against a national dataset that suggests the utilization of those preventative care services are down versus pre pandemic levels 10% to 15% for our book of business they are not. As a predictor then to the future, we see that as a mitigant for an elevation of acuity, all other things remaining equal, because you're consistently identifying an earlier stage through the preventative diagnostics or the preventative services. Equally as important, as I noted in my prepared remarks, are, for example, within our Evernorth portfolio and within our Evernorth Pharmacy portfolio, for those customers being served by our mail order, we've actually seen get even further elevation of medication adherence. That's really important for the chronic population to avoid spikes in acuity moving forward, whether it's for a diabetic, COPD, asthmatic or other patients from that standpoint.",0.9040031,0.949
CI-2021-Q1-2021-05-07,136,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So, broadly speaking, we're working tirelessly to get the right clinical quality and services to be consumed and supported with the clinical resources we have to avert spikes and acuity going forward. And therefore we don't expect a large spike in acuity on a look forward basis, given the strong preventative or medication compliance. As it relates to your M&A question, there's not a simple way to answer your question, importantly, though, to frame. We look at all either growth or expansion of capability opportunities through buy-build - ally frameworks. We relentlessly go through a buy-build-ally framework. So for example, today within our Evernorth benefit portfolio, we're organically building out additional post acute care capabilities after evaluating buying, further partnering or insourcing those capabilities.",0.6634279,0.863
CI-2021-Q1-2021-05-07,141,Question,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And also you mentioned the effective supply chain initiative again this quarter. Just curious what that means for 2021 in particular, whether is that just code for better drug purchasing and procurement this year? Are there other factors within the ""supply chain initiative"" driving better results? Thanks.",0.4395647,0.572
CI-2021-Q1-2021-05-07,142,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, it's David. So two-point questions. First, there's no doubt there are some pockets of generic deflation within the within the pricing environment which is the cost environment. Importantly, they're in line with our expectations. So it's not a deviant or driver of deviation for us in any way shape or form in terms of our broad portfolio. But unequivocally there are some pockets of deflation there in line with our expectations. As relates to the supply chain activity, I would ask you just to continue to think about supply chain initiatives as being an inherent strength within the overall portfolio through a variety of lenses, whether it's collaboration on the medical side of the equation, the traditional supply chain activity, the value-based supply chain activity, et cetera.",0.753595,0.985
CI-2021-Q1-2021-05-07,143,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And we have a continuous drive to improve value, albeit, to partner as we go through the process and as we get into some more of the complex dimensions of the higher costs, drugs and medications, we think there's further opportunity through the supply chain activity around value based care relationships, aligned incentive relationships more specifically with the manufacturers and with ourselves on a go forward basis. So I wouldn't call out any unique driver. More importantly, it's a continuous improvement part of our portfolio, and it's an underlying strength of our portfolio. And lastly, our sustained growth supports that in a very positive way.",1.8546444,0.586
CI-2021-Q1-2021-05-07,146,Question,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hi, good morning. Thanks for squeezing me in. I wanted to come back to the telemedicine topic and David thinking about your capital light strategy relative to providers and network. I'm wondering if Evernorth and Cigna has an opportunity to leverage MDLIVE into your collaborative care partnerships or otherwise into partnered networks as opposed to own networks in your case? And then alternatively, do you have an opportunity to use MDLIVE to feed volume or refer volume, catch volume if you so to speak in parts of -- other parts of Evernorth, especially pharmacy mail or delivery, things like that by owning and controlling telemedicine through MDLIVE?",0.8274388,0.958
CI-2021-Q1-2021-05-07,147,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning. Appreciate the question. So twofold. The first part of your question, the simple answer is yes. So to be really clear. Again, we see the opportunity, obviously, from a standalone, if you will fulfillment and delivery of the service but also an opportunity in collaboration in alignment as a panel extender for high performing collaborative accountable care relationships. And those conversations are dynamic and underway.",0.6886902,0.983
CI-2021-Q1-2021-05-07,148,Answer,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","To the second part of your question, very thoughtful framework and appreciate it. If we come back and think about first and foremost, our ability to further improve affordability. You may recall at our Investor Day, we talked about four major ways in which we further improve affordability off of our strong overall cost environment today. One, is to further increase the percentage of utilization that takes place in the highest performing clinical settings, be they physicians or facilities. Second, is to work to reduce the cost of drugs further. Third, is to effectively leverage alternative sites of care. For example, the difference between a knee replacement that is inpatient versus outpatient is about a third less than cost. And we see a massive shift at the physical side of care is similar in virtual side of care.",1.0652934,0.97
CI-2021-Q1-2021-05-07,152,Closing,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","First, thanks for our time today. We really appreciate spending time to discuss our Cigna results and our outlook. I just want to wrap up our call with a few headlines. First and foremost, we delivered strong financial performance during the quarter as we continue to navigate through what is undoubtedly a dynamic environment. And we work to meet and balance the needs of all of our stakeholders, as we act as champions for healthcare that is affordable, predictable and simple.",0.5969685,0.981
CI-2021-Q1-2021-05-07,153,Closing,2021-05-07,1,2021,David Michael Cordani,"President, Chief Executive Officer & Director","In addition, our strong foundation driven by our growth framework and track record of success gives us confidence in our ability to achieve our increased EPS outlook for 2021 of $20.20. As well as positions as well for our ongoing long term average annual revenue growth rate of 68% and our 10% to 13% average annual adjusted EPS growth rate, all while continuing to pay attractive dividend. With that again, we thank you for joining our call and we look forward to our future conversations.",0.7361057,0.077
CI-2019-Q4-2020-02-06,13,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks Will and good morning, everyone. Thank you for joining our call today. In 2019, we delivered consolidated adjusted revenue of $140 billion and grew earnings per share by 20% to $17.05. As a result, we exceeded the guidance that we'd already raised each quarter during 2019 for revenue, earnings and EPS as well as cash flow from operations.",0.9378158,0.891
CI-2019-Q4-2020-02-06,14,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director",Today I'll comment on how we delivered these exceptionally strong results and on the contributions made by each of our four growth platforms led by Health Services and Integrated Medical segments. I'll also discuss how we are positioned to drive attractive growth in 2020 and achieve our 2021 EPS target of $20 to $21 per share.,1.0139914,0.917
CI-2019-Q4-2020-02-06,15,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Finally, I'll highlight a key point of differentiation and a driver of future growth, our focus on being the undisputed partner of choice in health care. Following my comments, Eric will share more details about our full year 2019 financial results and 2020 outlook, and then we'll take your questions. Let's dive in.",0.9584143,0.856
CI-2019-Q4-2020-02-06,16,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","At our Investor Day last year, we committed to building on a decade long track record of delivering industry leading cost trends, consistent growth, and effective capital stewardship. In 2019, we delivered on each of these commitments. While remaining focused on our customers and patients, we executed well across each of our businesses, deepened our customer relationships and achieved our integration priorities. Together this fueled our outstanding performance.",0.8083949,0.943
CI-2019-Q4-2020-02-06,17,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","In Health Services, we delivered market leading customer and client retention including 97% retention for the 2020 selling season and continued strong organic growth in prescriptions. In commercial, we again delivered industry leading medical cost trend and grew our commercial medical customers for the 10th consecutive year, led by another year of double digit growth in the select segment.",1.1298096,0.818
CI-2019-Q4-2020-02-06,18,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And in a government business, CMSs most recent stared ratings position as to have 87% of our Medicare Advantage customers enforced our higher plan for 2021 a reinforcement of our strong customer satisfaction and high levels of clinical quality.",1.1165954,0.802
CI-2019-Q4-2020-02-06,19,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Additionally, we made significant progress in advancing our five key integration priorities. First and foremost, we kept that promises in the marketplace by ensuring our more than 170 million customer relationships around the world experienced ongoing high service quality throughout the year.",1.0171007,0.807
CI-2019-Q4-2020-02-06,20,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Second, we delivered medical and pharmacy cost savings for the benefit of our customers and clients, effectively completing their transition to industry leading pharmacies solutions, including Accredo's specialty pharmacy, and Express Scripts customer friendly home delivery pharmacy. Additionally, more than 95% of our customers have access to safeguard Rx, an innovative suite of value based programs that improve care and value for customers with challenging medical conditions.",0.5666537,0.977
CI-2019-Q4-2020-02-06,21,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Third was a focus on talent. As a Health Service company, our talent and their engagement is key to our performance and ongoing growth. Our retention and engagement levels today, one year into a combination are above our already strong pre-transaction levels.",1.2697241,0.948
CI-2019-Q4-2020-02-06,22,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Fourth, we made significant progress towards securing base operating expense synergies. The organizational efficiency plan we announced earlier today is another important step toward achieving these targets.",0.457054,0.848
CI-2019-Q4-2020-02-06,23,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And finally, we kept our vision top of mind by accelerating marketplace innovations that improve affordability, predictability and simplicity, including our embark benefit protection program, which improves customer access to life changing gene therapies, while shielding clients from the price shock of multimillion dollar treatments.",1.0691799,0.836
CI-2019-Q4-2020-02-06,24,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Our digital health formulary, to better carry and generate value from the 300,000 digital health apps in the marketplace today in a patient assurance program, where insulin dependent patients with diabetes pay a maximum of $25 for a 30 day supply of insulin. As a result of this program, our customers are already realizing significant out of pocket savings.",1.4648271,0.796
CI-2019-Q4-2020-02-06,25,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Overall, 2019 was an exceptionally strong year for Cigna and gives us considerable momentum for ongoing attractive growth in 2020 and beyond. Our achievements were and continue to be driven by the focus, commitment and passion of our employees who wake up every day to fulfill our mission to improve the health well-being peace of mind to those we serve.",1.1189273,0.972
CI-2019-Q4-2020-02-06,26,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","In 2020 we will continue to drive significant growth and customer relationships, revenue, earnings and EPS as well as strong cash flows. In Health Services, we expect adjusted script growth in a range of 20% to 23% over our year end 2019 levels. In integrated medical, we are on track for continued medical customer growth highlighted by our government business, where we expect 13% to 16% customer growth and Medicare Advantage and we remain positioned for very attractive growth over the next five years.",0.9288768,0.97
CI-2019-Q4-2020-02-06,27,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Additionally, after a very successful first year as a combined company, we remain on track to complete our integration activities over the next year. We also expect to close the sale of our group disability and life business to New York Life by the third quarter this year. And we're on track to return a balance sheet to normalized levels of debt by year end 2020. In short, we're on pace to meet the commitments we made when we announced the combination nearly two years ago, and meet the commitments we made at our Investor Day in May of 2019.",1.0524679,0.556
CI-2019-Q4-2020-02-06,28,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Looking forward a key point of differentiation and growth driver for Cigna in 2020 and beyond is our orientation toward partnering in order to achieve accelerated innovation, improved affordability, predictability and simplicity and to further expand our distribution reach. Several recent examples demonstrate our proven differentiation.",1.2250291,0.866
CI-2019-Q4-2020-02-06,29,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","First is our new arrangement with Prime Therapeutics. Starting in April 2020, together we will make pharmacy care more affordable, financing, pharmacy networks and pharmaceutical manufacturer value for Prime's 28 million members who are covered by 23 health plans including employer programs, Medicare and Medicaid.",1.1620676,0.681
CI-2019-Q4-2020-02-06,30,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Together Express Scripts and Prime will help each other to continue to grow in the market across the country by innovating new solutions to improve affordability, increased access to medicine and further improve individual health. This agreement shows our ability to work across healthcare and partner with those who seek to deliver innovative high quality health services and solutions to employers, health plans and governmental agencies for the benefit of customers and patients.",0.7314419,0.97
CI-2019-Q4-2020-02-06,31,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","A second example of our partnership orientation is our work with emerging and highly innovative companies. A great recent example of this is a partnership with Oscar Health. With Oscar, we will deliver new innovative solutions for small businesses, which all too often are left with limited options that are highly priced. We will offer small businesses access to affordable, fully insured health plans that brought in choice and prioritize whole person health. We will focus in four geographies with Oscar later this year and we'll take our proven tessellated framework to accelerated growth over time.",1.1787796,0.921
CI-2019-Q4-2020-02-06,32,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","A third example is our trusted relationships with healthcare professionals. We have a long history innovative value based arrangements with healthcare professionals in both our US commercial and government businesses, including more than 650 collaborative accountable care relationships. Today, more than 65% of Cigna's medical payments are in value based arrangements across our top 40 commercial markets and all our Medicare markets.",0.5134085,0.93
CI-2019-Q4-2020-02-06,33,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Importantly, 92% of healthcare providers in our programs are delivering differentiated levels of quality. And 90% of healthcare providers believe Cigna is the industry leader in this area. These deep partnerships drive our growth, particularly in Medicare Advantage where we focus on geographies, where our commercial business already has aligned high performing collaborative accountable care relationships in place.",1.3540614,0.854
CI-2019-Q4-2020-02-06,34,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Approximately 25% of Medicare eligible seniors live in geographies where commercial business has deep ties in delivery systems, but we have no Medicare Advantage presence today. That provides a meaningful growth opportunity for our Medicare Advantage business that we have begun to capitalize in 2020 by accelerating our geographic expansion and bringing new PPO solutions to market.",1.2907112,0.923
CI-2019-Q4-2020-02-06,35,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","This combined with the fact that 87% of our Medicare Advantage customers are in four star or greater plans in 2021 and our high customer and PS levels, which approximate 70 across all of our markets, make us excited about our future customer growth, which we project to be in the range of 10% to 15% on an annualized basis over the next five years. Each of these examples gives a clear view of how diverse healthcare stakeholders view Cigna as their best partner for future success and how being the partner of choice in healthcare marketplace will contribute to our sustained differentiated growth over time.",0.9553051,0.967
CI-2019-Q4-2020-02-06,36,Remarks,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Now briefly, to summarize, at Cigna we delivered exceptional full year 2019 financial results across our four growth platforms led by Health Services and our Integrated Medical segments. These results drove strong financial performance in 2018 and provide us with considerable momentum as we step into 2020 with outstanding strategic and financial flexibility, and we remain on track to deliver our EPS goal of $20 to $21 per share in 2021.",1.0205985,0.926
CI-2019-Q4-2020-02-06,38,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Thanks, David. Good morning, everyone. In my remarks today, I'll review Cigna's 2019 results and provide our outlook for 2020. Key consolidated financial highlights for 2019 include adjusted revenue of $140 billion, earnings of $6.5 billion after tax, earnings per share growth of 20% to $17.05 and operating cash flows more than doubled this year to $9.5 billion. These results reflect strong consistent execution across our businesses throughout 2019.",1.0280273,0.917
CI-2019-Q4-2020-02-06,39,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Regarding our segments, I'll first comment on Health Services. Full year 2019 revenues were $96.4 billion and pre-tax earnings were $5.1 billion. Results for 2019 reflect organic growth, with outstanding client retention and the addition of 2.7 million pharmacy customers, strong volumes with 1.22 billion adjusted pharmacy scripts fulfilled and growth in specialty pharmacy. Overall, Health Services performed well in 2019 with results in line with our expectations and reflecting significant progress across our integration activities.",0.7089472,0.964
CI-2019-Q4-2020-02-06,40,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to Integrated Medical, 2019 revenues grew 11% to $36.5 billion driven by commercial customer growth and expansion of specialty relationships, premium growth reflecting underlying cost trends, and the inclusion of the Express Scripts Medicare Part D business. We organically grew our global medical customer base to 17.1 million lives. In 2019, we once again delivered double digit organic customer growth in our select segment with continued enrollment gains in middle market. Full year earnings grew 9% to $3.8 billion reflecting growth in medical customers and specialty relationships, strong operating expense discipline, and continued effective medical cost management.",0.9615523,0.953
CI-2019-Q4-2020-02-06,41,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to medical cost, for our total US commercial book of business, full year medical cost trend for 2019 was approximately 4%, which marks the seventh consecutive year Cigna has delivered an industry leading result. Our full year 2019 total medical care ratio or MCR was 80.8%, finishing the year at the low end of our guidance range.",1.2213439,0.273
CI-2019-Q4-2020-02-06,42,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Our MCR performance reflects stable trends and focused execution of affordability initiatives across our commercial and government businesses and the pricing effect of the health insurance tax suspension. Full year 2019, Integrated medical earning benefited from $85 million pre-tax of favorable net to prior year reserve development. Overall, Cigna's Integrated Medical segment delivered strong financial results in 2019.",1.174991,0.881
CI-2019-Q4-2020-02-06,43,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"In our international markets business, revenues grew to $5.6 billion, an increase of 8% on a currency adjusted basis. And full year 2019 pre-tax earnings grew to $762 million reflecting continued business growth, partially offset by unfavorable foreign currency impacts.",0.7768595,0.599
CI-2019-Q4-2020-02-06,44,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our group disability and other operations segments, full year 2019 revenues were $5.2 billion. Full year pre-tax earnings for this segment were $501 million with strong performance in life and continued administrative efficiencies, partially offset by higher disability claims.",0.6852318,0.71
CI-2019-Q4-2020-02-06,45,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our corporate segment, the full year 2019 loss was $1.8 billion, primarily driven by $1.7 billion of interest costs. As Will mentioned, during fourth quarter, we reported a special item charge of $162 million after tax for severance costs related to our organizational efficiency plan. Under this plan, we will implement efficiency initiatives that we identified primarily through our integration work. These actions reflect our commitment to providing affordable quality solutions to the marketplace and the savings associated with this plan are included within the multi-year administrative expense synergy targets that we previously communicated.",1.1239669,0.893
CI-2019-Q4-2020-02-06,46,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Overall, Cigna's 2019 results reflect focused execution across each of our businesses. Before discussing our outlook for continued attractive growth this year, I would remind you of the 2019 earnings per share baseline adjustments that we quantified on our third quarter earnings call. Specifically, Cigna's earnings per share performance in 2019 should be adjusted for the following three items.",0.9166367,0.889
CI-2019-Q4-2020-02-06,47,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"First, $0.12 share for the tax item we've favorably settled in the second quarter of 2019. Second, $0.18 per share of favorable net prior year reserve development. And finally, $0.25 per share associated with the industry tax, which was suspended for 2019, but returns in 2020 a final year. This impact is increased to reflect the incremental timing effect of the recent repeal of the industry tax. When adjusting for these impacts, Cigna's 2019 earnings per share baseline was $16.50.",1.0183255,0.842
CI-2019-Q4-2020-02-06,48,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to outlook, we have entered 2020 well positioned to drive both continued growth and innovation. We also expect to complete our integration activities associated with the Express Scripts combination over the next year. For full year 2020, we expect consolidate adjusted revenues in the range of $154 million to $156 billion, representing growth of 10% to 11%.",1.2407474,0.836
CI-2019-Q4-2020-02-06,49,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We expect full year 2020 consolidated adjusted income from operations to be $6.8 billion to $7 billion or $18 to $18.60 per share. This represents growth in the range of 9% to 13% over our 2019 baseline. We expect the cadence of earnings per share 2020 to be approximately 47% in the first half and 53% in the second half of the year, taking into consideration seasonality patterns within our businesses. For 2020, we project an expense ratio in the range of 8.6% to 9.1%, and the consolidated adjusted tax rates in the range of 23% to 24%.",0.8030902,0.718
CI-2019-Q4-2020-02-06,50,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Additionally, our outlook excludes any contribution from future share repurchases, and prior year reserve development and assumes a full year of contributions from our group disability and life business. And as previously communicated in 2020, we will no longer report transitioning client contributions since those transitions were substantially complete as of December 31, 2019.",0.9461013,0.0
CI-2019-Q4-2020-02-06,51,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I will now discuss our 2020 outlook for our segments. For our Health Services business we expect full year 2020 earnings in the range of $5.3 billion to $5.45 billion. This represents year-over-year growth in the range of 4% to 7%. In Health Services, we expect first quarter 2020 earnings to grow by a mid-single digit percentage over first quarter 2019.",0.5964786,0.382
CI-2019-Q4-2020-02-06,52,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,This outlook reflects solid underlying growth and the benefits of increased year-over-year administrative expense synergies. I'd also note that we expect our first quarter 2020 Health Services SG&A expense ratio to be higher than first quarter 2019 reflecting impacts of the client transitions we've discussed previously and including startup costs associated with our collaboration with Prime Therapeutics.,1.0,0.785
CI-2019-Q4-2020-02-06,53,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For 2020 we expect adjusted pharmacy scripts in the range of 1.47 billion to 1.50 billion claims. This reflects the impact of completing the in sourcing of Cigna pharmacy services, growth associated with the first year of the Prime collaboration and additional organic growth of 25 million to 35 million adjusted pharmacy scripts. All in this represents a year-over-year growth of 20% to 23%.",1.1976285,0.778
CI-2019-Q4-2020-02-06,54,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For integrated medical, we expect full year 2020 earnings in the range of $4 billion to $4.1 billion, which represents growth of 11% to 13% over the 2019 baseline. This outlook reflects strength and growth in our businesses, driven by continued benefits from organic customer growth, deepening of customer relationships and effective medical cost management. This outlook also included the benefit of administrative expense synergies.",1.2134387,0.957
CI-2019-Q4-2020-02-06,55,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Key assumptions reflected in our Integrated Medical earnings outlook for 2020 include the following, regarding global medical customers, we expect 2020 growth in the range of 150,000 to 250,000 customers, driven by continued organic growth in our commercial business, led by the selected middle market segments, partially offset by lower national accounts enrollment. We also expect Medicare Advantage customer growth of 13% to 16%.",0.7272727,0.765
CI-2019-Q4-2020-02-06,56,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Our growth outlook also includes an expectation of lower enrollment in our US individual business, and the expected loss of our Texas Medicaid contracts collectively resulting in a reduction of approximately 90,000 customers.",0.6316924,-0.226
CI-2019-Q4-2020-02-06,57,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to medical costs, for our US commercial employer book of business, we expect full year 2020 medical cost trend to be in the range of 3.5% to 4.5%. We expect the 2020 medical care ratio to be in the range of 80.2% to 81.2%, reflecting the return of the health insurance tax in 2020, and continued strong performance of our commercial and government businesses, offset by the mix impact of new Medicare Advantage life and normalized margins in our US individual business.",1.1243263,0.818
CI-2019-Q4-2020-02-06,58,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,We also expect strong contributions from our international markets with disability and other businesses as they continue to deliver solutions that enhance affordability and predictability and provide a more simplified experience for those we serve.,1.4286741,0.612
CI-2019-Q4-2020-02-06,59,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Regarding interest expense, we expect costs of approximately $1.6 billion pre-tax in 2020. So all in for full year 2020, we expect consolidated adjusted income from operations of $6.8 billion to $7 billion or $18 to $18.60 per share. I would also remind you that our outlook excludes the impact of future share purchases and prior years of development, and assumes a full year of contributions from our group disability and life business.",1.0657564,0.751
CI-2019-Q4-2020-02-06,60,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Overall, these expected results represent a very attractive outlook, aided by the strong performance across our differentiated portfolio of businesses. These expected results also position us well to achieve our 2021 earnings per share target of $20 to $21 per share.",1.1106719,0.9
CI-2019-Q4-2020-02-06,61,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now, moving to our capital management position and outlook, our subsidiaries remain well capitalized and we expect them to continue to drive exceptional cash flow with strong returns on capital even as we continue reinvesting to support long-term growth and innovation. In 2019, we deployed $5.2 billion to repay debt, and we repurchased 11.8 million shares of stock for $2 billion. We ended 2019 with a debt to capitalization ratio of 45.2% an improvement of 570 basis points over a year and 2018.",1.0280273,0.91
CI-2019-Q4-2020-02-06,62,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For 2020, we expect greater than $7.5 billion of cash flow from operations reflecting the strong capital efficiency of our well performing businesses. As previously discussed, with a near term focus on accelerated debt repayment and remain on track to return our debt to capitalization ratio to the upper 30s by the end of 2020. In 2020, we expect to deploy $4.5 to $5 billion to debt repayment, and $1 billion to capital expenditures.",1.0237154,0.44
CI-2019-Q4-2020-02-06,63,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"As a reminder, our capital priorities remain as follows. Reinvestment back into our businesses to drive further innovation and growth, strategic M&A on a targeted basis and returning capital to shareholders, which historically we have done primarily through share repurchase. Year-to-date, as of February 5, 2020, we've repurchased 1.2 million shares for $245 million and we have $3.72 billion of remaining share repurchase authorization. Our balance sheet and cash flow look remain strong, benefiting from a highly efficient service based orientation to drive strategic flexibility, strong margins and attractive returns on capital.",0.9662235,0.974
CI-2019-Q4-2020-02-06,64,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now, to recap, our full year 2019 consolidated results reflects considerable strength and momentum across our four growth platforms and continued effective execution of our focus strategy. We are confident in our ability to deliver our full year 2020 earnings outlook. We will remain on track to achieve our $20 to $21 earnings per share target for 2021. Further, our clear strategic focus, differentiated value proposition across our businesses and outstanding financial flexibility give us continued confidence in our long-term targets for growth in revenue, earnings and EPS.",0.3208768,0.985
CI-2019-Q4-2020-02-06,65,Remarks,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"With that, we'll turn it over to the operator for the Q&A portion of the call.",2.0977363,0.0
CI-2019-Q4-2020-02-06,67,Question,2020-02-06,4,2019,Justin Lake,,"Thanks. Good morning. I wanted to ask a quick numbers question and then a little bit about the capital deployment. So first, just in terms of the group disability sale on numbers. I know you have it in there. Just want to understand how you keep - you deploy capital that you receive to keep this earnings neutral for 2020. Wouldn't the company have to begin buying back stock early or doing ASR given the earnings of go away at a moment in time, and yet the share - the capital deployment might take time.",0.0214531,0.807
CI-2019-Q4-2020-02-06,68,Answer,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Justin it's Eric, thanks for the question on that. So just to step back, so for the group disability and life transaction, as we noted, in December, we entered into that agreement, we expect $5.3 billion of after tax proceeds, and we're on track for that to close in the third quarter. Since the $5.3 billion first will be incremental to operating cash flow for the year. We've got flexibility in terms of the timing of how we deploy things and how we deploy capital for the year. Our primary focus is on achieving our debt to capitalization ratio of below 40% by the end of the year and we've got flexibility beyond that and throughout the year to begin to what to do share repurchase and such. We haven't provided any specific guidance in terms of the exact timing of the share repurchase, but we do have flexibility to get started on that even as advanced with the close.",0.852677,0.889
CI-2019-Q4-2020-02-06,69,Question,2020-02-06,4,2019,Justin Lake,,"Okay, but will it be earnings neutral through the year, the combination of anything to disability and the capital deployment?",0.4007437,0.115
CI-2019-Q4-2020-02-06,70,Answer,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"That's our expectation, and that's the guidance that we provided back when we announced the transaction.",1.5300036,0.0
CI-2019-Q4-2020-02-06,71,Question,2020-02-06,4,2019,Justin Lake,,"Okay, and then if I could just ask a question about the Prime relationship. Congratulations on that obviously. Wanted to understand two things, one, in terms of the relationship itself, it's somewhat narrow in focus, but sounds like it could expand over time. How do you kind of look at the risk versus opportunity to risk being that some of your existing Express Scripts customers we have a much broader relationship, move to Prime and therefore could be somewhat dilutive versus the opportunities to work with these blues and potentially expand that partnership and kind of offset some of that risk.",0.0895309,0.904
CI-2019-Q4-2020-02-06,72,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Justin, good morning, it's David. First and foremost, let me just re-underscore how pleased we are to have entered that relationship. The validation of our deep commitment to servicing health plans, partnering with health plans and growing those relationships. Two, your ability to retain any relationship be a commercial health one otherwise is based on a couple of basic tenets. A, are we able to drive partnership and alignment; B, deliver differentiated value; C, innovate together? We're committed to doing so. And actually we view the opposite of the maybe risk that you identified. This further broadens our reach and our opportunity to serve more lives, both individual customers and patients and a broader portfolio of health plans as we go forward. So we're delighted by securing this and we look forward to beginning to serve that relationship in the second quarter of this year.",1.2666148,0.97
CI-2019-Q4-2020-02-06,75,Question,2020-02-06,4,2019,Kevin Fischbeck,Bank of America / Merrill Lynch,"Okay, great. Thanks. Actually it's a quick numbers question. First two, it sounds like you're saying that the guidance basically is similar to what you were saying with Q3, but you've got another $0.05 drag from this being removed in 2021. Do I just have that right that that's the main change versus Q3 initial outlook?",0.3977716,0.519
CI-2019-Q4-2020-02-06,76,Answer,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Kevin its Eric, really two small things to think about there, the incremental drag of a few cents that you noted and we have the benefit of a few cents' pickup because of the lower share count as we completed repurchase from the time period. Those are the two differences.",0.7039166,0.273
CI-2019-Q4-2020-02-06,77,Question,2020-02-06,4,2019,Kevin Fischbeck,Bank of America / Merrill Lynch,"Okay, and then the question being, I think that when you guys provided initial membership guidance at the beginning of this year, that was kind of a little bit disappointing. And I guess it's clear now that some of its individual, some of its Medicaid, but you in your presentation have long-term commercial top line growth of 8% to 10%, which is a higher number than I think most people think about as far as commercial growth. How much of that is able to be driven by just growth in the selected middle market accounts? Or do you need to be starting to grow national accounts and individual to kind of achieve that over the long term? And how do you - if so, how do you turn that around?",0.3559889,0.917
CI-2019-Q4-2020-02-06,78,Answer,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Kevin its Eric, I'll start on that. First of all, those targets are very consistent with the results we've driven in the commercial markets for a number of years now. And I think the growth in that - the brinks that we target in that business is being driven by really three things. The first category would be around continued customer growth as we continue to grow in the select middle market segments. We've got a lot of opportunity to continue to grow in those segments. The next one, I'd say would be on deepening our existing client's relationships. So as we work to identify new solutions and deepen our existing solutions in terms of new product sales and again other programs and services. And then the third category I think about would be around, working to innovate and to deliver new solutions more broadly. But again, that's the recipe that we've used for a number of years now. And we see a lot of opportunity to continue on that track in the commercial market.",1.1354653,0.949
CI-2019-Q4-2020-02-06,79,Question,2020-02-06,4,2019,Kevin Fischbeck,Bank of America / Merrill Lynch,And you don't need massive account growth per se together or is that part of the growth platform?,1.3520891,0.637
CI-2019-Q4-2020-02-06,80,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Kevin its David, when you think about national accounts, put it back in context, we defined that segment to remind you much more narrow than maybe the market in total. So for Integrated Medical, its commercial employers, 5000 or more employees that are multi-state. Based on that definition and our strategy we view that marketplace as a flat to somewhat shrinking marketplace based on our strategy within Integrated Medical. Now, Eric's point two and point three reinforce how we continue to actually grow and deepen relationships with national accounts. Even today, we're able to successfully do that. And then lastly, we're quite excited about is adding to that more broadly off of our Health Services platform, the ability to offer broader coordinated services. So we could see deepening of relationships and broadening of relationships with the national accounts, even with the medical membership performance that you're making reference to. And over time, we see the ability to even further accelerate that by leveraging our Health Services portfolio. So that will be a net contributor as well.",0.9246016,0.891
CI-2019-Q4-2020-02-06,83,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, it's David. First and foremost, we're really pleased with the start to 2020. As we indicated in 2019, we expect to grow this platform 10% to 15% and we're on track to do 13 to 16. Just back to remind me of some of the context we're well positioned today in 2021. Our Stars rating picks up yet further to 87% of our lives enforced are greater plans. And our net promoter score is tracking yet tad over 70 across our broad portfolio. So our ability to grow both in markets on platforms, net new geographies being adjacent counties and new markets are opening and broadening our PPO platform will feel this and drive it on a go forward basis. Clearly the rate and pace of that growth may put a little margin pressure and draw us toward the low end of our margin range or at times, maybe a tad below that. We'll balance that in our portfolios. We continue to invest as we are today. But we like the growth outlook, we like to aggregate margin profile and we like to sustainability. The last sub note maybe have there in terms of the coding and otherwise, our value based provider relationships and our high engagement programs are well positioned to coordinate the care of the services et cetera as reinforced by the stars rating and as reinforced by our overall performance. So we feel good about the outlook for this year and the trajectory going forward.",1.2429071,0.988
CI-2019-Q4-2020-02-06,86,Question,2020-02-06,4,2019,Steve Tanal,Goldman Sachs,"So I guess one on Oscar. This sounds like a very interesting partnership, but trying to understand what elements of their business are difficult or costly for Cigna to build their offer independently. So just trying to really understand what are the functions each of the companies will do in the context of the partnership. And maybe that's it for me.",0.1140212,-0.274
CI-2019-Q4-2020-02-06,87,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Steve thanks, it's David. So stepping back, as I noted in my prepared remarks. First, at a philosophical level, we view that the notion of partnering and beyond partnering, striving to be the undisputed partner choice is a competitive advantage and something we want to build on. Why? It accelerates pace of innovation, it accelerates value creation, whether it be around affordability, predictability, simplicity, it could broaden speed and absolute reach within the marketplace. Oscar is a wonderful example of that. And if you take it up to the macro level, you'll recall that Cigna has historically not participated in the smallest end of the employer marketplace, be it under 50 or under 100, depending on where the regulatory lines are drawn from that standpoint. Two, we believe that's an underserved marketplace with less choice and less leverage of some of the most innovative solutions, not at the core of your question. When you're open minded to partnering, you could have both focused and acceleration in this case by leveraging Oscar's phenomenal technological infrastructure, digital first infrastructure and information flow infrastructure, which is similar to our philosophy, but we just apply it up market and select the middle and national. And this is a case where we're philosophically aligned, but the durable infrastructure is there to serve the unique needs of the small employers and then we're able to port over our value based network configurations, our high performing engagement, clinical behavioral pharmacy capabilities to make one plus one equal a lot more than two. So we're excited about that. And as I noted in my prepared remarks, we're staged to open up four markets to the latter part of this year, and then fuel some growth.",1.1095997,0.981
CI-2019-Q4-2020-02-06,90,Answer,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Eric. On the item related to the Leap Year and the February having an extra day this year that doesn't move the pattern around a little bit in the Integrated Medical segment, all else equal, that runs the loss ratio up a little bit for the first quarter, it'll normalize out over the course of the year, of course, fully factored into our guidance and such, but that does put a modest amount of pressure on the first quarter that will recover over the balance of the year. Nothing that I would call out is particularly significant. As it relates to the range more broadly, there aren't any big items I'd call out other than just the rate and pace of our spending and our investments in terms of future growth. As you know, we have continued to invest in building the capabilities in the like and spend every year as we get ready for new clients to come on board and things along those lines, so it would be those types of items that I think about more than anything else at this point.",1.2655408,0.844
CI-2019-Q4-2020-02-06,93,Question,2020-02-06,4,2019,Ralph Giacobbe,Credit Suisse,"Thanks, good morning. I want to go to interest expense guidance, so it looks like your run rating to 1.6 billion at least as of the fourth quarter. The guidance calls for 1.6 billion of interest costs in 2020 despite the 4.5 billion to 5 billion debt pay down. So is it just timing related? Maybe if you can kind of help reconcile that? And then along those lines, I guess to Justin's first question, so I'm sure - that's your repo, I mean, to the extent that you're doing in an accelerating it early on as an offset to the group disability and life does that mean any upside essentially in the first half of the year essentially is not going to carry through to the EPS line simply because of timing I guess. Thank you.",0.3265602,0.957
CI-2019-Q4-2020-02-06,94,Answer,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Ralph its Eric, so on the interest expense, really nothing in particular I'd call out other than it may be looking out to the decimal point a little bit further and the timing throughout the year. Obviously, to the extent we were to extinguish that earlier, the interest expense will go down, but again, our current expectation would be for 1.6 billion as I noted in my prepared remarks. In terms of the timing on the capital deployment, the mechanics are consistent with what I outlined to Justin's question. And we do have flexibility in terms of the timing of which we would deploy or our expectation is that we would fully offset the absence of the group transition by reducing the share count through share repurchase. And we'll approach that as we go through the course of the coming months and quarters yeah.",1.3575278,0.944
CI-2019-Q4-2020-02-06,97,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Sarah, good morning, it's David. So first and foremost, I wouldn't view it as a shift. We didn't go from something and away from something to something. So the individual HMO continues to be a bedrock of the platform and in fact is the major driver of our growth in 2020 as an example of that. We start to add the individual PPO platform to a portfolio invested to do so, stood it up and have the arrangements with the database provider community to be able to offer that. So it's expanding choice and building on a successful platform and track record. And as we both enter new markets and expanding counties, we will make our decisions in terms of individual HMO, individual PPO or both on a go forward basis. We just see it as an end, I mean, natural extension of our portfolio. Additionally, to your important point, we view that the employer marketplace is also a very attractive addressable market. And as you know, our national accounts are broad while performing commercial portfolios of employee relationships presents another opportunity for that. And it's on our growth trajectory. We're just very disciplined as it relates to building the momentum. So going from the proven HMO to adding the PPO, expanding geographies and you should expect us over time to come back and talk with you about the very attractive additional growth opportunities that exist in the employer marketplace for us as well.",1.2658375,0.983
CI-2019-Q4-2020-02-06,101,Answer,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Hey, Gary its Eric. On the first part of your question, the short answer is yes. I think of that as not having a specific impact in terms of the quantification given there's not a way to specifically build that into how you bid for MA. On the second portion of your question, absolutely the answer is yes. The dynamics you outlined are really the biggest pieces here. When you adjust for the Prime volumes, I mean, you adjust for the Cigna transition volumes. I think of the core aside from those items is being consistent.",0.8171038,0.758
CI-2019-Q4-2020-02-06,105,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Matthew its David, so specific to the commercial marketplace and I think you're going into the select segment. Recall that we offer choice in that marketplace. The choice is heavily oriented around a well configured integrated value proposition with the medical, the pharmacies, the behavior of the care management programs, et cetera and building choice around funding options. Today, think about from a new standpoint, it's tracking about 50-50. About 50% of a new business we're writing right now is risk about 50% of it is ASO stop loss plus or minus, and that vacillates in any given year, a little bit more of one a little bit more of the other and we're delighted with that. We're delighted to be able to be in position to offer it in that way. I'd also remind you from prior conversations, one of our friends, when you offer that choices, oftentimes you're literally offering that choice side by side. And it's a good validation for the purchaser, in this case, the client of our conviction to the ASO proposition when you're able to put the guarantee cost side by side. But today, think about it, the new business running about 50-50. And I wouldn't describe any difference we're seeing in terms of your terminology from a response standpoint and performance, it's performing really well for us.",1.2716673,0.95
CI-2019-Q4-2020-02-06,109,Answer,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Josh its Eric. I appreciate the way you frame that up. Obviously, we're very excited about the capital generation that we've got, the cash flow from operations visibility that we've got for 2020 and into 2021 and that gives us a lot of flexibility. And we've got a really good track record of not to use your word sitting on cash, we will deploy the capital in a way that's effective and aligned with our shareholders interest and such versus just accumulating to be clear, but again, the overall history we've got from a - track record we've got from a effectiveness of capital deployment and managing our capital coupled up with the visibility and flexibility that we've got coming with the capital available for us is an exciting combination. David, I don't know what else to add that on that.",1.2759612,0.95
CI-2019-Q4-2020-02-06,110,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Just to reinforce Josh and I appreciate your question. Recall from the - our strategic positioning, pre combination, aided to buy the combination, et cetera. Our ability to generate a significant amount of operating cash flow is a critical competency and we believe the strategic advantage with $9.5 billion in 2019, at least $7.5 billion in 2020 and at least 8.5 billion in 2021, so quite deliberate as Eric said. We note the importance of that responsibility, not something we take lightly, but our effective capital stewardship responsibility will be clear as we go forward and we have tremendous value creation opportunity in front of us right now.",1.3272445,0.966
CI-2019-Q4-2020-02-06,113,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Lance, good morning, it's David. I'll take the first question and I'll ask Eric to take the second part of your question. Individual business line, I'm presuming you're referencing the individual exchange. Just to remind everybody the individual exchange marketplace, we took a very focused deliberate posture on that - in that marketplace in 2014 and has stayed steady within that marketplace systematically, but slowly growing our posture. We're in 10 markets today. Think about the positioning of being in 10 markets highly oriented around leveraging our value based provider relationships. And that marketplace has performed pretty darn well in the last couple of years. Going forward we'll monitor the competitive landscape, but we see the ability to continue to grow that reasonably over time with fair returns. Cornerstone to our value proposition though is ensuring that in those states, we go down to sub MSA level and make sure we're building the value proper the offering around our highest performing physician relationships and getting the requisite alignment with the delivery system and thus far that's performed well for us. And we look forward to year in year out making individual decisions of additional market expansion. Eric, I'll ask you to address the SG&A comment.",1.2254178,0.988
CI-2019-Q4-2020-02-06,114,Answer,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes. Lance its Eric. On the Health Services fourth quarter probably two items to have you think about on that front, one, as we noted throughout both David and my prepared remarks continue to spend to invest in terms of building a new and additional capabilities and such. Additionally, we're spending on facilitating and effectuating the transitions associated with the full reinforcing of the Cigna volumes in the life. The other item, I would just note that we've provided some commentary throughout the year last year around the effect of the transition in client going away since as the volumes that are transitioning clients wound down that added costs back into the core, if you will. And we're well on track to extinguish that as we work through 2020.",1.1731944,0.691
CI-2019-Q4-2020-02-06,118,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Peter its David. First, broadly speaking, just to reiterate, we're really pleased with the positioning we have in our existing MSAs and expanding into new markets are individuality to more platform is the lead offering still and the lead part of the growth chassis, aided by the new market entrees as well as the PPO platform. Specifically to your question of how we go-to-market, think about that as an end proposition, so it's a multi-channel approach relative to captive partnered and otherwise and expect that to continue to expand over time. Specific to the margins, as I mentioned to the prior question, the margins we would expect to be at the lower end of the range that we've put out as a long-term range, as we accelerate our growth trajectory over the near term, potentially taking below that having said that, with a growth we would have earnings growth, that that brings along with it. And finally relative ESRD, as we flagged in the past when asked that question, it will be a smaller impact on our aggregate franchise. We will manage the final ESRD posture, MSA by MSA, benefit offering by benefit offering in alignment with our value based physicians. And we will be well positioned to manage that to the extent the final changes transpired is currently proposed from that standpoint. Net-net taken together attractive growth, even at the lower end of the margin range, we will be experiencing earnings expansion while simultaneously investing for growth going forward.",1.448115,0.982
CI-2019-Q4-2020-02-06,121,Question,2020-02-06,4,2019,Frank Morgan,RBC Capital Markets,"Thank you, two real quick questions. Any thoughts on last night CMAs proposed rule around 2021 you may rate updates and in any update on the Cigna Anthem litigation. Thanks.",0.3317056,0.557
CI-2019-Q4-2020-02-06,122,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Frank its David. Specific to the rate notice, as you might imagine, we're digesting the detail of a given the magnitude of it. It's the preliminary notice you know the process in terms of getting to the final rate notice. And big picture, I would suggest the aware in macro in line with the aggregation of what that rate notice indicates. And when we think about the posture that rate notice, the expansion of our shores proposition for 2021 will be in good shape for 2021. More to follow, but big picture, our impact is broadly speaking in line with what the rate notice speaks to. And as it relates to the - you asked specifically about the Cigna Anthem litigation that is on course to resolve itself by the end of this calendar month.",1.2320249,0.485
CI-2019-Q4-2020-02-06,123,Question,2020-02-06,4,2019,Frank Morgan,RBC Capital Markets,Any other color you can hear on that? What gives you confidence it would be wrapped up this month and will that result in a settlement payment?,1.6198116,0.566
CI-2019-Q4-2020-02-06,124,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Probably in specificity relative to litigation other than I would reinforce, we feel very strong about our position relative to our contractual responsibility and contractual ability to collect a break fee and the court is on is on track to resolve that by the end of this calendar month.",1.1150408,0.771
CI-2019-Q4-2020-02-06,128,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Yeah, I'm not going to go through the micro pieces of the components of the relationship, but I'd rather just reframe what we're trying to achieve together. This is a wonderful example of two organizations identifying philosophical alignment and strategic alignment and then pursuing leverage that results in additional value for customers and clients. That's the end of and the net- net of this, which is improved affordability, potentially improved coordinated access and then clinical program leverage on a go forward basis. We will continue to work with Prime in terms of the best ways in which we could add additional value for them. There's 28 million individual relationships that - or customers and members that are within the Prime relationship and we'll be guided by the components that they feel we can create the most value for will make value added suggestions and evolve that over time, all with the objective of creating more value for their members and clients and therefore getting some benefit for Cigna as well over time. So we're delighted with it. It's another validation of our ability to work with other likeminded partners to create mutual value.",1.1134862,0.996
CI-2019-Q4-2020-02-06,130,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","I appreciate the question. We think about it the exact opposite way. It's a dynamic marketplace and those who create the most valuable win, those who try to preserve or regress to control value will lose over time. So big picture, we're more oriented around a perpetual innovation cycle and continue to drive more value. And we like to do that with others and create mutual value. We have a long track record, the legacy of the ESI has that, the legacy of Cigna has that and we're fueling more of it. So this is an opportunity to create more value for 28 million more customers starting in 2020, and further improve affordability and further improve quality from that standpoint, that's a great outcome. Each organization has to continue to innovate. Each organization has to deliver value and there's ample growth opportunity in front of both organizations going forward and we'll align to mutually identify beneficial opportunities for both organizations to grow. But the cornerstone is innovation and more value delivery. So we view it as upside not downside.",1.4341236,0.996
CI-2019-Q4-2020-02-06,133,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Ricky, good morning, its David, specific to the 2021 PBM selling season break that up as new components, health plan relationships, corporate relationships, as we sit here today, they help find relationships as you would expect and draw close your completion sooner given the size, shape and scope of those relationships. They're substantially completed through the renewal cycle and we feel great about the outcome. So that would be the picture I give you for 2021, continued trends from that standpoint. The corporate part of the relationships are getting into full steam right now. We think we're going to have another very good year from that standpoint and our value proposition is resonating very well in the marketplace, specifically relative to our value proposition and some of the new innovations that we put into the marketplace, be it the patient assurance program, be it health connect 360, et cetera.",1.3202487,0.965
CI-2019-Q4-2020-02-06,134,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Put a circle around it in aggregate, think about the size of the book moving or up to move about from a normal standpoint. As it relates to Medicare Advantage, pleased that you're calling out the fact that a bit ahead of the market we put down before, remind you we said 10% to 15% on average over time, we said in our first year, we were expected to be at the lower end of the range as we were stepping into that new result. There's no one driver, what moves us to the 13% to 16%, I would call out a bit higher retention. So what we had initially put into our projection our retentions even higher, we love that. And as I noted in my prepared remarks, we're sitting in an MPS right now, just in excess of 70 across the aggregate book of business that we have and the vast majority of our customers in this space are in value based arrangement. So I wouldn't call it anything else. My existing platforms drove the majority of it, our new markets contributed, and we had a bit higher retention rate.",1.3486203,0.84
CI-2019-Q4-2020-02-06,138,Answer,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Hey Scott its Eric. Overall, nothing that I would call out as particularly notable, we finished the year with the trends of above 4%, which is right in the middle of our expectations. So there's nothing that I would call out as a particular change in trajectory in either the commercial or in the government business.",1.1002515,0.0
CI-2019-Q4-2020-02-06,142,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, it's David. I'll take the first question and I'll ask Eric to take the second question. We don't get into individual actions we're taking relative to our supply chain or procurement strategy. I would just step back and say we have a broad portfolio of tools, solutions and capabilities. And we're going to continue to dynamically manage those to get the best possible value for existing and prospective customers and clients going forward. Beyond that, we're not going to comment on any individual actions we're taking in the supply chain activity. Eric, could you comment on the trend.",0.9176059,0.914
CI-2019-Q4-2020-02-06,143,Answer,2020-02-06,4,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yeah, Steve on the trend, we've had pharmacy trend in that low to mid-single digits range for some time now, I mean, that would be the expectation we'd have going into 2020 as well. Just to remind you Express Scripts delivered in 2018 a 0.4% commercial trend. We're publishing our Express Scripts client or trends report later this month, and expect another really attractive result there. But to begin, nothing else I would call out.",1.07977,0.659
CI-2019-Q4-2020-02-06,146,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Charles good morning, first to your point, we're delighted with the fact that we have seven years now going into a plus in terms of delivering the lowest medical cost trend in the industry. And our clients and customers benefit from that immediately, especially given the profile of our business highly ASO oriented from that standpoint and will continue to drive exceptional value for our clients and customers. Two, I appreciate you calling out the CPI level goal and objective. A couple of years ago we put forth a strategic objective which said we strive to deliver a level of medical cost trend approximating CPI by 2021. We view that is indicative of a sustainable trend that the system and society could tolerate and manage on a go forward basis and indicative of a responsible trend. I would note that today we feel like we're well on our way to that journey.",1.3692188,0.949
CI-2019-Q4-2020-02-06,147,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And I would underscore that with the fact that many of our clients today who have established relationships with us and are leveraging our most advanced consumer engagement, health improvement and value based relationships are benefiting from CPI or better trend from that standpoint. So there's a toolkit we have that will continue to innovate and evolve around how do we get engagement in support of the consumer in the life journey? How do we evolve the precision and speed of the health improvement programs, especially as we continue to expand in the whole person health arena on an accelerated basis with our market leading behavioral health and pharmacy capabilities? And then just further deepening the activation of value based care delivery platforms that we have in the marketplace and we're already able to deliver as I indicated, CPI are better for many of our clients. We're going to see - further expand that in 2020 and beyond. I appreciate your question.",0.8278274,0.99
CI-2019-Q4-2020-02-06,149,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Thank you. To wrap up, I'd like to highlight just a few key points from today's conversation. First, to remind your Cigna delivered exceptional full year 2019 financial results across our four growth platforms led by Health Services and Integrated Medical segments. We exceeded the guidance we had already raised each quarter for 2019 for revenue, earnings and EPS as well as for cash flow from operations. Looking forward, our 2019 performance gives us considerable momentum for attractive growth in 2020 and beyond. In 2020, we will continue to drive significant growth in customer relationships, revenue, earnings, EPS, as well as continued strong operating cash flow.",0.4644384,0.973
CI-2019-Q4-2020-02-06,150,Answer,2020-02-06,4,2019,David Michael Cordani,"President, Chief Executive Officer & Director","We are on track to complete our integration activities associated with our combination with Express Scripts over the next year. We expect to close the sale of our group disability life business to New York Life in the third quarter. We're on track to return our balance sheet to normalized levels and debt and be in a position to provide exceptional strategic financial flexibility moving forward, just as we committed to when we announced our combination two years ago. And we're well positioned to drive attractive growth beyond 2020 and on track to deliver our 2021 EPS target of $20 to $21 per share. We thank you for joining our call today and we look forward to our future conversations.",1.0478041,0.906
CI-2019-Q2-2019-08-01,10,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks, Will. Good morning, everyone. And thank you for joining our call. Today I'll highlight Cigna's strong second quarter financial results, which reflect continued momentum across our businesses. I'll also discuss how our differentiated health service model fuels our ability to drive innovation and accelerated growth and build a more sustainable healthcare system.",1.7578702,0.961
CI-2019-Q2-2019-08-01,11,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","I'll begin with our second quarter performance, which included continued innovation, which drove strong revenue and earnings growth, exceptional service delivery, and deepening of our customer and client relationships. Cigna's consolidated adjusted revenue for the quarter was $34.4 billion, and we grew our earnings to $1.6 billion. Our results [indiscernible] Health Services and Integrated Medical segments, with Health Services delivering strong revenues and earnings that were modestly above our expectations and our Integrated Medical segment delivering a 10% increase in revenues with earnings growth of 8%.",1.8993393,0.94
CI-2019-Q2-2019-08-01,12,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","In addition, Cigna continue to deliver solid performance across our international markets and other businesses. Overall, we're pleased with our second quarter results, which continue to demonstrate momentum across our portfolio of businesses. We're also making very good progress on our integration priorities. As we continue to provide excellent services across our portfolio of businesses, retain and meaningfully grow our client relationships, deliver leading medical and pharmacy cost trend, drive medical and pharmacy synergies for the direct benefit of our customers and clients and deliver on our synergy capture for the benefit of our shareholders. All in we're on track to achieve our integration goals.",2.0571318,0.961
CI-2019-Q2-2019-08-01,13,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Collectively, our second quarter performance gives us confidence to again raise our revenue in earnings outlook for 2019, representing 17% to 19% EPS growth over Cigna's strong 2018 performance. Our strong results and confidence in continued long-term sustainable growth are fueled by the same thing. Our portfolio of leading assets that we connect to provide better care, greater choice, and approved affordability for those we serve. We are led by clear mission and more than 74,000 talented colleagues focused on improving health, well-being and peace of mind for those we serve.",1.8297707,0.992
CI-2019-Q2-2019-08-01,14,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Our four growth businesses give us a path for attractive growth in a dynamic marketplace and regulatory environment. In commercial, we are executing our plans to expand our go deep markets by 25% over the next three to five years, building on the success of our proven strategy. In Medicare Advantage we expect 10% to 15% average annual customer growth, driven by both product and geographic market expansion beginning in 2020.",1.5876409,0.96
CI-2019-Q2-2019-08-01,16,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And in international markets, we continue our product and distribution channel expansion to drive sustained attractive growth. By leveraging these distinctive assets, and guided by our clear strategic direction, Cigna is accelerating the future of healthcare.",1.6346677,0.832
CI-2019-Q2-2019-08-01,18,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Now, our transformative model of healthcare is building on the progress we have made to position us to lead the industry including a better, more sustainable healthcare system. Our focus is in three critical areas, treating the whole person body and mind, targeted rapid innovation to meet customers need for more affordable, personalized solution, and leveraging data and technology to serve as a connective tissue between our customers and their health care professional partners of choice.",2.1375826,0.895
CI-2019-Q2-2019-08-01,19,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Let me briefly touch on these components beginning with the first two, treating the whole person and investing in targeted innovation to meet the needs for more affordable personalized solutions. We see extraordinary opportunities to achieve better whole person health by building personalized solutions at scale in a way nobody else does. As we offer holistic, connected approach to addressing emerging threats to health.",1.7182277,0.804
CI-2019-Q2-2019-08-01,23,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","I'll provide two examples of the benefit of our integrated approach. The first relates to our work to address the mental health needs of first responders. 85% of firefighters, police officers and paramedics and other first responders have experienced symptoms related to mental health issues. However, many have trouble accessing coordinated local care.",1.6898562,0.542
CI-2019-Q2-2019-08-01,24,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","In a first of its kind initiative, we work closely with the City of San Diego, and local healthcare professionals to give first responders easy, coordinated access to behavioral wellness treatment. We're bringing together our capabilities with data and technology to help first responders cope with traumatic and high stress situations while on the job, thereby improving their overall health and well-being.",2.0575204,0.802
CI-2019-Q2-2019-08-01,25,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","The second example is our partnership with a large global client to help employees avoid work related stress. In this example, our client's employees are tasked with sorting through social media content, some of which can cause symptoms and health challenges similar to PTSD.",1.5864749,-0.25
CI-2019-Q2-2019-08-01,29,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Let's take a simple yet critically important example. We know that 50% to 60% of people with chronic illness, miss taking the medication, or take the wrong dose or discontinue treatment prematurely. The cost of inconsistent and incomplete care is staggering, $300 billion in the U.S. alone. Approaching almost 10% of what our country spends on annual health care costs.",2.1115429,-0.052
CI-2019-Q2-2019-08-01,30,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","One way we're addressing this challenge is by turning it into an opportunity, one individual at a time, leveraging technology to empower patients and providers to address condition specific challenges like diabetes, which impacts more than 30 million people in the United States.",1.1045472,0.831
CI-2019-Q2-2019-08-01,31,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Our glucose monitoring technology enables targeted clinical intervention for people with diabetes, by generating personalized real time analytics, and alerts to inform targeted outreach and coaching from our diabetes specialist pharmacist and clinical teams.",2.092499,0.273
CI-2019-Q2-2019-08-01,32,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Through our diabetes care value program, we provide physicians with the data they need to help people better manage their diabetes. In addition to improving the adherence and clinical outcomes, it also improves quality of life. And within our commercial plans, for example, those enrolled in this program saw a 4.3% decline in spending in 2018 versus a 4.1% increase for these conditions overall.",2.1581811,0.952
CI-2019-Q2-2019-08-01,33,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So, as you can see at Cigna, our focus on whole person health is more than just words. It's a clear strategic intent, a focused guide to action, and a catalyst for the development of products, programs and services. Additionally, our approach along with our technology and innovation capabilities has helped us create personalized, high impact, life changing solutions that truly matter to our customers and clients. These are just a few tangible examples of how Cigna is shaping and defining the future of health and wellness. One person, one provider, one client at a time.",1.9444229,0.938
CI-2019-Q2-2019-08-01,34,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Now to wrap up, Cigna delivered strong second quarter financial results, reflecting continued momentum across our businesses, including consolidated adjusted revenue of $34.4 billion, and earnings of $1.6 billion. Collectively our second quarter performance results gives us confidence again to raise our revenue and earnings outlook for 2019, representing a 17% to 19% EPS growth rate over Cigna's 2018 performance.",2.1566265,0.848
CI-2019-Q2-2019-08-01,35,Remarks,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Our strong results and our confidence in continued long-term sustainable growth are fueled by a portfolio of leading assets that we connect to provide more complete whole person care for those we serve. And as a result, improving affordability and predictability, as well as personalized quality and sustainability, as we drive for medical costs growth no greater than CPI by 2021.",1.9766809,0.963
CI-2019-Q2-2019-08-01,38,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Thanks, David. Good morning everyone. In my remarks today, I will review key aspects of Cigna's second quarter results and discuss our updated outlook for the full year.",1.6022278,0.7
CI-2019-Q2-2019-08-01,39,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Key consolidated financial highlights for second quarter 2019 include adjusted revenues of $34.4 billion, earnings of $1.6 billion after-tax, earnings per share of $4.30, reflecting continued growth and deepening of customer and client relationships across each of our businesses, underlying strength in medical and pharmacy cost performance, operating expense efficiencies, and the quarter was further aided by the favorable resolution of a tax matter. Second quarter results also included strong cash flow from operations, driven by continued strong execution across our businesses.",1.756378,0.961
CI-2019-Q2-2019-08-01,40,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Regarding our segments, I will first comment on Health Services. Second quarter revenues were $24 billion and pre-tax earnings were $1.16 billion. Results for second quarter reflect organic growth with the addition of 236,000 pharmacy customers in the quarter and $1.9 million customers on a year-to-date basis, strong volumes with 294 million adjusted pharmacy scripts fulfilled in the quarter and continued growth in specialty pharmacy, driven by strong volumes.",1.3197988,0.927
CI-2019-Q2-2019-08-01,41,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Overall, Health Services performed very well in the second quarter. Consistent with the seasonal ramp of earnings in this business, Health Services earnings in the second quarter were significantly higher than the first quarter. And as expected, Health Services earnings for the second quarter 2019 were lower than the Express Scripts second quarter 2018 earnings on a comfortable basis. We remain on track for a full year outlook for this business, and I'll provide more commentary on this momentarily.",1.2234998,0.541
CI-2019-Q2-2019-08-01,43,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our Integrated Medical segment, second quarter revenues grew 10% to $9 billion, driven by customer growth and deepening of customer relationships, premium growth reflecting underlying cost trends, and the inclusion of the Express Scripts, Medicare Part D business. We ended the second quarter with 17 million global medical customers, driven by an organic increase of 207,000 lives over second quarter 2018, led by growth in our select and middle market segments, partially offset by lower national accounts enrollment.",1.3496227,0.785
CI-2019-Q2-2019-08-01,44,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Second quarter earnings grew 8% to $1 billion, reflecting strong medical and specialty contributions and continued effective medical cost management.",1.3392023,0.751
CI-2019-Q2-2019-08-01,45,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our Medical Care Ratio or MCR, our second quarter MCR of 81.6% reflect strong underlying fundamentals including continued effective medical cost performance. Compared with second quarter 2018, our MCR increased, as expected, due to the inclusion of Express Scripts, Medicare Part D business, the pricing effect of the suspension of the health insurance tax, and a higher MCR in our individual business. As we've discussed previously, we expect margins in our individual business to be lower in 2019 than last year.",1.5274883,0.859
CI-2019-Q2-2019-08-01,46,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Second quarter 2019 Integrated Medical earnings benefited from $28 million pre-tax, a favorable net prior year reserved development, compared to $20 million pre-tax in second quarter 2018. Overall, Cigna's Integrated Medical segment delivered strong results in the second quarter.",1.5767158,0.751
CI-2019-Q2-2019-08-01,47,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our international markets business, revenue grew to $1.4 billion, representing 8% growth over second quarter 2018, on a currency adjusted basis. Second quarter earnings grew to $207 million, reflecting continued business growth and strong margins, partially offset by unfavorable foreign currency impacts.",1.838304,0.818
CI-2019-Q2-2019-08-01,48,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our Group Disability and Other Operations segment, second quarter revenues were $1.3 billion. Second quarter earnings for this segment were $149 million, driven by solid performance in both disability and in life.",1.769673,0.153
CI-2019-Q2-2019-08-01,49,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our Corporate segment, the second quarter 2019 loss was $453 million, primarily driven by $428 million of interest costs.",1.9787999,0.178
CI-2019-Q2-2019-08-01,50,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Lastly, I would note that the second quarter results include a $45 million non-recurring benefit from the favorable resolution of a tax matter. Overall, Cigna's second quarter results reflect continued strong revenue and earnings growth led by our Health Services and Integrated Medical businesses.",1.8929213,0.902
CI-2019-Q2-2019-08-01,51,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I'll now discuss our outlook for 2019. For full year 2019, we now expect consolidated adjusted revenues in the range of $136 billion to $137 billion. This represents an increase to our prior outlook of $2.5 billion to $3.5 billion, reflecting higher pharmacy contributions. Our increased revenue outlook for 2019 includes approximately $1.5 billion of incremental revenue from the transition of Cigna Pharmacy Script volume from OptumRx, which began in July.",1.771829,0.527
CI-2019-Q2-2019-08-01,52,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We now expect full year consolidated adjusted income from operations to be in the range of $6.34 billion to $6.46 billion, or $16.60 to $16.90 per share. This represents an increase of $0.25 to $0.35 per share over our prior expectation, and represents growth in the range of 17% to 19% over 2018. For 2019, we now project an expense ratio of less than 10%, which reflects additional revenue leverage, including the in-sourcing of pharmacy services from OptumRx, ongoing efficiencies, and administrative expense synergies.",0.0643191,0.872
CI-2019-Q2-2019-08-01,53,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For 2019, we now project the consolidated adjusted tax rate in the range of 23% to 24%, an improvement of 50 basis points from our previous outlook, primarily reflecting resolution of the tax matter, I mentioned earlier.",1.4929932,0.477
CI-2019-Q2-2019-08-01,54,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I will now discuss our 2019 outlook for the Health Services and Integrated Medical segments. For our Health Services business, we continue to expect full year pre-tax earnings in the range of $5.05 billion to $5.2 billion. Consistent with this outlook, we continue to expect Health Services earnings to be higher in the second half of 2019, than the first half due to several factors.",1.9281351,0.0
CI-2019-Q2-2019-08-01,55,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"First, we've executed a number of supply chain initiatives in the first half of the year that will take full effect in the second half. I would note that the impact of these initiatives is more heavily weighted to the back half of 2019 compared with the pacing of initiatives in 2018.",1.4552641,0.077
CI-2019-Q2-2019-08-01,56,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Second, in the second half of 2019, we expect continued strong performance in specialty pharmacy, including the full run rate benefit of specialty generics introduced earlier this year. And finally, the realization of administrative expense synergies associated with the Cigna Express Scripts combination. These second half growth drivers are partially offset as previously communicated by stranded overhead costs associated with the early termination of the Anthem contract.",1.5860582,0.836
CI-2019-Q2-2019-08-01,57,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We now expect adjusted Pharmacy Scripts in the range of 1.21 billion to 1.23 billion scripts, an increase of approximately 40 million scripts from our previous outlook. The increase to our script outlook reflects volumes we expect to transition from OptumRx in 2019.",1.8368667,0.557
CI-2019-Q2-2019-08-01,58,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Additionally, for Health Services, we now project a 2020 retention rate in the range of 97% to 98%, an increase of 50 basis points from the midpoint of our previous expectations as our innovative pharmacy solutions continue to resonate in the marketplace, and enable us to deliver greater value for those we serve.",1.3704635,0.869
CI-2019-Q2-2019-08-01,59,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our Integrated Medical business, we now expect full year earnings in the range of $3.78 billion to $3.85 billion, an increase of $50 million to $80 million from our previous outlook. This outlook reflects strength and growth in our businesses, driven by deepening customer relationships, industry leading medical cost trend performance, and well managed administrative expenses.",1.2504492,0.848
CI-2019-Q2-2019-08-01,60,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Key assumptions reflected in our Integrated Medical earnings outlook for 2019 include the following. Regarding global medical customers, we now expect 2019 growth of approximately 200,000 customers. Our updated guidance reflects continued growth in the select and middle market segments. Relative to previous expectations, while we continue to project attractive customer growth in middle market and international, our updated outlook now assumes lower growth in those segments.",1.7797341,0.878
CI-2019-Q2-2019-08-01,61,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to medical costs, for our U.S. commercial employer book of business, we continue to expect full year 2019 medical costs trend to be in the range of 3.5% to 4.5%. We continue to expect the 2019 medical care ratio to be in the range of 80.5% to 81.5%. I would note that our outlook for both medical costs trend and the medical care ratio is unchanged and is indicative of both stable underlying cost trends across our commercial and government businesses. And our leading approach to driving better clinical and cost outcomes through advanced consumer engagement, physician partnership and further aided by our combination with Express Scripts.",1.6140855,0.938
CI-2019-Q2-2019-08-01,62,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We also continue to expect solid contributions from our international markets, group disability and other businesses, as we continue to innovate in the marketplace and deliver a differentiated value for our customers. All in, for full year 2019, we now expect consolidated adjusted income from operations of $6.34 billion to $6.46 billion, or $16.60 to $16.90 per share, this represents 17% to 19% growth over 2018.",1.5432986,0.875
CI-2019-Q2-2019-08-01,63,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I would also remind you that our outlook continues to exclude the impact of future share repurchases and any additional prior year reserve development. Overall, our updated outlook reflects continued strong execution across our four differentiated growth platforms. Our 2019 outlook is also consistent with our multiyear growth expectations and we remain confident in our ability to achieve our 2021 earnings per share target of $20 to $21 per share.",1.4721524,0.949
CI-2019-Q2-2019-08-01,64,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now moving to our 2019 capital management position and outlook. As previously communicated, our top capital deployment priority is accelerated debt repayment, and we are on track to return our debt to capitalization ratio to the upper 30s by the end of 2020. On an ongoing basis, our capital priorities remain as follows: first, reinvesting back into our businesses for innovation and growth; second, strategic M&A on a targeted basis; and third, returning capital to shareholders primarily through share repurchase.",1.6945742,0.153
CI-2019-Q2-2019-08-01,65,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Consistent with these priorities in the second quarter, we deployed $1.3 billion to repay debt and we repurchased 2.6 million shares of stock for $406 million. Additionally, in July, we repurchased approximately 1.2 million shares for $196 million. Our debt to capitalization ratio was 47.2% as of June 30, 2019, down from 50.9% as of December 31, 2018.",1.6848724,-0.153
CI-2019-Q2-2019-08-01,66,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For 2019, we continue to project cash flow from operations of approximately $8 billion. In the year, we continue to expect to deploy approximately $4.2 billion to debt repayment. We continue to expect to have capacity for $1.5 billion of share purchases in 2019. And through the end of July, we had already deployed $1.1 billion of that total. Our balance sheet and cash flow from operations outlook remain strong as our capital efficient businesses continue to deliver attractive margins and returns on capital.",1.7290693,0.827
CI-2019-Q2-2019-08-01,67,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now to recap, our second quarter consolidated results reflect continued strong execution and focus on creating differentiated value for our stakeholders. We're well positioned to achieve the attractive financial targets we've established for 2019, and we maintain strong visibility toward our $20 to $21 earnings per share target for 2021.",1.4890406,0.947
CI-2019-Q2-2019-08-01,68,Remarks,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Further, our clear strategic focus, strong fundamentals across our businesses, and outstanding financial flexibility, give us greater confidence in our long-term targets for growth in revenue, earnings and earnings per share.",1.6891843,0.968
CI-2019-Q2-2019-08-01,73,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to the products and solutions, you should think about it as from that standpoint, the core of the franchise being leveraged against it. So the select framework, the middle market framework, targeted national accounts opportunities, and very importantly, Medicare Advantage opportunity. So we cross reference all of those. And then finally, we look at the individual or the public exchange business. So this is more on the integrated approach and the integrated side of the house. They're separate initiatives and separate focus on the health services portfolio side of the house.",1.8212204,0.874
CI-2019-Q2-2019-08-01,74,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So, successful past, attractive opportunities in front of us and the ability to leverage those product portfolios through core commercial, individual commercial and MA off of our successful collaborative accountable care relationships.",1.4360668,0.961
CI-2019-Q2-2019-08-01,76,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Josh, it's Eric. I would just think of the increase there as we've gotten additional visibility as we continue to move through the year and getting our clients lined up. We're really pleased with the progress that we've had and the dialogue that we've had with our clients, we think 97% to 98% is an outstanding result and pleased to be able to deliver that now two years running in terms of the retention in that segment.",1.3586058,0.938
CI-2019-Q2-2019-08-01,80,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, it's David. So, relative to the membership outlook for the medical customers. First, to be clear, we're very pleased with our track record of sustained commercial growth now that spans 10 years of sustained organic growth. For 2019, we recognize that our outlook is lowered a bit to 200,000 lives still an attractive result that is largely driven by lower commercial national accounts, and a little lower performance at the upper end of the middle market portfolio.",2.0878352,0.898
CI-2019-Q2-2019-08-01,81,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","I'd remind you that those buyer groups are typically less integrated offerings. We've retained outstanding focus in select and core middle market and as such, continue to have strong underlying life growth as well as specialty growth including behavioral, dental, pharmacy, et cetera.",2.0443063,0.929
CI-2019-Q2-2019-08-01,82,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates for the mix of business, we have seen a bit more guaranteed cost our risk business over the recent past to complement our ASO strength. And as you recall, we go to market with a diverse portfolio of funding mechanisms and offer choice, it's an inherent strength of our organization. And we believe that the sustained strong medical costs trend performance we've been able to deliver in the marketplace again, posting the lowest rate of growth year-in year-out is resonating well and we're complementing sustained ASO performance and Stop Loss performance with a bit higher guaranteed cost performance.",1.161679,0.735
CI-2019-Q2-2019-08-01,83,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director",We do not see that as a corollary to changes within the marketplace year-in year-out. That's a more sustained medical costs performance outlook for us. So good balance in funding mechanisms. And we think that'll continue to perform as we step into 2020.,1.7396036,0.493
CI-2019-Q2-2019-08-01,86,Question,2019-08-01,2,2019,Justin Lake,,"Thanks. Good morning. Appreciate the comments on the healthcare services result being above expectations. Wanted to follow up there and ask whether you can tell us how this business looked on a year-over-year basis adjusted for all the moving parts. Basically the same way you indicated, it was down modestly in the first quarter, at the Investor Day. And then given we're more than halfway through the year and all the focus on the PBM, I was hoping you might give us a view on where you expect to come in relative to the guidance range at $5.05 to $5.2. Any thoughts whether we should expect to kind of higher end or lower end given we're seven months into the year. Thanks.",1.0826659,0.9
CI-2019-Q2-2019-08-01,87,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Justin, it's Eric. I'll start here. So first of all, just to reiterate the second quarter results were consistent with or even a bit ahead of our expectations, and reflect the strong performance of the businesses there. And particularly strong, especially pharmacy performance and the growth in the volumes as we had expected. As you alluded to, the number of different items in terms of adjusting comparability for this year's second quarter versus Express Scripts standalone items that were reported last year. And I'd point you back to the same factors that we talked about at our Investor Day in terms of that reconciliation is being present here.",1.1972691,0.859
CI-2019-Q2-2019-08-01,88,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Also, as you might expect, there are number of different supply chain activities that were on hold kind of at the time period leading up to the close of the combination that we executed over the first part of this year. And we've got good visibility into those in terms of driving results in the back half of the year.",1.4092706,0.494
CI-2019-Q2-2019-08-01,89,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"So overall, that helps to inform the pattern. So year-on-year we'd characterize the results for the second quarter versus second quarter is down in the single-digits percentage for the quarter. And I'd note as we look ahead then, as you might expect in the third quarter, we expect the pattern to flip. We expect we'll be up mid-single digits, or single-digits in terms of the performance for the Health Services business relative to the Express Scripts piece from last year's third quarter.",1.4563421,0.434
CI-2019-Q2-2019-08-01,90,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,So we'll bring those capabilities online. The effect of the supply chain initiatives and such will drive us to the growth over the back half of the year.,1.7337406,0.382
CI-2019-Q2-2019-08-01,92,Question,2019-08-01,2,2019,Justin Lake,,"Okay. And, Eric, just to be clear, you said mid-single digits down in the second quarter?",0.1810641,0.542
CI-2019-Q2-2019-08-01,97,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Sarah good morning. As you may recall from Investor Day, we walked through a little bit of a crosswalk of some of the tools, levers, initiatives we've been executing now for many years to generate a lower medical cost trend in the industry at large. And you may recall Matt Manders walked through a framework that over the last seven years or so we've delivered about a 4% medical cost trend with the last few years being a little closer to 3%.",2.0722892,0.178
CI-2019-Q2-2019-08-01,98,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So point one is sustained, point two is trending downward or even more favorable going forward. We're not providing guidance for 2020. So I don't want to tell you anything is ratable. There's dynamism in the portfolio. We're pleased that here in 2019 we're setting about 3.5% to 4.5% medical cost trend outlook, which is by far and away best in the industry yet again, and we have a variety of tools and initiatives in front of us to step down that medical cost trend for the benefit of our clients, customers and patients as we look forward.",1.8103381,0.949
CI-2019-Q2-2019-08-01,99,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So, again, I don't want to talk about ratability, rather, the trajectory is positive, it benefits our clients and customers and enhances our overall value proposition.",1.8258842,0.847
CI-2019-Q2-2019-08-01,100,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","To the last part of your comment, I would not correlate the size, shape and scope of our portfolio and diversity of our funding mechanisms, we do not -- to be very clear, we do not view that a lower medical cost trend environment could generate less revenue growth, could generate SG&A deleveraging, that is not an issue that we worry about. And I would encourage you not to worry about that, in terms of the diversity of our portfolio and how we deliver services.",1.6004664,0.558
CI-2019-Q2-2019-08-01,103,Question,2019-08-01,2,2019,Kevin Fischbeck,Bank of America / Merrill Lynch,Great. Thanks. Just wanted to be -- you guys raised guidance by less like it's in the upside that we saw in the quarter. So I just wanted to see how you were thinking about that. Is there anything in the back half of the year that you're kind of now incorporating into the outlook?,0.9768802,0.848
CI-2019-Q2-2019-08-01,104,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Kevin, it's Eric. Well, first, I just note, we're really pleased with the strong results in the quarter and with being in position to be able to raise the guidance again for full year 2019. So I think the 17% to 19% growth coming off of a strong 18% is a good result and reflects the accretion from -- Express Scripts coming through and good momentum and the underlying business.",1.6144448,0.96
CI-2019-Q2-2019-08-01,105,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"In terms of the outlook pieces, the main thing I'd note here would just be around us continuously managing the rate and pace of our investments and capabilities and such for the future. And so we're taking the opportunity to continue to invest into capabilities and the like. So that'd be the main thing I'd call out in terms of a difference of how we're seeing the back part of the year versus our prior outlook.",1.6687028,0.649
CI-2019-Q2-2019-08-01,106,Question,2019-08-01,2,2019,Kevin Fischbeck,Bank of America / Merrill Lynch,"I guess, one thing that you did kind of change was -- that you're I guess now taking on or including taking on Cigna's, some of the Cigna's volume. It sounds like you're just really updating the revenue in the script number, you're not updating the earnings contribution at all. How should we think about that, and does bringing Cigna on add earnings contribution at some point in 2020 or 2021?",1.2888579,0.422
CI-2019-Q2-2019-08-01,107,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes, and that one, go back to some of the dynamics we talked about at our Investor Day in terms of the impact of once we're through the transition and such. But overall, would note and I think you've got the major dynamics, correct there, that the update to revenues, the update to script counts this year primarily are the impacts of the transition do not think of that as a driver in terms of net income as it relates to 2019.",1.5961193,0.71
CI-2019-Q2-2019-08-01,108,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Over time, we'd expect the transition to be slightly accretive as it gives us additional fixed cost leverage and the like, but in the short-term and the near-term, wouldn't really think of that as driving the bottom line income.",1.3007546,0.19
CI-2019-Q2-2019-08-01,113,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Peter, good morning, it's David. Let me take the first part of your question. I'll ask Eric to take the second part of your question. First, to be very clear, the three to five years, as you recall that was specific to the timeframe to drive the 25% growth in our go deep market. So you're correct in terms of isolating that acceptable.",2.0155461,0.866
CI-2019-Q2-2019-08-01,114,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","To the specific part of your question, we see tremendous growth opportunity in MA, starting in 2020. It will be driven by further in market growth and traction. Expanding into new markets. We have multiple new HMO markets and even more markets from a PPO standpoint, which is topic three, expanding into the PPO space.",2.0050525,0.791
CI-2019-Q2-2019-08-01,115,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","We had highlighted that that 10% to 15% organic customer life growth is our customer life growth over the near-term to intermediate long-term range, that's in front of us and we will be at the lower end of that range in 2020 as we ramp the initiatives going forward.",1.9238243,0.459
CI-2019-Q2-2019-08-01,116,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director",o you don't have to wait three to five years. But think about it the lower end of the range as we step into 2020 and ramping up as we go forward. I'll ask Eric to answer the second part of the question.,1.721337,-0.296
CI-2019-Q2-2019-08-01,117,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes, Peter, on the Part D benchmarks again, not providing the specific guidance in terms of 2020 at this point. But I would just know that the benchmarks were actually quite consistent with how we were thinking about them. There weren't any big surprises in terms of our view of where the benchmarks came through.",1.864894,0.557
CI-2019-Q2-2019-08-01,118,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Overall, we'll be in a better position to provide customer growth guidance as the full visibility into all the competitors positioning is kind of region by region comes into view. And we work through our marketing plans there, but overall, no surprises in terms of where the benchmarks came through.",1.9119655,0.318
CI-2019-Q2-2019-08-01,120,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","We haven't provided 2020 earnings guidance, we will do that as the year comes to a close. Step up in the overall portfolio will have attractive growth in our overall enterprise earnings portfolio for 2020 that guides us to 2021. So stay tuned for the guidance as we provide for 2020 from that standpoint, but we think we have a very attractive both growth and overall fundamental earnings profile for the business.",2.127089,0.875
CI-2019-Q2-2019-08-01,123,Question,2019-08-01,2,2019,Ralph Giacobbe,Credit Suisse,"Thanks, good morning. First just wanted to go to the MLR that came in a little bit higher, I know you contributed -- you attributed to a few of the different things it seemed like the incremental piece, maybe the individual business at least relative to kind of 1Q. If you could just maybe break out what you're seeing there, and maybe your commitment to expansion in that market? Thanks.",1.8697388,0.915
CI-2019-Q2-2019-08-01,124,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes, Ralph, it's Eric. On the loss ratio, so a couple of different comparison points to think about there. The biggest driver from a sequential perspective versus 1Q is just up to the normal seasonality of things as we work through the customers kind of coming through deductibles and working through that ramp.",1.6183974,0.103
CI-2019-Q2-2019-08-01,125,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"In terms of the drivers, in terms of the second quarter year-on-year, really three things that I would point to, and they're each about the same impact. So roughly a 30 each, that's the inclusion of the Express Scripts is being part of the loss ratio this year and not part of the calculation last year, the Part D business specifically, one. Two, the pricing effects of the suspension of the industry fee.",1.606899,-0.318
CI-2019-Q2-2019-08-01,126,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"And third, is the IFP, the individual segment margin this year versus last year. Each one of those three factors is about a third of the variants when we think about things quarter versus quarter.",1.4236436,0.0
CI-2019-Q2-2019-08-01,127,Question,2019-08-01,2,2019,Ralph Giacobbe,Credit Suisse,"Okay, that's helpful. And then just quickly wanted, I hope, you could flush out the lower enrollment growth commentary, specifically in select middle markets. I think you said in the prepared remarks, you've obviously had a lot of success there for some time and done well with sort of bundling your specialty lines. A lot more recently your peers have talked more aggressively moving in that direction. So, just hoping if you could give us a little bit of sense as sort of the competitive dynamic there both as it relates to sort of the medical side as well as some of those specialty lines in terms of competition. Thanks.",1.7910015,0.969
CI-2019-Q2-2019-08-01,128,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Ralph, good morning, it's David. Very specifically our select portfolio continues to perform very well. And within the select portfolio, you're correct, we go to market with a fully integrated solution. We'd remind you that we use the full breadth of the funding mechanisms that exists if you will, asking and allowing and working consultatively with our employer clients one by one to determine how they want to best finance their solution that resonates quite well for us. And then we continue to drive very good targeted innovation in our clinical programs and our coaching programs and our service programs, et cetera.",1.9401477,0.969
CI-2019-Q2-2019-08-01,134,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes, Gary, it's Eric. So I would say my commentary in terms of our expectation for growth on 3Q would be on an apples-to-apples basis. So once you take the Express Scripts reported numbers and adjust for the items that we talked about at the Investor Day our re-segmentation, the changes in terms of depreciation and amortization, the change in terms of the enterprise value initiative, and then the work from there. Once you get to that baseline, then we would grow from that baseline. That's the basis that we're speaking to.",1.7100252,0.807
CI-2019-Q2-2019-08-01,137,Question,2019-08-01,2,2019,Steve Tanal,Goldman Sachs,"Good morning, guys. You've obviously covered a lot of ground, I guess just one thing, maybe if you could give us a little bit more commentary on sort of MCR by line of business, maybe thinking year-on-year, but if you could just touch on sort of the key things there commercial, Medicare, Medicaid, how those performed relative to expectations.",1.757672,0.238
CI-2019-Q2-2019-08-01,138,Question,2019-08-01,2,2019,Steve Tanal,Goldman Sachs,"And then maybe just within that line thinking about all the good growth and market share gains you've had in the commercial risk side of the business, how are those margins sort of relative to the overall average or base business if you wouldn't mind commenting there? Thanks a lot.",1.6518519,0.872
CI-2019-Q2-2019-08-01,139,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Steve, it's Eric. So on the loss ratio it's kind of by business, actually, we really put both of them right down the middle. So consistent with expectations and consistent performance in both the commercial and the government business. So feel good about those. The Medicaid business is a small business for us, but has actually performed consistent with our targets as well. So, again, certainly no variation that I'd call out in terms of the commercial versus the government versus the Medicaid business, to note in the quarter.",1.6270212,0.507
CI-2019-Q2-2019-08-01,140,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And Steven, relative to the question relative to -- I think your -- second part of your question around the margins and margin differentiation by funding mechanism or type of business. If you step back from that, you may recall that our approach to the marketplace is such that we're a bit funding mechanism agnostic. So that enables our sales force our client managers, et cetera, toward client by client to determine the last step which is once the right solution is put in place in terms of clinical programs, network design, service program designs, et cetera. How do you want to fund and finance it.",1.7695297,0.382
CI-2019-Q2-2019-08-01,141,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So backing into that, that means that when you look at on an apples-to-apples basis, in general, the margins and the returns across the various funding mechanisms are attractive and have some similarity relative to them. There are some nuances, but think about the margins as being strong and differentiated in guaranteed cost. Think about the margins, that are being strong and differentiated in our core packaged ASO Stop Loss portfolio businesses. Hope that helps.",1.5938593,0.927
CI-2019-Q2-2019-08-01,146,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","A.J., it's David, let me take your first question. And, obviously, Eric will take the second piece of it. So your recollection is pretty clear, the 2019 selling season for the core pharmacy services business had higher volume of business on a relative basis. That's cycle time. So there's cycles on the contracts and it was a more intense cycle. And as Eric noted, just outstanding client retention. 2020 selling season, which is far into the season right now.",1.8884571,0.886
CI-2019-Q2-2019-08-01,150,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Sure. A.J., just on your seasonality, we're not providing a specific guidance in terms of third quarter versus fourth quarter. But there are a handful of items I'd point you to as you think about the expectations over the back part of the year.",1.5695293,0.318
CI-2019-Q2-2019-08-01,151,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"First of all, our Integrated Medical segment, as you know, has income that tends to be bias towards the early part of the year, just given the normal seasonal impact of deductibles and such. Second of all, the Health Services business tends to be biased later in the year due to both customer behavior and growth in script volumes and just the timing of generic launches. And we've talked about the ramp that we're on 1Q to 2Q to Q3 to Q4 over the year for that business.",1.1778656,0.026
CI-2019-Q2-2019-08-01,152,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"And additionally, this year specifically, you should expect the synergies to continue to build throughout the year and the impact of deleveraging to continue to play through the corporate segment over the course of the year. So those will be the major moving items that I'd think about as we look sequentially into the next couple of quarters.",1.5856989,0.34
CI-2019-Q2-2019-08-01,156,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Dave, it's Eric. So just on those pieces, I think you've got the math right there in terms of the moving pieces and the components. The things I would point you toward would be just the timing of which the prior year reserve development has kind of unfolded and in year development of cost, this year's second quarter versus last year's second quarter. Last year's second quarter, we had more in year development in the second quarter than we had this year, just to given the favor ability that we experienced an individual book of business last year.",1.646784,0.612
CI-2019-Q2-2019-08-01,157,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"So I really think of it more as an adjustment to the last year first Q -- first quarter to second quarter dynamic versus anything else going on this year, broadly would characterize the loss ratio dynamics in our second quarter this year is aligned with our expectations.",1.3176428,0.34
CI-2019-Q2-2019-08-01,159,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, it's David. So specific to national accounts first in the commercial space, so not in the server side of the equation, but in the commercial space. Let me remind you how we define national accounts because we define it differently than the marketplace. It's commercial only 5,000 or more employees that are multi-state. So very specifically that excludes large single state blocks of business where that's a fundamental part of our middle market business.",2.0785076,-0.103
CI-2019-Q2-2019-08-01,166,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Steve, it's Eric. So overall, with respect to the loss ratio, we continue to be on track for our full year guidance. We've got good visibility to achieving the loss ratio guidance. So, no change there. And as I pointed out, the dynamics in terms of the second quarter were fully contemplated.",1.0740208,0.312
CI-2019-Q2-2019-08-01,167,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now, specifically on a risk adjustment true up, we did record a risk adjustment item in the individual business in the second quarter this year, order of magnitude $40 million to $50 million pre-tax. So -- and that's an unfavorable true up, that was in the result this year. But again, in line with the expectations in terms of the margin being a bit more compressed in the individual business this year. And we continue to be on track for the full year outlook.",1.6270212,0.34
CI-2019-Q2-2019-08-01,171,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Alexa, it's Eric. So just to be clear, we did not say on a per script basis. We just talked about the aggregate dollars reported in the Health Services segment compared to an adjusted or recast, Express Scripts number to get it to an apples-to-apples basis. We're just talking about the total adjusted income from operations pre-tax will have growth in Health Services segment in the third quarter.",1.1961912,0.671
CI-2019-Q2-2019-08-01,174,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Hi Lance, it's David. First specific to specialty pharmacy, we're extremely pleased with the performance of our specialty pharmacy services that are delivered through Accredo. Just stepping back for a moment, as you know we deliver an exceptional patient clinical outcome and service outcome one patient at a time. And as such work to deliver the right affordability outcome and our overall costs outcome leads the industry from that standpoint. And this is a validation of the kind of satisfaction level. We have NPS approaching 80 patients that are in our high clinical coordination programs.",1.8814613,0.7
CI-2019-Q2-2019-08-01,176,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director",So strong underlying fundamentals is what you should think about growing it. Not expenses or otherwise through that lens.,1.939759,0.648
CI-2019-Q2-2019-08-01,177,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to your forward looking question, we do say the opportunity for further -- to your point either cross seller penetration opportunities. Because we're able to get the best of both companies. indisputably we get both more structural flexibility in terms of benefit and solution design, attached to the broad portfolio of Express Scripts capabilities, as well as even a further step function to the overall affordability proposition and clinical services proposition.",2.1301982,0.956
CI-2019-Q2-2019-08-01,182,Answer,2019-08-01,2,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Charles, it's Eric. I'll start on the kind of pacing item. We haven't provided any specific expectations there other than just the aggregate numbers that we've talked about. So as I noted in my prepared remarks, think about the in-sourcing is worth $1.5 billion over the back half of the year, and $40 million to $45 million in scripts coming through over the back half of the year associated with the transition. I'd also refer you back to the material we used at our Investor Day a couple of months back now in terms of the complete impact once we get to 2021, in terms of the volumes and such there.",1.4214876,0.422
CI-2019-Q2-2019-08-01,185,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Everything we are seeking to do in terms of leveraging the best of both companies is seeking to deliver improved affordability off of a basis of strength. So, importantly, directionally aligned with the initiatives to seek to improve more affordability and choice from that standpoint.",1.7120093,0.943
CI-2019-Q2-2019-08-01,187,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So we're highly engaged and aligned with improving overall affordability. And the structure of our technology and innovative solutions puts us in good position, not just to react to but actually be in a leadership position as the programs change.",1.6537116,0.741
CI-2019-Q2-2019-08-01,191,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","David, good morning. So, a variety of attributes in your question. Stepping back, our orientation relative to benefit design, specialty design, mail order incentive, or design, et cetera. It's a one client at a time approach.",2.1469102,0.813
CI-2019-Q2-2019-08-01,192,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So I'll try to give you a macro piece, but really importantly, we do not go to market with a product or a preferred solution offering and try to force it, we try to work one client at a time, whether it's a commercial client or health plan client from that standpoint, and try to design what works for them based upon the strategy, the culture, the need set, et cetera. And to your point, we pull from a broad portfolio of capabilities around that.",1.8476487,0.746
CI-2019-Q2-2019-08-01,193,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to design, more receptivity today than ever relative to pursuing value based care or value based reward configurations, especially in the specialty environment. That may lead to a little bit more focused on some of the subspecialties and recall that Accredo is not for example, one Specialty Pharmacy, there's 15 sub-specialty pharmacies within that that specialize based on health or disease burden from that standpoint.",1.9067237,0.887
CI-2019-Q2-2019-08-01,195,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","But I can't tell you that mail order is kind of binary going from more intensified approach in 2020 than it was in 2019. There is receptivity, but it's client-by-client from that standpoint. And we think that's an inherent strength of our company to be consultative from that standpoint.",1.7396036,0.649
CI-2019-Q2-2019-08-01,197,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Thank you. So briefly just to wrap up our call, I'd like to highlight some of the key points from our discussion. Overall, we're very pleased with our second quarter results, which continue to demonstrate momentum across our portfolio of businesses.",1.9766809,0.862
CI-2019-Q2-2019-08-01,200,Answer,2019-08-01,2,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And we are on track to deliver our $20 to $21 EPS objective in 2021 as we expect to deliver 10% to 13% on average annual EPS growth over the long-term. In addition, we continue to drive cost trend to a level in line with CPI by 2021. We thank you for joining our call today. And we look forward to our further discussions.",1.6696463,0.625
CI-2020-Q1-2020-04-30,9,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks Will and good morning, everyone. Thanks for joining our call today. I'd like to begin by acknowledging the unique and unprecedented challenge of COVID-19's global pandemic and the tireless effort of those on the frontline caring for patients in need. At Cigna, we have worked to ensure the health and safety of our customers, patients and collogues and we will continue to partner across the system to lead through this crisis.",0.5996891,0.922
CI-2020-Q1-2020-04-30,10,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","While the COVID-19 emergency understandably and rightfully dominates much of our focus, we do want to take the advantage of our time together today to provide you with an update on our first quarter results and our outlook for the balance of 2020. Following my comments, Eric will share more detail about our first quarter financial results and expectations for the balance of 2020. Then we'll take your questions.",0.3960358,0.273
CI-2020-Q1-2020-04-30,11,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Let's begin by discussing the rapid and decisive steps we've taken to respond to the COVID-19 crisis. From the beginning of this health emergency, we established three primary goals for response efforts, first and foremost, to attend to the needs of our stakeholders across the globe. For customers and patients we've taken steps to remove costs and barriers for testing a treatment, ensure they have access to the medications and expand access to care including through additional telehealth services for medical, behavioral and recently for dental health.",0.7901283,0.318
CI-2020-Q1-2020-04-30,12,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","For clients, we've leveraged our consultative approach and proactively provided them with support and services they need. This includes serving as trusted advisors for those seeking guidance and how to navigate this dynamic and challenging environment and providing relief for those in financial distress. For our healthcare provider partners, we've given them administrative as well as targeted financial support. Additionally, in partnership with New York Life, we've created the Brave of Heart Fund for the true heroes of the COVID-19 crisis.",0.9113875,0.96
CI-2020-Q1-2020-04-30,13,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","This fund, with contributions from our respective foundations aims to provide $100 million or more in monetary and other assistance to frontline health care workers, their support teams and the families. We're proud to have taken this action which reinforces the service orientation of both Cigna and New York Life, as we work together on an accelerated basis to bring peace of mind to the brave men and women who are so valiantly serving our communities.",0.6579868,0.957
CI-2020-Q1-2020-04-30,14,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Additionally, for 70,000 colleagues around the globe, we've also taken appropriate steps to protect their health and well-being. For example, we are providing premium pay for those essential workers whose jobs continue to be Cigna site dependent. And we're providing 10 additional days of emergency time off to cover absences related to the virus and allow our co-workers to care for themselves and their loved ones during this challenging time.",0.3517295,0.854
CI-2020-Q1-2020-04-30,15,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Our second goal in responding to COVID-19 crisis is to ensure that we maintain a healthy organization that is well positioned to deliver significant value for all of our stakeholders today and into the future. We know and appreciate the fact that many are depending on us now more than ever, and we need to be there for them in this time of crisis and beyond. We're focused on balancing all of these needs and ensuring we maintain strength of our franchise by continuing to invest in growth, our cape abilities, ongoing innovation and in our talent.",0.4469491,0.958
CI-2020-Q1-2020-04-30,16,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Finally, another key goal of our response to COVID-19 crisis is to ensure we are a proactive part of the solution partnering both at national as well as local levels. We've played an active role in driving a high level of collaboration across government, not for profit and private sector organizations in response to this pandemic. While we are proud of our response to date, we will continue to drive our entire organization to give voice to and work for the benefit of our key stakeholders.",0.4935873,0.91
CI-2020-Q1-2020-04-30,17,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Now, turning briefly to our results, our first quarter results were strong, consolidated adjusted revenue grew to $38.4 billion and after tax earnings grew to $1.76 billion, including high single digit earnings growth in our Health Service business, which was somewhat ahead of our expectations. Our team achieved these results through focused execution of our business strategies and by continuing to expand key relationships and partnerships and working to make healthcare more affordable, predictable and simple.",0.744656,0.869
CI-2020-Q1-2020-04-30,18,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Now, the strength of our first quarter results driven by the performance of our underlying fundamentals reinforces our confidence that our well positioned diverse Health Service portfolio will again deliver attractive top line and bottom line growth in 2020, including strong cash flows. As such, we are reaffirming our full year EPS outlook of $18 to $18. 60. Well, the impact of COVID-19 is still developing, we clearly see headwinds driven by the recession it's causing, including, for example, disenrollment within our commercial customers, both in our Integrated Medical business as well as our Health Service business, as well as some pressure in our Group Disability business.",0.5790906,0.965
CI-2020-Q1-2020-04-30,19,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","As for medical cost, we expect somewhat offsetting impacts from elevated COVID-19 claims cost and lower medical cost from deferred procedures. We fully recognize this is a dynamic environment. However, we expect the strength of our first quarter to drive us to another strong year for revenue, earnings and free cash flow. All while we continue to invest in and support the needs of our key stakeholders. As we look forward, there is no doubt that COVID-19 pandemic has highlighted opportunities for improvement in the healthcare system, which we believe will accelerate change in our industry.",1.7322192,0.93
CI-2020-Q1-2020-04-30,20,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","This evolution is likely to usher in a new call for an embrace of innovative and disruptive solutions, a new wave of broadened partnerships, and a need for even greater levels of differentiated value in the marketplace. At Cigna, we have both the capabilities and orientation to further differentiate ourselves in this rapidly evolving industry. The work we've done to harness the full capabilities following our combination with Express Scripts has positioned us to deliver exceptional value for the benefit of our customers, patients and clients in an environment that is demanding solutions to health care's most pressing problems.",0.8764089,0.867
CI-2020-Q1-2020-04-30,21,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","To achieve this, we have deep and broad clinical strength from our medical, behavioral and pharmacy services, and broad data and insight capabilities. In addition, we have substantial financial strength and capital health, aided by our capitalized framework. As we have positioned our company, not to be tied to capital intensive investments in bricks-and-mortar assets or care delivery ownership. This gives us tremendous strategic flexibility and positions us to drive forward with solutions that make healthcare more affordable, predictable and simple for those we serve. Our approach is further fueled by our partnership orientation.",0.6579868,0.935
CI-2020-Q1-2020-04-30,22,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Recent examples include, MDLIVE and Buoy Health, each of which make it more simple for individuals to access care. With MDLIVE for example, earlier this year Cigna became the first partner to offer virtual care for annual checkups. And as the COVID-19 crisis evolved, we temporarily transferred hundreds of our nurses and physicians to MDLIVE to further expand their capacity. With Buoy Health, in January we harnessed Buoy's capabilities to quickly launch an early intervention tool, which is now available to assess COVID-19 risk for individuals in the US. With this innovative technology, customers can assess their symptoms and make informed decisions about their next steps for care all within the comfort and safety of their homes. MDLIVE and Buoy Health are just two recent examples of our broad portfolio of partnerships around the world.",0.6910222,0.924
CI-2020-Q1-2020-04-30,23,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Now to summarize, Cigna's strategic framework provides us with the foundation to respond quickly and effectively to the COVID-19 health emergency, all while we delivered strong first quarter results. We have expanded our services and support for customers, patients, clients, healthcare partners, colleagues and communities. All while continuing to ensure that our company remains well positioned to deliver value whenever and however it is needed, both today and into the future. This fuels our expectations of delivering sustained attractive top line and bottom line growth in 2020 and continuing in 2021.",0.5926934,0.957
CI-2020-Q1-2020-04-30,24,Remarks,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Now, none of this would be possible without the hard work and dedication of our colleagues around the globe. Every day, their commitment and passion embodies our mission to improve the health well-being and peace of mind to those we serve. This has never been more clear and defining than over the last several months, as they've stepped up in countless ways to support the needs of our key stakeholders around the globe at a time when they most need us.",0.3968131,0.912
CI-2020-Q1-2020-04-30,26,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Thanks David and good morning everyone. In my remarks today, I'll briefly review key aspects of Cigna's first quarter results, discuss our outlook for the full year inclusive of the impacts and our response to the COVID-19 pandemic. And although my remarks today will be primarily financially focused, I'd like to acknowledge that in full alignment with Cigna's mission strategy during these uniquely challenging times our company is focused on serving the needs of our customers, our clients and our providers, as well as ensuring the safety of our employees.",0.5019763,0.959
CI-2020-Q1-2020-04-30,27,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now regarding our first quarter consolidated results, a few key financial highlights include adjusted revenue of $38.4 billion, adjusted earnings of $1.76 billion after tax, adjusted earnings per share of $4.69 and continued strong operating cash flow of $1.9 billion. Cigna's first quarter results reflect the underlying strength of our businesses and the value we deliver to our customers and clients.",0.3848365,0.878
CI-2020-Q1-2020-04-30,28,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Within our business segments, Health Services, Integrated Medical and International, all performed at or somewhat ahead of our expectations. But also note that given the timing of the pandemics onset and progression in the United States, its impact to first quarter results was limited. Overall, Cigna's first quarter results demonstrate the strength of our diverse portfolio of businesses, each of which remains intensely focused on improving the health, well-being and peace of mind for those we serve.",0.4725117,0.927
CI-2020-Q1-2020-04-30,29,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now, as we look to the balance of 2020, I'd start by observing that at Cigna we fully recognize that we are in unprecedented times as we navigate the ongoing COVID-19 pandemic. And I'm proud of the many ways that Cigna's responding with an acceleration of our efforts in the marketplace to make healthcare more affordable, predictable and simple. We're partnering across the ecosystem and we are leading in providing resources and services as well as in adapting plan designs to ensure we're meeting those needs.",0.310097,0.778
CI-2020-Q1-2020-04-30,30,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Aided by our strong and diverse portfolio of businesses, we're reaffirming our full year 2020 outlook for consolidated adjusted revenues in the range of $154 billion to $156 billion. And to put some additional context around our full year expectations or adjusted earnings per share, I'd remind you that Cigna ended 2019 with considerable strength and momentum across their businesses. And that carried through the first quarter, with strong underlying fundamentals, evident in both results above our previous expectations and in the meaningful amounts of capital we deployed, including ongoing reinvestment for growth, debt repayment, and returns to shareholders through share repurchase.",0.1897233,0.939
CI-2020-Q1-2020-04-30,31,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We recognize the COVID-19 pandemic presents challenges for all businesses and Cigna's no exception. In the first quarter, we saw the onset and incidence of virus begin to ramp globally. But its pace and the diversification of our businesses resulted in a limited impact. Over the balance of this year, we expect headwinds to our performance from the pandemic to include declines in customers across our Commercial Employer and Health Services businesses relative to our prior expectations and some unfavorability in our Group Disability business.",0.3823212,-0.422
CI-2020-Q1-2020-04-30,32,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Regarding medical costs, we expect higher costs associated with COVID-19 treatment offset by lower levels of utilization related to the deferral of procedures. Now, it's important to note that we serve 85% of Cigna's US Commercial customers through self-funding arrangements. And as such, our medical cost performance is highly aligned with our clients. The quarterly progression of earnings within Integrated Medical will vary somewhat from historical patterns, with lower utilization expected in the second quarter and an expectation of elevated services in the back half of 2020.",0.1171398,-0.382
CI-2020-Q1-2020-04-30,33,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"From an enterprise perspective, I'd highlight that we continue to expect strong volume growth this year in Pharmacy Services, Specialty Pharmacy Care, and in Medicare Advantage, all while we continue to drive overall expense efficiencies. These considerations underscore the strength and diversity in our portfolio of businesses, which continue to deliver solutions directly aligned with marketplace needs throughout the year. We will continue to invest in innovation and in capabilities to serve our customers and clients and to have the ability to flex to meet their needs.",0.0927057,0.972
CI-2020-Q1-2020-04-30,34,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Impacts from COVID-19 to our financial outlook will be influenced by the duration and the extent of the pandemic and the related economic and employment challenges. We will continue to monitor developments related to the pandemic as we progress through the year and are committed to supporting our customers, clients, health care partners and communities that they confront the many challenges this environment presents.",0.2468559,0.872
CI-2020-Q1-2020-04-30,35,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"To enable our customers and clients to better afford in access care, we are working to customize our solutions and arrangements, as well as leveraging our partnerships with the healthcare delivery system. Taken as a whole, we continue to expect full year consolidated adjusted earnings per share in the range of $18 to $18.60.",0.1404959,0.878
CI-2020-Q1-2020-04-30,36,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I would also remind you that our financial outlook excludes the impact of future share repurchases and any additional prior year reserve development and also assumes a full year of contributions from our Group Disability and Life business, although we continue to expect our divestiture of that business to close in the third quarter. Overall, these expected results are driven by strong underlying fundamentals, disciplined expense management, and deployment of capital, partially offset by pressures associated with the COVID-19 pandemic.",0.1347467,0.494
CI-2020-Q1-2020-04-30,37,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now, moving to our 2020 capital and liquidity position and outlook, our capital efficient businesses generate a substantial amount of cash flow, which provides us with financial flexibility, particularly in times of stress. In the first quarter, we generated $1.9 billion of cash flows from operations. We also deployed $1.1 billion to debt repayment in the first quarter. And on a year-to-date basis, we have repurchased 5.9 million shares of stock for $1.1 billion. For 2020, we continue to expect greater than $7.5 billion of cash flow from operations, reflecting the strong capital efficiency of our well performing businesses.",0.2296083,0.906
CI-2020-Q1-2020-04-30,38,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Looking to our liquidity and flexibility, as of March 31, 2020, we had $1.6 billion of cash available to the parent. In April, we entered into a term loan for $1.4 billion to further enhance our current liquidity position in light of disruptions in the commercial paper market. We feel very good about the cash flows that our businesses generate and our overall liquidity. And I would also note that we have access to an additional $4.25 billion in committed and untapped revolving lines of credit.",0.0927057,0.784
CI-2020-Q1-2020-04-30,39,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Finally, we're on track to close the sale of our Group Disability and Life business in the third quarter, generating $5.3 billion in net proceeds, which we expect to deploy to share repurchase and debt repayment in 2020. Our debt to capitalization ratio was 44.7% as of March 31, down from 45.2% as of December 31 of 2019. And we remain on track to return our debt to capitalization ratio, the upper 30s at the end of 2020. Our balance sheet and cash flow outlook remain strong, benefiting from a highly efficient service based orientation to drive strategic flexibility, strong margins, and returns on capital.",0.2270931,0.778
CI-2020-Q1-2020-04-30,40,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now, to recap, against the challenging backdrop of the COVID-19 pandemic, Cigna's intensified our focus on delivering exceptional value for the benefit of our customers, patients and all of our stakeholders. We're fully committed to ensuring the safety of our employees, providing continuity of services for our customers and clients and working collaboratively with physician partners. We're also doing so while seeking to deliver differentiated sustainable value back to our communities. We ended 2019 with strength across our diversified portfolio of global businesses, which we carried through to a strong first quarter performance.",0.4408911,0.966
CI-2020-Q1-2020-04-30,41,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"The fundamentals of our business are strong and durable, which positions us very well to support our customers, clients, healthcare partners, and communities in this challenged and dynamic environment. Although mix of these contributions is somewhat different, we expect these strong fundamentals across a diverse portfolio of businesses to enable us to manage through the various impacts of the current environment. And as such, we're reaffirming our full year adjusted EPS outlook for 2020 and remain committed to our objective of achieving $20 to $21 of earnings per share in 2021.",0.9144808,0.947
CI-2020-Q1-2020-04-30,42,Remarks,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"With that, we'll turn it over to the operator for the Q&A portion of the call.",2.0384477,0.0
CI-2020-Q1-2020-04-30,45,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","A.J., good morning, it's David, good to hear your voice. Hope you and your family are well. So for 2021, to put context first and foremost, you know that we established that target when we announced our combination with Express Scripts over two years ago, and since then we have remained on track to achieve it. We recognize and doubt that the current environment is highly disrupted. Although we believe the goal is both achievable and remains an appropriate target. You're correct. I wouldn't use the word cushion. I would use the word momentum and strength. So we've been able to effectively execute our integration and that remains on track and performing quite strong, the core businesses within our portfolio, our service oriented portfolio with diverse solutions and diverse funding mechanisms to be able to flex in a very dynamic marketplace and environment from that standpoint. And when we look at our performance stepping in through 2020, we consider our first quarter results through and then carry through the month of April. As we look at our results, we believe that target is still appropriate and achievable from that standpoint, I would note clearly inferred in your comment, the biggest wildcard for every industry is the - would be the depth and breadth and duration of a global recession. So that crystal ball no one has perfectly, but the ballast of our business portfolio and high performing diverse business portfolio gives us confidence that that's the proper target.",0.3536728,0.958
CI-2020-Q1-2020-04-30,49,Answer,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Gary, it's Eric, I'll give you a couple of perspectives on that. So overall, we're really pleased with the performance of the services - Health Services business in the first quarter. As David noted, a minute ago, we've made really good progress in terms of the transition of the Cigna Life again and continue to work on integration and the like. You referenced kind of the impact of any amounts that were pulled forward and things along those lines. I would note that we had approximately 5 million scripts or 1%, 1.5% of the volume that we ended up having in the first quarter. That was - we view as being pulled forward from later periods, so we point to that as a relatively modest impact in terms of the impact of the results in the first quarter. And more generally, we just come back to strong results and continued traction in terms of integration program. At last, I would not call out any additional synergies or differences there versus our prior expectations.",0.6241466,0.936
CI-2020-Q1-2020-04-30,52,Question,2020-04-30,1,2020,Ralph Giacobbe,Credit Suisse,"Thanks. Good morning, David, I was hoping you could expand your thoughts on sort of the lingering or long-term consequences of COVID and just the potential impact and how you see it to your business both in terms of employer appetite or not for risk bearing ASO versus fully insured, that holistic approach that you kind of bring to the market with your suite of products. And then just your positioning and interest in segments of the market like individual or Medicaid or where you've historically been a smaller player. Thanks.",0.6393324,0.959
CI-2020-Q1-2020-04-30,53,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, Ralph. So if we step back, I think one of the perspectives that the current environment reinforces is the power of an importance of the role of the employer. So stepping back, we need to understand the fact that for an employer to have a vibrant business, they need healthy, productive, present highly engaged co-workers. And in some way the crisis actually reinforces the role of the employer in terms of creating a safe environment, but an environment that actually creates a healthy environment and an environment that has a level of productivity and engagement. And I for one I'm just pleased to see how corporations have stepped up relative to co-worker safety, co-worker engagement protocols, even the number of employers that have stepped forward where they had employment dislocation by maintaining continuity of benefits. So point one is we see that is quite important.",0.4003109,0.988
CI-2020-Q1-2020-04-30,54,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to the funding mechanism, I don't see a broad swing. We don't project forwarded broad swing. Having said that, we maintain a diverse portfolio of funding mechanisms and we offer choice for employer clients on a regular basis that has been and that will continue to be a strength, so our ability to have the flexibility we think is quite important, but we don't see this broadly swinging one way or the other from ASO to guarantee costs or vice versa.",0.5281772,0.767
CI-2020-Q1-2020-04-30,55,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to segment expansion, we've positioned our business portfolio to be able to continue to expand, so our Health Service portfolio is really critical strategic expansion. We're offering a broad array of services, both to corporate clients, health plans, governmental entities and increasingly over time, healthcare delivery infrastructures on all sorts of products and programs and services we see as mission critical, so cutting across funding mechanisms up through Medicaid from that standpoint.",0.279829,-0.596
CI-2020-Q1-2020-04-30,56,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And then finally, we've systematically expanded our individual business and our biases to do so. And as you'll note, my final comment is from the past, we see over time, the state base risk bearing program or performance based program is an additional growth opportunity for us, if there is high level of clinical engagement, clinical coordination, so we like our positioning. Appreciate the role of the employer, employers are stepping up big in the marketplace today taking care of their employees as best they can and dynamically doing so. And we see for the growth opportunities in our core chassis in our expanded Health Services as well as individual programs.",0.6121259,0.98
CI-2020-Q1-2020-04-30,59,Question,2020-04-30,1,2020,Justin Lake,,"Thanks. Just wanted to - I have a question and also a follow up. So just first to follow up on A.J's question around 2021, can you talk specifically about the building blocks that are going better, that will offset the potential headwinds to employer growth? And then my question was around share repurchase. You bought a bunch of stock in the first quarter. Can you talk about the turn potentially into April? Can you tell me about the timing of that first of all? And then given that it looks like the repurchase is a little bit bigger than I would have expected. Can you talk about, one, is that a personal purchase that's tied to the - are you buying back with proceeds that you expect to get from the Disability sale in the third quarter? And anything about a potential pause into repurchase relative to what you were seeing kind of others do out there would be helpful as well? Thanks.",0.6696224,0.936
CI-2020-Q1-2020-04-30,60,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Justin, you have packed a lot in there. So let me take the first and make a qualitative comment on the second, but ask Eric to take the second question. Broadly speaking, we're not going to walk through the detailed building blocks for 2021. We'll do that when we get into providing detailed guidance for 2021. I would ask you to consider going back and looking at the Investor Day walkthrough that Eric provided. And he put forth the building blocks that exists in terms of cross walking us from '19 to '20 to '21 from that standpoint. I'll remind you of a few just as illustrations for the broader audience, right. The impact of deleveraging, we know it, we understand it, it's more within our control versus not the impact of synergies, we know it, we understand it. Our integration program is well in track and well in hand, our impact of capital deployment, before we get into the foundation and fundamental pieces of the equation from that standpoint.",0.3116984,0.71
CI-2020-Q1-2020-04-30,61,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And then finally, inverting your comment was the effective disenrollment, two comments. One is what we're seeing thus far and it's just that thus far is both in our Integrated Medical business as well as in our Health Service business. For those corporate employers who have had co-worker dislocation, fully half of those employers are maintaining continuity of benefits, either through the word furlough or by having layoffs, but with benefit continuity, which reinforces an expectation of a more short lived effect, as well as the roles that the employers are playing. And then finally, related to that our health service portfolio gives us a much broader level of services to offer to the marketplace, as opposed to being held to just Integrated Medical sale versus not.",0.5989118,0.887
CI-2020-Q1-2020-04-30,62,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","The qualitative comment I'd give you on stock repurchases. I hand it over to Eric for more specifics is we recognize the dynamic dynamics of the environment. Just two points, one, our stock repurchase that was done in the first quarter was largely done before the COVID-19 epidemic spiked up intensely in the United States. And secondly, given the unique nature of having a large strategic divestiture, which is what we have for later this year. That is a more unique event where the responsible thing to do is to put that capital back in our shareholders hands largely because it is a unique onetime event from that. But I'll ask Eric to expand a little further on the repo.",0.4333463,0.927
CI-2020-Q1-2020-04-30,63,Answer,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"David, thanks, and Justin, I hope you're doing well. With respect to the share repurchase, as you noted, we did deploy just over a billion dollars over the course of the first quarter. And really think of that as - back in the framework that I've talked about in terms of our use of capital and touched overall for the year, right. So between the cash flow from operations that we expected to generate, as well as the proceeds from the group divestiture that we expect to close in the third quarter, we talked about having both of those as sources of capital available for deployment and that we would navigate toward year-end debt to capitalization ratio of below 40% and reduce the share count to effectively offset the portion of the year where we don't have the group business so that the impact would be neutral on EPS for the year. And we've got flexibility in navigating through that. And that's the framework in which we deployed the capital in the first quarter.",0.6263026,0.954
CI-2020-Q1-2020-04-30,65,Question,2020-04-30,1,2020,Kevin Fischbeck,Bank of America / Merrill Lynch,"Great, thanks. Just wondering I guess we can all kind of do the math on how the recession will impact the health benefits side of the business. But I guess if you could talk about the Health Services side a little bit more? It's not 100% clear to me how that business would be expected to perform in a recession, so any color you can give on kind of typical declines in utilization per person during a recession, as well as kind of your overall membership mix within that, how much of that businesses is related to commercial numbers versus serving Medicare or Medicaid numbers for your customers? Thanks.",1.1445682,0.657
CI-2020-Q1-2020-04-30,66,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Kevin, good morning, it's David. Appreciate your question. Broadly speaking, we would see it just in terms of painting a macro picture relative to traditional integrated corporate facing medical and integrated benefits a little less disruptive versus not. Why? Point two is think about that business is serving corporate clients, typically larger corporate clients. Secondly, health plans with diverse portfolios of services from commercial through Medicare, Medicaid and other governmental programs and then a large government contract. Second, in the services that it provides, those services are somewhat foundational in nature. So the pharmaceutical utilization broadly speaking that individuals need do not change dramatically as a result of a recession.",0.30548,0.568
CI-2020-Q1-2020-04-30,67,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","It's not a deferrable event typically from that standpoint, so it has a bit more balance in terms of both the diversity of the client base that exists within it and then the core foundational aspect that comes along with it. As I noted to a prior question, as well, we're seeing in the Health Service space that for those corporate clients, and I'll ask Eric to give you a little bit more color in terms of broader split in a second, for those corporate clients. Those that actually have had a reduction in workforce, fully 50% of them are maintaining benefits on behalf of those individuals. So headline, we see it is a bit less disrupted from a recession versus the traditional business you would think of in terms of measuring it against for the reasons I mentioned. I'll ask Eric to just give you a little bit more color in terms of splits.",0.9867859,0.288
CI-2020-Q1-2020-04-30,68,Answer,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yeah, so Kevin, it's Eric. Maybe a couple of things I would add here to David's answer. So first of all, we did provide some statistics in terms of a little bit of a makeup of kind of the distribution of scripts across the different channels and such. In fact, in the Investor Day last year, an order of magnitude about 400 million of the scripts associated with the commercial business, so though a meaningful block of business to be sure, but one of several different components of the book of business that we have within Express Scripts, so pretty well diversified. I think David covered the dynamics in terms of the consistency of the volumes and such for the benefit of our patients and such. I think maybe the last thing I would note is just the positive impacts of mail order that that we experienced in the first quarter and we think will be durable. Yeah, right. So as we've talked about for some time, mail order carries with it a number of benefits, right, better dispensing accuracy. Once you get on mail order, you're more likely to stay with your prescription that helps to keep gaps in care from being remaining open or being open and such. And obviously we've got a quite a leading operation in terms of the home delivery pharmacy. So we feel really good about the ability to use that to help serve our customers as well.",0.5443766,0.995
CI-2020-Q1-2020-04-30,72,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Yeah, George, I appreciate it. And it's a bit of a different dynamic that we're confronting on a whole variety basis. So let's maybe unpack that a little bit. First, on the cost side of the equation, headline answer is no. So what I mean by that is, your inference of a falloff in medical costs is that similar to the fall off in pharmacy costs, no, because in furthering your comment is the fall off in medical costs is correlated to the deferrable experiences of medical, there's not a similar one-for-one correlation in pharmacy as relates to fall off. Now, there may be a small amount if there's a deferrable procedure, and there would have been a follow on script of that individual retaking on the back end that procedure, but by and large, I would separate those two as having a different effect in the different impact.",0.6459386,0.19
CI-2020-Q1-2020-04-30,73,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Specific to the disenrollment dynamic, put one is what we see is corporations and it's an important pause moment in the United States, corporations we see are really striving to where it all possible, take care of their co-workers and see this as ideally a more temporary dislocation of their business. And hence want to maintain continuity or tethering, meaning ties, positive ties with the co-workers as such fully 50% both in our Integrated Medical and our Health Service business or maintaining benefits with their employees from that standpoint, not with a 30 day timeline currently, obviously, there'll be re-visitations of that from that standpoint, but it's sort of full on expectation of those individual corporations expecting - fully expecting to bring business back.",0.8690245,0.854
CI-2020-Q1-2020-04-30,74,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","You'll also note - bring employees back when the business comes back. You'll also note that part of the Federal narrative right now is around stimulus evolution and regulatory evolution is providing further evaluation of providing further incentives and subsidies to employers beyond the small employer subsidy around the benefit continuity because the data would show that the benefit continuity is better for society at large by keeping people healthy in the first place from the transition standpoint. So point is it's a unique time corporations are reaching I think constructively where at all possible, both large, medium and small where possible to maintain that level of continuity and evolving governmental posture around providing additional incentives or support to be able to do so. Hope that's helpful?",0.6362223,0.97
CI-2020-Q1-2020-04-30,78,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Ricky, I appreciate your framing. Clearly there's a lot of scenarios. In close there's uncertainty, so we agree on both. I don't think it's constructive to take multiple different hypothetical's and then try to pinpoint how an individual lever would move within that scenario in a given point in time, but we recognize and I appreciate your framing, there are multiple scenarios that exist. Our view is that is we've played through a variety of scenarios and a variety of sensitivity tests in understanding what we have within our control running our business that the reaffirmation of our EPS as well as our revenue outlook is appropriate for 2020. And as I noted to the prior questions, the leverage we have within our control, as we best understand the environment right now for 2021 that that target is also appropriate and achievable for a corporation from that standpoint.",0.4698795,0.968
CI-2020-Q1-2020-04-30,79,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","The last thing I would say is the whole notion relative to a second surge or otherwise, we've seen elevated experiences now that society is adjusting to and we would expect to see further adjustments in both clinical protocols, community protocols, the way in which businesses operate from a more flexible standpoint and we would expect to see further accelerated evolution of treatments ideally beginning to be introduced to the market in the second half of this year as well, but having said that, we continue to believe that our outlook for 2020 is an appropriate outlook and a seeable outlook for us.",0.195103,0.467
CI-2020-Q1-2020-04-30,82,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, Robert, it's David. So let me frame that in two dimensions, Health Services and then a little bit of walk over to Integrated Medical. But specific Health Services, we're delighted, we're pleased with the strength and we would view the 96% to 98% expectation for retention rate yet again for 2021 to be really, really strong. Now that's delivered with - as a result of sustained strong service delivery, sustained strong pharmacy cost delivery and ongoing innovation. And wrapping around that the team could be consultative in working with our clients. Specific to that retention rate, I would remind you that first, you should expect that the health plan portfolio business, those renewals largely complete and largely completed before the spike of COVID-19. So I would not correlate that result to a passivity or reluctance of people to evaluate the marketplace. Secondly, the large corporates within that portfolio, also more meaningfully renew on the earlier side of the timeline versus not.",0.127089,0.975
CI-2020-Q1-2020-04-30,83,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Now bridging to your comment, this disruptive environment, I think creates a higher hurdle rate, all other things remaining equal for a corporation or a benefits manager to introduce even more disruption to their world. I think that's a basic solid tenet to take place because of so much disruption. However, we still see business moving and that comment carries from Health Services across the Integrated Medical because at its core, employers in the case of this comment now are still looking for differentiated value and being able to bring them whether it's an innovative offering or a coordinated Health Service offering they can deliver innovative step function value, that affordability, predictability and simplification is even more important today, but all things remain equal. I think your basic tenet is right from this point going forward. In terms of the selling season, there's a bit of a higher hurdle to get across. I just wouldn't draw that conclusion up against the Health Service renewal of 96 to 98% because so much of that was then completed before the spike of the epidemic.",0.4959192,0.598
CI-2020-Q1-2020-04-30,87,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Hey, Josh, good morning, it's David. I appreciate the way you frame the question. So point one is really strong start to the year. Fundamentals are strong across multiple of our business portfolios. And as in the case in most quarters, there were some items that you could call out is potentially being non-run ratable. Point two, within our International business there was a large favorable item that came through that aided further the strong fundamentals within the business. Having said that, we believe the outlook is both appropriate, achievable and prudent given that we're a bit ahead of our own expectations and the Street's expectations in the first quarter, given the uncertainty that exists in the latter part of the year. So strong fundamentals, top line, bottom line aided by some items that are non-run ratable and take the International item as an example, but added to a strong quarter within International. And as we take it all into consideration, we think it's prudent to maintain our EPS outlook at this point in time, given the uncertainty and potential puts and takes in the second half of the year.",0.5697629,0.936
CI-2020-Q1-2020-04-30,93,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Hey, Scott, good morning, it's David. I'll grab that. And if I missed anything, I'll ask Eric to add to. Great question, so stepping back as you articulate we're global Health Service company, so we did have an early look into the COVID-19 dynamic, including our own co-workers in Wuhan. It's a city where we had a meaningful number of co-workers. I highlight two specific learnings that we're able to take starting from that, but not limited to that and carrying it forward. And then I'll give you a little bit on your specific question relative to the medical cost a little bit more difficult. Point one is we're able to learn and everybody's learning how to dynamically flex a global workforce pretty darn rapidly into a work at home environment. But not just a simple work in home environment, a work in home environment with the technology, infrastructure, connectivity and then workflows to keep the execution transpiring not just in terms of the base of the business, but ongoing innovation, some of the creative work that needs to transpire from that standpoint. Second, indisputably, we're able to learn and retest the imperative around public private partnership.",0.6910222,0.962
CI-2020-Q1-2020-04-30,94,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","In every country we operate in, you see, the public private partnership is being integral to being able to respond to this from worksite management, to workers safety, to testing access, testing protocols, to treatment, to community support, et cetera, et cetera, et cetera. So we saw that in country after country after country, which we'd like to believe that helped us be in position in the United States to be able to expect that proactively reach out for that and engage. As it relates to the medical cost dynamic, we see more of that through our global employer businesses covering the globally mobile population. It's a large business, but it's thin across the globe. So you see really small snippets and bytes of that everywhere, as opposed to a density of that, broadly speaking from that standpoint. And my final comment would be, even in the markets that had the earliest onset we see consumer behavior coming back pretty rapidly, quite rapidly as it relates to the activation of the consumer, from a social interaction standpoint, to the consuming services to the sale process, including your individual sale process. Eric, anything to add?",0.6373883,0.905
CI-2020-Q1-2020-04-30,100,Answer,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yeah, Steve, it's Eric. I'll start here. Overall, I think step to recognize this is a bit unprecedented, right. So stepping into this, I think the things we've been looking at here are, one, it's a pretty different set of dynamics across different geographies. So I think understanding the path and approach across different geographies and how this plays out across different geographies. I would just note, I think there'll be variations there. As the COVID impact, certainly been more impactful in some geographies than others. I think that will lead to more disruption in some geographies than in others, so to start with that one. Two, I think we would view that there will be some things that are deferred out of the second quarter, as I noted in my prepared remarks that will come into the back half of the year. Now, I don't think it'll necessarily be one for one. I mean, in terms of all of the things that were deferred from the second quarter are occurring in the third and fourth quarters, but it's appropriate to think of at least some of those coming back in the back half of the year. And as we continue to progress through this, we'll be working to refine our estimates and PTO posted as we think about it. David, I don't know what else you'd add there.",0.1800216,0.833
CI-2020-Q1-2020-04-30,101,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Yeah, I agree with your comments for sure. I would remind you, Steven, specifically for our business, I ask you to remember 85% of our commercial business is ASO. So our employer clients are seeing and aligned with what we're experiencing from that standpoint. And even when you carry that forward to our MA portfolio, today, approximately 85% of our MA customers are in a value based relationship with the healthcare system from that standpoint. And then a final thought is we need to think about the capacity, right, the healthcare systems capacity to either get back to its prior level of utilization service fulfillment versus a massive uptick in that over a short period of time, and I don't mean that in a coded way, we need to recognize the fact that our healthcare delivery system is taxed right now. Different dimensions of it are taxed, but some facilities are redeploying surgeons and otherwise who are not doing deferrable procedures in doing triage procedures or virtual care from that standpoint. So as Eric noted a lot of uncertainty here, but important for us we're aligned with our employer clients, and they'll see the benefits of that aggregate cost experience in the first half of the year and a bit more reversion in the second half of the year based upon the scenarios we're operating with right now.",0.551885,0.889
CI-2020-Q1-2020-04-30,103,Answer,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Scott, its Eric, some of our - some of the most effective markets, you could see care deferrals or reduction in cost of as much as 30% for the first few weeks in April.",0.4814948,0.765
CI-2020-Q1-2020-04-30,107,Answer,2020-04-30,1,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Okay. Hey, David, it's Eric. I'll start and then ask David if he wants to add anything else on here. And overall, broadly, I wouldn't point to the current COVID pandemic as a driver in terms of the membership results, we reported from a first quarter perspective overall. And again, just stepping back a little bit, we note we're really pleased with the continued customer growth in the Select segment. So on a year-on-year basis up about 10% in terms of now versus where we were a year ago. We've talked about it in a lot of different settings. This is a business that grows continuously throughout the year, right. So we've got pretty consistent growth quarter in quarter out to get good momentum there, I mean, on a year-on-year basis as well you're up a bit in mid market, so it's again, you're pretty consistent performance there. So again I wouldn't point to any disruption in the first quarter actual as we as we think about the pandemic dynamic at any broad scale. David, what else would?",0.6352857,0.965
CI-2020-Q1-2020-04-30,108,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Yeah, the only thing I'd add is - just reaffirm the point which I think is sometimes maybe lost is the Select segment ramps throughout the course of the year. And we can see the value proposition and the complicated offering we have in that space is resonating quite well.",0.5934707,0.571
CI-2020-Q1-2020-04-30,112,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Charles. Good morning. Let me try to kind of compartmentalize your question here. So I think you're building a little bit of an off the digital formulary and then you referenced the telehealth services et cetera. So maybe stepping back, the digital formulary was an innovative offering, is an example of one of many innovative offerings I should say, where we're trying to seek to help our clients, meaning corporate customers and health plans as they seek to utilize that as well as our customers in terms of making more informed decisions. So the digital formulary has a specific purpose to take the curate and digital applications that are out there to 300,000 plus and growing and try to evaluate them against specific criteria.",0.3696075,0.922
CI-2020-Q1-2020-04-30,113,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","More broadly inferred in your statement, which I agree with is society at large has been aggressively ramping appetite for more personalized, simplified, convenient ways of accessing services, information and increasingly care. So with telehealth wasn't that long ago that I think we as a society would be using telehealth as a small slice of triage intervention. And the COVID-19 epidemic is reinforcing to us it could be a larger portion of an overall integrated or coordinated healthcare offering. And we see that as a big part of both today and the future. We like our positioning both partnering as well as having proprietary capabilities. And as I noted, we were the first to offer annual checkups. We brought to market a dental capability, et cetera, around that.",0.3832103,0.791
CI-2020-Q1-2020-04-30,114,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And then lastly, just wrapping the example around it, with the Buoy Health capability that we're able to bring to market very rapidly is another way of harnessing both through partnership, but putting the customer or patient front and center and providing an actionable, virtual tool with which to assess oneself and make informed decisions going forward from that standpoint. So big picture is we see a re-envisioning of what we call the front end of care, the way in which individuals access both information as well as the care system as having a tremendous opportunity to harness new technologies, tools and capabilities, which start with virtualization, and carrying that through a part of the coordinated care delivery system. And we like our positioning by not being tethered to or beholden to whether it's bricks-and-mortar or care fulfillment resources that will be in conflict with that. And the appetite right now is high and the satisfaction level from consumers who are experiencing that is quite high. And we think that will grow going forward.",0.3089778,0.983
CI-2020-Q1-2020-04-30,116,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So fair question, I'd say stay tuned for more, but to give you a little bit of framing relative to it. We do some telehealth today on our own platform, so the Cigna Medical Group out in Arizona today is fulfilling approximately 80% of all our patient experiences today through either telephony or video interaction and less than 20% of their fulfillment is taking place through physical interaction during the COVID environment, so we can see that firsthand. Secondly, we've co-developed telehealth capability with some of our more advanced value based healthcare partners in certain markets, having said that, we have successfully partnered on scale. Bigger picture, expect to see us be oriented around at a minimum, the IP or Intellectual Property, the data, the data management, the data algorithms, the predictive capability to deliver the personalization, the clinical quality, we're going to be more oriented around that and then open architected to own some and then partner with some in very different ways to be able to bring it to the marketplace to offer the respective choice. Hope that helps?",0.6844151,0.98
CI-2020-Q1-2020-04-30,118,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Thank you. And thanks everyone for joining our call today. I want to start by acknowledging again the tireless efforts of all the frontline workers of the COVID-19 crisis for their selfless and caring nature for the patients that they're servicing. From Cigna's perspective, as we lead through this crisis, we will continue to attend to the needs of our stakeholders across the globe, work to maintain a healthy organization that is well positioned to deliver significant value to all of our stakeholders both today as well as into the future and ensure that we work to be a proactive part of the solution, partnering in both national and local levels.",0.1484648,0.938
CI-2020-Q1-2020-04-30,119,Answer,2020-04-30,1,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Relative to our performance, our team achieved strong results in the first quarter, through focused execution of our business strategies and by continuing to expand our key relationships and partnerships and working to make healthcare more affordable, predictable and simple. This fuels our expectations of delivering sustained, attractive top line and bottom line growth in 2020 and continuing this growth in 2021. With that, we thank you for joining the call. We wish you safety and health during these challenging times for both you and your family members and we look forward to future discussions.",0.1519627,0.974
CI-2021-Q3-2021-11-04,8,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks, Alexis. And thank you to everyone for joining us on our call today. This morning I'm going to spend a few minutes talking about our strong results for the quarter, how we are advancing our growth strategy, and I'll provide some additional perspective on our 2022 outlook, and then Brian will share some more details about our third quarter results and our outlook for the remainder of the year, and then we'll take your questions. Let's jump in. During the quarter we delivered adjusted revenue of $44 billion, and adjusted EPS of $5.73 per share, all while continuing to reinvest back in our business to fund growth, expansion, and ongoing innovation, and we continue to return significant value to our shareholders.",0.3513408,0.969
CI-2021-Q3-2021-11-04,9,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","These results reinforce we are delivering for our customers, our patients, clients, provider partners, as well as for you, our shareholders. With our high performing health service portfolio and sharp focus on executing our strategy, we are confident in our ability to continue driving growth and are again raising our full-year 2001 guidance for adjusted EPS and revenue. Our performance is strong, considering the ongoing impact of the pandemic on medical costs, as well as the higher claims we've experienced amongst the special enrollment period or SCP customers within our individual business.",0.7306646,0.946
CI-2021-Q3-2021-11-04,10,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to our MCR in the quarter, our commercial business did improve from the second quarter to the third quarter, and our Medicare Advantage business also improved sequentially. We continue to execute a series of actions in 2021 and 2022 to further improve our MCR. And Brian will walk through this in more detail in a few moments. Separately in early October, we also announced an agreement with Chubb to sell our Life, Accident and Supplemental Benefits business in our international markets platform in 7 countries from $5.7 billion -- $5.75 billion. We expect to realize about $5.4 billion in net after-tax proceeds and to complete the transaction in 2022 following regulatory approvals.",0.3000389,0.912
CI-2021-Q3-2021-11-04,11,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Guided by our strategy and similar to our 2020 divestiture of our group insurance business, this transaction unlocks the value of the best-in-class leading asset, while also enabling us to even more sharply focus our business on health and well-being services. So overall, our performance for the quarter reflects our clear strategy and strong execution and delivering attractive results, and importantly, our ongoing commitment to prioritize and support the evolving health and well-being needs of those we serve. Now, I'll walk through some additional detail for our Evernorth and U.S. medical businesses.",0.9366498,0.96
CI-2021-Q3-2021-11-04,12,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","A year-ago we launched Evernorth to tip the marketplace as our health service platform, focused on servicing health plans, employers, government organizations, and healthcare providers. Since that time, Evernorth has established itself with unique partnerships and innovative services that are resonating with multiple buyer groups. Our Evernorth pharmacy and our medical offerings through our U.S. medical platform are the 2 primary gateways through which most of our clients and customers form their base relationship with us.",0.6684804,0.718
CI-2021-Q3-2021-11-04,13,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Wrapping around these two exceptionally strong platforms are additional suites of Innovative Health Services through Evernorth, including benefits management, care solutions, and intelligent solutions. These help us to expand and deepen existing relationships. In the third quarter, Evernorth retained and expanded our relationship with the Department of Defense TRICARE pharmacy program, and renewed a 7-year contract. It's our privilege to serve almost 10 million active-duty service members, retirees, and their families.",0.3894287,0.974
CI-2021-Q3-2021-11-04,14,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Evernorth will continue supporting TRICARE pharmacy operations, including specialty pharmacy services, military pharmacy claims, and retail network pharmacies. The new contract also allows for expansion of specialty and care coordination services through 2029. As we look to the balance of the year and into 2022, Evernorth will continue to grow revenue and earnings. Turning to our U.S. Medical platform. In U.S. commercial, our teams are leveraging in deploying the innovative solutions from Evernorth to expand our service offerings and address the evolving needs of our clients and customers.",0.703459,0.9
CI-2021-Q3-2021-11-04,15,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","For example, in our U.S. commercial platform, we are leveraging Evernorth 's MDLIVE capabilities to expand virtual care options for our customers through their employers with primary, urgent, behavioral, and dermatology care. As part of these value-based arrangements during virtual visits, MDLIVE physicians are leveraging our Evernorth intelligence capabilities, enabling them to provide more connected and coordinated experience. And we continue to expand our capabilities with MDLIVE as we recently launched a virtual-first health plan for employers.",0.4768752,0.937
CI-2021-Q3-2021-11-04,16,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Another great example of Evernorth in U.S. commercial partnering to bring more value to our health plan clients is a new arrangement we have with University of Pittsburgh Medical Center Health Plan. We will make in-network care available to UPMC customers who live, work, or travel outside their network service area. UPMC has been an Evernorth pharmacy client for 16 years, and this agreement illustrates how we are collaborating across our enterprise to deliver greater affordability and differentiated value for health plan clients.",0.3909833,0.958
CI-2021-Q3-2021-11-04,17,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","We are pleased how the market continues to recognize the value we are delivering through our broad suite of solutions, and as such, we continue to grow through both our U.S. commercial and Evernorth platforms. Within Medicare Advantage, consistent with our strategy, we continue to grow in our existing markets and are expanding into new geographies. Our progress is further supported by our overall value of our offerings. For the 2022 calendar year, 89% of our Medicare Advantage customers will be in 4-star or greater plans nationally.",0.5468325,0.952
CI-2021-Q3-2021-11-04,18,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","This is the highest level we've ever achieved, and it marks the 5th year in a row we've improved our stars performance. And at our Individual and Family Plan business, we've driven strong growth in this year, increasing customers by 47% through the third quarter. A substantial portion of this growth did come from the extended special enrollment period. As I previously noted, some of the MCR impact in the third quarter was driven by the medical cost, amongst those we added during the outpaced SEP growth.",0.1418578,0.949
CI-2021-Q3-2021-11-04,19,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director",We do expect this will moderate in 2022. We are positioning ourselves to build on this momentum in the individual and family plan business by expanding our addressable markets again as we enter in 3 new states and 93 new counties in 2022. These new markets offer the potential to reach an additional 1.5 million customers. The continued strength of our results and the growth we're generating through the execution of our strategy gives us confidence we will deliver against our commitments in 2021.,0.7975126,0.866
CI-2021-Q3-2021-11-04,20,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","We will deliver EPS in line with our long-term targets and revenue growth well above our long-term targets for yet another year. We will also deliver EPS within our long-term target range in 2022. Specifically, for 2021, we are committed to delivering our increased guidance for full-year adjusted EPS of at least $20.35. For full-year 2021, we remain on track for generating at least $7.5 billion of cash flow from operations and we expect to return more than $7 billion to shareholders in 2021 through dividends and share repurchase.",0.5829771,0.844
CI-2021-Q3-2021-11-04,21,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Looking to 2022, we expect to grow EPS by at least 10% off of our increased 2021 guidance of at least $20.35 per share. We anticipate a number of tailwinds, including core growth in our business and additional contributions from margin expansion in our U.S. Medical business as we drive pricing actions, execute affordability and efficiency initiatives and benefit from the return of Medicare risk adjustment revenue to more normalized levels. We're also expecting year-over-year headwind as we plan for net investment income to be more in line with historical levels.",0.662262,0.863
CI-2021-Q3-2021-11-04,22,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And of course, the rate and pace of ongoing strategic investments will vary from year-to-year. In short, 2022 will be another strong year for Cigna. Now to briefly summarize, as we've demonstrated through the quarter, and throughout 2021, we are delivering for our customers, patients, clients, and provider partners as they experience the ongoing challenges of the pandemic.",0.491644,0.557
CI-2021-Q3-2021-11-04,23,Remarks,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","We're also taking significant value enhancing actions, such as divesting a portion of our international business, returning substantial amounts of capital to our shareholders, and continuing to strategically invest in our capabilities and strategic partnerships. All of which position us to continue to advance our long-term growth agenda and continued to deliver shareholder value. With that, I will turn the call over to Brian.",1.0909444,0.84
CI-2021-Q3-2021-11-04,24,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"Thanks, David. Good morning, everyone. Today, I will review key aspects of Cigna 's third quarter results, including the ongoing impact of COVID-19 on our business. And I will discuss our updated outlook for the full year. During the quarter, total medical costs were higher than our expectations within our U.S. Medical segment. Driven largely by the impact of the Delta variant in our U.S. commercial business and increased medical costs for special enrollment period customers in our U.S. individual business. Importantly, I would remind you that approximately 80% of our revenues are from service-based businesses that are not significantly exposed to medical cost fluctuations.",0.2473013,0.903
CI-2021-Q3-2021-11-04,25,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"Our balanced portfolio and multiple levers for value creation resulted in Cigna 's overall revenue and earnings exceeding our third quarter expectations. This strong third-quarter performance, coupled with capital deployment activities, led to an increased outlook for full-year 2021, which I will discuss shortly. Now, turning to Enterprise results, key consolidated financial highlights in third quarter 2021 include adjusted revenue growth of 9% to $44.3 billion, adjusted earnings growth of 20% to $1.9 billion after tax, and adjusted earnings per share growth of 30% to $5.73.",0.3405299,0.951
CI-2021-Q3-2021-11-04,26,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"Results in the third quarter reflects strong top and bottom-line growth with contributions across all of our businesses, with overall performance above our expectations. I will now discuss our segment level results, and will then provide an update on the details of our outlook, as well as our capital positioning. Regarding our segments, I'll first comment on Evernorth. Third quarter 2021 a adjusted revenues grew 13% to $33.6 billion. A adjusted pharmacy script volume increased 8% to 411 million scripts, and adjusted pretax earnings grew 7% to $1.5 billion compared to third quarter 2020.",0.3503435,0.872
CI-2021-Q3-2021-11-04,27,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"Evernorth strong results in the quarter were driven by organic growth, including strong volumes in retail and specialty pharmacy, along with ongoing efforts to improve affordability for the benefit of our clients, customers, and patients. And deepening of existing relationships, partially offset by significant strategic investments to support ongoing growth, including our virtual care platform and technology capabilities.",0.3925417,0.973
CI-2021-Q3-2021-11-04,28,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"Overall, Evernorth continues to create differentiated value for clients and customers, while driving overall revenue and earnings growth that exceeded our original expectations through the first 3 quarters of 2021. Turning to U.S. Medical. Third quarter adjusted revenues were $10.5 billion and adjusted pretax earnings were approximately $1 billion. Overall, our U.S. Medical earnings exceeded our expectations during the third quarter, reflecting the impact of favorable net investment income and increased specialty contributions, partially offset by higher claim costs due to the net impact of COVID-19, and increased medical costs for special enrollment period customers in our individual business.",0.313052,0.947
CI-2021-Q3-2021-11-04,29,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"The net effect of these claim cost impacts produced a medical care ratio of 84.4% in the third quarter. Looking ahead, we are actively managing overall medical costs and our MCR with the range of actions. Including continuing to leverage our insights from our strong data and analytics capabilities to address key drivers and identify opportunities such as guiding customers to more effective and efficient sites of care.",0.1776251,0.964
CI-2021-Q3-2021-11-04,30,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"Continued discipline in our pricing and rate actions, and we're also continuing to promote preventative care and access to behavioral services to provide meaningful support to patients, and moderate overall medical costs over the longer term. Turning to membership, we ended the quarter with 17 million total medical customers, an increase of approximately 368,000 customers year-to-date. In U.S. Medical, the year-to-date customer growth was driven by net growth in select and middle markets within U.S. commercial and continued organic growth in Medicare Advantage and individual within U.S. government. In our international markets business, third quarter adjusted revenues were $1.6 billion and adjusted pretax earnings were $250 million.",0.6123651,0.963
CI-2021-Q3-2021-11-04,31,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"These results were in line with our expectations. Corporate and other operations delivered a third quarter adjusted loss of $275 million. Overall, Cigna's broad portfolio of services continues to serve the needs of our customers and clients. Cigna remains committed to delivering value for all of our stakeholders, leveraging our well-positioned businesses. Now, turning to our updated outlook for full-year 2021. We are raising our adjusted earnings per share guidance for full-year 2021 to at least $20.35 per share, reflecting the strength of the quarter, the favorable impact of our year-to-date share repurchase, and acknowledgment of the ongoing fluidity of the broader environment.",0.5112856,0.92
CI-2021-Q3-2021-11-04,32,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"This represents EPS growth of at least 10% from 2020, consistent with our long-term EPS growth range of 10% to 13%, even with the ongoing challenges associated with COVID-19 and while having significantly increased our dividend in 2021. As we look forward, it is clear that COVID-19 will continue to have an impact in the fourth quarter and in 2022. And as time progresses, COVID related impacts and the ongoing performance of the business are becoming more intertwined.",0.4298332,0.848
CI-2021-Q3-2021-11-04,33,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"Therefore, we no longer believe it's instructive to continue to quantify the impact of COVID-19. These dynamics are fully contemplated in our 2021 expectation for adjusted EPS of at least $20.35 and our 2022 expectation for EPS growth of at least 10% off this 2021 guidance. Turning to revenue, we now expect full-year 2021 consolidated adjusted revenues of at least $172 billion, representing growth of at least 11% from 2020, when adjusting for the divestiture of our group disability in Life business.",0.9931305,0.625
CI-2021-Q3-2021-11-04,34,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"I would note this revenue growth rate significantly exceeds our projected long-term average annual growth goal of 6% to 8% and represents the third consecutive year of significant revenue outperformance since our combination with Express Scripts in late 2018. I will now discuss our 2021 outlook for our segments. For Evernorth, we continue to expect full-year 2021 adjusted earnings of at least $5.8 billion representing growth of at least 8% over 2020, reflecting the significant value we create for our customers and clients.",0.2252208,0.917
CI-2021-Q3-2021-11-04,35,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"For U.S. Medical, we continue to expect full-year 2021, adjusted earnings of at least $3.5 billion. Underlying this updated outlook, we now expect the 2021 medical care ratio to be in the range of 84% to 84.5%, which includes our expectations for elevated medical costs for individual special enrollment period customers. Regarding total medical customers, we continue to expect 2021 growth of at least 350,000 customers. Now, moving to our 2021 capital management position and outlook.",0.2595682,0.818
CI-2021-Q3-2021-11-04,36,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"We expect our businesses to continue to drive strong cash flows and returns on capital even as we continue reinvesting to support long-term growth and innovation. For full-year 2021, we continue to expect at least $7.5 billion of cash flow from operations, reflecting the strong capital efficiency of our well-performing businesses. Year-to-date as of November 3 rd 2021, we have repurchased 26.5 million shares for $6.3 billion. And we now expect full-year 2021 weighted average shares of approximately 342 million shares.",0.6388616,0.967
CI-2021-Q3-2021-11-04,37,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"This includes the impact of the $2 billion accelerated share repurchase that we announced in the third quarter. On October 27th, we declared a $1 per share dividend payable on December 22nd to shareholders of record as of December 7th. Our balance sheet and cash flow outlook remains strong, benefiting from our highly efficient, service-based orientation that drives strategic flexibility, strong margins, and attractive returns on capital.",0.3091266,0.955
CI-2021-Q3-2021-11-04,38,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"So now to recap, results in the third quarter reflects strong top and bottom-line growth with solid contributions across our businesses. Cigna has shown the ability to deliver value through dynamic environments with our breadth of businesses and multiple earnings levers. We continue to support our customers, clients, and coworkers, and deliver on our financial commitments.",0.0407262,0.95
CI-2021-Q3-2021-11-04,39,Remarks,2021-11-04,3,2021,Brian C. Evanko,CFO,"We now expect 2021 full-year adjusted earnings of at least $20.35 per share, representing growth of at least 10% from 2020, consistent with our long-term EPS growth rate range of 10% to 13%, and we expect to grow 2022 adjusted EPS, at least 10% off our raised 2021 guidance. With that, we'll turn it over to the Operator for the Q&A portion of the call.",0.0147203,0.751
CI-2021-Q3-2021-11-04,41,Question,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks. Hello, everybody. Just maybe to try to drill down a little bit on that expectation for at least 10% growth of the new updated numbers for this year. I know it sounds like you're getting away from talking about that $250 of net COVID impact you're absorbing this year and others various inputs there, but I was wondering, because their last quarter it sounded like you were carrying a lot of your expectation for COVID related costs broadly defined into next year. As you think about your updated thoughts about '22, can you comment on how much of ongoing COVID headwind are you expecting and is there any other big changes to the puts and takes you'd laid out last quarter as you think about '22?",0.7909056,0.128
CI-2021-Q3-2021-11-04,42,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hey A.J., good morning. It's David. Let me try to shape our insights relative to 2022, now that we're much deeper into 2021. First, you're right earlier this year, we've tried to frame the magnitude of the headwind and indisputably COVID had many disruptions to the marketplace, whether it's testing, treatment, revenue, dislocation, etc.",0.7361057,0.892
CI-2021-Q3-2021-11-04,43,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Against that backdrop, as you know, our broad service portfolio and a broad funding mechanism continued to perform quite well, and we're able to deliver from a marketplace standpoint. If you think about 2021, there's really four big chunky items. One was up pulling the headwind category. The headwind created by the COVID cost and the headwind created by MRA revenue decrement. And then, positives offsetting that somewhat which were favorable net investment income and some operating expense items.",0.3711621,0.772
CI-2021-Q3-2021-11-04,44,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Now as we think about and look at the 2022 environment, our visibility in terms of our growth outlook, our rate execution, our affordability initiatives, our efficiency initiatives, and our understanding of how this year is coming to close, broadly speaking, those puts and take in 2021 largely offset one another as we step into 2022, the headwinds and tailwinds. Our at least 10% growth in 2022 off of our elevated 2021 EPS, essentially represents capital deployment in line with our strategic target of 4% to 5% of accretion.",0.6513797,0.778
CI-2021-Q3-2021-11-04,45,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And the residual at least 5% to 6% from fundamental operating growth to get us to that at least 10%. To recap, additional visibility in terms of the drivers for 2022 growth -- mix of growth, rate execution affordability. And then secondly, the puts-and-takes in 2021 are configuring in a way that they've largely offset one and other as we step into 2022, underscoring that at least 10% is largely fundamental for our business portfolio.",0.0540225,0.836
CI-2021-Q3-2021-11-04,48,Question,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks very much, and good morning. David, I just wanted to better understand how you're thinking about the Ever-north business as we think about 2022? I know you've talked in the past about some of the business losses, but if you can give us an update as to how to think about Ever north going into 2022, and then as we think about the Ever-north business and think about the virtual primary care offerings that are out in the marketplace, what are you thinking with MDLIVE?",1.2697241,0.926
CI-2021-Q3-2021-11-04,49,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, Lisa. So relative to Ever north, first as we step into 2022, as Brian and I both noted, we're quite pleased with the underlying performance of Ever north. If you look at the inherent growth that ever north has delivered for the organization, and the diversity of the growth, we're quite pleased with that.",1.059075,0.975
CI-2021-Q3-2021-11-04,50,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Secondly, our ability to both drive fundamental growth because you'd invest in innovation and extend our partnerships, we feel quite good. So just framing Ever north and then coming to the MDLIVE question, our Ever north portfolio has 4 specific portfolios of services that are positioned well: Evernorth pharmacy, Evernorth care, Evernorth Benefits, and Evernorth intelligence. Our positioning growth at the serving health plans, large employers, expanding with governmental agencies, and increasingly with healthcare providers continues to resonate well in the marketplace.",0.3420132,0.912
CI-2021-Q3-2021-11-04,51,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","For 2022, to your comment relative to some losses, we expect to retention rate in the Evernorth pharmacy business in the mid-90s, which is still a strong result even with the known losses we'd identified. And given the strength we've had of growth over the last several years, we're quite committed to maintaining price discipline in the marketplace, so the business portfolio will grow yet again. Specific to MDLIVE, we're delighted to have the MDLIVE capabilities in our portfolio and that now resides within Evernorth care.",1.1986009,0.981
CI-2021-Q3-2021-11-04,52,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","We see the utilization of those services continue to grow. As I noted, beyond important, urgent or Triage care. But two primary behavioral dermatology. And then we've recently expanded our virtual-first offering. So, we see it as a great opportunity to both expand access, improve affordability. But finally, it presents a platform to broaden some access to care in terms of alternative side of care capabilities. So, in a nutshell, we're pleased, we'll grow again and we're investing in further growth, including within the virtual capabilities of MDLIVE.",0.7306646,0.791
CI-2021-Q3-2021-11-04,55,Question,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks. Good morning. I wanted to ask David about the international sale. First, in terms of multiple, it looks like you've got about 10 to 12 times kind of net income for that business. Is that correct? In the right ballpark? And then if so, just curious in terms of the strategic nature of the sale in terms of -- the multiple looks depressed relative to a business that's historically been looked at as a double-digit top-line grower. And then could you tell us how we should think about capital deployment once you get those funds? Is it going to be similar to what we saw with the Life and Disability, where there's a lot of share repo or should we think about something else? Thanks.",0.1080451,0.912
CI-2021-Q3-2021-11-04,56,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Sure. Good morning, Justin. Let me start and have Brian shape a little further both how we feel about the value realization here in the capital deployment. First, stepping back, we're quite proud of what has been built in our international portfolio over a long period of time. This specific portion of our international portfolio, so direct to individual life, accident and supplemental businesses, we've successfully grown over a long period of time. But using our strategy as a guide, the important underscore here, our strategy guides us to further enhance and deepen our health and well-being solutions.",0.1807229,0.97
CI-2021-Q3-2021-11-04,57,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","This portion of our portfolio was less directly aligned over time to that. So, we use the strategy as a guide number 1. 2, we feel very good about the value realization, and the net value realization area is quite important in terms of a high-performing asset. And I appreciate your correlation to the group transaction, another high-performing asset where we felt quite good about using our strategy as a guide and capitalizing on a very attractive valuation.",0.2483482,0.459
CI-2021-Q3-2021-11-04,58,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And then finally, that strategic action is done to allow us to even further intensify our focus in the sub segments of the business that are more health and well-being oriented, both in the U.S. as well as globally from that standpoint as we'll continue to grow. I'll ask Brian to speak a little bit more towards how we look at the valuation and our capital deployment philosophy going forward.",0.3000389,0.947
CI-2021-Q3-2021-11-04,59,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"Yeah, sure, David. And good morning, Justin. The math that you asked about in terms of the 10 times to 12 times multiple is in the right ballpark if you're looking at U.S. GAAP earnings contributions from the divested businesses, but very importantly, this is a case where economics and accounting don't necessarily square up. If you look at the discounted cash flows of the business here and the purchase price that we were able to get, it's quite an attractive deal economically that we're quite pleased with the financial terms for that reason, as you look at the timing of when dividends were available to be extracted, as an example.",0.6957802,0.459
CI-2021-Q3-2021-11-04,60,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"In terms of deployment with the proceeds, the the broad template as, David made reference to of our group disability and life divestiture, is what we would expect to fall in this instance as well, with the exception of we don't have the same need for long-term debt repayment as we did with the group disability and life transactions. So, we would expect the primary use to be for share repurchase. And when we indicated in the press release that this would be neutral to slightly diluted to our 2022 EPS outlook. That's under the assumption that the primary use is for share repurchase.",0.045633,0.361
CI-2021-Q3-2021-11-04,62,Question,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hey guys, this is Michael Hall on for Ricky. Thanks for the question. So, as it relates to 2022 commercial growth, a number of your peers have already mentioned expecting strong growth. They diffuse concerns around member attrition, and the dynamic, and emphasize share gains, I think one of your peers even mentioned '22 shaping up to be one of the strongest national account selling seasons in history. So, with that said, it's been a bright area, but also hard to imagine that everyone is winning contracts and gaining share. So, with that context, what are you guys seeing with the competitive landscape? And are you able to grow next year when everyone else comes in taking share?",0.1900505,0.951
CI-2021-Q3-2021-11-04,63,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Mike, good morning. It's David. Just a minute of backdrop relative to our performance in the commercial market and then I'll jump right into '22. We have a very focused strategy and a long track record over the last decade of successfully growing in the commercial marketplace. As we seek the sub-segment and deliver the right solutions for our respective clients in that marketplace. And if you think about it over the last decade - ish, we've generally grown low-single-digit medical membership. We couple that with significant and targeted cross-selling of our new and innovative services.",0.4621065,0.969
CI-2021-Q3-2021-11-04,64,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And then we complement that with appropriate pricing actions and the net of that yields higher single-digit revenue growth. So that's the big picture of our strategic approach. I'd also highlight with Evernorth, we are further expanding the services that we're able to bring through to deepen relationships, like our prior conversation relative to virtual care as an example. Now, specific to 2022, to be clear, we'll grow again. We will clearly grow our medical customer base again, and specifically, within the commercial market, we have good visibility in terms of having net growth in our national accounts in large account business portfolio, and we'll have another year of growth within our select segment.",0.0909444,0.886
CI-2021-Q3-2021-11-04,65,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So, the net of all that, in a marketplace that is competitive, as we are oriented around solutions that have affordability and high engagement programs with the right funding mechanisms, we will again have another year of net growth in the U.S. commercial portfolio, and it's something we're quite proud of and positioned to continue on.",0.0116595,0.0
CI-2021-Q3-2021-11-04,68,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"Good morning, Kevin, it's Brian. I'll start on the first piece of your question. I think this was in the context of our U.S. Medical performance in terms of your question on specialty. So, as you reflect on our third quarter performance for that segment, again, the earnings in totality were above our expectations in the quarter. We had two areas of favorability, as you called out, investment income, and specialty contributions. And your specialty contributions includes pharmacy, behavioral, dental, the full suite of portfolio capabilities we have in the specialty domain.",0.2806673,0.103
CI-2021-Q3-2021-11-04,69,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"That was partly offset by the two sources of claims pressure that I articulated in the COVID related pressure in commercial as well as the special enrollment period. MCR is now in elevated in the Individual exchange. Specifically on the favorability that we recorded in the third quarter. The investment income is non-recurring, so you should not consider that to be something that would occur again in the fourth quarter or '22.",0.0441609,0.262
CI-2021-Q3-2021-11-04,70,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","We would expect the specialty contributions to persist as favorability as we head into fourth quarter and into '22. That was a smaller component of the 2 in terms of the favorable items in the third quarter, but that is something we would expect to continue to persist going forward. David maybe will comment on the pricing environment for commercial.",0.6455499,0.925
CI-2021-Q3-2021-11-04,71,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Sure. Good morning, Kevin. Relative to the pricing environment for commercial, and I'm going to maybe sneak in a little bit on the individual marketplace here as well. But specifically, that market has continued to be a competitive market, and it remains that meaning the commercial marketplace, more broadly, the employer commercial market. And with that as a backdrop into my prior answer, we will grow our commercial book of business and we will improve our MCR. Our visibility has us both growing and improving our MCR within the commercial book of business.",0.27089,0.934
CI-2021-Q3-2021-11-04,72,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So, to do that, we will be quite disciplined, Kevin, to be clear, and we're willing to make targeted trade-offs for MCR or margin versus volume. And the net of that will yield net customer growth and net margin improvement as we step into 2022. An add-on specifically in the individual market -- our visibility in the individual market is that there are significant pockets of competitiveness in certain markets. And as such in the Individual marketplace, we would expect for 2022 to see no growth or more likely negative growth, some shrinkage in our book of business, but improvement in the MCR within that portfolio. And that's fully contemplated in our 2022 outlook of net growth for the portfolio, as well as earnings expansion.",0.2079285,0.361
CI-2021-Q3-2021-11-04,76,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"Morning, Gary. It's Brian. So, I'll try to take the various components of that question here. So, as you think about where we are running in 2021 on the MCR, maybe I'll talk in terms of the full-year guide. I think that that's probably the most constructive way to pull it apart. the 84% to 84.5% refresh guidance that we issued. If the special enrollment period lives within the individual exchange portfolio had not grown to the level that they are, and had not had the elevated MCR that they did in the quarter, we would've had an MCR performance for the full-year that was more like the higher end of our prior guidance range, so towards the higher end of the 83% to 84% range, if you exclude the impact of the Individual SCP customers from the full-year outlook.",0.3091266,-0.296
CI-2021-Q3-2021-11-04,77,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"So just to give you a little bit of dimensioning as to the materiality there. Those customer lives have built up over the course of the year, so there were not that many in the second quarter, there were many more in the third quarter. And the elevated MCR hit us, particularly, significantly in the third quarter and we expect that pressure to continue into the fourth quarter. As David did reference to in a prior question, we would expect that to dissipate into 2022 as many of those lives attrit into our choose new carriers.",0.2212954,0.866
CI-2021-Q3-2021-11-04,78,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"As it relates to other parts of the portfolio. The commercial business in the third quarter, we had some elevated COVID related costs, particularly in August and September, with the Delta variant hitting younger ages more significantly than earlier in the pandemic. So that created some elevated commercial claim cost pressure in the third quarter. I would note in our Medicare Advantage book, the MCR in the quarter was a little bit favorable to our expectations, which gives us greater confidence here as we head into 2022 on that subset of the overall U.S. Medical book of business.",0.1315015,0.609
CI-2021-Q3-2021-11-04,79,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"Hopefully it gives you a little bit of a picture for how 2021 is shaping up. In terms of your question, looking forward on commercial utilization, are we caught up, etc. we have seen much less deferred care in the commercial line of business throughout the pandemic, and all the indicators that we track, whether that be preventive care utilization or whether that be rates of new cancer diagnoses, etc. I would tell you that there's not a significant amount of future pent-up demand or catch-up care to come. With that said, our pricing posture, as David mentioned earlier continues to be a prioritization of margin expansion as we head into 2022.",0.9627085,0.637
CI-2021-Q3-2021-11-04,82,Question,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks. Good morning. I guess I want to go back -- you guys specifically called out the increased specialty contributions, and obviously that's always been part of the story. So hoping you can give more details there, what the specific drivers are there, and anything to call out. And then maybe within that, I was hoping you could talk about the stop loss product. I would have imagined that just given higher commercial trend that maybe more of that is being triggered and maybe some underperformance there. But we just like to get your commentary on how that's performed and how we should think about that for 2022 from a re-pricing perspective. Thanks.",0.1916051,0.91
CI-2021-Q3-2021-11-04,83,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Morning, Ralph, it's David. Just a couple of minutes on the shaping and I'll hand it over to Brian. As you articulate the specialty components, so we look at that broadly back to our strategy. Our strategy has been and continues to be how do we wrap the right suite of solutions, employer by employer, to help to get the overall health and wellbeing offering aligned in the overall affordability line. And historically, one thinks about a specialty suite of a few products of behavioral pharmacy, Dental has expanded tremendously to 25, 30 different services when you take the subsegments of decision, support, chronic care management, specialty services, now virtual alternative services, etc.",0.5239021,0.541
CI-2021-Q3-2021-11-04,84,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","My point of underscoring this has been as you articulated and continues to be a really important part of our strategy to try to get the right value to be realized for our for our clients, our customers, and our patients. And as I noted, our Evernorth service capabilities continue to grow, which add to the portfolio of services to be levered there. I will ask Brian to talk a little bit more in terms of the drivers.",0.2261951,0.84
CI-2021-Q3-2021-11-04,85,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"Sure, David. Good morning, Ralph. So in terms of the specialty contributions we called out they're the couple of areas I'd particularly point to as more material within our self-funded business, we had some strength in pharmacy in particular, and as I mentioned earlier, to a prior question, we would expect that to persist as we head into 2022. We also saw some upside within our behavioral health offerings as demand for that has continued to grow throughout the pandemic. So we saw some increased uptake there, which drove some additional margin for us within the quarter.",0.8979392,-0.914
CI-2021-Q3-2021-11-04,86,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"And again, those are two areas we would expect to persist as we head into the new year. Relative to stop loss, obviously you gotta pull this one apart further because you got Individual stop loss cover as well as aggregate stop loss cover, and the dynamics there behaved a little bit differently throughout the pandemic, meaning most COVID related claimants didn't actually hit our Individual stop-loss thresholds. Yet we saw a little bit of pressure earlier in the pandemic on our aggregate stop loss business.",0.2109912,0.862
CI-2021-Q3-2021-11-04,87,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"That business gets repriced along with our typical 12-month contract cycles for all the clients that we have. So we feel good about how we positioned there on a prospective basis. I'd also note we're seeing good demand for that product. You probably saw on the supplement there, we had 7% premium growth on our stop loss line in the quarter-over-quarter. So, feeling good about all the specialty solutions when you look at the total portfolio.",0.4499509,0.765
CI-2021-Q3-2021-11-04,91,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"Good morning, Josh. So I'll try not to be too redundant with some of my prior comments, but just to kind of summarize a few important points here as you pull apart the MLR for the full year, as I mentioned earlier, the refresh 84% to 84.5% outlook reflects particular pressure from the Individual exchange lives and specifically the special enrollment period enrollees. So removing that, we would have been toward the higher end of our prior guide of 83% to 84%, but a sub bullet there is the individual open enrollment lives are actually performing pretty well.",0.0667321,0.814
CI-2021-Q3-2021-11-04,92,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"So when we look at the profitability of the overall individual portfolio, we have good performance on the standard open enrollment lives. We have poor performance on the special enrollment period lives and the total picture there is therefore a bit elevated. Medicare Advantage as I made reference to actually ran a little bit favorable to our expectations in the third quarter. And then commercial was a touch higher than our projections due to the effect of the Delta variant in the months of August and September in particular.",0.218842,-0.289
CI-2021-Q3-2021-11-04,93,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"So those are the broad buckets that I paint for you, do you think about what's inside the medical care ratio. Relative to stop loss, we do have a range of attachment points depending on the client. So we tend to see particular popularity around the $15,000 to $75,000 level, but it really depends on the risk appetite for a given client. So it's hard to say that there's one that's always the preferred choice. We have a distribution and the distribution evolves depending on the appetite for clients at any given point in time.",0.8631011,0.765
CI-2021-Q3-2021-11-04,96,Question,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hi, this is James Stewart on for Kevin. Just maybe with the sale of Chubb, you're signaling more of a focus to core healthcare business. Are there any other segments within the Company that you consider a non-core that you might be looking to dispose off in the future?",0.8495919,0.964
CI-2021-Q3-2021-11-04,97,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning. It's David. As you noted, the action we took relative to that part of our portfolio and previously the action we took relative to our group insurance business, we deem to be a good fiduciary management of the portfolio and looking at the strategy as a guide to our actions, headline is I would not signal anything of materiality that sits on the horizon. I would reinforce, it's a dynamic process. Our responsibility is to dynamically manage that. But I would not signal anything on the horizon. I'm quite proud of the organization and pleased with the successful execution of both transactions: one completed, second under regulatory review right now.",0.170618,0.361
CI-2021-Q3-2021-11-04,100,Question,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","But should we think about -- is that still the usable framework going into '22, or should we think about maybe less operational growth, and maybe more from capital deployment. Just any additional thoughts around those components might help knowing that its preliminary right now.",1.4197435,0.966
CI-2021-Q3-2021-11-04,101,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Sure. Good morning, it's David. Big picture as you look to 2022, brief reference to this previously, but our view of the earnings visibility and the growth visibility relative to 2022 essentially, if you take the -- at least 10%, we underscore that with capital contribution to our EPS growth in line with our strategic target, which is 4 to 5. Then if you back away from that, that leaves you 5 to 6 fundamental organic earnings growth contribution to get to the at least 10% number. And we think that's an appropriate and prudent and attractive outlook given the fluidity and dynamism of the marketplace.",0.1612903,0.44
CI-2021-Q3-2021-11-04,102,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Broadly speaking, both components are in line with our long-term strategic objectives and we have a track record including 2021, which is a disrupted year of delivering in line with that. Good fundamentals, a little more than 50% of it being organic, a little less than 50% of it being capital deployment, and very much in line with our long-term strategic targets.",0.1298096,0.586
CI-2021-Q3-2021-11-04,105,Question,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Yes. Thank you. Just wanted to ask what you're seeing in terms of customer preferences and actions in the middle market, particular degree of interest in alternate ASO type funding for the products versus what you've seen over the last few years. And then maybe in the stop loss market associated with that. Am I correct that some of the other carriers may be correcting for what was perhaps overly aggressive pricing in earlier years, which is maybe giving you a little bit of a tailwind there on your own growth?",0.6148465,0.844
CI-2021-Q3-2021-11-04,106,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Matthew, good morning, It's David. So you referenced middle market. I don't think there's a singular common definition middle markets, so let me try to frame your important comment. First, as you look at our go-to market offerings, we have a broad suite of funding alternatives and we seek to offer to our clients their respective decision of how they want to finance the purchase after the benefits are configured, after the access profile is configured, after the clinical programs are configured, and the service models are configured to align as Brian referenced before, the risk transfer in the balance relative to them, so having that broad suite is really important.",0.3855422,0.261
CI-2021-Q3-2021-11-04,107,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","If we look at the select segment, 100 to 500 live clients, it varies from year-to-year in terms of how much of the client demand is guaranteed cost versus self-funded with stop-loss, but self-funded with stop-loss has been a meaningful portion. And as you walk from that into the heart of what I might consider middle-market, the further you walk up an average size, on average, more demand for self-funded, less demand for risk transfer. And in the in between range, some for shared returns of a fundamentals that exist.",0.8064516,-0.361
CI-2021-Q3-2021-11-04,108,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So a little bit of linearity as you just go off in respect to size from that standpoint, but the important part is choice that we offer in the marketplace and try to separate the financing decisions. from the design features from the program. I would say to the last part of your question, I do not believe that there's a boomerang or reconfiguration effect that happened that we've benefited from a stop-loss standpoint. We've seen just consistency in how we use stop loss.",0.1562379,0.917
CI-2021-Q3-2021-11-04,109,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And I'm remind ed from prior conversations, we have a large book, we have a dedicated team that manages that book because it needs to be specialization in that like many other aspects of our business. And it's both performed for clients, importantly, giving them the peace of mind and revenue predictability and expense predictability they need, as well as for us over a long period of time. But I would not call out anything unique in terms of ebbing and flowing that's changed our rate of growth in stop loss over the recent past.",0.8091722,0.361
CI-2021-Q3-2021-11-04,112,Question,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, guys, and thanks for taking the questions. David and Brian, just a couple of being counting ones and a quick question. David, I just want to make sure that 2035 or whatever the number is post Q4 is the right jumping off point for the 10% or better growth in 2022, given it sounds like you're saying all the other pushes and pulls are on mute now, can you quantify PBM to commercial medical cross-sales this selling season? And I'll pause right there.",0.08356,0.957
CI-2021-Q3-2021-11-04,113,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So George Hill it's two questions I heard. Question 1, yes. The at least $20.35, which is our raised EPS is the appropriate jump off to attach the at least 10% growth. We're pleased to have that underlying strength in that clarity of message. The second question, I think you're asking relative to PBM, commercial cross-sell penetration, etc. In respective growth, I don't have an Individual number for you. We have not historically walk-through individual numbers there. I'd ask you to step back and remember our strategy here. We have a high cross-sell and high integrated offering within our medical business.",0.7271667,0.765
CI-2021-Q3-2021-11-04,114,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","As you think within the prior question that Matthew asked, as you go to our select segment, think about that as 100% integrated. It is so integral to our offering, and as you move upmarket, it's more of a standalone sale that needs to be made. We see continued progress there, and we're pleased to either have it as an integrated part of our medical offering or a standalone PBM offering that we could harness and sell additional services because at the end of the day, as I called up my prepared remarks, there were 2 fundamental ways in which a client or customer establishes their primary health and wellbeing relationship.",0.5915274,0.892
CI-2021-Q3-2021-11-04,115,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director",Either a pharmacy relationship or largely off of a medical relationship. and we're positioned to lever both. So I would leave you with a directional answer on the PBM commercial. Brian referenced PBM strength over pharmacy strength in our commercial portfolio. That's a net positive. And we continue to see on traction both on standalone pharmacy as well as integrated pharmacy within our business.,0.4815391,0.361
CI-2021-Q3-2021-11-04,118,Question,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hi, thanks. Just wanted to come back to the individual market commentary you made. Appreciate that you're pricing, I guess conservatively in a fairly competitive backdrop. How much of the way back towards your target margins do you think that's going to get you in 2022? And then how should we think about growth beyond 2022 as you previously have talked about, doubling this market through 2025? Thanks.",0.1472989,0.844
CI-2021-Q3-2021-11-04,119,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, Stephen. We were seeking to be quite clear in terms of -- there's argue -- indisputably, there's some pockets of intense competitive pricing in the IFP marketplace or the Individual exchange marketplace as it's probably articulated. Given the breadth of our portfolio, we're going to be able to achieve both our aggregate growth as well as our aggregate earnings objectives, while maintaining price discipline in temporarily dislocated markets, and we deem that to be 1.",0.5736494,0.855
CI-2021-Q3-2021-11-04,120,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So we expect to see a net flat or decrement in our volumes in the Individual exchange business and a margin improvement. I'm not going to give you a margin number. We're not guiding in detail for 2022 yet and we typically don't guide relative to individual margins. Having said that, we expect to improve that margin from 2021 to 2022, to a more attractive and more sustainable level and we'll maintain the discipline there.",0.0062184,0.727
CI-2021-Q3-2021-11-04,121,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to intermediate to long term, we continue to see this as a growth market. But as we've managed it and if we demonstrate it over time, if there were temporary dislocations, we'll maintain discipline, and will lever other parts of the business to ensure the portfolio delivers. And as I noted in my prepared remarks, we've entered 3 more states and almost 100 additional counties, to give us access to an addressable market of approximately 1.5 million additional customers to sell to.",0.5270113,0.0
CI-2021-Q3-2021-11-04,122,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And we've been in this marketplace since its inception in 2014. And we have a track record of sustained performance, albeit episodically needing to sharpen focus as we will in 2022, given the market conditions.",1.2254178,0.361
CI-2021-Q3-2021-11-04,124,Question,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hi, thanks for taking my questions. David, I'm interested in your views, albeit early, on this Build Back Better bill that appears to be moving toward a vote, and maybe specifically, what you think the impact of government negotiation on a top 10 or 20 drugs beyond our exclusivity would have on your PBM business?",0.3120871,0.959
CI-2021-Q3-2021-11-04,125,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, Dave. So clearly a lot of fluidity right now on the health and we've operated for a long period of time in an environment and we'll continue to that has an active both legislative and regulatory agenda. So we understand that fully. Big picture stepping back, any initiatives that are constructive and sustainable, that improve affordability and value for individuals, we're actively open to engaged in and generally supportive of.",0.1663428,0.875
CI-2021-Q3-2021-11-04,126,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Specifically in the pharmacy space where you double-click down on. We think the most meaningful way to test sustainable policies -- policy change that could further affordability is to stimulate and further accelerate more competition. And if a heart come back as an example to make it tangible, hepatitis C was, I think, a very positive example that reinforces that. But as the marketplace rapidly move from 1 to 2 suppliers for hepatitis C services, which was a breakthrough drug that society benefits from, the overall affordability changed dramatically.",0.4621065,0.869
CI-2021-Q3-2021-11-04,127,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","That's an action that is different than who's negotiating or it's very different than putting in artificial cap on a rate of growth from that standpoint. Big picture, we will await specific details and we will remain actively engaged, no doubt. We believe the most sustainable way to further improve affordability, is to expand choice and expand competition.",0.0314808,0.681
CI-2021-Q3-2021-11-04,128,Answer,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","That's what's worked in the marketplace in the model. And lastly, per prior conversation we've had our well-performing and broad portfolio pharmacy services and tools is well-positioned to be able to deliver value in a changing environment, and we're confident in the capabilities we have over the strategic horizon here.",0.1488535,0.791
CI-2021-Q3-2021-11-04,132,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"Good morning, Lance. It's Brian. So within the third quarter in Evernorth, we fulfilled about 4 million COVID vaccine prescriptions. So to put that into context, that's about 1% of our total script volume, and year-to-date, we're up to about 16 million across the three quarters here in 2021. So again, roughly about 1% of total script volumes for Evernorth, but not a material contribution from an income standpoint.",0.3287537,0.709
CI-2021-Q3-2021-11-04,133,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"And if that number goes up or down next year, it won't materially move the needle for the Evernorth segment. More broadly on the second part of your question, as we think about specialty generics, and you can even broaden that to include biosimilars. We're really excited about those for the future from the standpoint of driving affordability on behalf of our clients and customers. We think competition is a good thing and ultimately, Specialty Generics.",0.0736016,0.896
CI-2021-Q3-2021-11-04,134,Answer,2021-11-04,3,2021,Brian C. Evanko,CFO,"While the timing with which they're introduced is hard to predict and does create some variability in our quarterly income patterns. Ultimately, we view that as a great thing for our clients, customers, and ultimately for our business. And fortunately, we have a wide range of earnings levers that allow us to capture value in a variety of ways depending on how different client contracts are constructed. We're really excited about especially generics and biosimilars going forward.",0.1619235,0.791
CI-2021-Q3-2021-11-04,137,Closing,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Just to briefly wrap up our call. I do want to underscore how proud and appreciative I am of our more than 70,000 co-workers around the globe who continue to be dedicated to the many stakeholders we serve. Our team is working to support our patients, our clients, our customers, our partners, in this very fluid and ongoing challenging environment.",1.3365721,0.979
CI-2021-Q3-2021-11-04,138,Closing,2021-11-04,3,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And the team is -- continue to step-up time and time again to make sure we're providing the level of support, again for our clients, our customers, our patients, as well as our communities. And through it all as an enterprise, we remain focused on executing our strategy guided by our framework of delivering value every day, partnering and innovating to expand, and then expanding our addressable markets to broaden our reach. We thank you for your engagement today. We look forward to providing future updates on our success going forward, and ask you to enjoy the rest of your day. Thanks.",0.6972406,0.077
CI-2020-Q3-2020-11-05,14,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks, Alexis. Good morning, everyone, and thank you for joining our call today. I will begin by providing a few brief comments on Tuesday's election results, which are certainly top of mind for all of us. Then, I will speak to how Cigna's strategy accelerated by our recent launch of Evernorth, positions us to continue building on our history of delivering strong performance in dynamic and rapidly evolving environments. I will also provide comments on our strong third quarter results and I will conclude a few brief overview comments relative to 2021 before turning the call over to Eric.",0.9844539,0.962
CI-2020-Q3-2020-11-05,15,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","First, relative to the election. Certainly, we along with everybody else awaits to see a clear and orderly conclusion. Regardless of the final outcome, our mission to improve the health, well-being, and peace of mind of those we serve around the world has not changed and is more critical than ever.",0.4943646,0.845
CI-2020-Q3-2020-11-05,16,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","We are ready to continue engaging in critical discussions on healthcare with members of both sides of the aisle at federal, state and local levels. And we look forward to working constructively with the current administration or a new administration as we have been privileged to do so in the past.",0.7050136,0.671
CI-2020-Q3-2020-11-05,17,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Looking forward, the long-term health needs of individuals and society at large transcends the results of any particular election or political climate. There is no question that simply continuing with the status quo for healthcare is not sufficient under any circumstances.",0.9020599,-0.296
CI-2020-Q3-2020-11-05,18,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Take for example that today's children are likely to be the first generation in American history to live shorter lives than their parents. Clearly, this is unacceptable. And the COVID-19 crisis has only reinforced our unsustainable healthcare challenges, including eroding individual health status, increased mental health impacts from heightened stress, anxiety and loneliness, health disparities and social determinants of health, and gaps in our healthcare delivery infrastructure.",0.8507579,-0.852
CI-2020-Q3-2020-11-05,19,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director",Many U.S. states are seeing their healthcare systems overwhelmed and only exacerbated by the underlying chronic conditions such as diabetes that increase the risk of severe complications from COVID-19.,0.6653712,-0.296
CI-2020-Q3-2020-11-05,20,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","The bottomline is that there is no one healthcare system that is perfectly positioned. In our view, the conversation regarding healthcare must focus less on who pays the cost of an unsustainable system.",0.7007384,0.459
CI-2020-Q3-2020-11-05,21,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","In fact, systems around the world continue to struggle with unsustainability and rising costs including nationalized systems. What is important is that we work together to find solutions to meet the diverse underlying needs that are unique to a population in the most effective way possible.",1.7011271,0.556
CI-2020-Q3-2020-11-05,22,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Regardless of the political climate, more than ever, people, governments and employers, as well as health plans are looking for healthcare systems that focus on keeping people healthy and not just treating them when they are sick, caring for the whole person, both mind and body and ensuring the most affordable, high value delivery of healthcare services. At Cigna, we are delivering on this promise and our strategy is designed to answer the call for healthcare system that is more affordable, predictable and simple.",0.6288379,0.878
CI-2020-Q3-2020-11-05,23,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Our strategy guides us to customize our solutions to meet the diverse needs of our clients, our customers and our patients, and look at every decision and action we take to ensure it is addressing the demands for more value.",1.5308978,0.718
CI-2020-Q3-2020-11-05,24,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","We have amassed a targeted portfolio of capabilities to accelerate this direction and when combined with our partnership orientation, our focus on data driven innovation and capital flexibility, we are positioned to deliver differentiated value for those we serve and sustainable attractive growth.",0.8616401,0.898
CI-2020-Q3-2020-11-05,25,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","As you know, we recently introduced Evernorth, an evolution of our high performing health service portfolio and another important milestone in delivering on our strategy. With Evernorth, we have a distinct and dedicated platform of services and innovative healthcare solutions for health plans, employers, government organizations and healthcare providers.",0.8507579,0.813
CI-2020-Q3-2020-11-05,26,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","The launch of this new brand in September was met with overwhelming support and excitement from these viral groups. Through this dedicated platform we were demonstrating our commitment to meet their unique needs and invest in their success. Additionally, the platform further reinforces our position as the partner of choice to create more shared value for our clients and open their customers.",0.8635834,0.969
CI-2020-Q3-2020-11-05,27,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","A recent example of this is our growing partnership with Prime Therapeutics. Through our Prime relationship, we expand our retail pharmacy network and rebate administration services to more Americans through their 23 Blue Cross/Blue Shield Plans. We achieve this by enhancing the retail pharmacy network and increasing affordability from pharmaceutical manufacturers.",0.8635834,0.459
CI-2020-Q3-2020-11-05,28,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","With Evernorth, our relationship with Prime will be further expanded. This includes the option for Prime's plans to access the Accredo Specialty Pharmacy and Express Scripts' home delivery in network pharmacies beginning on January 1, 2021.",0.7050136,0.0
CI-2020-Q3-2020-11-05,29,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Evernorth reinforces our deep commitment to leverage our broad capabilities to serve health plans, employers, government entities and healthcare professionals, and pursue mutually beneficial partnerships.",2.4426739,0.671
CI-2020-Q3-2020-11-05,30,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","At the same time, we are continuing to further invest in our Cigna brand, under which are U.S. Commercial, U.S. Government and International businesses go to market. We will continue be known for a customer- and client-focus approach and for delivering industry leading trends and outstanding customer service.",1.1993782,0.612
CI-2020-Q3-2020-11-05,31,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","For example, I am pleased to announce that our Medicare Advantage business achieved an annual customer Net Promoter Score of plus 74, the fourth consecutive year we have shown an increase. In addition in 2021, 88% of our customers will be in four-star plus rated plans and we are the only major plan to achieve an increase year-over-year.",0.7442674,0.818
CI-2020-Q3-2020-11-05,32,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","This is just one example and important one of our Cigna-branded companies will continue to deliver differentiated value in the marketplace. With Cigna and the recent addition of Evernorth platform, we now have two powerful brands from which to drive sustained growth today and well into the future.",0.7637,0.866
CI-2020-Q3-2020-11-05,33,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Now, turning to our third quarter performance. We delivered strong results that were in line with our expectations. As a result, and as expected, we experienced the return of elevated utilization to more typical levels and ongoing impact of COVID-19.",1.2394092,0.511
CI-2020-Q3-2020-11-05,34,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","We also continue to take actions to support our customers, our clients, our coworkers, our healthcare professionals and our communities in these exceptionally challenging times. Additionally, we remain on track to complete the integration of Cigna and Express Scripts by the end of this year.",1.4508356,0.556
CI-2020-Q3-2020-11-05,35,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Our consolidated revenue was $40.8 billion with after-tax earnings of $1.6 billion. In our Evernorth segment, we continue to deliver strong performance, demonstrating the value we bring to health plans, employers and government clients.",0.5837544,0.691
CI-2020-Q3-2020-11-05,36,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Within the U.S. Medical segment, we saw an increase in cost as expected as utilization returned to more typical levels. And our International business continues to deliver revenue and earnings growth, as we meet the needs of our global customers as they navigate the disrupted environment due to COVID-19. With our strong third quarter results, we are confident that we will achieve our updated 2020 revenue and EPS outlook.",0.7753595,0.886
CI-2020-Q3-2020-11-05,37,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Looking forward to 2021, we have a number of tailwinds including continued growth momentum, favorable impacts from synergies from our Express Scripts combination and further administrative synergies. We expect year-over-year headwinds from increased medical costs largely driven by the ongoing impact of COVID-19.",0.3956471,0.796
CI-2020-Q3-2020-11-05,38,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Diving a bit more deeply into our growth momentum, we expect to drive continue to organic growth across each of our well-positioned platforms. I'd specifically highlight strong growth within our pharmacy service portfolio, including specialty and underlying script growth aided by projected 98% client retention level and continued expansion of our U.S. Government business including Medicare Advantage, where we continue to drive both strong market and product expansion, as well as in-market growth, putting us on track for customer growth in our targeted range of 10% to 15% in 2021 and an individual changes where we have increased our addressable market footprint by over 50%. All-in, we are positioned for both very strong revenue and continued earnings growth in 2021, and we remain on track to achieve our strategic goal of $20 to $21 of EPS.",0.6385542,0.988
CI-2020-Q3-2020-11-05,39,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director",We expect a strong operating momentum and capitalized framework to drive attractive operating cash flows of greater than $8 million. This significant cash flow generation combined with our ongoing deleveraging will give us significant strategic and financial flexibility for 2021 and beyond.,0.4772639,0.914
CI-2020-Q3-2020-11-05,40,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Now to summarize before turning it over to Eric. Cigna has a long history of delivering strong performance in dynamic rapidly evolving environments, focused first and foremost on addressing the health and well-being needs of the individuals we serve. This approach transcends the results of any particular election cycle.",0.457054,0.818
CI-2020-Q3-2020-11-05,41,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","We continue to build on this foundation as we delivered another strong quarter driven by the outstanding dedication of our more than 70,000 colleagues around the world who focused every day on our mission to improve the health, well-being and peace of mind of those we serve.",0.6980179,0.946
CI-2020-Q3-2020-11-05,42,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Our mission and our strategy as champions were affordable, predictable and simple healthcare will continue to guide us, as we provide exceptional value for the benefit of our customers, patients and clients. And the launch of Evernorth will further fuel our strategy and expand our ability to serve more individuals.",1.4049747,0.908
CI-2020-Q3-2020-11-05,43,Remarks,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Finally, as we usually do, we look forward to providing more detailed and complete guidance for 2021 on our fourth quarter earnings call.",0.7753595,0.0
CI-2020-Q3-2020-11-05,45,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Thanks, David, and good morning, everyone. Today, I will review key aspects of Cigna's third quarter results including the ongoing impact of COVID-19 on our business and discuss our outlook for the full year.",0.7675171,0.7
CI-2020-Q3-2020-11-05,46,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Key consolidated financial highlights for the third quarter of 2020 include, adjusted revenues of $40.8 billion, adjusted earnings of $1.6 billion after-tax and adjusted earnings per share of $4.41. Our results this quarter and year-to-date reflects focused execution across our businesses in a dynamic rapidly evolving environment.",0.8343514,0.751
CI-2020-Q3-2020-11-05,47,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Regarding our segments, I will first comment on Evernorth. Third quarter adjusted revenues grew to $30 billion and adjusted pretax earnings grew to $1.4 billion. As previously discussed, in Evernorth, the cadence of quarterly earnings is more typical in 2020 than in 2019, where earnings were more weighted to the second half of the year due to the timing of certain supply chain initiatives.",0.6424722,0.273
CI-2020-Q3-2020-11-05,48,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Evernorth's strong results in the quarter were driven by organic growth and customers and script volumes, the effective execution of supply chain initiatives and continued performance and expansion of specialty pharmacy services through Accredo, our industry-leading specialty pharmacy.",0.485088,0.84
CI-2020-Q3-2020-11-05,49,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We fulfilled 381 million adjusted pharmacy scripts, a 22% increase over the third quarter of 2019. Overall, Evernorth continued its positive momentum and delivered another strong quarter financial results.",1.1735537,0.9
CI-2020-Q3-2020-11-05,50,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our U.S. Medical segment. Third quarter adjusted revenues were $9.6 billion and adjusted pretax earnings were $757 million. These results reflect unfavorable prior period development, primarily related to the second quarter of 2020, COVID-19-related impacts and the return of the health insurance tax.",0.4344233,0.0
CI-2020-Q3-2020-11-05,51,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"COVID-19 related impacts include the return of medical utilization to more typical levels, the direct costs of COVID-19 testing and treatment, decreased especially contributions and lower net investment income.",0.0571326,-0.354
CI-2020-Q3-2020-11-05,52,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"It also reflects the actions we have taken throughout the year to support our stakeholders in this disruptive environment. For all customers, we continue to waive cost sharing for COVID-19 testing and treatment. For our Medicare Advantage and individual and family plans customers, we continue to waive cost sharing for in-office and telehealth visits for primary care, specialty care, and behavioral health.",1.3719008,0.92
CI-2020-Q3-2020-11-05,53,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For clients, we have provided premium relief programs and for our providers, we have implemented a variety of financial assistance programs. I am proud of the way that we at Cigna continue to respond to the pandemic in support of our stakeholders.",0.3780093,0.836
CI-2020-Q3-2020-11-05,54,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to membership, we ended the quarter with $17 million global medical customers, less than a 1% decline sequentially. Our U.S. commercial book of business remains resilient due to the industry mix of our clients and continued commitments that employers are making to the health and wellbeing of their employees through COVID.",1.2421847,0.128
CI-2020-Q3-2020-11-05,55,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We also continue to see growth in Medicare Advantage, where we have grown membership 18% through the end of the third quarter and we also continue to grow in the Select segment. Overall, with the exception of the unfavorable prior period development, results in our U.S. Medical segment are in line with our expectations.",0.8257276,0.557
CI-2020-Q3-2020-11-05,56,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our International markets business, third quarter adjusted revenues were $1.4 billion and adjusted pretax earnings were $208 million, reflecting continued operational efficiency, lower claims due to COVID-19 and ongoing business growth.",0.485088,0.44
CI-2020-Q3-2020-11-05,57,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our Group Disability and Other Operations segment, third quarter adjusted revenues were $1.3 billion. Third quarter adjusted pretax earnings for the segment were $70 million, reflecting elevated life claims due to the pandemic.",0.3065038,0.0
CI-2020-Q3-2020-11-05,58,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our Corporate segment, the third quarter of 2020 loss of $356 million reflects lower interest expenses due to the lower levels of outstanding debt. Overall, as a result of focused execution in a dynamic environment, we continue to deliver value for all of our stakeholders and strong financial results.",0.0413223,0.866
CI-2020-Q3-2020-11-05,59,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now, looking forward to our outlook for full year 2020. As we look to the balance of the year, we expect continued strong execution across our portfolio of businesses. We expect medical utilization to remain at more typical levels with continued direct costs of COVID-19 testing and treatment and we expect some increase in commercial disenrollment due to continued dislocation in the broader labor market.",0.2134387,0.681
CI-2020-Q3-2020-11-05,60,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"In the fourth quarter, we will also continue to make investments to support our clients, customers and employees in this disrupted environment. And taken as a whole, we now expect full year 2020 consolidated adjusted revenues of approximately $158 billion and we now expect full year consolidated adjusted earnings per share in the range of $18.30 to $18.60.",0.5727632,0.599
CI-2020-Q3-2020-11-05,61,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I would remind you that our financial outlook excludes the impact of future share repurchases and assumes a full year of contributions from our Group Disability and Life business, although we continue to expect our divestiture of that business to close in the fourth quarter. Overall, these expected results are driven by strong underlying fundamentals, disciplined expense management and the effective deployment of capital.",0.446281,0.823
CI-2020-Q3-2020-11-05,62,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now moving to our 2020 capital and liquidity position and outlook, third quarter cash flows from operations of $895 million, reflect the additional third quarter tax payments of approximately $826 million that was delayed from the second quarter as permitted under the CARES Act, as well as the payment of $445 million for the health insurance tax for the full year.",0.4283148,0.604
CI-2020-Q3-2020-11-05,63,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Through the end of the third quarter, cash flows from operations were $6 billion, and for 2020, we now expect cash flows from operations of greater than $8 billion. Our businesses generated substantial amount of cash flow and in combination with $5.3 billion in net proceeds expected from the sale of our Group Disability and Life business, we have significant capital and financial flexibility.",2.8778297,0.758
CI-2020-Q3-2020-11-05,64,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Through the end of the third quarter, we deployed $1.7 billion to debt repayment and our debt to capitalization ratio of 42.8% as of September 30th is improved from 45.2% in December 31, 2019. We are at $1.2 billion of cash available at the parents at the end of the third quarter, and on a year-to-date basis, we have repurchased $16 million shares of stock for $2.9 billion.",0.1965505,0.077
CI-2020-Q3-2020-11-05,65,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Following the close of the group transaction, free cash available to the parents is expected to be at least $7 billion and we expect to deploy $4 billion to $5 billion to return our debt to capitalization ratio below 40%.",0.0032339,0.202
CI-2020-Q3-2020-11-05,66,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Our balance sheet and cash flow outlook remains strong, benefiting from our highly efficient, service-based orientation that drives strategic flexibility, strong margins and returns on capital.",1.1052821,0.902
CI-2020-Q3-2020-11-05,67,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now to recap, our third quarter consolidated results reflect focused execution across our businesses and the dynamic rapidly evolving environment with particular strength the momentum in our Evernorth segment.",0.4523895,0.813
CI-2020-Q3-2020-11-05,68,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We are well positioned to meet the financial targets we have established for 2020, all while continuing to support our clients, customers and employees, and as such, we now expect 2020 full year adjusted EPS of $18.30 per share to $18.60 per share and remain on track to deliver on our target of $20 to $21 of adjusted earnings per share in 2021.",0.9575997,0.856
CI-2020-Q3-2020-11-05,69,Remarks,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"With that, we will turn it over to the operator for the Q&A portion of the call.",2.1591807,0.0
CI-2020-Q3-2020-11-05,71,Question,2020-11-05,3,2020,Justin Lake,,"Thanks. Good morning. I want to ask, first, can you give us a little more color on the negative development that you said that you attributed to the second quarter in terms of the drivers and maybe what business would have been? And then, secondly, can you give us any update on the deal close, what states or what needs to happen to get this close and what you might give us some more fulsome kind of thought process around capital deployment given post that deal close over the next 12 months, 14 months, you will have somewhere by my math $8 billion to $10 billion to deploy, but thoughts on dividend things like that? Thanks.",0.7173913,0.847
CI-2020-Q3-2020-11-05,72,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Thanks, Justin. Good morning. So I will start with the reserve development piece first. So stepping back here about, just to remind you, as we look back to the second quarter, we had significantly lower utilization in April and May, and as we close out the second quarter we had to make estimates around the claims associated with the month of June.",0.4901186,0.557
CI-2020-Q3-2020-11-05,73,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now with the benefit of hindsight, utilization in the month of June came back a little bit faster than we previously estimated. So the way I'd have you think about this Justin is we recorded about 1 point in the loss ratio in the third quarter that really should have been back in the second quarter.",0.67553,0.178
CI-2020-Q3-2020-11-05,74,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"So, again, think about 100 basis points on the loss ratio in this third quarter results relating to in-year reserve development that's associated with the second quarter. That's the headline in terms of the reserve development. As you think about the thesis, I would point that primarily to the Commercial business in terms of the line of business, et cetera.",0.4164571,-0.318
CI-2020-Q3-2020-11-05,75,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"In terms of the deal close, to go to that part of your question, we are on track for closing in the fourth quarter. We have put out a release a couple of -- in September, so a handful of weeks to go now, nothing that we had 55 out of the 65 required regulatory approvals. We now have 63 of the 65 required regulatory approval, so we are right at the cusp of getting that transaction closed and going from there. I will let David take the kind of forward-looking comments in terms of capital deployment and the like.",0.4020841,0.681
CI-2020-Q3-2020-11-05,76,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Justin, good morning. Appreciate your question. And embedded in your question is acknowledgement of the strategic positioning of our portfolio. As you noted, we will be producing a significant -- need to produce a significant amount of cash flow that is deployable from that standpoint.",1.2848815,0.802
CI-2020-Q3-2020-11-05,77,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","From our point of view, stepping back, as noted in Eric's prepared remarks, you saw that we were pretty active in the share repurchase domain over the third quarter and saw some tremendous opportunity there.",0.5915274,0.896
CI-2020-Q3-2020-11-05,78,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Specific to your question, as I noted, we are going to look forward to providing 2021 guidance on our fourth quarter call and you might expect that as we complete our group closure, as Eric articulated in the fourth quarter and stepping into the first quarter, we have an opportunity not just to refresh our 2021 outlook, but also to refresh our capital deployment priorities and alike off of that very strong base. So we look forward to that conversation.",1.1169841,0.778
CI-2020-Q3-2020-11-05,82,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Hi, Gary. It's Eric. So on the first one, just to be clear, yes, we are reaffirming the $20 to $21 target and I don't think there's any ambiguity on that. That's been a target we have had for some time and we continue to be on track for that. So, again, I think the short answer to that question is, yes.",1.1243263,0.791
CI-2020-Q3-2020-11-05,83,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"On the experience-rated business, so as customers, as our clients have different levels of utilization and if there are favorable utilization, we accrue for that in the period. So, I would not think about there being any future headwinds here. Many kind of the dynamics associated with lower utilization are already reflected in the results and in the current period. So I would not think about that as a headwind in the future.",0.6643909,0.459
CI-2020-Q3-2020-11-05,87,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Andrew, good morning. It's David. Thanks for referring me to the question. So stepping back, we are delighted with our performance in 2020 for starters, and as we laid out that multiyear 10% to 15% growth objective. We also underscored the fact that we were going to systematically expand our positioning in the market from less than 20% of the addressable market in 2019 to 50% of the addressable market 2024. So we are systematically expanding our geographies and we have added a new platform in terms of individual PPO in 2020. So that continues to carry forward.",0.753595,0.919
CI-2020-Q3-2020-11-05,88,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to 2021, our view of -- our positioning of our offerings in the marketplace, we feel quite good about that. As I noted in my prepared remarks, we have a strong base to jump off of relative to 80% star rating and a Net Promoter Score of 74. We remain committed to that 10% to 15% range. We look forward to providing you updates as we go forward. We always strive to perform at our best.",0.8857365,0.929
CI-2020-Q3-2020-11-05,89,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And I appreciate your optimism and make sure that the senior team knows your optimism as well relative to this, but we are excited to end 2020 with a strong year and step into 2021 with some great growth momentum and look forward to continuing that beyond 2021.",0.1476875,0.975
CI-2020-Q3-2020-11-05,91,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So specific to inorganic opportunities, we have continued to have a portfolio of inorganic priorities. We have historically had five priorities or so that we have walked through and we previously refreshed them about a year ago at our Investor Day from that standpoint and U.S. seniors remains on that list. The underpinning growth chassis for this business is an organic growth chassis, to be clear.",0.721337,0.856
CI-2020-Q3-2020-11-05,92,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So we will be opportunistic and always open minded relative to inorganic opportunities. But the growth chassis here is an organic growth chassis aided by our end market growth, our platform expansion into individual PPO, our new market entry, which I referenced before, as well as over time additional employer, right, with growth from that standpoint. So it's organic first and opportunistic on an organic as appropriate in the future.",0.627672,0.917
CI-2020-Q3-2020-11-05,96,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","A.J., good morning. It's David. So specifically relative to Evernorth, as I noted, we are quite excited to have launched that in September. We view it as a further reinforcement of an acceleration of our health service strategy. We have talked for quite some time as a business -- an evolving business portfolio of services and a health service portfolio.",0.9801788,0.726
CI-2020-Q3-2020-11-05,97,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Specific to Evernorth, the way I'd ask you to think about it is, one, it's a further reinforcement of the dedication we have of resources for supporting large complex employer needs, health plan needs, governmental entity needs, both federal as well as state agency needs, as well as healthcare-integrated systems and healthcare providers who were taking performance based risks or value based programs around that.",2.440342,0.751
CI-2020-Q3-2020-11-05,98,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Within our portfolio today, we have a large well performing pharmacy services portfolio solutions, we have a benefit management solutions to bring forward to the marketplace, we have care management solutions and a growing portfolio of data and analytics solutions from that standpoint.",1.0707346,0.915
CI-2020-Q3-2020-11-05,99,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And lastly, to your comment, we see this not only as an attractive organic growth platform and our performance reinforces that we are building from strength, but also an opportunity for tuck-in or expansion capabilities as we go forward.",0.3373494,0.82
CI-2020-Q3-2020-11-05,100,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And illustratively from that standpoint, we continue to see the opportunity to expand services that we offer to individuals around care delivery and care coordination from that standpoint, embracing technology, embracing virtual services, expanding our home healthcare capabilities, et cetera. We are readily building some of those capabilities organically today and we will be opportunistic from an inorganic standpoint.",0.4970851,0.886
CI-2020-Q3-2020-11-05,101,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So just an acceleration of our service portfolio, dedication of resources, reinforcing our partner of choice orientation and a very broad portfolio of services today that will continue to expand for the benefit of those we can serve.",0.7924602,0.649
CI-2020-Q3-2020-11-05,105,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Josh, good morning. It's David. So, first, as a backdrop, as you know, we have had a long history within the Cigna portfolio of integrated offerings from employers, with a deep conviction relative to integrating those offerings with medical off of the then Cigna PBM, behavioral health, and care management services and that continues.",0.372328,0.727
CI-2020-Q3-2020-11-05,106,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","The combination helps us further strengthen that value proposition in terms of furthering the affordability dimension of it, but also bringing some more systemic flexibility for solution design that we can bring toward middle market and larger client from that standpoint. And I would say that that continues, continued traction relative to the integrated proposition.",0.9646327,0.863
CI-2020-Q3-2020-11-05,107,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","In addition to that, our results show the underlying strength of the pharmacy services from a point solution as we think about it or a specific either PBM, PBM and specialty, or broader suite of services around that. And then through Evernorth, we see the opportunity to further expand that by coordinating, say, behavior health with pharmacy services going forward.",0.7182277,0.863
CI-2020-Q3-2020-11-05,108,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So to the core of your question, our strength and momentum continues, the strong clinical outcomes we are delivering continues, many employer/buyers value that integrated proposition and were oriented around that within the Cigna brand, but some larger corporate buyers orient still around either an a la carte or point solution and increasingly looking for some additional leverage around that, we talked about coordinated benefits by bringing, say, pharmacy and behavioral together to coordinate those services and as a combined corporation with the Cigna brand and the Evernorth brand, we are really well-positioned to deliver for either buyer orientation.",0.7260008,0.883
CI-2020-Q3-2020-11-05,111,Question,2020-11-05,3,2020,Kevin Fischbeck,Bank of America / Merrill Lynch,"Hi. Great. Thanks. I wanted to ask about the commercial membership trends. In the quarter, you mentioned that things are getting better in part because of furloughs or also in part because of your customer segments that you are targeting. It sounds like you are assuming that attrition will accelerate in the future. But I guess, have your thoughts changed at all about the size of the decline that you might see during this recession and how resilient your customer membership might be over the next few quarters even with unemployment at these levels?",0.7774373,0.739
CI-2020-Q3-2020-11-05,112,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So, Kevin, good morning. It's David. First, as we get into the commercial conversation, I do want to pause for a second and recognize from what we see is just a tremendous contribution that employers are making right now in these disruptive times facing COVID.",0.5592693,0.291
CI-2020-Q3-2020-11-05,113,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","We are seeing employers of all sizes work, stretch, innovate to do everything possible to support their employees and their family members, whether those are expanded services, additional coverages relative to testing and treatment costs.",1.1550719,0.71
CI-2020-Q3-2020-11-05,114,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And they are working tirelessly to either minimize the layoffs or when they need to transpire, doing them through furloughs and having coordination. So I do think it's important to pause there and recognize the power of that system right now and corporations of all shapes and sizes working really hard to support individuals.",1.2394092,0.472
CI-2020-Q3-2020-11-05,115,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to membership, as Eric noted, in the big picture of a disruptive environment, we are pleased with our performance. Our portfolio tends to be well-positioned by industry sub-segment and our transparency of our programs has us highly aligned with employers.",0.7050136,0.153
CI-2020-Q3-2020-11-05,116,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","For example, through the third quarter, our employer clients because of our transparent funding mechanisms have about $3 billion less spending than they otherwise would have projected to have given the environment and the continuity of cash flow that takes place around that is quite helpful, above and beyond that we have taken some additional steps.",0.9673533,0.475
CI-2020-Q3-2020-11-05,117,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","As we look forward, we know it's a disruptive environment. We expect right now as we look at the environment that we will continue to see employer customer disruption throughout the residual part of this year and into 2021. That's factored into our outlook when we talk about 2021 in detail. Next quarter, we will try to give you more insight relative to that.",1.0660707,-0.586
CI-2020-Q3-2020-11-05,118,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","We are expecting, net-net, with our new growth, as well as retention as well this enrollment, we would go from the end of this calendar year's number to the beginning 2021 with approximately stable commercial membership, as we continue selling to Select segment, continue to have some retention losses, but all within our strategic range.",0.711232,0.422
CI-2020-Q3-2020-11-05,119,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And then throughout the course of the year, while we expect to see some continued disenrollment pressure, our outlook relative to growth is quite positive with some known traction into 2021. We expect to see some slight growth going forward.",0.8184998,0.784
CI-2020-Q3-2020-11-05,120,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So, all in all, in a highly disruptive environment, we are very pleased with the results were able to deliver and we are fortunate to be partnered with so many commercial clients that are putting their employees first front and center.",0.3202487,0.542
CI-2020-Q3-2020-11-05,123,Question,2020-11-05,3,2020,Ralph Giacobbe,Credit Suisse,Great. Thanks. Good morning. I was hoping you talk a little bit more about how the onboarding Prime has gone and the opportunity not just on the retail but on the specialty side? And how the option or I guess options perhaps works for each of the blues? And then what impact that could have either in 2021 or if we have to consider a certain cost and whether it's more of 2020 impact? Thanks.,0.2746734,0.936
CI-2020-Q3-2020-11-05,124,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, Ralph. So, first and foremost, relative to Prime, as I noted in the prepared remarks, we work every day to try to earn that right to be as we call it an undisputed partner of choice. It's a strategic imperative. It guides our actions and underlying that, we need to have the products, programs and services to deliver value. But we also have to have the orientation to partner and to seek mutual alignment.",1.0342013,0.735
CI-2020-Q3-2020-11-05,125,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","We are pleased with the early configuration with Prime. We established that and stood up in April of this calendar year and it's performing well. The further dedication we had around Evernorth and our performance relative to that first expansion services earned us the right, as we noted, too and the opportunity to be able to serve Prime in a more expansive basis. We will see that growth continue systematically throughout 2021.",1.1107656,0.856
CI-2020-Q3-2020-11-05,126,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","As I noted in my prepared remarks, the plans have choices. We are a choice-based framework. But the, for example, the Accredo value proposition is a tremendous value proposition and we are excited to expand that starting in January 1st for many of the Prime plans.",0.6051302,0.856
CI-2020-Q3-2020-11-05,127,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director",There's investments -- there's ongoing investments we are making. That's factored in to our outlook for this year. There will be further investments we are making in the fourth quarter of this year for the tremendous underpinning of growth around that.,0.8091722,0.382
CI-2020-Q3-2020-11-05,128,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","But we are well-positioned to be able to make that happen and achieve our goals and objectives for 2020 that Eric noted in terms of our refreshed objective and as we get into the detailed 2021 guidance next quarter, we will try to give you a little bit more color.",0.6704236,0.0
CI-2020-Q3-2020-11-05,129,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","But we just see this as an ongoing expansion of a mutually beneficial relationship, where we are able to create together some tremendous value that individuals will benefit from as we expand those we are able to serve.",1.7574815,0.893
CI-2020-Q3-2020-11-05,133,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Matt, it's Eric. Good morning. So, with respect to the component pieces, I touched on it a little bit on my prepared remarks, but to unpack the components. I would have you think about putting COVID aside, utilization being slightly below kind of what we would have said would be normal. So call it 95%-ish for the third quarter in terms of kind of normal levels of utilization.",0.3205174,0.556
CI-2020-Q3-2020-11-05,134,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"When you add on top of that the impact of testing and treatment for COVID and on top of that the additional actions that we have taken to reduce barriers or reduce cost sharing and to ensure our customers have access to the care, that puts you all together a little bit above the normal.",0.811714,0.881
CI-2020-Q3-2020-11-05,135,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"And you might remember, in the second quarter, we had set an expectation that the loss ratio for the second half of this year would be elevated relative to what you otherwise might call it a normal loss ratio. So when you put those pieces together, those are that big building blocks.",0.9414301,-0.671
CI-2020-Q3-2020-11-05,136,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"The only other thing I note is, it really does vary by geography. So as we have had the COVID play in and out of different geographies that kind of move things up and down and such. But, again, when you roll it all up together in aggregate, it would be consistent with what I just described.",0.8056055,0.34
CI-2020-Q3-2020-11-05,140,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yeah. Scott, it's Eric. Good morning. So I would not call out any particular initiative or program. I think about the opportunity here as really being much more in our continued ongoing drive for improving affordability of our services overall. I mean, just think about things like leveraging technology, improving the efficiency, automation, et cetera, of all the different processes throughout the organization. But, I think, again, it's just part of the culture of us continuing to create efficiencies versus any particular program.",0.5167086,0.965
CI-2020-Q3-2020-11-05,144,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","It's David. Let me take it in reverse order. So when we step forward and put forth the CPI goal and objective, I think, it caused the market to question whether or not that was theoretical possible or otherwise. But it was a conversation that needs to be had, because we established it around an orientation that it was a symbol of sustainability, not that it was perfect, but it's a symbol of sustainability.",0.61096,0.329
CI-2020-Q3-2020-11-05,145,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Said otherwise, if total basket of goods costs from a societal standpoint are increasing by X, whatever X is, 2%, businesses need to find a way to approximate that to create a level of sustainability or better from that standpoint.",0.3408473,0.612
CI-2020-Q3-2020-11-05,146,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And we are proud of the fact that we have delivered the lowest medical cost trend, and by the way the lowest pharmacy trend in our space as best anybody could tell apples-to-apples year in, year out. So that continuation is mission critical. This is a unique year, as everybody knows, relative to COVID in terms of disrupting the trend. But we continue to drive toward that.",0.54178,0.202
CI-2020-Q3-2020-11-05,147,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Second within the context of your question, we see many, to your term, disruptive or innovative models to drive step function improvements and we have many clients today pre-COVID that are benefiting from CPI or well better than CPI trend who are on the highly innovative dimension of consumer engagement, incentive alignment, heavy leverage and utilization of value-based care provider groups and center of excellence leverage from that standpoint, et cetera, et cetera.",0.7170618,0.971
CI-2020-Q3-2020-11-05,148,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So, you used the word disruption, I will use the word innovation. We see the need for relentless drive relative to that, because as I noted in my prepared remarks, we can't continue to afford and no society can continue to afford paying at the levels that are being driven.",1.3921492,0.0
CI-2020-Q3-2020-11-05,149,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","The last point I'd make here is, our open-framed partner orientation has us embrace, if you will, innovators or disruptors be they care delivery systems or alike from that standpoint. So, more to follow here. I appreciate you highlighting it and we remain extremely committed to driving optimal value here.",0.2320249,0.926
CI-2020-Q3-2020-11-05,150,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to your first point, there's a bunch of, I'd say, hypotheticals and theoreticals within that. The way I hear your first point though more broadly is, it's another example of pressing for a sustained affordability 340B was designed with a specific purpose and intent in mind.",2.1399145,0.0
CI-2020-Q3-2020-11-05,151,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","There are many hospitals and delivery system infrastructures that need 340B to make them work. It's an interesting time to have that conversation, whereby delivery system infrastructures are strained in ways we haven't seen in the past due to COVID causing massive revenue ramifications, of which governmental intervention and some player like our self and others in our space are providing support from that standpoint.",0.6455499,0.637
CI-2020-Q3-2020-11-05,152,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So, it's an interesting time to have that theoretical conversation, but unlike most programs it will most likely evolve and our broader service portfolio is positioned to evolve with it.",0.6886902,0.246
CI-2020-Q3-2020-11-05,157,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, Rob. It's David. I will take the first question and I will ask Eric to address your second question. The simple answer is, no. We don't see a C change in terms of buyer behavior relative to wanting more of or less of. It's one client at a time. We have a very much of a consultative orientation trying to find the right configuration of benefits and funding mechanisms that work for clients.",0.5176836,-0.077
CI-2020-Q3-2020-11-05,158,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Now, within that, our Select segment is an integrated offering, full stop, period, the end. It's designed to be an integrated offering, whether it's on an ASO platform or a guarantee cost platform.",1.4073066,-0.052
CI-2020-Q3-2020-11-05,159,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","As you move upmarket into commercial employer space within middle market and national accounts, you see different buying behaviors and it ebbs and flows. And I think the important message here is that, as an entity, we are extremely well-positioned to deliver what a client wants, whether they want a fully integrated offering, whether they want a point solution, a best-in-class PBM or best-in-class specialty pharmacy or both from that standpoint, or increasingly you are looking to get some additional value off coordination of services, be it care management services, behavior health, et cetera, relative to that.",1.1811115,0.852
CI-2020-Q3-2020-11-05,160,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","But I wouldn't say there's a C change. I would say think about Evernorth and Cigna together as being extremely well-positioned to deliver on the value that buyers want, be it integrated, point solutions if you want standalone pharmacy services in this case or evolving some coordination of services to get another step function of value that come along with that. Eric?",0.7260008,0.727
CI-2020-Q3-2020-11-05,161,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yeah. On the G&A ratio, in particular, there's just a couple of things I call out here. At the most macro level, we do continue to spend and continue to invest in building additional capabilities in this business and you see that in the G&A.",0.9762846,0.296
CI-2020-Q3-2020-11-05,162,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"There are a couple of other impacts that caused it as well. One, as you might remember, we talked a bit in the past, after the close of the acquisition, just kind of rebuilding of the amortization. So the amortization on the assets you acquired gets reset and then we have to rebuild that expense into that -- have built over the -- up over time.",0.5878548,0.612
CI-2020-Q3-2020-11-05,163,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Offsetting that is us continuing to work to find synergies and find additional efficiencies. So, again, those would be the biggest buckets that play into that ratio in any given quarter. But it's not we will be looking to continue to spend and build additional capabilities there as we go forward.",0.3043478,0.612
CI-2020-Q3-2020-11-05,167,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Lance, good morning. It's David. I will take the first part of your question. I will ask Eric to take the second part of your question. I think to frame the first part of your question broadly is, first and foremost, we need to earn the right to serve clients each and every day.",1.1853867,0.44
CI-2020-Q3-2020-11-05,168,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","We were fortunate to be selected to be a partner with Prime as we set up the opportunity earlier this year, began servicing them in April and those service offerings are working quite well. That positioned us and was -- reinforced with our commitment with Evernorth to expand those services and we will have the ability to grow at a choice based on the Prime participants as they so choose relative to our specialty pharmacy and alike.",0.7924602,0.923
CI-2020-Q3-2020-11-05,169,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","It allows us to have an opportunity to mutually grow together. Your point relative to the sell-through and otherwise, our team is focused on strengthening the value proposition of Prime and of the Prime members -- member plans to have more value offered to their customers and grow their portfolio businesses, full stop.",0.8923436,0.881
CI-2020-Q3-2020-11-05,170,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","That is the commitment of the team supporting the Prime relationship, and therefore, it should allow for us to continue to grow off of the existing platform. It should allow for us to continue to grow as the Prime representation grows and it should allow us to continue to grow, as to your point, their sell-through has more traction on a go-forward basis and our business model is designed to do so.",1.0217645,0.848
CI-2020-Q3-2020-11-05,171,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So stay tuned for more. But the positioning that we have today we really love, because now we will be able to leverage our high performing specialty portfolio, as well as our very strong and well-performing a mail order pharmacy services operation for their benefit. Eric?",1.3641663,0.921
CI-2020-Q3-2020-11-05,172,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yeah. On the specialty contribution, Lance, to the comments that I made around specialty contributions here refers to the portfolio of specialty capabilities we have benefits overall. So things like health, behavioral, disease management, care management, et cetera, et cetera, et cetera. This has been a core part of our go-to-market approach for some time and a high performing business.",0.5576716,0.868
CI-2020-Q3-2020-11-05,173,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"And as you know, we did call out, a bit lower contribution from these products in the quarter. And as you think about a couple of items here, one, as an example, we have seen significant increases in behavioral costs in 2020 in the third quarter in particular. Utilization there above our prior expectation as we have seen stresses and anxiety take a toll just on the mental health of the nation at large, one.",0.6791232,-0.625
CI-2020-Q3-2020-11-05,174,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"And then, two, the impact our volumes, right? So as we had a little bit of lower volume that comes through this business as well. But those would be the items that I'd refer to you in terms of specialty contributions.",1.015451,0.042
CI-2020-Q3-2020-11-05,178,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Hi, Sarah. It's Eric. So on the -- good memory, I remember your question from the last call as well on that front, and I would still say, we haven't seen a change in speed of submission or anything along those lines from a claims perspective.",1.1250449,0.612
CI-2020-Q3-2020-11-05,179,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now the month of June, as I noted in response to one of the other questions and in my prepared remarks that, the most recent month we estimate really based more off of our estimation of activity, not so much extrapolating from kind of the claims that have been received yet or anything along those lines.",0.6859504,0.226
CI-2020-Q3-2020-11-05,180,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"So, and as I noted, all else equal, we would have exited the month of June now a bit higher than what we did a quarter ago. But think of that as pretty isolated in terms of the impact. As we now have looked at the development of June and looked at our experience in July, August, September even if the emerging experience from October seem quite consistent in terms of the return to normal, the levels of utilization, levels of speed of processing, et cetera.",0.3327345,0.226
CI-2020-Q3-2020-11-05,181,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"And if you look at our day claims payable metric, well, that metric is not perfect, I mean, you see actually a pretty good degree of consistency in terms of the basically entail the metric for where we sit here at the end of third quarter 2020 compared with prior third quarters or things along those lines. So, at a macro level, quite comfortable that we have got the right estimates and such year, and the estimation of claims and the overall speed of utilization, et cetera.",0.1918793,0.831
CI-2020-Q3-2020-11-05,183,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yeah. So we placed through -- yeah. So we placed through the assumptions consistently by month. So, again, just to unpack that a bit further, we had estimated the month of June, I made some comments a quarter ago about June being closer back to normal levels of utilization with the benefit of hindsight, it was much closer to normal.",0.2285304,0.751
CI-2020-Q3-2020-11-05,184,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"So, previously, think about that as having been the single-digit closer to kind of a zero level of variation from utilization and we placed those types of assumptions all the way through in terms of each of our estimates for the month since then. So, again, we would think that the June impact was isolated to the month of June.",0.2450593,-0.318
CI-2020-Q3-2020-11-05,186,Question,2020-11-05,3,2020,Stephen Tanal,Goldman Sachs,"Good morning, guys. Thanks for the question. I guess, David, I hope to follow-up in your comments in the commercial market and clarify the point about enrollment into 2021, maybe tie that back to the selling season for group accounts. I think I heard national accounts enrollment might be down 20%, 21%, but offset by Select and middle market growth. I just wanted to clarify that? And also wondering if you could elaborate on your comment in the actions employers are taking in response to the pandemic as it relates to this business. Are you seeing benefit buy down there, what kind of innovation that you mentioned is resonating with employers into 2021, maybe if you could give us a sense for how pricing is going in the group insured side as well that would be helpful?",1.2976689,0.953
CI-2020-Q3-2020-11-05,187,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning. Let me take it in reverse order. So specific to employer actions, obviously, unique to each employer, but if we step back and talk about a few of the general trends. First and foremost, the press for improved affordability and value transcends buyers of all shapes and sizes.",0.8596969,0.848
CI-2020-Q3-2020-11-05,188,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And through our both prepared remarks and our dialogue today, we continue to reinforce the actions we are taking relative to further improvement of affordability and value trend deflection in the light from that standpoint and our results remain quite strong relative to that.",0.6490478,0.872
CI-2020-Q3-2020-11-05,189,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Beyond that, employers are both reaching. So expanding services of a self-funded employer determines, are they going to waive the cost responsibility for individuals around testing, around treatment from that standpoint, example one.",0.7407695,0.202
CI-2020-Q3-2020-11-05,190,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Two, are they going to expand services for telehealth or virtual service fulfillment at little to no cost from that standpoint? Many employers have expanded those services.",0.3120871,0.097
CI-2020-Q3-2020-11-05,191,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Third, pressing, as Eric articulated before to recognize that the behavioral challenges that had been ramping from a societal standpoint, as we have been oriented around mind and body, have stepped up to another threshold level.",0.2903226,0.077
CI-2020-Q3-2020-11-05,192,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So, reaching for identifying additional, we will call it, behavior health and wellbeing services to help to deal with beyond the core of what mental health services are dealing with around stress or on anxiety, around resiliency, around loneliness from that standpoint.",1.0695686,-0.363
CI-2020-Q3-2020-11-05,193,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So we are seeing employers step into a whole variety of actions and press from an innovation standpoint, press themselves from a care delivery standpoint, et cetera, before we get to the decisions they make when they decide to furlough somebody versus lay them off to try to have continuity of benefits for the benefit of those individuals.",0.8616401,0.886
CI-2020-Q3-2020-11-05,194,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Back to the comments relative to the selling season, I must try to provide a little bit of direction there so I punch it up a little bit, but we will go through the appropriate detail on the fourth quarter call.",0.6758647,0.0
CI-2020-Q3-2020-11-05,195,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","What I indicated is as we look at the overall commercial medical customer environment. First and foremost, our results through three-quarters of this year are strong, given the dislocations happening in the environment and our overall portfolio continues to perform well from that standpoint.",0.0579091,0.66
CI-2020-Q3-2020-11-05,196,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Second, I indicated that as we sit here today, we would expect that the medical membership that will end the year with and we expect to see continued disenrollment pressure throughout the course of this year. The medical membership that will end this year with will be about the same medical membership we will have on January 1 plus or minus. There's puts and takes there.",0.4298484,-0.296
CI-2020-Q3-2020-11-05,197,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","There's always some lost accounts. Although, our retention outlook is quite strong. There's always some one accounts that come through from that standpoint and this enrollment will continue. The net of all that in the month of January, our estimation is that we will be about stable and that we will see some membership growth throughout the course of the year.",1.0559658,0.726
CI-2020-Q3-2020-11-05,198,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","In part, what you heard with that is the Select segment sells every month. Every month is the most important month for that segment. So we will see continued growth contributions come along relative to that.",1.3365721,0.571
CI-2020-Q3-2020-11-05,199,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","We have visibility relative to some additional growth in the mid part of the year, and then ultimately, we are expecting that the disenrollment pressure in 2021 will continue at a minimum throughout the first half plus of 2021. So I hope that color helps you kind of shape both what we are seeing in terms of the buying environment as well as what we are seeing relative to our outlook.",1.2199767,0.807
CI-2020-Q3-2020-11-05,203,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning. It's David. So as we step back to think about there's two different examples to use the digital formulary and Embarc, but embedded in the first part of your comment. As we look at what the COVID environment has done, it's probably jumped multiple years of adoption relative to additional services from that standpoint.",0.1542946,0.238
CI-2020-Q3-2020-11-05,204,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Not unique to our industry but specific to our industry, as we take telehealth and as we take the kind of re-envisioning what can be fulfilled in the home, both safely and a highly personalized way in a more affordable way, leveraging technology in a different way.",0.7780801,0.84
CI-2020-Q3-2020-11-05,205,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So we see, what we call, virtual care, so taking telehealth a little bit more broadly in a more comprehensive way as a market trend that will not reverse itself, where we will see some both tremendous adoption growth, and importantly, value for individuals not just from an affordability standpoint, but from a personalization standpoint through that lens and there are a variety of issues, we have both through partner relationships, we have organic initiatives we have and alike.",0.3047027,0.709
CI-2020-Q3-2020-11-05,206,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Specific to digital formulary, Embarc, I would not ask you to think about any one launch within our portfolio as the launch or the silver bullet. Rather, we are really proud of the fact that even over the first two years as a combined corporation, we have had a consistent drumbeat of new innovations and new offerings that we have been able to bring to market for the benefit of our existing and prospective clients that we are able to serve through that through the Evernorth framework and there's a dedicated innovation infrastructure and body resources there. So, the digital formulary has had very good receptivity.",0.3260785,0.935
CI-2020-Q3-2020-11-05,207,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Embarc, Embarc is a little bit of a different value proposition, where it's client-by-client opportunities, but it also is indicative of us changing the narrative, trying to take a problem statement that societies said is unsolvable relative to the high cost game changing super specialty drugs from that standpoint and trying to turn it into a more affordable, predictable simplified offering and you should expect us to bring more offerings akin to that to the marketplace. So we see those as positive contributors, indications of also our conviction relative to innovation and conviction relative to value delivery, and it's contributing to our revenue growth chassis.",0.4135251,0.964
CI-2020-Q3-2020-11-05,210,Answer,2020-11-05,3,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yeah. Ricky, it's Eric. I will start. So, in terms of calling anything out in the quarter, I really wouldn't note any particular impact. I think the potential here is meaningful in the future. So quite excited about the future opportunity as there are more therapies and treatments in the market and things along those lines, but I wouldn't call out anything related to the third quarter in terms of notable impact.",0.5389867,0.629
CI-2020-Q3-2020-11-05,211,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Ricky, picking up on an Eric's point, I agree with his statements instead picking up on the opportunity. As we think about biosimilars fallout from a U.S. societal dimension, it represents a tremendous opportunity.",1.4477264,0.796
CI-2020-Q3-2020-11-05,212,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And while it is grounded in supply chain it's by no means limited to supply chain, because the biosimilar dimension, you need to have deep and broad political acumen, both in the pharmaceutical arena, but then the additional reach within the practicing physicians to ensure that the decisions made one patient at a time are grounded in the appropriate clinical orientation.",0.6214536,0.361
CI-2020-Q3-2020-11-05,213,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And as a combined corporation now we not only have the supply chain infrastructure and the deep and well performing pharmacy clinical infrastructure, but we have deep medical relationships through value based care underlying relationships that positions us quite well.",1.0621842,0.891
CI-2020-Q3-2020-11-05,214,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And we are excited to get on with biosimilar adoption rate, where the U.S., if we are honest with ourselves lags, some other countries relative to the approval rate and from an affordability and value standpoint, we need to get on with it and we are well-positioned as a combined corporation to deliver great value there.",1.1080451,0.935
CI-2020-Q3-2020-11-05,219,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning. It's David. So, in your first point, there is there's multiple dimensions within that. But stepping back on the vaccine, in the current configuration, we don't step into this viewing that the vaccine presents a unique revenue generation opportunity. It's a service opportunity. It will be facilitated through Evernorth for sure.",0.983288,0.869
CI-2020-Q3-2020-11-05,220,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","The pricing, the reimbursement structure, et cetera, that will evolve will be very based on the specific vaccines that manifest themselves, as you know. Our political leadership team is highly embedded in the national dialogue relative to this including the distribution, complexity that comes along with these vaccines that our society is starting to get their arms around relative to more than one dose, the continuity that needs to transpire, how society will be kind of prioritized from medical professionals through first responders, to high-risk individuals, et cetera.",0.9813447,0.0
CI-2020-Q3-2020-11-05,221,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director",And we are well configured as a large service provider to be in support of and in service to that initiative and we look forward relative to that. Our team is taking prudent estimates relative to what we think the cost of the vaccines would be relative to 2021 outlook as well through that lens.,0.8865138,0.71
CI-2020-Q3-2020-11-05,222,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","As relates to the Alzheimer's drug, I think, it's another good example of ongoing innovation where as we hit the pause button for a moment and recognize that the vast majority of innovation in the present environment and as we extrapolate forward around healthcare innovation is and will continue to transpire pharmaceutically, right?",0.5755927,0.866
CI-2020-Q3-2020-11-05,223,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","The chapter is evolving on an accelerated basis that clinical innovation globally will be heavily pharmaceutically oriented from that standpoint. And the Alzheimer drug, which is quite exciting from a societal standpoint, is also extremely complex and costly. Hence having market leading specialty pharmacy capability per Accredo position does quite well and to your last point, presents additional opportunities to potentially expand the Embarc program, which we would suggest would transpire over time.",1.3124757,0.894
CI-2020-Q3-2020-11-05,224,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So I think it's a good concrete example of what the future has in store relative to very exciting and life-changing drugs, but also highly complex and costly and having the capabilities to be able to serve and support that, whether who the Alzheimer drug you just questioned or previously Ricky questioned relative to biosimilars going the other way, our Evernorth portfolio is really well-positioned to be able to create great value for society here.",1.1585698,0.944
CI-2020-Q3-2020-11-05,226,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Thank you. So as we wrap up here, I'd like to first and foremost acknowledge Cigna's more than 70,000 colleagues around the globe, who again have worked tirelessly and with great empathy throughout this pandemic in support of those we are able to serve around the world, customers, patients and clients. Our mission at Cigna to improve the health, wellbeing and peace of mind of those we serve has never been more important and continues to guide all the actions.",0.8581422,0.947
CI-2020-Q3-2020-11-05,227,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Specific to Evernorth, it represents an exciting new chapter for our company and along with our other growth platforms, we seek to leverage our broad suite of capabilities to create innovative and flexible solutions to tackle some of society's toughest healthcare issues and drive sustained growth.",0.9261562,0.929
CI-2020-Q3-2020-11-05,228,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","From a results perspective, we once again deliver strong results this quarter and remain on track to complete the integration of Cigna Express Scripts by the end of this calendar year. We are also well-positioned to deliver very strong revenue and EPS outlook for 2020, as well as our 2021 EPS target of $20 per share to $21 per share.",0.702293,0.902
CI-2020-Q3-2020-11-05,229,Answer,2020-11-05,3,2020,David Michael Cordani,"President, Chief Executive Officer & Director","With that, we thank you for joining our call. Hope everybody remains healthy and safe in these trying times. Thanks.",0.169452,0.917
CI-2018-Q4-2019-02-01,13,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks Will. Good morning everyone and thank you for joining our call today. I'll begin my comments with highlight from our exceptional 2018 financial results with Cigna delivering substantial revenue and earnings growth across our businesses. I will also review how our combination with Express Scripts further strengthens the affordability of our programs, expands choice for those who we serve. Then I'll offer initial insights into our exceptional expectations for 2019 before Eric addresses our full-year 2018 financial results and 2019 outlook in more detail. Eric and I will take your questions after which I'll wrap up our call with a few closing comments.",0.2052079,0.948
CI-2018-Q4-2019-02-01,14,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Let's dive in to review some of our performance highlights from last year where we delivered strong revenue and earnings growth. Our full-year consolidated adjusted revenue increased by 15% to $48 billion and we reported full-year adjusted income from operations of $3.6 billion or $14.22 per share representing a per share increase of 36%. These results were driven by substantial growth in contributions across each of our businesses including strong retention levels, the continued expansion and deepening of our customer and client relationships, and solid new growth across our portfolio.",1.5546055,0.971
CI-2018-Q4-2019-02-01,15,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Cigna also delivered industry-leading medical cost trend for the sixth consecutive year. Our sustained market-leading performance will further be strengthened as we integrate and leverage the core capabilities of Express Scripts. Express Scripts concluded 2018 with continued strong performance and delivered its lowest commercial pharmacy trend on record of 0.4% details of which will be provided next week in our annual Drug Trend Report. Express Scripts also achieved better than 98% client retention for 2019 all while continuing to invest in innovations to benefit customers, patients, clients, as well as healthcare providers.",1.5837544,0.889
CI-2018-Q4-2019-02-01,16,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Overall Cigna delivered very strong results in 2018 with growth across our portfolio of businesses. Our continued growth reflects Cigna's proven approach to service integration and how it delivers real value for the benefit of our customers, patient, clients and healthcare provider partners.",0.0171007,0.922
CI-2018-Q4-2019-02-01,17,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Our recent report on the value of integration which was externally validated show the clients with Cigna medical, pharmacy, and behavioral benefits reduce annual medical costs by an average of $645 for each person with an identified health improvement opportunity. Savings can increase to nearly $10,000 for individuals with certain chronic conditions. As we look forward, Cigna is evolving our definition and approach to integration, driven by the insights we gain from a deeper understanding of our customers, as well as the broader capabilities from our Express Scripts combination.",1.6121259,0.962
CI-2018-Q4-2019-02-01,18,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director",Our approach to integration focuses on the coordination of services around the individual and their whole person health needs; both body and mind. This approach also further expands choice to accesses available anytime anywhere based on our customer and patient's needs and preferences. To do this we must remove friction and help our customers and patients connect to the services which are best aligned to their health status.,0.1752818,0.807
CI-2018-Q4-2019-02-01,19,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","In an environment where some are restricting access in order to nearly drive affordability, at Cigna we see an opportunity to further expand customer choice and to make it easier for people to access the health services they need, how and when they need them. This includes accessing care in a doctor's office, an urgent care center, a retail setting or an employer clinic or for more acute needs at a facility-based setting such as a hospital or outpatient service center. Increasingly, at home in a coordinated fashion and through digital platforms that are linked with the healthcare professionals.",0.0478041,0.91
CI-2018-Q4-2019-02-01,20,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","This choice-based delivery model also allows us to guide our customers and patients toward solutions that help the healthy stay healthy, better predicting address risk factors for the healthy at risk and ensure we deliver affordable high quality healthcare choices for the chronically ill as well as those facing acute conditions. Making it easier for our customers and patients is important, but is also critical for healthcare provider partners.",0.2681695,0.66
CI-2018-Q4-2019-02-01,21,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","At Cigna, we see our roles being the connective tissue that links customers and patients with the healthcare providers in order to help them improve their health and well-being. We continue to partner align with and enable healthcare providers rather than seeking to own, compete with or disintermediate them. Our combination with Express Scripts strengthens and accelerates our focus on coordinating services around our individual customers and patient needs.",0.160513,0.823
CI-2018-Q4-2019-02-01,22,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","One of the steps that is essential for Cigna to unlock additional value for stakeholders is the effective integration and leveraging of Express Scripts' capabilities. Our immediate priority is to ensure we deliver on our commitments to customers, patients and clients in 2019 and our position to do so in 2020. This includes the strong service delivery we were able to create in January 2009 an important implementation period.",0.6066848,0.93
CI-2018-Q4-2019-02-01,23,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","I couldn't be more proud and appreciative of our teams' focus, passion, and delivery as we stepped into 2019. As a health service company we see our 74,000 coworkers around the world as the greatest asset we have in carrying out our mission and delivering exceptional value for those we serve.",0.4205208,0.96
CI-2018-Q4-2019-02-01,24,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","As we move through 2019 and beyond with a focus on improving affordability, expanding choice, and broadening our reach, we have three key areas of focus; first, to optimize the significant medical and pharmacy costs synergy opportunities which will directly benefit our customers, patients, and clients and help to improve affordability; second, to harness the breadth and depth of our combined data to better predict and identify conditions or behaviors and improve connectivity between our customers, patients, and healthcare providers; and third, to leverage new growth opportunities and expand reach across our businesses as we enter new geographies and broaden our solution portfolio.",1.4073066,0.985
CI-2018-Q4-2019-02-01,25,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Let me use Accredo as an example of how we will create real value in improving affordability and leveraging data, the first two items I referenced. Accredo, Express Scripts' specialty pharmacy business brings a comprehensive patient-centered care model to improving, prescribing, adherence, and clinical program coordination. Accredo has more than 500 specialty pharmacists and a field force of 550 nurses providing in-home care across the United States.",0.431403,0.96
CI-2018-Q4-2019-02-01,26,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","In fact, an Accredo at-home nurse is within just one hour of a home visit for 85% of Americans today. Cigna plans to begin leveraging specialty pharma services from Accredo in 2019 to deliver affordability improvements and better health outcomes for our customers and clients. Considering the specialty pharmacy is the fastest growing cost category in healthcare today, this will create clear and meaningful affordability benefits.",1.5456665,0.926
CI-2018-Q4-2019-02-01,27,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Second, when looking at leveraging data, today Accredo and Express Scripts apply advanced informatics to identify patients who are likely to be non-adherent or have demonstrable gaps in care. For example, Bluetooth-enabled health monitoring devices tied to blood glucose monitors or rescue inhalers track patient's health in real-time basis and trigger targeted outreach and support.",1.577536,0.906
CI-2018-Q4-2019-02-01,28,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Moving forward, we will further strengthen and deepen the actionable sites for this type of pharmacy data by connecting with our medical and behavioral data. Additionally, we will share resulting insights with our collaborative accountable care physician partners to further improve their patients health outcomes. Connecting our physician partners with these actionable insights is especially important when supporting people who suffer from chronic conditions.",0.0905558,0.885
CI-2018-Q4-2019-02-01,29,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","For example, those with chronic conditions are seven times more likely to suffer from depression and as many as six in 10 Americans live with at least one chronic condition, all of which further demonstrate the importance of effectively leveraging medical, pharmacy, and behavioral data to drive better health.",1.5270113,-0.042
CI-2018-Q4-2019-02-01,30,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Building on the consultative selling success, Cigna and Express Scripts teams, our teams are already on a targeted basis identify and pursuing new enterprise growth opportunities. An example includes expanding PBM services for some health plans that we currently serve through Cigna's payer business. Additionally, we have already engaged in targeted expansion opportunities for Cigna health management capabilities to be offered to Express Scripts health plan clients. Taken as a whole, our integration and value creation initiatives are off to a very strong start and we look forward to discussing this in more depths with you at our Investor Day on May 31.",1.5009716,0.965
CI-2018-Q4-2019-02-01,31,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Before I close, let me briefly comment on our 2019 outlook. Our growth [indiscernible] has a proven track record of delivery and provides multiple paths for sustained growth in 2019 and beyond. For 2019 we expect revenue growth, attractive EPS growth, and strong free cash flows, all positioning us to deliver 15% average annual EPS growth over the next three years and enabling us to achieve our $20 to $21 EPS target in 2021.",0.27089,0.966
CI-2018-Q4-2019-02-01,32,Remarks,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","To conclude, our team, strategic framework, along with capital position and significant free cash flow position us to lead in an environment of continuous change, improve affordability, expand choice and enhance predictability for our customers, patients, and clients all while focusing on treating the whole person; both body and mind. We are positioned to continue delivering attractive sustainable growth. We have significant strategic flexibility and financial flexibility and high visibility towards achieving our 2021 EPS target of $20 to $21 per share.",0.18733,0.967
CI-2018-Q4-2019-02-01,34,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Thanks, David. Good morning everyone. In my remarks today I will review Cigna's 2018 results and provide our outlook for 2019. Key consolidated financial highlights for 2018 include adjusted revenue growth of 15% to $48 billion, earnings growth of 33% to $3.6 billion after-tax, earnings per share growth of 36% to $14.22, and continued strong operating cash flow. These results reflect the underlying strength of our business and provide us with considerable momentum as we drive growth and advance our integration priorities in 2019.",0.2705713,0.972
CI-2018-Q4-2019-02-01,35,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Regarding our segments, I'll first comment on Integrated Medical. 2018 revenues grew 13% to $33 billion, driven by commercial customer growth and expansion of specialty relationships, as well as premium growth reflecting underlying cost trends. We ended 2018 with $17 million global medical customers driven by an organic increase of $584,000 lives led by growth in our select, middle-market and government segments.",1.1225296,0.881
CI-2018-Q4-2019-02-01,36,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"As we completed our eighth consecutive year of organic medical customer growth, we continue to grow in both risk and ASO funding arrangements with a highly consultative approach that aligns affordable solutions with the needs of our customers and clients. Full-year earnings grew 20% to $3.5 billion on a pretax basis reflecting growth in medical customers and specialty relationships, continued effective medical cost management, and favorability in our U.S. individual business.",0.8181818,0.785
CI-2018-Q4-2019-02-01,37,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to medical costs, for our total U.S. commercial book of business full-year medical cost trend for 2018 was 3.6%. We are pleased to have delivered industry-leading medical cost trend results for a sixth consecutive year and we are focused on further expanding our capabilities to improve health outcomes and medical cost performance which drives increased value for customers and clients as they continue to confront challenges with the affordability of healthcare.",0.8763924,0.889
CI-2018-Q4-2019-02-01,38,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Our combination with Express Scripts accelerates our ability to create that value enabling us to drive further personalization of services and deeper engagement and collaboration with customers, patients, clients and healthcare professional partners. Our total medical care ratio or MCR of 78.9% for full-year 2018 reflects the continued effectiveness of our medical cost management capabilities in both our commercial and government businesses, favorability in our U.S. individual business, and the pricing effect of the resumption of the health insurance tax.",2.3489041,0.9
CI-2018-Q4-2019-02-01,39,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Full-year 2018 Integrated Medical earnings benefitted from $97 million pretax a favorable net prior year reserve development including $8 million of favorable prior year development in the fourth quarter. I would note that Days Claims Payable or DCP was 40.7 at December 31, for the Integrated Medical segment, reflecting an increase of 0.7 days over the prior year and a decline of 2.9 days sequentially due to the normal fourth quarter claim payment seasonality in our STAR+PLUS business and consistent with prior years.",1.2791951,0.881
CI-2018-Q4-2019-02-01,40,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Days Claims Payable is generally lower for the Integrated Medical segment than for our previous Global Healthcare segment as a result of the reclassification of International Healthcare Products which had higher than average Days Claims Payable due to longer claim payment cycles. That business transitioned to the International Market segment. Overall, Cigna's Integrated Medical segment delivered very strong financial results in 2018.",0.4394538,0.338
CI-2018-Q4-2019-02-01,41,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our Health Services business, full-year 2018 revenues were $6.6 billion and pretax earnings were $380 million. Results for 2018 reflect solid performance from Cigna's mail order pharmacy operations and support of our integrated value proposition and contributions from Express Scripts business following the close of the combination on December 20.",0.0750988,0.691
CI-2018-Q4-2019-02-01,42,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our International Markets business, our full-year 2018 results reflect continued attractive growth and profitability as revenue grew to $5.4 billion, an increase of 9% and full-year 2018 pretax earnings grew 12% to $735 million, reflecting solid business growth, continued administrative efficiency, and strategic investments for long-term growth.",0.8181818,0.945
CI-2018-Q4-2019-02-01,43,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our Group Disability and Other Operations segment, full-year 2018 revenues were $5.1 billion. Full-year pretax earnings for this segment increased to $529 million with strong performance from our life business offset by unfavorable disability claims. Overall, Cigna delivered strong growth and profitability in 2018 across each of our growth platforms.",0.7596119,0.933
CI-2018-Q4-2019-02-01,44,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"As I turn to a discussion of our outlook for 2019 and specifically our expectations for continued attractive growth relative to our 2018 performance, I will start by highlighting the headwinds and tailwinds that we've quantified previously. Specifically, the 2018 earnings per share performance should be adjusted for the following three items; a reduction of $0.40 per share of U.S. individual business outperformance, a reduction of $0.30 per share of favorable prior-year reserve development, and finally an increase of $0.20 per share associated with the industry tax, was in place for 2018 but is suspended for 2019. While adjusting for these impacts, Cigna's 2018 earnings per share was $13.72.",0.9816745,0.758
CI-2018-Q4-2019-02-01,45,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"As we continue to drive strong value for our customers and clients, we step into 2019 with momentum in each of our businesses. We remain intently focused on delivering on our promises to the marketplace of outstanding service delivery and clinical quality, continued innovation, and deepened customer and client relationships, all while we continue to advance our integration priorities.",0.823931,0.948
CI-2018-Q4-2019-02-01,46,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,I would remind you that our outlook for 2019 adjusted revenues and adjusted income from operations excludes contributions from transitioning clients. For full-year 2019 we expect consolidated adjusted revenues in the range of $131.5 billion to $133.5 billion. We expect full year 2019 consolidated adjusted income from operations to be $6.2 billion to $6.4 billion or $16 to $16.50 per share. This represents very attractive growth in the range of 17% to 20% over our 2018 baseline.,0.3992095,0.806
CI-2018-Q4-2019-02-01,47,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We would expect the cadence of earnings per share in 2019 to be approximately 45% in the first have and 55% in the second half of the year, taking into consideration seasonality patterns within our businesses with our Health Services segment in particular, driving a greater proportion of its earnings in the second half of 2019, as well as continued progress on realization of administrative expense synergies throughout the year.",0.743083,0.823
CI-2018-Q4-2019-02-01,48,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For 2019 we also project an expense ratio in the range of 10% to 10.5%, which reflects ongoing efficiencies and administrative expense synergies in line with our previous estimate of $112 million pretax. I would also note that our outlook includes approximately $200 million pretax of temporarily stranded operating costs associated with Anthem's early termination of pharmacy services. For 2019 we project a consolidated adjusted tax rate in the range of 23.5% to 24.5%. Additionally, our outlook excludes any contribution from future share repurchases as well as prior year reserve development.",1.2773985,0.71
CI-2018-Q4-2019-02-01,49,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I'll now discuss our 2019 outlook for the Integrated Medical and Health Services segments. We expect full-year Integrated Medical pretax earnings in the range of $3.65 billion to $3.80 billion. This outlook reflects strength and growth in our businesses driven by continued benefits from organic customer growth, deepening of customer relationships, and effective medical cost management. This outlook also contemplates a return to more normalized margins in our U.S. individual business.",1.905857,0.92
CI-2018-Q4-2019-02-01,50,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Key assumptions reflected in our Integrated Medical earnings outlook for 2019 include the following; regarding Global Medical customers we expect 2019 growth in the range of 300,000 to 400,000 customers, driven by continued strong customer and client retention and new growth in our commercial business, as well as mid-single-digit percentage growth in Medicare advantage enrollments and our outlook for medical customer growth also contemplates an expected enrollment decline in our U.S. individual business of approximately 70,000 customers.",0.338843,0.941
CI-2018-Q4-2019-02-01,51,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to medical costs, for our U.S commercial employer book of business we expect full-year 2019 medical cost trend to be in the range of 3.5% to 4.5% with the expected increase over 2018 full-year trend due to expected higher utilization of services as well as continued benefits from our initiatives to improve affordability, including those we are further enabling through the combination with Express Scripts.",1.8135106,0.836
CI-2018-Q4-2019-02-01,52,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We expect the 2019 medical care ratio to be in the range of 80.5% to 81.5% reflecting continued strong performance of our commercial and government businesses, the impact of the health insurance tax suspension in 2019, as well as changes in business mix. For our Health Services business we expect full-year 2019 pretax earnings in the range of $5.05 billion to $5.2 billion. For 2019 we expect adjusted pharmacy claims in the range of 1.17 billion to 1.19 billion claims.",0.0513834,0.823
CI-2018-Q4-2019-02-01,53,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I would note that this range includes all claim volumes associated with Cigna's mail-order and specialty pharmacy operations in addition to claims associated with the acquired Express Scripts business. Our 2019 guidance range is consistent with Express Scripts previous expectations of 2% to 3% growth in core adjusted pharmacy claims. Our guidance does not include Cigna pharmacy claim volumes we expect to transition from OptumRx and consistent with all of our key performance metrics, this guidance range does not include pharmacy claim volumes associated with transitioning clients.",1.4074739,0.382
CI-2018-Q4-2019-02-01,54,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We also expect strong growth in contributions from our International Markets, Group Disability and Other businesses as they continue to deliver more personalized and affordable solutions for the benefit of those we serve.",0.0165289,0.863
CI-2018-Q4-2019-02-01,55,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Regarding interest expense, we expect total costs of approximately $1.7 billion pretax in 2019 inclusive of approximately $900 million of incremental interest associated with the financing of the combination with Express Scripts in the Corporate segment. All in, for full-year 2019, we expect consolidated adjusted income from operations of $6.2 billion to $6.4 billion or $16 to $16.5 per share. This represents 17% to 20% growth over our 2018 baseline.",1.1879267,0.869
CI-2018-Q4-2019-02-01,56,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,I would also remind you that our outlook continues to exclude the impact of future share repurchases and prior year reserve development. Overall these expected results represent a very attractive outlook aided by strong performance of our diverse and differentiated portfolio of businesses and the highly accretive combination with Express Scripts. These expected results are also consistent with our multiyear growth outlook and position us well to achieve our 2021 earnings per share target of $20 to $21 per share.,0.6521739,0.931
CI-2018-Q4-2019-02-01,57,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now moving to our 2019 capital management position and outlook, our subsidiaries remain well-capitalized and we expect them to continue to drive exceptional free cash flow with strong returns on capital even as we continue reinvesting to support long-term growth and innovation. In 2018 we deployed $130 million of parent company cash to repay current maturities of long-term debt. We completed our debt offering to finance the combination with Express Scripts and we repurchased $1.6 million shares of stock for $329 million with the resumption of share repurchase following the close of the combination.",0.1512756,0.917
CI-2018-Q4-2019-02-01,58,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We ended 2018 with a debt to capitalization ratio of 50.9%. As previously discussed, our top capital deployment priority is accelerated debt repayment with the objective of returning our debt to capitalization ratio to the upper 30s and debt to EBITDA ration in the mid 2s within the next 18 to 24 months. For 2019 we project capital available for deployment of approximately $6.2 billion. In 2019 we expect to deploy approximately $4.2 billion to debt repayment and approximately $0.8 billion to capital expenditures.",0.3614804,-0.866
CI-2018-Q4-2019-02-01,59,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"As we have communicated previously, while we reduce leverage over the next two years we expect to also have capacity for additional capital deployment which could be allocated toward reinvestment back into our businesses to drive further innovation and growth, strategic M&A on a targeted basis and/or returning capital to shareholders primarily through share repurchase. In January 2019 we repurchased $1.1 million shares for $209 million. Our balance sheet and free cash flow outlook remained strong benefiting from a highly efficient service-based orientation that drives strategic flexibility, strong margins and returns on capital.",0.1710384,0.972
CI-2018-Q4-2019-02-01,60,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now to recap, our full-year 2018 consolidated results reflect considerable strength and momentum across our diversified portfolio of global businesses and continued effective execution of our focused strategy. The fundamentals of our business is strong and we have entered 2019 intently focused on delivering on our commitments to the marketplace, while we advance our integration priorities, and are well positioned to achieve the attractive financial targets we've established for 2019 through 2021. We are confident in our ability to achieve our full-year 2019 earnings outlook and have strong visibility into our $20 to $21 earnings per share target for 2021 which represents a 15% average annual growth rate over the next three years.",0.2971613,0.985
CI-2018-Q4-2019-02-01,61,Remarks,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"With that, we will turn it over to the operator for the Q&A portion of the call.",0.985627,0.0
CI-2018-Q4-2019-02-01,63,Question,2019-02-01,4,2018,Ralph Giacobbe,Credit Suisse,"Thanks, good morning. Just hoping you could help with the bridge or the underlying assumptions a bit more within the guidance. I know you mentioned the jumping off point being closer to 1372. I think in the past you talked about sort of high single digit growth in the legacy Cigna business.",0.3305515,0.917
CI-2018-Q4-2019-02-01,64,Question,2019-02-01,4,2018,Ralph Giacobbe,Credit Suisse,"Even if we use 7% that's kind of 1465 and I think at the time of the deal you said core Express would be mid teens accretive, which I think is at least $2 dollars sort of in incremental and would sort of suggest above the high end of guidance. So just hoping you could maybe help with where that's off or if something has changed from your initial view and just the assumption in underlying core performance between the segments? Thanks.",0.408926,0.826
CI-2018-Q4-2019-02-01,67,Answer,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,I think those are the major headlines David. Thanks.,1.3126123,0.44
CI-2018-Q4-2019-02-01,71,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","A.J. good morning it's David. So just appreciate the questions. Stepping back we are 100% committed to providing affordable, high quality health and wellbeing services to our customers, patients and clients in the U.S. and across the globe. A key driving force behind our strategic combination with Express Scripts is to further improve on affordability and we built off our strength with another year of outstanding medical cost trend in the Cigna business portfolio of 3.6% six years in a row and just a phenomenal result in the Express Scripts portfolio at 0.4% pharmacy trend.",0.2258065,0.952
CI-2018-Q4-2019-02-01,72,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","The headline number one is, the proposed rebate rule will not have a meaningful impact on our growth or earnings trajectory. Specifically, as you noted, the proposed rule as will be evaluated over the next 60 days applies to Medicare Advantage and PDP. The mechanisms that exist in terms of the way rates are built up for Medicare Advantage as well as PDP largely by design, flow and respect, the rebates and pass through the way the rates are billed. So we don't see a major implication to that business portfolio. And then inferred in your comment, it does not apply to the commercial marketplace.",0.2250291,0.846
CI-2018-Q4-2019-02-01,73,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","We do see some opportunities in the proposed rule as articulated. For example, it provides a mechanism to even further accelerate value based care programs with the pharmaceutical manufacturers. You'll recall from the day we announced our proposed combination on March 8th we talked about that as an important initiative that we passionately believe in. This will provide some further accelerant to that, as well as potentially open up some additional chassis to work with pharmaceutical manufacturers to get better alignment. But big picture, we do not see it having a material effect on the business portfolios configured and are on track to deliver the 17% to 20% EPS growth in 2019.",0.1935484,0.958
CI-2018-Q4-2019-02-01,77,Answer,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Hey Josh, it's Eric, I'll take the first part of the question. I think to the nearest dollar, $2 is probably the right number that's actually a little bit less than that, so we think of it in the $1.50 to $2 range in terms of the accretion from the Express Scripts acquisition for next year. David I'll let you take the other portion of the question.",0.2727273,0.077
CI-2018-Q4-2019-02-01,78,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Josh, first specific to the go-to-market proposition, important to note that each portfolio and each platform is performing well and growing well. We're delighted that we're able to step into 2019 with very strong growth within the ESI portfolio and another year of strong organic growth within the Cigna portfolio.",0.1535173,0.968
CI-2018-Q4-2019-02-01,79,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Additionally, important to highlight as it relates to growth as we look even to 2020 within our organization growth starts with outstanding retention, deepening of relationships in addition of new business relationships. Within the Express Scripts portfolio they'll be a lower percentage of their business that's out the bid for 2020 than was for 2019 and you recall a phenomenal retention result for 2019.",0.2281384,0.881
CI-2018-Q4-2019-02-01,80,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Think about that as about 30% less business out today for 2020 versus 2019. The early look in that has the health plan part of the portfolio which is the earlier part of the portfolio, that is up for renewal in terms of the decision making process and we're pretty well through that process with all of them clients thus far making decisions renewing and no known losses from that standpoint, so strong platform.",0.3167509,0.685
CI-2018-Q4-2019-02-01,81,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","We'll step forward through 2019 and 2020 with evolve value propositions to answer the core of your question. Interactions are starting to take place with the broker and consulting community and that will happen in a phased mechanism. There will not be a singular new product offering that is pushed on the market, rather additional capabilities that will offer more choice, both through the legacy of the Cigna distribution model, as well as through the Express Script distribution model, so strong foundation an early look at outstanding retention, stepping into 2020 within the Express portfolio already today and then emerging momentum around expanding choice as we sit here in 2019 with building momentum to 2020.",1.9315974,0.914
CI-2018-Q4-2019-02-01,85,Answer,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"It's Eric. A number of moving pieces in there, so probably not constructive to walk through all of the different kind of ins and outs and dynamics there. Fundamentally, we've got growth reflected in terms of the operations that make up the Health Services segment as well as the Integrated Medical segments there is good growth in both, but really not able to kind of pull the pieces apart on the call today.",0.6108516,0.7
CI-2018-Q4-2019-02-01,86,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","And Gary, it's David. I just want to add on and maybe we'll ask Will and team to followup with you afterward. As the new business segments are configured you may recall and I know it's all net new is, a portion of the Cigna pharmacy business for example has moved into the Health Service business, the mail order aspect et cetera, however the integrated aspects of the pharmacy business remain in the Integrated Health portfolio. So we could take that offline with you and follow up to walk through the pieces, but at the end of the day there's solid organic growth in both of those portfolios driven by our retention and expansion relationships and the net new business adds.",0.3913719,0.637
CI-2018-Q4-2019-02-01,89,Question,2019-02-01,4,2018,Justin Lake,,"Thanks, good morning. I just wanted to clean up the $200 million commentary and then I had a question. So to be perfectly clear, you're saying that 2019 is carrying this overhead reduction of this $200 million. Is that the total number of lost overhead contribution from Anthem or is there going to be more in 2020?",0.2405606,0.927
CI-2018-Q4-2019-02-01,90,Answer,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Justin it's Eric. So I think of the $200 million as the amount stranded in 2019 associated with the transitional time at about $0.40 earnings per share. Ultimately, as that business transitions we will hit those costs out of the system. We're on track for our $20 to $21 in 2021. The final exact timing will play out in terms of cost coming out this year versus next year as the Anthem works through their transition plan and such. But again, think of that as the amount we've estimated for this year that we will absorb and that will need to come out of the system as we go into 2021.",0.0118577,0.557
CI-2018-Q4-2019-02-01,91,Question,2019-02-01,4,2018,Justin Lake,,"Okay and to be clear that's a drag on the services business. So even though it might look like there's not much growth there that would be $200 million that you didn't expect to have this year. And is that also a drag versus the accretion number given you probably didn't expect to have that as well because of the timing, should you track those dollars off the accretion that $2 of accretion?",0.2168192,0.529
CI-2018-Q4-2019-02-01,92,Answer,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"That's correct on all fronts, So think about that as almost entirely within the Health Services segment and think about that as in the short term a drag on the cost. It is temporary and we still are on track for our long term expectations there.",0.1103126,-0.226
CI-2018-Q4-2019-02-01,93,Question,2019-02-01,4,2018,Justin Lake,,"Okay and then if I could just sneak in my question on rebates, Express historically put out a number of $400 million. I know you don't think it all goes away with commercial and all, but can you give us an update there, worst case scenario, if rebates go away where do you think that would be in any comment, CVS put out some discussion on rebate guarantees being affected by inflation, anything there that you see as a headwind for 2019, those two things would be helpful? Thanks.",0.1810641,-0.477
CI-2018-Q4-2019-02-01,95,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Second, per prior conversation about 50% of all clients within Express Scripts opt for today full pass through rebate models. That covers importantly about two-thirds of the volume. So there's a little disproportionality of that. The net of that is we have multiple funding mechanisms already in hand today and align payment models that work for clients across the commercial health plan and government agency sector that work for them and work for us to get levels of alignment and we'll continue to evolve those over time.",0.1912165,0.671
CI-2018-Q4-2019-02-01,96,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Specific to the rebate guarantees, you'll note that we did not call that out as a headwind, stepping back our industry broadly speaking has guarantees as a part of it. Whether that's in the formal nature of a guarantee cost offering, a discount guarantee, a rebate guarantee, a trend guarantee or otherwise and both legacy organizations have a great track record of effectively gaining alignment and managing those on a go forward basis.",0.119316,0.941
CI-2018-Q4-2019-02-01,97,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Lastly, I would just add that Express Scripts had some visibility into the decelerating trend environment as such took appropriate actions with their services contracts. So again, we have not called that out as a headwind.",0.4356782,0.0
CI-2018-Q4-2019-02-01,100,Question,2019-02-01,4,2018,Kevin Fischbeck,Bank of America / Merrill Lynch,"Great, thanks. I wanted to go to the cash flow guidance that you guys are providing here. The numbers that you've been giving generally speaking have kind of excluded Anthem as a client, does that $6.2 billion number include any cash flow that you'd be earning from Anthem acquisition clients this year or it is excluding that? And then just trying to think about this number as kind of a base to think about next year, is there anything one-time in this number or is this a good number to think about for 2020 cash flow available for the parent if we just add earnings growth per se to that?",0.3899721,0.935
CI-2018-Q4-2019-02-01,101,Answer,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Kevin its Eric. And so overall think about the $6.2 billion figure that I referenced as all in. So it is comprehensive for the enterprise in terms of capital generated. There will be - the rate and pace of achieving our synergies, the rate and pace of capital investments and the rate and pace of our debt repayment will be the main things that will go into - that come to mind in terms of the kind of the top tier impacts. But we would expect to have in excess of $6 billion for each of the next couple of years available in this framework.",0.5199425,0.144
CI-2018-Q4-2019-02-01,102,Question,2019-02-01,4,2018,Kevin Fischbeck,Bank of America / Merrill Lynch,"Okay, so even though Anthem goes away, earnings growth kind of makes up for that and the $6 billion a starting point before all the other uses of cash.",0.0395543,0.542
CI-2018-Q4-2019-02-01,107,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Steve, good morning it's David. No, there will not be any impact. We - from the day of the announcement we excluded transitioning clients from all aspects of how we looked at the combination, the business, the outlook, et cetera, but there are no other impacts that you need to be concerned about.",0.3816557,-0.485
CI-2018-Q4-2019-02-01,109,Answer,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes, Steve it's Eric. So in terms of the moving pieces with the MLR, I think the industry fee suspension, this is the single biggest piece, the other changes I would call out would be more also factors we've already talked about. So industry fee suspension is the single biggest piece. We've talked about the normalization of our individual plans, margin and then the absence of prior year development in our outlook. Those would be the pieces that would account for the movement from this year into our guidance for next year.",0.0718649,0.402
CI-2018-Q4-2019-02-01,112,Question,2019-02-01,4,2018,Stephen Tanal,Goldman Sachs,"Good morning guys. Thanks for the question. Just had two sort of topics I wanted to touch, one is just thinking about the long term earnings growth algorithm or target, the 10% to 13% you guys used to put out there, how are you thinking about that now? And then secondly, just to round out kind of the discussion on the earlier transition of Anthem, I guess could you kind of just give us what the new level of year one accretion assumed in the low and high end of the guidance provided is now? And how comfortable are you that those costs are truly temporary?",0.0478183,0.919
CI-2018-Q4-2019-02-01,113,Question,2019-02-01,4,2018,Stephen Tanal,Goldman Sachs,"And I guess just separately, like why was an earlier transition of Anthem business not sort of contemplated in the initial accretion targets provided given the change of control provision in the contract?",0.7405858,0.361
CI-2018-Q4-2019-02-01,114,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Steve it's David. First, relative to your broader or big picture question, first by way of background, we've delivered approximately 15% EPS CAGR since 2009, so take 2009 the initiation of our strategy to 2018, we've been above the high end of the articulated 10% to 13% range. Over the next three years, the next chapter of our strategic horizon, we are on track again to deliver 15% EPS accretion on average over the next three years and we look forward to refreshing our long term outlook as we go forward. So we'll have an excess of a decade of 15% EPS growth out performing our long term targets.",0.0645161,0.382
CI-2018-Q4-2019-02-01,115,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to the latter part of your question, all along we understood that we had transitioning clients and we excluded transitioning clients from our EPS outlook, our accretion outlook, et cetera. No one could predict the rate pace and timing of terminations. The termination is an early termination. It creates a temporary dislocation as Eric articulated of approximately $0.40 of EPS or $200 million before tax.",0.2063739,-0.361
CI-2018-Q4-2019-02-01,116,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Even with that, we're able to deliver 17% to 20% EPS CAGR year-over-year off of a tremendous base in 2018 and we did anticipate it. Hence EVI initiatives are underway, but we're taking those in a paced fashion and we will deliver on the EVI initiatives as well as tremendous organic growth. So those costs will be eradicated. There was just a temporary dislocation that takes place in 2019 and even with that we're able to deliver the 17% to 20% EPS growth.",0.0369219,0.857
CI-2018-Q4-2019-02-01,117,Question,2019-02-01,4,2018,Stephen Tanal,Goldman Sachs,"Thanks and so just with that, I guess it sounds like maybe you're still guiding to double-digit accretion ex the $0.40 or at the midpoint of guidance or any color on that part?",0.1428571,0.66
CI-2018-Q4-2019-02-01,118,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","The way I would think about it Stephen is, we've discussed before, the core accretion fundamentals of the combination remain intact. Hence, we're on target for about $20 to $21 and the core fundamentals of the Cigna business portfolio remain intact. As Eric referenced in the prior question that was asked, if you take the accretion that would have been inferred and date of announcement of mid teens of about a $1.90 you're back off about $0.40 for the temporary dislocation of overhead and you want to back into a build up you're about right there in 2019 and even with that we're delivering to 17% to 20% EPS growth rate. Thanks.",0.0994948,0.813
CI-2018-Q4-2019-02-01,122,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Zach, good morning it's David. So stepping back I'll remind you, today we own and operate our own PBM and successfully done so for many years. We also implemented a successful strategy five, six years ago to break it into modules and to partner with others to perform some of those modules for us, initially Catamaran that transitioned to Optum and it's worked quite well and successfully with Optum as a good constructive partner.",0.1165954,0.955
CI-2018-Q4-2019-02-01,123,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director",Earlier this year we announced an aligned plan and timeframe with Optum in terms of our shared view in terms of an orderly transition that will take place. That positions us in a way to have a very disciplined orderly transition of those services and relationships and there's a good track record of transitioning services to them and transitioning services back to us within their respective modules and that will take place over the next approximate two-year horizon.,0.1811115,0.796
CI-2018-Q4-2019-02-01,124,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","It will create some significant volume uptake for Express Scripts which is a positive. One way you could think about that is the Cigna volumes on today's basis when internalized within Express Scripts make up order of magnitude $75.00 maybe a little higher 75% of the loss volumes from Anthem. So it is quite significant, but it will take place on a ratable basis over the next couple of years. And again, we have a successful track record of in a very disciplined basis of transitioning services to and from other providers. I hope that helps.",0.1053245,0.947
CI-2018-Q4-2019-02-01,127,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Yes, good morning. The answer to your question is no. We had a very orderly and disciplined process laid out and we have a very successful and growing captive PBM. We have a very successful strategy approach that we've been executing within the captive PBM and a very strong partnership relationship with Optum around shared value delivery.",0.3960358,0.968
CI-2018-Q4-2019-02-01,128,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director",We laid out in a very orderly timeline that allows for a disciplined two-year transition putting our customers front and center and the coordination services with our physician partners. So that timeline and the strategy around that is commensurate what we believed was appropriate and highly aligned with our service provider partner.,0.1733385,0.0
CI-2018-Q4-2019-02-01,130,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","I'm not going to get into dates and timing. I think Peter, to the second part of your statement a way to think about the overhead that we articulated before, there are three mechanisms to dispatch of that and it will be removed. First and foremost a very disciplined EVI plan that was laid out and is being executed on an orderly basis; two, good organic growth and then we start 2019 with good organic growth in the Express Scripts portfolio; and third, the very disciplined leverage of the Cigna volumes within the portfolio. All of that will contribute to and the EVI program was put in place to actually take out the cost structure, so we see some additive opportunities as we look to the future from the sustained organic growth and the leverage of the Cigna capabilities.",0.6603187,0.935
CI-2018-Q4-2019-02-01,133,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","David, good morning. So to your first question, I appreciate it tremendously and Express Scripts is built in has a proven track record of having a pretty phenomenal mail order fulfillment capability, so it's a service capability that's aided by quite innovative technologies, patents, et cetera. And we will on a disciplined fashion continue to look at how that core capability that you come back to, potentially could be used and leveraged for other services that benefit customers, patients or clients on a go forward basis and I appreciate the call out. Specific to the clinical integration and clinical leverage, absolutely, absolutely.",0.0485814,0.949
CI-2018-Q4-2019-02-01,134,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director",A core part of what both organizations got excited about from early conversations was the shared leverage. I articulated in the prepared remarks a little bit between leverage around the Accredo capabilities relative to the deep clinical excellence they have coupled with the Home Health coordination services that exist and bringing some of that together.,0.0073844,0.869
CI-2018-Q4-2019-02-01,135,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Secondly, from a data set standpoint, the ability to enrich insights for practicing clinicians to more comprehensively understand the life or health needs of patients, and as you articulate within the core Evercore capabilities, there are tremendous opportunities where we are on a focus basis already working through additional step function improvements in the clinical capabilities of the combined Corporation which going back to benefiting our customers and clients and further improving affordability and clinical quality. So yes to both points and we couldn't be more excited on the early traction on the second point already.",0.3066459,0.929
CI-2018-Q4-2019-02-01,138,Answer,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Hey Scott, it's Eric. Thanks for that. A couple of headlines that come to mind for me there, so first of all will continue to have good growth momentum in both businesses. We would expect that we will continue to grow in both and the differentiated return to work platform with regard to the disability business continues to services well and again continues to be a growth chassis for us.",0.3154869,0.902
CI-2018-Q4-2019-02-01,139,Answer,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"In the International Markets business, again continue to grow that platform as well. We closed on November 30, on our acquisition of OnePath Life in New Zealand and this is an example of the continued expansion of the International Markets platform and chassis and so continue to move that forward as well, but overall, really no changes to the underlying growth story and the momentum that we've gotten into those businesses.",0.5328782,0.31
CI-2018-Q4-2019-02-01,142,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Hi, good morning, it is David. We don't have a theoretical EPS answer to the theoretical action you articulate. Stepping back in an attempt to be helpful again about 95% of all discounts and rebates within the Express Scripts portfolio pass-through and shared about 50% of all clients opt for today full pass-through rebate relationships and that equates to - because of the scale of those clients it equates about two-thirds of the volumes and previously indicated Express Scripts retains about $400 million, that's a before tax number.",0.0034979,0.813
CI-2018-Q4-2019-02-01,143,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","I would add the reason why I think your question is unanswerable is the model continues to evolve. So the evolution of value based contracts and our share direction in terms of continuing to move toward and more comprehensively toward total cost, total value relationships with our clients, whether they are commercial clients, health plan clients or governmental agencies, is the direction that Express Scripts was on. It's the direction of the Cigna, has been on and it's the direction that the combined corporation goes forward on.",0.0143801,0.718
CI-2018-Q4-2019-02-01,144,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director",So those tools and levers continue to evolve and you will see us continue to move away from trying to perceive maximize a single lever as opposed to maximize the overall value which is total cost and total qualities go forward.,0.1752818,0.34
CI-2018-Q4-2019-02-01,148,Answer,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Charles it's Eric. I'll start with a couple of the pieces and maybe ask David to give some more overall color and commentary. So at a Macro level we continue to be on track with the synergies as assumed and as we discussed back in 2018 and as we disclosed in last quarter last year, the synergies that we put out and that were quantified there, primarily reflect the administrative costs and we had expected that those would occur over multiple years over the first four years of the transaction.",0.7215235,0.0
CI-2018-Q4-2019-02-01,149,Answer,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We're generating $112 million of pretax administrative synergies for 2019 and that builds to $600 million in 2022. You're correct that we expect to generate meaningful additional improvements, in the pharmacy and medical costs, through the combination both through the clinical combinations and some of the other items as David discussed today. Those benefits will primarily in order to the benefit of our customers and client. As it is again, in terms of the synergy pieces those are the pieces you should think about and we are on track and consistent with how we teed up the transaction initially. David will give some additional color here.",0.4275961,0.848
CI-2018-Q4-2019-02-01,150,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Yes, and so just bridge, when you think about today to 2021 we try to articulate there's three major building blocks to get to the $20 to $21 per share. The underlying base performance of both assets, the synergies that Eric just made reference to and you articulated the $600 million before tax synergies and the impact to the P&L of the de-leveraging which were already on board for the de-leveraging path, that's the basic cross-walk between 2018 and 2021.",0.1655655,0.572
CI-2018-Q4-2019-02-01,151,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Additional opportunities above and beyond that which we've said are not built into the accretion model are further leverage and enhancements of the growth chassis of the portfolio as we go forward and identify additional opportunities for growth, whether it's net new growth or further deepening of relationships, anything beyond what the core businesses are performing is excluded from that today as well as potential additional value at a shareholder level versus passing back to the customer and clients from the leverage of Express Scripts for the transition of the Cigna portfolio into the Express Scripts portfolio. So the basic cross-walk is base performance, synergies and de-leveraging to get us from 2018 to 2021.",0.0528566,0.92
CI-2018-Q4-2019-02-01,155,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Ana, good morning, it's David. Let me try on the points to be responsive here. Specifically as Eric has articulated a couple times there's a $112 million of synergies show the synergies we signed up for in 2019, so a step towards the $600 million. You'll note we're being very disciplined. We are making sure that the expenses come out in an orderly basis. We may outpace that, but the business plan and the guidance we've articulated doesn't assume that and with that and with the transitioning client impact, et cetera, we're delivering 17% to 20% of EPS growth.",0.024485,0.775
CI-2018-Q4-2019-02-01,156,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Specifically as it relates to the medical and pharmacy cost synergies and value creation, that will unfold throughout 2019 and 2020 and benefit our clients and customers on a client or customer basis depending on the products, programs and services they have. And I would note that we have very good growth and outstanding retention in all of our business portfolios stepping into 2019. We're going to have another good growth year and I articulated an early glimpse to Express Scripts renewals for 2020 which are tracking very, very favorably right now.",0.5398368,0.977
CI-2018-Q4-2019-02-01,157,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to proof of concept, you should not think about Cigna coming back to you with a net new proof of concept of something De novo we are seeking to build that doesn't exist today as a concept to roll out in the marketplace, rather we are systematically further enhancing the value propositions for our commercial clients, for health plan clients, for governmental agency clients and offering more choice which will unfold in 2019 and 2020 with expanded capabilities and further clinical integration and effective use of data.",0.915274,0.671
CI-2018-Q4-2019-02-01,158,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","At our Investor Day we will seek to bring some of those to life with both words, examples, and challenge ourselves to give some tangibility even in terms of some of the supporting technologies and workflows, but it is not a net new concept. The capabilities unfold pretty rapidly throughout 2019 and we will expand additional choice for the benefit of clients and customers as we step into 2020.",1.8810727,0.924
CI-2018-Q4-2019-02-01,160,Question,2019-02-01,4,2018,Frank Morgan,RBC Capital Markets,"Good morning. Thanks for the color on the Anthem-Optum swap of businesses as 75% of that volume could be recovered. But when I think about it from a profitability standpoint, how should you be thinking about the profitability on the Anthem book loss versus the savings you'll realize by bringing that back in-house? That's number one.",0.3592606,0.791
CI-2018-Q4-2019-02-01,161,Question,2019-02-01,4,2018,Frank Morgan,RBC Capital Markets,"And then number two, was just one of the headwinds you're calling up for the year was the outperformance you saw last year in the Integrated Medical segment, I think mainly the individual segment, is there anything specifically that you would like to call out as to why that should revert or it just simply conservatism? Thank you.",0.2643879,0.649
CI-2018-Q4-2019-02-01,162,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, it's David. On your first question I would ask you not to think about the profitability of those two components. Step away from it. We've excluded the transitioning clients from all aspects of our conversation from the day we announced the proposed combination and the earnings impact of that from an EPS standpoint have been excluded.",0.0069957,0.052
CI-2018-Q4-2019-02-01,163,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director",We have in 2019 this temporary dislocation of overhead that from a full transparency basis we will walk through laid out $200 million before tax and that will be removed from the system in a pretty expeditious fashion and we have multiple levers to address that. But I would ask you not to think about profitability of the Cigna portfolio versus the Anthem portfolio because they're not comparables from that standpoint.,0.0742324,0.649
CI-2018-Q4-2019-02-01,164,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to the individual market, you are correct. We articulated in our third quarter call the fact that, we're quite pleased with the performance of the individual portfolio of businesses. We expected to be profitable in 2018, it is.",1.2075398,0.726
CI-2018-Q4-2019-02-01,165,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director",It has outpaced the high end of our strategic margin threshold and for 2019 planning purposes we believe it's prudent when you look at that program and the design of that program to plan for margins that are more in line with our strategic margin trajectory which is somewhere between 4% and 6% before tax and for 2019 and we've planned for it to be at the higher end of the range which we think is a more sustainable indication of what that portfolio programs.,0.0392538,0.0
CI-2018-Q4-2019-02-01,166,Answer,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director",There is nothing systematic beyond in terms of dislocation in that marketplace. We just believed it was appropriate to plan for in view that that marketplace runs in a 4% to 6% before tax margin versus a significant margin that was delivered above and beyond that in 2018.,0.0283716,0.202
CI-2018-Q4-2019-02-01,169,Answer,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes David, it's Eric. So maybe I'll take second one first on that. Really just thinking about the $200 million just kind of a timing matter right, so the cost that would have been allocated to the contract they would have been gone away for all the reasons David described earlier in the Q&A session here. I'm thinking about it as timing just because of the earlier transition now that those costs won't be able to be allocated to the volumes that would be going away through there, but think about it that way.",0.2612289,0.226
CI-2018-Q4-2019-02-01,170,Answer,2019-02-01,4,2018,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"On a group wise and disability, we've talked in a number of different calls over time about the variability that can happen on any one line quarter by quarter or things along those lines, but we didn't call out anything particularly, systemic or anything along those lines, but just that we had favorable life insurance experience and a little bit unfavorable disability experience in the quarter here.",0.1588214,0.747
CI-2018-Q4-2019-02-01,172,Closing,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","Thank you. To wrap up our call I'd just like to highlight some key points from our discussion. Cigna delivered substantial earnings and revenue growth across our businesses in 2018. We are committed to broadening our approach to integration which focuses on coordination of services around the individual and their whole person health needs both body and mind. This approach also further expands choice, so access is available anytime anywhere based on our customers and patients needs and preferences.",0.1165954,0.906
CI-2018-Q4-2019-02-01,173,Closing,2019-02-01,4,2018,David Michael Cordani,"President, Chief Executive Officer & Director","We have a well positioned portfolio of businesses with multiple paths for sustained growth in 2019 and beyond. For 2019 we expect revenue growth, attractive EPS growth, and strong free cash flows, which position us to deliver 15% average annual EPS growth over the next three years and put us on target to deliver our $20 to $21 EPS target for 2021. We thank you for joining our call today and we look forward to our future conversations.",0.1935484,0.97
CI-2021-Q4-2022-02-03,3,Remarks,2022-02-03,4,2021,Ralph Giacobbe,Credit Suisse,"Great, thanks. Good morning, everyone, and thank you for joining today's call. I'm Ralph Giacobbe, Senior Vice President of Investor Relations. With me on the line this morning are David Cordani, Cigna's Chairman and Chief Executive Officer; and Brian Evanko, Cigna's Chief Financial Officer. In our remarks today, David and Brian will cover a number of topics, including Cigna's Fourth quarter and full year 2021 financial results as well as our financial outlook for 2022.",0.1995646,0.93
CI-2021-Q4-2022-02-03,4,Remarks,2022-02-03,4,2021,Ralph Giacobbe,Credit Suisse,"As noted in our earnings release, when describing our financial results, Cigna uses certain financial measures, adjusted income from operations and adjusted revenues, which are not determined in accordance with accounting principles generally accepted in the United States, otherwise known as GAAP. A reconciliation of these measures to the most directly comparable GAAP measures, shareholders net income and total revenues, respectively, is contained in today's earnings release, which is posted in the Investor Relations section of cigna.com. We use the term labeled adjusted income from operations and adjusted earnings per share on the same basis as our principal measures of financial performance. In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2022 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note of today's earnings release and in our most recent reports filed with the SEC.",0.2590711,0.144
CI-2021-Q4-2022-02-03,5,Remarks,2022-02-03,4,2021,Ralph Giacobbe,Credit Suisse,"Before turning the call over to David, I will cover a few items pertaining to our financial results and disclosures. First, as previously disclosed with our Form 8-K filing and investor call on January 24, we announced changes in our segment reporting effective for the fourth quarter of 2021. These changes were made to align with the company's organizational structure as a result of the pending divestiture of Cigna's International life accident and supplemental benefits businesses in seven Asia Pacific markets.",0.1683599,0.382
CI-2021-Q4-2022-02-03,6,Remarks,2022-02-03,4,2021,Ralph Giacobbe,Credit Suisse,"Effective in the fourth quarter, Cigna's results will be reported through the following three groups: Evernorth, Cigna Healthcare and Corporate and Other Operations. The international businesses that will be divested pending the close of the transaction will now be reported in Other Operations, which is included within Corporate and Other Operations in our earnings release and quarterly financial supplement. The International Health business to be retained by Cigna will join our U.S. commercial and U.S. government offerings in a new segment called Cigna Healthcare. This segment replaces the prior U.S. Medical segment.",0.1523948,0.66
CI-2021-Q4-2022-02-03,7,Remarks,2022-02-03,4,2021,Ralph Giacobbe,Credit Suisse,"Second, regarding our results. In the fourth quarter, we recorded an after-tax special item charge of $119 million or $0.36 per share related to a strategic plan to further leverage the company's ongoing growth to drive operational efficiency through enhancements to organizational structure and increased use of automation and shared services. We also recorded an after-tax special item charge of $70 million or $0.21 per share for integration and transaction-related costs. As described in today's earnings release, special items are excluded from adjusted income from operations and adjusted revenues in our discussion of financial results. Additionally, please note that when we make prospective comments regarding financial performance, including our full year 2022 outlook, we will do so on a basis that includes the potential impact of future share repurchases and anticipated 2022 dividends.",0.3838897,0.965
CI-2021-Q4-2022-02-03,8,Remarks,2022-02-03,4,2021,Ralph Giacobbe,Credit Suisse,"Also, our full year 2022 outlook assumes that the pending divestiture of Cigna's International life accident and supplemental benefits businesses will close in the second quarter of 2022, but does not assume any impact from other business combinations or divestitures that may occur after today.",0.2187954,-0.064
CI-2021-Q4-2022-02-03,9,Remarks,2022-02-03,4,2021,Ralph Giacobbe,Credit Suisse,"Finally, I would like to announce our intention to host an Investor Day in June where we will discuss our long-term strategic growth and value creation story. We look forward to sharing more details in the coming weeks.",0.1081277,0.886
CI-2021-Q4-2022-02-03,10,Remarks,2022-02-03,4,2021,Ralph Giacobbe,Credit Suisse,"With that, I will turn the call over to David.",0.4898403,0.0
CI-2021-Q4-2022-02-03,11,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks, Ralph. Good morning, everyone, and thank you for joining our call today. As we step into 2022, our clients, customers and patients continue to face a rapidly changing landscape with new COVID variants, changing testing and treatment protocols and pressures on the global economy. Throughout these challenges, we have remained focused on addressing and balancing the evolving needs of all of our stakeholders. As a result, our 70,000-plus colleagues around the world continue to deliver differentiated value for those we serve and also continue to grow our businesses.",0.3948698,0.883
CI-2021-Q4-2022-02-03,12,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Today, I'll share a perspective around our 2021 performance and the sustained growth opportunities we see for our organization in the year ahead. And Brian will provide additional details about our 2021 financial results and our 2022 outlook. Then we'll take your questions. With that, let's get started.",0.0544112,0.751
CI-2021-Q4-2022-02-03,13,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","In 2021, we grew full year adjusted revenues to $174 billion, a second consecutive year of growth above our long-term target. We delivered full year adjusted earnings per share growth of 11% and to $20.47, and we returned over $9 billion to shareholders in dividends and share repurchases. Additionally, we continue to invest in our capabilities to ensure we are positioned for sustained growth in 2022 and beyond. Our growth is and will continue to be fueled by our two high-performing platforms: Evernorth, our health services business, including pharmacy, care, benefits and intelligence services; and Cigna Healthcare, which includes our portfolio of U.S. commercial, U.S. Government and International Health businesses.",0.3000389,0.973
CI-2021-Q4-2022-02-03,14,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Our Evernorth and Cigna Healthcare platforms complement each other through the breadth of their capabilities and the ability to serve multiple buyer groups. Here, we typically lead with either a medical or pharmacy solution and then we build on those relationships by innovating and delivering new services. We have a proven track record with this approach, a diverse, high-performing portfolio of solutions and a sustained commitment to continued innovation to expand that portfolio. Additionally, we are positioned so that accelerated growth in one area can compensate for temporary pressure in another business within our portfolio. We see this as extremely valuable in a dynamic environment. Relative to our 2021 performance, it was a very strong year for Evernorth. We grew adjusted revenues by 14% in 2021 as Evernorth's corporate clients, health plans, governmental agencies and healthcare delivery system partners increasingly recognized the value of our health services, including in our specialty pharmacy business, which I'll discuss in more detail in just a moment, in our virtual health capabilities, which have been expanded through MDLIVE to include urgent and dermatology care as well as behavioral health services; in our core pharmacy services portfolio, which continues to generate outstanding results for our clients; and we are further broadening our reach through deeper and new partnerships.",0.4356782,0.987
CI-2021-Q4-2022-02-03,15,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","For Cigna Healthcare, we had sustained growth, leveraging the strength of our U.S. Commercial, U.S. Government and International Health businesses. As we previously discussed, we also experienced elevated medical costs. We had higher claims costs in our commercial insured and stop-loss businesses and continued higher claims from our special enrollment period customers within the individual business. These included the impact of elevated COVID costs for testing treatment of vaccines. The elevated trend continued throughout the year. As a result, our medical care ratio for Cigna Healthcare was 84% for full year 2021. As Brian will discuss in further detail, we took targeted pricing and affordability actions earlier in 2021 for 2022 impact, as we continue to prioritize margin expansion for 2022.",0.178391,0.893
CI-2021-Q4-2022-02-03,16,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","As I highlighted earlier, the breadth and complementary nature of our portfolio enabled us to exceed our revenue and EPS outlook and return over $9 billion of capital to our shareholders.",0.3326856,0.0
CI-2021-Q4-2022-02-03,17,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Looking forward to 2022, we expect to continue to capitalize on emerging growth opportunities and achieve sustained attractive performance. We see additional opportunities to drive growth by leveraging Evernorth capabilities to respond to three forces that we believe are fundamentally reshaping the future of healthcare. They are pharmacological innovation, the increased recognition of the link between mental and physical health; and third, the growing trend toward alternative sites of care. I'll start by highlighting how Evernorth will lead the way to capitalize on the first trend, pharmacological innovation.",0.3260785,0.97
CI-2021-Q4-2022-02-03,18,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","New drugs represent one of the most promising areas for medical innovation in the coming years. And we're seeing good dramatic growth in specialty pharmaceuticals, gene therapies and vaccines. These potentially life-saving and life-changing advances also bring intensifying pressures on affordability. This creates significant opportunity for Evernorth to provide customers, patients and clients with the most innovative new therapies in ways that are accessible, affordable and predictable.",0.6397202,0.949
CI-2021-Q4-2022-02-03,19,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","By 2025, for example, 66 biologic drugs currently in the market will have the patents expire, opening the door for increased biosimilar competition and an increasing opportunity to decrease healthcare spending by an estimated $100 billion. Importantly, this trend is already unfolding in 2022 and will accelerate further in 2023. We are positioned to lead and fully intend to capture a large portion of those savings for the benefit of our customers, patients and clients by combining and coordinating capabilities that include our Accredo capability, which provides differentiated specialty pharmacy care for a number of specific conditions.",0.1612903,0.914
CI-2021-Q4-2022-02-03,20,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","I'd also highlight that today specialty pharmacy already drives only 1/3 of our Evernorth revenue, and Accredo is one of the fastest-growing parts of our health service portfolio. Additionally, leveraging Express Scripts, which draws upon its expertise in delivering improved affordability, leveraging a broad network, supply chain expertise as well as clinical and service capabilities.",0.1539059,0.765
CI-2021-Q4-2022-02-03,21,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Managing biologics and specialty drugs is also a priority focus for our Cigna Healthcare business. Last year, we launched an innovative program to leverage biosimilars in the medical benefit that included incentives that improve access for integrated clients and customers. This illustrates just one way we will continue to leverage Evernorth's capabilities to drive greater affordability and value for Cigna Healthcare clients and customers. Evernorth will also continue to grow from the significant demand for more mental health services as well as the rapidly changing access to care models. For example, Evernorth is continuing to expand our virtual care services by leveraging our MDLIVE platform as well as expanding our behavioral care network. We know how important it is for both patients as well as clients. Our Evernorth research reinforces that total healthcare costs decrease when people, who are diagnosed with behavioral conditions receive coordinated, sustained treatment.",0.0540225,0.986
CI-2021-Q4-2022-02-03,22,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","For Cigna Healthcare in 2022, we expect to drive customer growth in each of our U.S. commercial market segments and grow earnings as we continue executing on our affordability and pricing actions throughout 2022. Additionally, Cigna Healthcare will continue to partner and leverage our Evernorth innovations. For example, we're continuing to expand digital experiences to help our customers connect with the highest performing and most affordable medical care.",1.1927711,0.877
CI-2021-Q4-2022-02-03,23,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Our recent approach, we developed for patients diagnosed with orthopedic and musculoskeletal conditions provide highly personalized and actionable information to guide their choices and support improved healthcare outcomes and affordability. In our U.S. government business, as we've noted previously, we are operating in a more competitive environment stepping into 2022. For Cigna, aided by the strength of our broad portfolio, we've prioritized pricing discipline for U.S. government business for 2022. For Medicare Advantage, we will start the year with flat membership. Looking forward to 2023, we are confident in our position to accelerate growth further, as our customer satisfaction metrics are high, our Star's ratings are very strong, and we steadily expanded our addressable market by entering new geographies.",0.1395258,0.973
CI-2021-Q4-2022-02-03,24,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","In our Individual & Family Plan business, as noted previously, 2021 customers grew meaningfully in part due to the extended special enrollment period. We expect a decline in customers in 2022, in part driven by our product and price positioning that will adjust for the special enrollment surge we saw in 2021. We do continue to view this as an attractive long-term opportunity. And to support that growth, we continue to enter new markets. For 2022, we entered three new states and 93 new counties. With these markets, for example, we have the ability to reach an additional 1.5 million additional customers. In International Health, we are sharpening our focus, and we'll continue developing our services for the globally mobile as well as go deeper into domestic health and health services.",0.0081617,0.958
CI-2021-Q4-2022-02-03,25,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","One of the key ways we will do this is with innovative partnerships such as Honeysuckle Health, an analytics-driven health service company establishing our joint venture with the nib Group in Australia. Now taken as a whole, 2022 will be another year of attractive growth for our company. our EPS outlook of at least $22.40 and the increase of our quarterly dividend by 12% reinforces the sustained growth and strength of our businesses.",0.3000389,0.938
CI-2021-Q4-2022-02-03,26,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Now before I wrap up, I want to reinforce a key aspect of our sustained performance is our positioning strategically to further expand our reach in addressable markets over time. Here, we will leverage organic partnerships and targeted inorganic opportunities to further strengthen our proven growth platforms. We see three areas of continued focus here. First, in U.S. government, we will seek additional growth opportunities and our ability to win in these markets is further enhanced by our current and expanding Evernorth service capabilities. Second, we will further expand our Evernorth service portfolio. This includes, for example, our Evernorth Care capabilities, including virtual, home and behavioral services. And third, in International Health, our decision to divest our Life accident and supplemental benefits business in several markets reinforces our discipline to focus on the health portion of our portfolio.",0.0342013,0.974
CI-2021-Q4-2022-02-03,27,Remarks,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Now to wrap up. Looking back at 2021, our business performed in a dynamic environment. We delivered adjusted EPS of $20.47 and returned over $9 billion of capital to our shareholders in dividends and share repurchase. 2022 will be another year of growth across our business, and we will continue to invest in innovation to position us for sustained long-term growth.",0.3727167,0.891
CI-2021-Q4-2022-02-03,29,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"Thanks, David, and good morning, everyone. Today, I'll review key aspects of Cigna's fourth quarter 2021 results, and I'll provide our outlook for 2022.",0.7016683,0.7
CI-2021-Q4-2022-02-03,30,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"Key consolidated financial highlights for full year 2021 include adjusted revenue growth of 9% to $174 billion or growth of 12% when adjusting for the sale of the Group Disability and Life business. Adjusted earnings of $7 billion after-tax and adjusted earnings per share growth of 11% to $20.47. We delivered these results despite an elevated medical care ratio in the quarter, partly driven by COVID-19-related claims. Our enterprise revenue and EPS results were slightly better than our expectations, reflecting the resilience and breadth of our portfolio, with particularly strong performance in Evernorth.",0.0407262,0.955
CI-2021-Q4-2022-02-03,31,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"Regarding our segments, I'll first comment on Evernorth. Fourth quarter 2021 adjusted revenues grew 15% to $35.1 billion, while adjusted pretax earnings grew to $1.6 billion. Evernorth's strong results in the quarter were driven by organic growth, including strong volumes in specialty pharmacy and retail, along with ongoing efforts to improve affordability and deepening of existing relationships. In the quarter, we also continued to increase the level of strategic investments to support ongoing growth of the Evernorth portfolio, such as our Accredo specialty pharmacy, our virtual care platform and our technology, including digital capabilities.",0.6938175,0.968
CI-2021-Q4-2022-02-03,32,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"Overall, Evernorth delivered a strong year, focusing on driving value for clients and customers, while achieving strong revenue and earnings growth above its long-term growth targets.",0.2600589,0.922
CI-2021-Q4-2022-02-03,33,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"Turning to Cigna Healthcare, which, as a reminder, now includes the prior U.S. Medical segment plus our retained International Health business. Overall, fourth quarter adjusted revenues were $11.2 billion, adjusted pretax earnings were $472 million and the medical care ratio was 87%.",0.4627085,0.511
CI-2021-Q4-2022-02-03,34,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"During the fourth quarter, we experienced elevated medical costs, driven in large part by dynamics related to COVID, including higher testing, treatment and vaccine costs, specifically the higher-than-expected fourth quarter costs are attributable to three primary areas: higher stop-loss claims, particularly in policies with lower attachment points that were triggered by the cumulative impact of COVID and non-COVID costs throughout the year. Continued pressure on our individual business, particularly the special enrollment period customers who were added in mid-2021 and higher claim costs in our commercial insured book. The elevated medical costs were partly offset by better-than-expected net investment income and fee-based specialty contributions, neither of which are reflected in the medical care ratio metric.",0.4259078,0.725
CI-2021-Q4-2022-02-03,35,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"For full year 2021, we finished with the medical care ratio of 84%. The unfavorable fourth quarter medical costs informed and sharpened our 2022 assumptions. We now expect full year 2022 medical costs to run above the corresponding 2022 baseline at a relative level that is consistent with full year 2021. This 2022 medical cost outlook is now higher than our previous expectations.",0.4386654,0.494
CI-2021-Q4-2022-02-03,36,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"In specific to stop-loss, we assume the pressure experienced in the fourth quarter will persist in 2022, and we will take appropriate future pricing action as this book of business renews throughout the year. Helping to offset these pressures, as we step into 2022, our targeted pricing actions we've taken in our U.S. Commercial business as we saw claim costs emerge in 2021, higher U.S. commercial enrollment and retention than previously expected in our fee-based business and incremental affordability actions, which I'll elaborate on in just a few moments.",0.0691855,-0.318
CI-2021-Q4-2022-02-03,37,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"Turning to membership; we ended the year with 17.1 million total medical customers, an increase of approximately 430,000 customers for the full year. 2021 customer growth was driven by Middle Markets and Select within U.S. commercial, Individual and Medicare Advantage within U.S. government and International Health. Overall, Cigna Healthcare supported and delivered for our customers, clients and partners during a challenging year and is well-positioned to both grow membership and expand margins in 2022.",0.484789,0.878
CI-2021-Q4-2022-02-03,38,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"Turning to Corporate and Other Operations. The fourth quarter adjusted loss was $115 million and now includes positive earnings contributions from our International Life accident and supplemental benefits businesses held-for-sale pending divestiture. As Ralph noted, during the fourth quarter, we reported a special item charge of $119 million after tax related to actions to improve our organizational efficiency. These actions will capitalize on our scale and the progress we have made through automation, increased use of digital tools and continued innovation to better enable us to grow and expand in this dynamic marketplace. Overall, Cigna's 2021 results reflect our balanced portfolio and our commitment to accretive capital deployment to augment our organic growth.",0.8518155,0.979
CI-2021-Q4-2022-02-03,39,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"As we turn to 2022, our affordability initiatives, pricing actions and focus on operating efficiencies will drive income growth and margin expansion in Cigna Healthcare. This performance coupled with continued growth in Evernorth and accretive capital deployment, will drive attractive EPS growth. For the full year 2022 outlook, I'd like to first remind you that our outlook assumes the divestiture of our International Life accident and supplemental benefits businesses will close in the second quarter of this year.",0.0834151,0.923
CI-2021-Q4-2022-02-03,40,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"In total for the company, we expect consolidated adjusted revenues of at least $177 billion, representing growth of approximately 4%, excluding the impact from previously announced divestitures. We expect full year consolidated adjusted income from operations to be at least $6.95 billion or at least $22.40 per share, consistent with our prior EPS commentary. We project an expense ratio in the range of 6.9% to 7.3%, further improving upon our operational efficiency and ensuring continued affordable solutions for our clients and customers. And we expect a consolidated adjusted tax rate in the range of 22% to 22.5%.",0.6658489,0.898
CI-2021-Q4-2022-02-03,41,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"I'll now discuss our 2022 outlook for our segments. For Evernorth, we expect full year 2022 adjusted earnings of approximately $6.1 billion. This represents growth of about 5% over 2021, within our targeted long-term income growth range, reflecting strong growth in Accredo specialty pharmacy, all while we continue to increase investments in order to drive new innovative solutions to the market. For Cigna Healthcare, we expect full year 2022 adjusted earnings of approximately $3.9 billion. This outlook reflects the strength of our value proposition and focused execution in our business, driven by organic customer growth and disciplined pricing in order to expand margin.",0.814524,0.98
CI-2021-Q4-2022-02-03,42,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"Some key assumptions reflected in our Cigna Healthcare earnings outlook for 2022 include the following: regarding total medical customers, we expect 2022 growth of at least 575,000 customers with the vast majority coming from an increase in U.S. Commercial fee-based customers. Within our U.S. commercial book, organic customer growth is driven by National, Middle Market and Select Market segments. We expect Medicare Advantage customers to be relatively flat compared to 2021, reflecting the competitive backdrop.",0.5480864,0.848
CI-2021-Q4-2022-02-03,43,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"And as David shared, we expect a decrease in our individual customers. We expect the 2022 medical care ratio to be in the range of 82% to 83.5%. As I noted earlier, this outlook assumes total medical costs will be above baseline in 2022. Importantly, we are actively managing overall medical costs with a range of affordability actions, including identifying opportunities such as guiding customers to more effective and efficient sites of care. For example, we focused our eviCore subsidiary on an incorporating site of care review to our existing processes. These improvements encourage the use of non-hospital settings, which can substantially reduce cost for customers while increasing patient satisfaction. This action has contributed to results within our commercial book of business, where we are now seeing fewer than 20% of all knee and hip replacements occurring in an inpatient hospital setting, down from over 75% in 2019.",0.7271835,0.987
CI-2021-Q4-2022-02-03,44,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"We are also continuing to promote preventive care, the targeted use of virtual care through our MDLIVE subsidiary and access to behavioral services to provide meaningful support to patients and moderate overall medical costs over the longer term. Through these affordability initiatives and our disciplined pricing actions, we expect to expand margins in 2022, while growing our medical customer base. Now moving to our capital management position and outlook. We expect our businesses to continue to drive strong cash flows and returns on capital, even as we increase strategic reinvestment to support long-term growth and innovation.",1.1015702,0.981
CI-2021-Q4-2022-02-03,45,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"In 2021, we finished the year with $7.2 billion of cash flow from operations. Additionally, we returned over $9 billion to shareholders via dividends and share repurchase in 2021, a significant increase from 2020. And now framing our capital outlook for 2022. We expect at least $8.25 billion of cash flow from operations, up more than $1 billion from 2021, reflecting the strong capital efficiency of our well-performing business. This positions us well to continue creating value through accretive capital deployment in line with our strategy and priorities.",0.8253189,0.941
CI-2021-Q4-2022-02-03,46,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"We expect to deploy approximately $1.25 billion to capital expenditures, an increase from our 2021 CapEx levels. The investments will be heavily focused on technology to drive future growth. We expect to deploy approximately $1.4 billion to shareholder dividends, reflecting our meaningful quarterly dividend of $1.12 per share, a 12% increase on a per share basis. And we expect to use the proceeds from the divestiture of our International Life accident and supplemental benefits businesses, primarily for share repurchase.",0.0490677,0.935
CI-2021-Q4-2022-02-03,47,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"Our guidance assumes full year 2022 weighted average shares to be in the range of 308 million to 312 million shares. Year-to-date, as of February 2, 2022, we have repurchased 2.5 million shares for $581 million. Our balance sheet and cash flow outlook remains strong, benefiting from our highly efficient service-based orientation that drives strategic flexibility, strong margins and attractive returns on capital.",0.2212954,0.962
CI-2021-Q4-2022-02-03,48,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"So now to recap. Our full year 2021 consolidated results reflect strong contributions from our focused growth platforms, led by Evernorth. Our 2022 outlook reflects meaningful contributions from each of our two largest segments, Evernorth and Cigna Healthcare, along with accretive capital deployment. We are confident in our ability to deliver our 2022 full year adjusted earnings of at least $22.40 per share, consistent with our prior EPS commentary.",1.2389598,0.948
CI-2021-Q4-2022-02-03,49,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"Finally, as Ralph noted, we are looking forward to speaking with you in more detail at our upcoming Investor Day in June.",1.4327772,0.0
CI-2021-Q4-2022-02-03,50,Remarks,2022-02-03,4,2021,Brian C. Evanko,CFO,"And with that, we'll turn it over to the operator for the Q&A portion of the call.",0.5294406,0.0
CI-2021-Q4-2022-02-03,53,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"Scott, it's Brian. So I'll start with the seasonality component as it relates to the EPS cadence as well as the MCR. For purposes of what we expect relative to quarterly EPS, the 2021 pattern is actually a reasonable starting point as we think about the 2022 quarterly EPS that will emerge for us. And so more specifically, we would expect a little bit less than half to transpire in the first half of the year. And based on what we're seeing so far in January, the impact of Omicron, et cetera, working its way through our book, there's actually quite a bit of resemblance in terms of January 2022 to 2021, which again reinforces that '21 is a reasonable framework to use in terms of what to expect relative to EPS seasonality.",0.7531894,0.273
CI-2021-Q4-2022-02-03,54,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"As it relates to MCR, the full year guidance, as I indicated, is between 82% and 83.5% for the Cigna Healthcare book of business. So the midpoint of that, you can view as a reasonable starting point for the first quarter. We would expect to run a little bit below that in the quarter just based on, again, what the early read is here in January, coupled with the pattern we saw last year. So again, think of a little bit less than 50% of the overall EPS in the first half of the year, think of the first quarter MCR being a bit below the midpoint of our full year guide for Cigna Healthcare. As it relates to the stop-loss book of business, within the quarter. And importantly, you need to think of this as a full year accumulation product. So what ends up transpiring with this business is over the course of the year, claims are accumulated and then the fourth quarter of the policy period, there's essentially a true-up.",0.9038273,0.318
CI-2021-Q4-2022-02-03,55,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"And what we had occur in the fourth quarter of this year is particularly the smaller end of our stop-loss book, we had some of the lower attachment points pierced slightly more heavily than we had been anticipating. And so that created round numbers, you can think of it as about $70 million of medical cost pressure in the fourth quarter. Importantly, though, that's an annual number because it reflects the accumulation over the course of the year in 2021. So that $70 million in the fourth quarter is really a full year '21 number. We have assumed that that $70 million pressure will recur in 2022. So we have not assumed that we'll be able to recover that, and that's embedded in our $3.9 billion income guide for Cigna Healthcare.",1.1697743,0.197
CI-2021-Q4-2022-02-03,56,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"So to the extent we're able to reprice some of the cases with the later effective dates in '22, that could provide some level of upside relative to the $70 million assumption that's embedded in the guidance.",0.3778214,0.477
CI-2021-Q4-2022-02-03,59,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"Steve, it's Brian. I'll start and then David can add some color. So as I mentioned, we're expecting net customer growth in Cigna Healthcare of at least 575,000 customers in 2022, which we're really pleased with. And it's actually above what we would have expected a few months ago based on stronger-than-expected enrollment and retention. And as I noted, the vast majority of that will come through in the form of fee-based ASO-related customer relationships. Our membership outlook for '22 does not anticipate any growth from Medicaid redeterminations in either the commercial book or the individual book. So as you know, we don't continue to participate in the health plan space today in Medicaid. And therefore, as we think of the impact of redeterminations, it's only upside relative to our customer outlook. We have not modeled anything in terms of benefit in there.",0.796369,0.886
CI-2021-Q4-2022-02-03,61,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Yes, I would say, as I noted in my prepared remarks, within the commercial segment, we're pleased that our full year outlook for 2022 has growth in each of our three employer subsegments. So we're pleased with the outlook as we start the year, and we're pleased with the outlook for the full year.",0.4364555,0.931
CI-2021-Q4-2022-02-03,65,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","A.J., it's David. Specific to the government expansion, stepping back, first, we continue to see the government space as an interesting and attractive growth space for us. We define that as MA individual exchange, we view as part of the government programs as well as Medicaid when we look at the space more broadly. To date, we focused in terms of using our levers and our focus more heavily on MA and on the individual business. In the end, we're pleased to highlight the fact that within our Evernorth service portfolio, our Evernorth service portfolio continues to be able to expand its Medicaid proposition through servicing health plans and other intermediaries. Additionally, as I noted in my prepared remarks, as we expand our Evernorth service capabilities, we see that as a meaningful value creator to MA, to the individual marketplace as well as to the Medicaid marketplace. And we think all of which are going to continue to evolve and be attractive.",0.0163234,0.983
CI-2021-Q4-2022-02-03,66,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Specific to the MA distribution channels, no doubt some headlines have been produced relative to a little different dynamic. And our posture coming into 2022 was that 2022 was going to be a bit more dynamic year from an MA standpoint. Hence, we managed our portfolio to reduce our internal expectations of life growth and focus heavily on margin expansion with an eye toward 2022 - 2023's growth being a more accelerated growth environment. And I think we'll see a little bit more shake out relative to some of the channels that are evolving. For us, our channel traction on our retention has been pretty darn reasonable for 2022. We saw less new business growth year-over-year for Medicare Advantage, and we expected to see less new business growth in Medicare Advantage given our product and our pricing position.",0.3493976,0.947
CI-2021-Q4-2022-02-03,70,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Gary, it's David. Your starting part of your frame is helpful. So when we think about it, we think about National, Regional or Mid and Select. Each of the segments have attractive growth for 2022 with National and Regional having very attractive growth outlook and all being - think about that as all fee-based. Second, to your point, within the Select segment, the Select segment has been and continues to be a very attractive growth segment for us. In any given year, the amount of new business we've written in that segment has varied anywhere between 70% ASO stop-loss and 30% risk to greater than 50% risk and less than 50% ASO stop-loss, it varies. So, we'll continue to write ASO stop-loss within the Select segment, and we'll write some guaranteed cost business in there, no doubt. But the aggregation of all the segments together and the strength of all three segments going to 2022 has a significant portion of our net customer growth being in the fee-based environment.",0.1892732,0.961
CI-2021-Q4-2022-02-03,75,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Sure. So let me start with the '23 selling season and put a backdrop of it. We're pleased with the performance we've carried now over multiple years within that subsegment of Evernorth and 2023 is guiding towards another attractive year for us. As it relates to - when you think about the growth equation you're asking about, we start with retention, we would expect at this point, our retention levels for 2023 to be at or above our 2022 retention levels. So we would see that as an attractive outlook. For 2023 growth, we have an active pipeline, and so we would see net new business adds coming through. And then context for you and our listeners, if you think about that business portfolio over the last several years, we've essentially had a net add of about 20 health plans into our portfolio of services. So positive and continued, I would say, sustained attractive performance. Importantly, in the earlier part of your comments in terms of you said contracts and programs, I think I'd draw your attention back to the programs. A cornerstone part of that business is to continue to innovate programs and services.",0.2413525,0.982
CI-2021-Q4-2022-02-03,76,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Said otherwise, it's not just a base PBM or access offering. There's an evolution of programs that you would know is safeguard programs and evolution of safeguard programs that continue to enhance clinical programs and clinical engagement and clinical care coordination leveraging both with Express Scripts has the ability to do what Accredo has the ability to do and increasingly, what we're able to leverage off of some of the Cigna Healthcare capabilities working in both directions off the medical side of the proposition. So expansion of the services using your term programs has been mission-critical. And the final note I would say is our PBM team, as you call it, does a really good job of working client by client, be it a corporate client or in case of health clients to co-collaborate the innovations that work for them. And by doing so, helping them, our clients drive growth, which is mutually beneficial to both organizations.",0.0684026,0.977
CI-2021-Q4-2022-02-03,77,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So wrapping up, we see 2023 as being another positive year, both from a retention as well as new business growth standpoint.",0.0684026,0.807
CI-2021-Q4-2022-02-03,81,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"Justin, it's Brian. So I think your question was really specific to the fully insured part of the commercial book of business. And as I noted in my comments, there in the fourth quarter, we saw some elevated medical costs. And all in, you can think of that as also in that same general zone as the stop-loss pressure I mentioned of about $70 million. So the three drivers of the pressure: the stop-loss, the individual exchange and the fully insured that you can think of them as about 1/3, 1/3, 1/3 in terms of the medical care ratio pressure we had relative to our expectations in the quarter. So the fully insured component of that going forward, as David indicated in his comments, we started to see pressure emerge in the second quarter of 2021. If you recall, our second quarter MCR was elevated relative to our expectations. And that began a cycle of margin expansion on this book of business. So we've been repricing over the course of '21 and into '22 with the expectation of expanding margins.",0.2939156,-0.557
CI-2021-Q4-2022-02-03,82,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"As we've talked about before, we don't expect that all to transpire in one year. And so when you look at the Cigna Healthcare income guide for next year - or this year, actually at $3.9 billion, that's up about $300 million from where we ended in 2021. That will improve our margin profile, but it doesn't get us all the way to our target margins in one year. So we have more opportunity in '23 and thereafter for further repricing actions. So in the fully insured book of business, in particular, the sold business so far has revenue yields in excess of cost trends. And you can think of that in the range of 100 to 150 basis points as we step into '22. So we'll get some margin expansion in that portfolio. We'd expect more in '23 as more of the business is repriced.",0.2222767,0.726
CI-2021-Q4-2022-02-03,85,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Matt, it's David. So specific to the Medicare Advantage environment for 2022, we were mindful of our willingness to trade, if you will, volume for margin as we're establishing our pricing for 2022, earlier in 2021. Did we have perfect insight? Of course, not, but we were mindful of that. To answer your question more specifically, clearly, when the competitive pricing by market became visible as you get ready to step into the annual enrollment period. We were able to look at market by market. And we're able to broadly see, in most markets, our level of benefit in price point positioning, clicking down one to three notches by market. So that gives you a context. And that's in an environment with the local scale with attractive medical cost configuration and with the Star's rating deep into the 80s. So as we looked at that environment, again, we were mindful of what was transpiring. And at that point, we were able to see that there would be more volatility.",0.1815002,0.966
CI-2021-Q4-2022-02-03,86,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","As I noted before, we saw reasonable retention, a little bit of pressure on retention, but less new business sales that came through. Now specific to your point, it's early, folks are coming through what was posted last night. But big picture, I put the headline number aside, it looks like a little over 4% net yields for the industry. And our assessment of ourselves, when you look at mix, kind of shaking you through, is about 4% yield with an eye for 2023. We view that as a positive, taking our current proposition, taking our current Star's rating, taking our current Net Promoter Score, taking the geographies we've expanded in and our disciplined orientation of stabilizing the environment for 2022. So we're looking forward to a very attractive growth opportunity for the Medicare Advantage portfolio of business in 2023.",0.2024874,0.97
CI-2021-Q4-2022-02-03,90,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","When you think about our inorganic priorities. First, our inorganic priorities augment our organic growth and then our disciplined focus to extending and expanding partnerships and then identifying inorganic opportunities. We have four categories, and I'll come to your core point in a second, four categories of focus: furthering our international proposition in key markets on the health space, furthering our U.S. government capabilities, furthering our care delivery and management capabilities more oriented toward the digital, the home, the behavioral side of the equation and then digital and technology support for our organization. As it relates to inorganic opportunities in the government space, I'm not going to call out any one as a priority, there's multiple subsegments. But as we look at inorganic priorities, to your point of scale, we have to conclude that, of course, they're strategically attractive, then we have to conclude they're financially attractive and then we have to conclude that we could essentially close them or create a level of certainty.",0.0614069,0.967
CI-2021-Q4-2022-02-03,91,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So within the context of that, we take into consideration all the items in your question. Regulatorily, we recognize the environment is quite fluid right now. From a financial attractiveness, this includes the organizational readiness and our ability to create and capture value, we have to conclude for a larger transaction that the transaction will be accretive in its first full year of operations and generate an attractive ROIC. So that's an important part of the equation for us in terms of the way in which we would approach a transaction from that standpoint.",0.2666148,0.927
CI-2021-Q4-2022-02-03,92,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And on a final note, we've built a diverse portfolio within Cigna, demonstrating that our Services portfolio is well positioned for continued growth and then within our Cigna Healthcare portfolio, we have multiple growth levers from Commercial to Government to our International Health capability. So we'll be opportunistic here if we see a significant value creator, but quite disciplined considering points I referenced relative to the strategic value creation - the financial value creation, which we're quite disciplined on and, of course, mindful of the regulatory environment.",0.288768,0.939
CI-2021-Q4-2022-02-03,96,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So first, just a calibration point, the digital formulary, you made reference to, transpired as we're combined entities. And I think it's a good reinforcement of innovation. So I agree with you using that as an example of innovation. Two, I do appreciate you broadening the leverage and the value creation of digital beyond, although virtual health is massive beyond that. As we look into the organization, we see significant opportunity to leverage digital capabilities beyond. So I'll cite two examples just to be succinct, one of which I made reference to in terms of supporting our customers and patients with specific, highly personalized, immediately actionable information as they make their personal health decisions around consuming care.",0.0237077,0.977
CI-2021-Q4-2022-02-03,97,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And I cited an example in orthopedics and musculoskeletal where there is a significant amount of preference and choice that the consumer patient has exercised. And we've learned over time, delivering information that is personalized and actionable at the moment that matters when decisions are being made is mission-critical, and we're able to improve value for that patient through better quality, better affordability and then share some of that benefit back to the client. So that's an example on the care side of the equation. On the administrative side of the equation, we talked about our ability to harness further leveraging the franchise off of shared services as well as our continued growth of our revenue portfolio. A digital-first framework is mission-critical within that. We have the ability to bring more personalized services on the administrative side of the equation, both to our customers as well as to our physician partners, and most of that lies upon a digital-first philosophy and framework and we continue to invest there.",0.3583366,0.98
CI-2021-Q4-2022-02-03,98,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","On a final note, some of the CapEx that Brian made reference to goes toward both of these dimensions, whether it's in the care enablement side of the equation or whether it's in the administrative service side of the equation. We see it as a meaningful value creator, and I appreciate you calling that out.",0.1496308,0.863
CI-2021-Q4-2022-02-03,101,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"Michael, it's Brian. I'll take the first question, and then David can pick up on the Medicare Advantage component. So as we announced this morning, we are taking a charge in the quarter associated with organizational efficiency. And you can think of that the charge amount itself was about $168 million pretax. Over time, that will run rate to a number in the $200 million, $225 million range. And you can expect that, that full run rate will be achieved by 2023. A portion of that will come through in '22. Of course, that won't all drop to the bottom line. A portion of that will be redeployed in the form of more competitive prices and premiums out into the market. And just to give you a little more context there, I talked about automation, digitization. So a piece of this will be essentially removing unnecessary work and some of that will be personnel. There's also a significant piece in here associated with real estate. We made the decision after a couple of years into the pandemic that some sites should be closed permanently and/or some floors restacked, so there's a component here associated with real estate optimization as well. David, do you want to pick up on the Medicare Advantage component?",0.4151129,0.888
CI-2021-Q4-2022-02-03,102,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Sure. And Michael, just transition from Brian's point, I'd point you to the fact that our SG&A ratio for 2021 was a very attractive number and our outlook for 2022 is a further improvement so back to embedded in our outlook as a further improvement to the SG&A ratio. Relative to the Medicare rate notice in the 2023 environment, we view it as just macro positive environment for us to lean into. I think to the core of your question, do we view it negatively or do we have regret relative to our growth posture for 2022 as we look to the rate notice for 2023? My answer to you is yes and no. Clearly, we would like more lives that are sustainable to be able to serve, but we believe being disciplined in this more fluid environment of '21 to '22, what was a better answer and better decision. And I would remind you, we're talking about numbers off of a book of business of about 550,000 lives.",0.2059852,0.957
CI-2021-Q4-2022-02-03,103,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So within our portfolio, that's about 10% - 5% of the enterprise revenue, we're able to make those trade-off decisions. Looking to 2023, we see more opportunity, and when we see that opportunity off of our base, we see the opportunity off of our geographic expansion off the last two years, and we see that opportunity being further enabled by the rate environment for 2023; so we're excited by that.",0.1675087,0.933
CI-2021-Q4-2022-02-03,106,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Kevin, appreciate your questions. Two very different markets in two very different market environments. Specifically to the individual exchange environment, our point of view is adding more lives at 0 or negative margin is not a shareholder prudent posture. Two, in a marketplace that is fluid year in, year out, we've been able to prove that as that marketplace is unrelated. Our discipline has played through safe for the special enrollment period that played through in 2021. Our discipline has played through in a net positive way, as we've been able to build more geographies, more focus in geographies and yield a sustainable proposition. But to be very clear, our conclusion is that adding additional lives in a marketplace that's fluid year in, year out, at 0 or negative margin in a capital-intensive subsegment of the marketplace is not prudent.",0.1962689,0.912
CI-2021-Q4-2022-02-03,107,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Looking forward, that marketplace will shake itself out as it has in the past, and we see attractive growth off of our existing geographies and new geographies. Relative to Medicare Advantage, your challenge is fair. I don't resist your macro challenge. In fact, we see that as opportunity versus downside relative to us. We've broadened our reach over the last couple of years meaningfully in terms of new MSAs as well as new counties. Our Star performance is deep within the 80s on a sustained basis, and our Net Promoter Score is quite high. So the cornerstone of the value proposition you can play through remains very attractive in the marketplace. I'd remind you that we've only participated in the individual market. And we've recently only participated in the individual HMO and PPO market over the recent vintage. So we looked within and said our strike zone was small, less than 20% of the addressable market. We've expanded that to about 30% of the addressable market. Now we'll continue to grow that over time.",0.7287213,0.951
CI-2021-Q4-2022-02-03,108,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So we look at this current environment for both of these businesses, we're in 2022, we're able to be disciplined for both of those businesses and not chase low or 0 margin business and yield attractive revenue and earnings growth for the franchise and put ourselves in a position for what should be a very attractive 2023 for both of those businesses with attractive meaningful, sustainable growth outcomes.",0.0734551,0.943
CI-2021-Q4-2022-02-03,112,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"So I'll do my best to tackle different aspects of that question. And importantly, the guidance is on the Cigna Healthcare basis. So for purposes of comparability, it's important as you go back and look at our historical financials that you're looking at the Cigna Healthcare basis and not the prior U.S. medical basis. But in aggregate, for full year '21, we landed at 84% for the full year MCR. And to your point, the guidance is 82% to 83.5%. So take the midpoint of that, it's 125 basis points of improvement from '21 into '22. So all in, as I mentioned in my comments, and you mentioned in your question, we are expecting the absolute level of medical costs relative to baseline in 2022 to be similar in full year '22 than what we saw in full year '21. And so we were previously assuming that there would be some level of cost abatement in '22. We are no longer assuming that. We think that's a prudent posture to take stepping into 2022 in light of the year that just ended. So as a result of that, the MCR improvement year-over-year is attributable to both our revenue outlook, our affordability actions and some mix of business changes.",0.2350343,0.902
CI-2021-Q4-2022-02-03,113,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"So to give you a little more specificity there, if you were to decompose the 125 basis points, think of about 75 basis points of that associated with revenue yields in excess of our cost trends, predominantly in U.S. commercial. So as Justin asked earlier about the fully insured book, we are seeing revenue yields in excess of cost trends as well as the other subsegments of that portfolio. We expect about 25 basis points of improvement to come from our Medicare Advantage book, specifically the risk adjuster headwind that we incurred in 2021 will fully unwind here in 2022. We've got a good level of visibility on that.",0.1629048,0.785
CI-2021-Q4-2022-02-03,114,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"And then, the final 25 basis points is associated with our Individual and Family Plans book, in particular, the special enrollment period live that we described earlier, we expect the level of normalization in the medical care ratio from that book, both from a combination of the pricing actions we took, the improvement in terms of risk adjuster coding in '22, less pent-up demand and some industry-wide risk pool normalization. All of that contributes to about 25 basis points of improvement on the individual and family plans. So you put that all together and you get 125 basis points from the final '21 to the midpoint of our 2022 guide. Those are the big chunks I would encourage you to think about.",0.1736997,0.895
CI-2021-Q4-2022-02-03,118,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"Yes, Stephen, it's Brian. I'll start and then if David wants to pick up on any aspects, feel free to jump in here. So we ended the 2021 calendar year with 378,000 lives and as you know, the open enrollment period just ended a few weeks ago. So there's still some dust to settle in terms of who will follow through with first premium payments. We have extended grace periods on some of the customers, et cetera. So pinpointing the exact number is a bit of a challenge for the first quarter. But for the full year, based on how the open enrollment period just ended up, we would expect lives to be down in the range of 20%, 25%. So you can think of the 378 that we ended at year-end '21 coming down by that sort of magnitude by year-end '22. Intra-year, there's likely to be some net attrition. So I won't try to pinpoint the Q1 number, but you can expect it will be down from the year-end number and then we'll see some further attrition over the course of the year. Based on the pricing actions we took, we've seen our competitive position slide down in most geographies. So the renewals that we did get, we were pleased with because the prices are certainly firmer than they were in '21, which gives us good confidence in the margin expansion.",0.1977429,0.972
CI-2021-Q4-2022-02-03,119,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"And following up on the question that Nathan just asked me, we would expect all-in MCR improvement on this book of business of several hundred basis points when you think of the loss of the special enrollment period lives and the revenue yields that we were able to achieve.",1.313052,0.527
CI-2021-Q4-2022-02-03,120,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So therefore, margins expanding in the book to your point, not quite at but approaching more reasonably what our target margins are for the book of business, but not quite at that for 2022.",0.382433,0.0
CI-2021-Q4-2022-02-03,123,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So Dave, again, let's start with big picture. Big picture, the performance of that book of business as we step into 2022 has a pretty reasonable retention level, retention point is a couple of points below where we would like it to be given the competitive environment, just less new business sales. So from a value proposition for those we are serving today largely off of an individual HMO chassis and increasing off of an individual PPO chassis, the value proposition resonates for those that are consuming our services. But the new business side of the equation a little bit more challenging given the dynamics in the marketplace. I think we always enhance the value proposition. So to the core of your point, I would point toward two areas. One, the ability to continue to accelerate and enhance the collaboration between the pharmacy, the specialty pharmacy and the behavioral subcomponent of the proposition.",0.4049747,0.955
CI-2021-Q4-2022-02-03,124,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And two, the ability to further leverage some alternative side of care opportunities for the benefit, in this case, of the senior beneficiary to deliver both better overall affordability and convenience. So you can think about that as alternative side of care being digital, home care or extending the services that could be delivered in a coordinated value-based physician relationship from that standpoint. We see both of those as net additional added value opportunities for both affordability as well as personalization for the individuals we serve. And both of those are enabled through further expansion of Evernorth.",0.3039254,0.981
CI-2021-Q4-2022-02-03,128,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Lance, it's David. You packed a lot into one question. Let us try to touch upon each. I'll take the Prime question. I'll take the upside on the Cigna book, and I'll ask Brian to take the specialty and specialty generic piece of the equation. First, specific to Prime, just at a more macro level, I'm not going to go through detailed renewal situation with the - on the line here. But if you take two steps back, Prime is a great reinforcement of our orientation around partnering. Our health plan business has continued to grow. I referenced previously, we've had net growth in our health plan portfolio of about 20 health plans over the last several years. Specific to Prime, we're proud to be able to serve our Prime both organization, health plans within it and the members. We've been able to expand the relationship and broaden the relationship over time. And importantly, Lance, we co-collaborate and co-innovate with the health plans within Prime to help to drive further growth for them. So we view it as a positive and it's a reinforcement of the meaningful and attractive sustained growth we've had in our health plan portfolio of businesses.",0.0715119,0.982
CI-2021-Q4-2022-02-03,129,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to upside within the Cigna portfolio, we continue to drive leverage between the Cigna Healthcare portfolio and the Evernorth portfolio. For example, our growth recently with UPMC is an example of leverage between the two organizations, where we leverage some of our Cigna Healthcare capabilities within the Evernorth relationship for a strategic long-term partner when we were able to expand the relationship in that way. Specific to your - I think the traditional part of the way you're asking the question, I'll wrap up here, is on the PBM penetration within the Select segment always deemed that to be fully penetrated. Within the Middle Market segment, the level of penetration varies based on client relationship. We see some additional penetration as having been achieved.",0.6016323,0.599
CI-2021-Q4-2022-02-03,130,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And then within National Accounts, it's an account by account relationship that is determined. So overall, we're pleased with our current state of penetration for PBM in Cigna Healthcare. It can move a little bit more, but I wouldn't have you look at it as a big barometer of movement rather the leverage of the relationships like a UPMC is a great example of, you're using the word penetration, we'll use the word cross-leverage and cross-value collaboration.",0.2211426,0.913
CI-2021-Q4-2022-02-03,131,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Brian, I'd like you take the specialty in specialty generic piece.",0.6066848,0.361
CI-2021-Q4-2022-02-03,132,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"Yes. Overall, just kind of big picture, specialty generics and biosimilars are both really important mechanisms to drive affordability for our clients and customers over time, as they drive competition. And that's a really important part of the landscape here. And specialty was a meaningful driver of our results in 2021. And it will be in 2022 in the Evernorth space. So, well, I won't specifically size the contributions from specialty generics. It was helpful contributor over a multiyear period now to our ultimate P&L for Evernorth. And as we step into '22, I mentioned in my prepared comments, specialty will drive revenue growth in Evernorth. All in, we would expect our Evernorth growth to be within our long-term targeted growth range, meaning at least 4% revenue growth, powered heavily by specialty. Specialty Generics will be a part of that as will biosimilars and other parts of the drug space.",0.1560353,0.971
CI-2021-Q4-2022-02-03,133,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"So all in, we would expect Evernorth revenue to grow at least 4% for the coming year, and we expect income growth of 5% with Specialty Generics being a component of that.",0.4617272,0.382
CI-2021-Q4-2022-02-03,136,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"John, it's Brian. So you're right. We found it increasingly difficult to try to segregate COVID and non-COVID and the commentary we had earlier in '21 about COVID headwinds, particularly as you're finding more and more situations where an individual might be admitted to the hospital with one condition and then found to have COVID later on or the situation with our special enrollment period lives, what it was tough to determine is that a COVID-related issue or not. So we found it increasingly difficult, which is why we talk about all-in medical costs relative to the baseline. As I mentioned earlier, for full year '21, we ran above the baseline persistently for all four quarters across the book, and we've carried that assumption forward into 2022.",0.3179588,-0.34
CI-2021-Q4-2022-02-03,137,Answer,2022-02-03,4,2021,Brian C. Evanko,CFO,"And so you should think of that as, when I say above the baseline, not 1% above the baseline, but a few percentage points above the baseline. So think of low single digit to mid-single digit above the baseline. And then over time, if there's some moderation, that will provide tailwind relative to our '22 and/or subsequent outlook.",0.1074583,-0.467
CI-2021-Q4-2022-02-03,140,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Yes. Efficient work, John, you grabbed another question there. I think your question points toward the criticality of sustained innovation. And if you - as I know you do, if you go back and look at the space over the last couple of decades, there continues to be periods of time where specialists will take a slice of the value proposition. And I don't say that as being an immaterial or on an important size of the value proposition, but we'll take a slice of the value proposition and try to drive super specialization within that. Typically, what that results in is either consolidation of those capabilities or accelerate innovation of those capabilities to be coordinated. So we don't think the picture you articulate is sustainable. We don't think your coworkers want to have multiple touch points coordinating them. We don't think medical professionals want multiple touch points coordinating them. But rather, the theme of a navigator is totally on strategy for us.",0.170618,0.964
CI-2021-Q4-2022-02-03,141,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","We have generations of that within our portfolio, within different solutions that have been in the marketplace for quite some time. One guy capability and certain clinical team capabilities and certain service capabilities, and having a digital-first philosophy, which is what I discussed previously, would reinforce to you that we continue to not only expand programs but expand the capabilities on a digital-first standpoint that could be able to do the navigation for our customers in a much more coordinated way. So we view that as on strategy, we view that as part of our CapEx, we view it as part of our capabilities within our portfolio and we have multiple positive proof points of how we've been able to convert that today, but we do not view that as an opportunity for the marketplace to disintermediate over a long period of time because that fragmentation is not sustainable; so opportunity for us.",0.1776137,0.916
CI-2021-Q4-2022-02-03,143,Answer,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","I appreciate your effectiveness, John. You have a great day.",0.0237077,0.778
CI-2021-Q4-2022-02-03,147,Closing,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","John reinforces that the operators suggestions are guidelines. But John, I do appreciate it very much. We want to thank everyone for your questions and importantly, your time this morning. And before I wrap up, I just have a couple of comments.",0.6490478,0.794
CI-2021-Q4-2022-02-03,148,Closing,2022-02-03,4,2021,David Michael Cordani,"President, Chief Executive Officer & Director","First, I want to say how appreciative and proud I am of our more than 70,000 colleagues for continuing to serve our clients, our customers and patients in a very challenging environment. We've all gained an even greater appreciation of the importance of health and well-being during this prolonged pandemic. And in Cigna, we're committed to continuing to innovate to deliver more affordability, simplicity and predictability of solutions for our customers, our patients and our clients. Our Evernorth and Cigna Healthcare platforms are well positioned for sustained growth, and we're confident that 2022 will be another strong year for Cigna.",0.2071512,0.987
CI-2017-Q4-2018-02-01,14,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks Will. Good morning everyone and thank you for joining our call today. I'll begin my comments by reviewing the highlights of our 2017 financial results, which reflect exceptionally strong performance across our portfolio of businesses.",0.5689856,0.898
CI-2017-Q4-2018-02-01,15,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Our sustained, differentiated results were driven by the effective execution of our go-strategy, along with the ongoing contributions of our talented and focused team to always put our customers at the center of all we do.",0.7773028,0.84
CI-2017-Q4-2018-02-01,16,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director",I will also highlight how we are continuing to deliver differentiated value and growth in our U.S. commercial employer market where we see effectively consultatively engage in customized solutions that improve our clients business and the quality of life for our customers.,0.7912942,0.936
CI-2017-Q4-2018-02-01,17,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","I'll then offer initial insight into our expectations for 2018 which includes sustained momentum across our businesses and a strong capital position, driven by the organic results we deliver as well as enhanced impact from recently passed tax legislation.",0.2436844,0.66
CI-2017-Q4-2018-02-01,18,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director",Eric will then address our fourth-quarter and full-year 2017 results in more detail and will provide the specifics for our outlook for 2018 before we take your questions and then I'll call a Q&A with some wrap up comments.,0.6078508,0.0
CI-2017-Q4-2018-02-01,19,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Let's dive in with some highlights from our share. Our results include strong performance across each of our priority growth platforms. Commercial employer, U.S. seniors, Global Supplemental Benefits and Group Disability & Life led by delivery of continued industry-leading medical cost trend.",0.4632724,0.866
CI-2017-Q4-2018-02-01,20,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","For 2017, our full year consolidated revenue increased by 5% to $41.6 billion. We reported full year adjusted income from operations of $2.7 billion or $10.46 per share representing a per-share increase of 29% with each of our business segments delivering strong growth over 2016.",0.5398368,0.889
CI-2017-Q4-2018-02-01,21,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","In addition, in 2017 Cigna grew to serve more than 95 million customer relationships worldwide all while continuing to generate strong margins and significant free cash flow for the benefit of our shareholders. Overall, we delivered very strong result in 2017 and as I'll discuss in more detail we are positioned to once again deliver competitively attractive revenue and earnings growth in 2018.",0.7920715,0.96
CI-2017-Q4-2018-02-01,22,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Now I'll spend the next few minutes delving further into our U.S. commercial employer business. We continue to view the employer marketplace as a very attractive growth opportunity. In a highly dynamic and disruptive environment, we continue to create value for employers by pursuing the right balance of affordability and personalization through a greater emphasis on alignment, transparency, and being the undisputed partner of choice.",0.6397202,0.938
CI-2017-Q4-2018-02-01,23,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","We improve our client's business by helping to ensure they have healthy, present and engaged employees all on a more affordable and predictable basis. We achieved this in three key ways; first, through a strategic orientation and focus on alignment and engagement, which helps our employer clients better manage costs, and leverage integration to improve health and productivity all in a personalized fashion. This approach enables us to drive growth across our U.S. portfolio of businesses including significant opportunities to continue to add new clients in the Select and Middle Market segments and on a targeted basis with international account segment.",0.1927711,0.981
CI-2017-Q4-2018-02-01,24,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Second, we continue to retain, develop and attract the best talent around the world, which enables us to operate with a high touch consultative service orientation for the benefits of our customers and clients.",1.1368053,0.902
CI-2017-Q4-2018-02-01,25,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","As we simplify many of the complexities in healthcare ecosystem, such as making it easier for our customers to connect to the right doctors, coaches and clinicians and take the customize employee benefit programs.",0.18733,0.7
CI-2017-Q4-2018-02-01,26,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","And third, our ongoing investments with our commercial employer business to further enhance affordability and personalization is in large part driven by effective, ongoing integration.",0.575204,0.477
CI-2017-Q4-2018-02-01,27,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Growth of the integration Cigna's approach differs considerably from traditional cross selling which simply combines multiple products into one sale and it differs from bundling, which improves only the pricing structure of a sale. Rather Cigna's integrated model goes beyond, meaning we use combined data across our solutions to develop insights that drive improved health outcomes.",0.6828605,0.848
CI-2017-Q4-2018-02-01,28,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","For example, our behavioural and medical teams work closely to identify Cigna customers with conditions which frequently lead to co morbidities in the behavioural realm, such as depression, positioning all behavioural colleagues to intervene on a preventative basis.",0.5744267,-0.572
CI-2017-Q4-2018-02-01,29,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","In addition, we continue to embed lifestyle coaching into our medical programs. This approach helps our customers achieve their specific health goals such as smoking cessation, achieving a healthier weight for better and more effectively managing their chronic conditions.",1.5239021,0.827
CI-2017-Q4-2018-02-01,30,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Pharmacy integration is another key driver for us to help improve overall health and affordability. Our integrated approach provides us with additional customer touch points to help ensure individuals who are taking their medication and to drive increase health engagement in specialty condition management, case management and health coaching.",0.4321803,0.935
CI-2017-Q4-2018-02-01,31,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","In addition our specialty pharmacy capability drives significant opportunities to improve affordability for the most complex cases, because our integrated model manages both the pharmacy and medical side of the cost.",0.5091333,0.743
CI-2017-Q4-2018-02-01,32,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","I would [Indiscernible] approach here help this drive the lowest medical cost trend in the industry again in 2017. Going forward, we will continue to define industry-leading integration by bringing innovative and new approaches to the market. For example, our initiative to reduce the use of opioids has pharmacy, behavioural as well as medical components, including close collaboration with our network partners to improve prescribing patterns.",0.7734162,0.791
CI-2017-Q4-2018-02-01,33,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Our approach to integration in addition to helping to drive clinical outcomes and affordability also helps to further improve the overall customer experience. An additional example of our ongoing investments in innovation is our recent acquisition of Brighter, one of healthcare's most innovative technology companies.",0.9599689,0.934
CI-2017-Q4-2018-02-01,34,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Brighter engages customers and healthcare providers to more effectively and efficiently deliver high-value healthcare in a personalized and seamless way. This acquisition further accelerates our ability to develop new digital platforms as well as to further innovate new end-to-end experiences that connect individuals and healthcare providers with the guidance, support and incentive they need to further improve affordability and personalization.",0.7815779,0.973
CI-2017-Q4-2018-02-01,35,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Taken together, our broad and diverse capabilities integrated solutions and customer centric approach have consistently fueled our ability to deliver best-in-class medical cost trend for many years running.",0.3295764,0.459
CI-2017-Q4-2018-02-01,36,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","To illustrate the importance of the impact of medical trend, I'll provide a specific employer example. A 1000 life employer working with Cigna would have experienced nearly $2 million in medical cost savings over the last five years, relative to the industry average medical cost trend of 67%, thereby providing opportunities for them to strengthen their business in this highly competitive environment, whether through further investments in innovation, expansion of the workforce or margin growth, and with approximately 85% of our U.S. commercial customers being serviced through transparent ASO funding arrangements, Cigna's medical cost trend results directly benefit our employer clients, their employees and families.",0.4345122,0.939
CI-2017-Q4-2018-02-01,37,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Now looking ahead to overall expectation for 2018, we will continue creating strong value for our customers, clients and as a result for our shareholders through our consistent focus on delivering affordability personalization as well as partnering with healthcare professionals to ensure our customers receive the highest quality healthcare.",0.9051691,0.891
CI-2017-Q4-2018-02-01,38,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","We expect to deliver revenue growth in line with our long-term objective of high single digit annual growth. Our outlook anticipates a 19% to 23% EPS growth rate over 2017 and I would note consistent to our practices, our EPS outlook does not include the impact of prior year reserve development or any future capital deployment in 2018.",0.8814613,0.778
CI-2017-Q4-2018-02-01,39,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Regarding recent U.S. tax reform, we anticipate positive earnings impact in 2018 inclusive of further investments in three critical areas, furthering our capabilities relative to innovation for the benefit of our customers, client and healthcare professional partners, furthering investments in market-based initiatives benefiting our external stakeholders including our communities and further investments in our Cigna colleagues.",0.5837544,0.785
CI-2017-Q4-2018-02-01,40,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Overall for 2018, we expect continued strong financial health and free cash flow inclusive of these investments. Now stepping back, at our investor day in June of 2017, we introduced an attractive EPS target of $16 per share for 2021. Each of our four growth platforms have remained well positioned for sustained growth. We have momentum from our 2017 performance expect to deliver another strong result in 2018 augmented by the U.S. tax reform.",0.8165565,0.965
CI-2017-Q4-2018-02-01,41,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","In addition to this strong positioning we are further aided by our tremendous ongoing capital position. As a result, today, we are pleased to increase our long-term EPS target from $16 per share to $18 per share for 2021.",0.1267003,0.91
CI-2017-Q4-2018-02-01,42,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","As I turn the call over to Eric, I want to recognize what our talented team of approximately 45,000 colleagues around the globe are positioned to achieve in 2018. As a team, we are poised to continue driving attractive growth and significant value creation for our customers, clients as well as our shareholders.",0.8849592,0.948
CI-2017-Q4-2018-02-01,43,Remarks,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","As a team, we remain driven by our unwavering mission of helping to improve the health, well-being in sense of security of those we serve around the world, and our innovative approach to meeting the needs of our customers and clients furthers our ability to deliver top and bottom line growth and gives us confidence we will achieve our very attractive full year 2018 outlook as well as our long-term objectives.",1.0870579,0.971
CI-2017-Q4-2018-02-01,45,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Thanks, David and good morning everyone. In my remarks today, I will review Cigna's 2017 results and provide our outlook for 2018. Key financial highlights for 2017 include consolidated revenue growth of 5% to $41.6 billion, consolidated earnings growth of 27% to $2.7 billion, earnings per share growth of 29% to $10.46 and continued strong free cash flow and $2.8 billion return to shareholders through share repurchase in 2017.",0.4610133,0.971
CI-2017-Q4-2018-02-01,46,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"These results reflect the underlying strength of our franchise and provide us with considerable momentum for continued growth in 2018. Regarding our segments, I will first comment on Global healthcare.",2.3126123,0.7
CI-2017-Q4-2018-02-01,47,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"2017 premiums and fees grew 5% to $29 billion driven by strong customer growth and specialty contributions across all commercial market segments and as expected, this growth was partially offset by lower seniors enrolment.",0.3826806,0.743
CI-2017-Q4-2018-02-01,48,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We ended 2017 with 15.9 million Global Medical customers, an organic increase of 710,000 lives which represents 5% growth over 2016. Full year earnings were $2.17 billion, reflecting growth in medical customers and specialty relationships, continued effective medical cost management and operating expense discipline.",1.1591807,0.863
CI-2017-Q4-2018-02-01,49,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to medical costs, we continued to deliver medical cost that reflect better health outcomes as a result of our deep engagement and collaboration with customers, clients and physicians. Our focus on personalization of care and the power of our differentiated speciality integration model.",0.3582465,0.844
CI-2017-Q4-2018-02-01,50,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our total U.S. Commercial book of business, full year medical cost trend for 2017 was better than the low-end of our previous guidance range of 3% to 4%. As David discussed, our commercial medical trend result once again reflects industry-leading performance and enabled our employer clients to make further investment in innovation, expand their workforce and grow their margins.",0.2443406,0.778
CI-2017-Q4-2018-02-01,51,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"The total commercial medical care ratio or MCR of 79.9% for full year 2017 reflects the continued effectiveness of our medical cost management capabilities as well as the impact of the health insurance tax suspension. This MCR also reflects better-than-expected medical costs in our U.S. individual business, which generated a small profit in 2017.",0.2813511,0.802
CI-2017-Q4-2018-02-01,52,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,The total government medical care ratio of 84.9% for full year 2017 reflects the impact of our innovative physician engagement model within Medicare advantage and is consistent with our expectations.,0.0136543,0.878
CI-2017-Q4-2018-02-01,53,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Full year 2017 Global Healthcare earnings also included favorable net prior year reserve development of $112 million after-tax. The Global Healthcare operating expense ratio of 20.9% for full year 2017 reflects the impact of the health insurance tax suspension, business mix exchanges and continued effective expense management. Overall, we've had another strong year in Global Healthcare.",0.3557312,0.859
CI-2017-Q4-2018-02-01,54,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our global supplemental benefits business. Our full year 2017 results reflect continued attractive growth and profitability as premium and fees grew to $3.7 billion an increase of 14% and full-year 2017 earnings grew 26% to $369 million, reflecting business growth, favourable point of experience and continued operating expense discipline.",0.3431549,0.92
CI-2017-Q4-2018-02-01,55,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For Group Disability and Life, full year 2017 premiums and fees were $4.1 billion. Full year earnings in our Group business increased to $285 million, reflecting strong performance in both our Disability and Life businesses.",0.1408552,0.66
CI-2017-Q4-2018-02-01,56,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Overall, as a result of the continued effective execution of our strategy, Cigna delivered strong revenue and earnings contribution from our Global healthcare, Global Supplemental Benefits and Group Disability & Life businesses in 2017. We also continued to generate strong free cash flow across our enterprise and maintain significant financial flexibility.",0.1275602,0.957
CI-2017-Q4-2018-02-01,57,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now I will discuss our outlook for 2018. As we continued to drive strong value for our customers and clients, we step into 2018 with momentum in each of our businesses. As a result, in 2017 we expect to deliver attractive financial growth by deepening our customer and client relationships, delivering on-going superior medical quality and cost outcomes and continuing to invest in innovative solutions to more effectively engage with our customers and healthcare professionals.",0.4707151,0.973
CI-2017-Q4-2018-02-01,58,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For full-year 2018, we expect consolidated revenues to grow in the range of 7% to 8% over 2017 with continued growth across our targeted market segments. We expect full year 2018 consolidated adjusted income from operations to be 3.08 billion to 3.2 billion or $12.40 to $12.90 per share. This represents growth in the range of 19% to 23%.",0.0100611,0.751
CI-2017-Q4-2018-02-01,59,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"This outlook includes approximately $425 million of incremental after-tax earnings resulting from U.S. corporate tax reform. I would note that this incremental earnings estimate is net of $150 million after-tax and additional investment in our employees, communities and partners as well as our capabilities that enable us to better serve our customers and clients while accelerating long-term growth.",0.1897233,0.765
CI-2017-Q4-2018-02-01,60,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For 2018, we project the consolidated adjusted tax rate in the range of 24% to 25%. Consistent with prior practice, our outlook excludes any contribution from future capital deployment as well as prior year claim development.",0.6130075,0.273
CI-2017-Q4-2018-02-01,61,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now putting our 2018 outlook and our 2017 actual result on a comparable basis, that is adjusting for the reserve development reported in our 2017 results, and excluding the impacts from tax reform, our outlook for earnings in 2018 reflects 4% to 9% growth over 2017, and our outlook for EPS growth is 7% to 12% before considering the impact of additional capital deployment.",0.5088034,0.637
CI-2017-Q4-2018-02-01,62,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I will now discuss the components of our 2018 outlook starting with Global Healthcare. We expect full-year Global Healthcare earnings in the range of approximately $2.6 million to $2.68 million. This outlook reflects strength in our commercial employer business, driven by continued benefits from organic customer growth, specialty contributions and effective medical cost management as well as continued solid performance in our Medicare advantage business.",0.4495149,0.935
CI-2017-Q4-2018-02-01,63,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Key assumptions reflected in our Global Healthcare earnings outlook for 2008 include the following; regarding total medical customers, we expect 2018 growth in the range of 300,000 to 500,000 customers, driven by continued strong customer and client retention and new growth in our commercial business. And approximately, 3% growth in Medicare advantage customers.",0.0765361,0.902
CI-2017-Q4-2018-02-01,64,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to medical costs. For our total U.S. Commercial Employer book of business, we now expect full-year 2018 medical cost trends to be in the range of 4% to 5%, with the increase over 2017 full year trend due to expected increases in utilization and pharmacy costs.",0.4635286,0.318
CI-2017-Q4-2018-02-01,65,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our total commercial book of business, we expect the 2018 medical care ratio to be in the range of 77.5% to 78.5% reflecting the impact from the health insurance tax in 2018.",0.1239669,0.494
CI-2017-Q4-2018-02-01,66,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our total Government book of business, we expect the 2018 Medical Care Ratio to be in the range of 84% to 85%. Regarding operating expenses, we expect our 2018 global healthcare operating expense ratio to be in the range of 22.5% to 23.5% reflecting the impact from the health insurance tax in 2018.",0.1516349,0.494
CI-2017-Q4-2018-02-01,67,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now moving to our Global Supplemental Benefits business, we expect full year 2018 earnings in the range of $380 million to $400 million, reflecting business growth and continued strong operational performance.",0.7294287,0.818
CI-2017-Q4-2018-02-01,68,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"And regarding the Group Disability and Life business, we expect full year 2018 earnings in the range of $330 million to $350 million driven by ongoing performance momentum in both our Disability and Life businesses.",0.1042041,0.0
CI-2017-Q4-2018-02-01,69,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Lastly, regarding our remaining operations that is other operations and corporate, we expect the loss of $230 million for 2018. To all-in for full year 2008, we expect consolidated adjusted income from operations of $3.08 billion to $3.2 billion, or $12.40 to $12.90 per share.",0.5594682,-0.026
CI-2017-Q4-2018-02-01,70,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,I would also remind you that our outlook continues to exclude the impact of prior year reserve development or any future capital deployment. Overall these expected results represent a competitively attractive outlook and underscore the strong performance of our diverse and differentiated portfolio of businesses.,0.4143011,0.649
CI-2017-Q4-2018-02-01,71,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now moving to our 2018 capital management position and outlook, overall, we continue to have excellent financial flexibility. Our subsidiaries remain well capitalized and are generating significant free cash flow to the parent with the strong return on capital in each of our business segments, while we maintain significant free cash and leverage capacity available at the parent company.",0.1016888,0.962
CI-2017-Q4-2018-02-01,72,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Our capital deployment strategy and priorities remain, first, funding our businesses to support long-term growth, next, pursuing strategic M&A and lastly, after considering these first two items we would return capital to shareholders primarily through share repurchase.",0.2461373,0.758
CI-2017-Q4-2018-02-01,73,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Regarding free cash flow, during 2017 we repurchased 15.7 million shares of common stock for $2.8 billion, and we ended the year with parent company cash of $1.2 billion including $250 million held for liquidity purposes.",0.2878189,0.671
CI-2017-Q4-2018-02-01,74,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Considering sources and uses the parent company cash, we expect to have approximately $2.8 million available for capital deployment in 2018 including approximately $260 million we deployed to repurchase 1.2 million shares in January 2018.",0.1189364,0.296
CI-2017-Q4-2018-02-01,75,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Our balance sheet and free cash flow outlook remains strong, benefiting from industry leading margins and returns on capital in our businesses and the high level of capital efficiency, particularly from our fee-based businesses.",0.4814948,0.844
CI-2017-Q4-2018-02-01,76,Remarks,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now to recap. Our full-year 2017 consolidated results reflect the strength for our diversified portfolio of Global businesses and continued track record of effective execution of our focused strategy. The fundamentals of our business are strong, and we are confident in our ability to achieve our full-year 2018 earnings outlook.",0.3050665,0.949
CI-2017-Q4-2018-02-01,80,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning. It's David. Clearly the announcement was not lost on us. So stepping back I think one way we look at the announcement is, it reinforces something we've been talking about for quite some time, which is - it's a pretty dynamic industry and the older orientation around focusing only on insurance or a fee-for-service healthcare delivery model is just fundamentally not sustainable as employers and customers demand more.",0.4135251,0.897
CI-2017-Q4-2018-02-01,81,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Secondly, from our point of view, it reinforces the imperative of focusing on transparency, focusing on alignment and focusing on in a demonstrable way helping to ensure that you have the ability to drive healthy productive present employees and making employer's business better and more effective. I would point to as an example something we're quite proud of not only the lowest medical cost trend in the industry year-in and year-out, but this year for 2017 we ended favorable to the lower end of our improved range, so less than 3% medical cost trend for the benefit of our clients and customers.",1.1045472,0.965
CI-2017-Q4-2018-02-01,82,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Looking forward, we actually see initiatives like this is actually presenting more opportunities than not. To your question there are been other different forms of coalitions forming, although this is a different coalition. Coalitions forming through the national business group on health, coalitions forming, you can look at it through private exchanges. And overtime each of them had presented opportunities interestingly for additional growth for us for both our medical and specialty offerings because we're oriented around transparent aligned funding relationships.",1.2642829,0.912
CI-2017-Q4-2018-02-01,83,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","So, taken as whole we view it as indicative of a changing dynamic environment, indicative of employers seeing this more as a strategic investment in the capital and employers seeking opportunities to get more leverage, more impact for the benefit of running the business and we can more opportunity than not.",0.6591527,0.883
CI-2017-Q4-2018-02-01,85,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"A.J. its Eric. Yes, 3% growth is the number we expected for the year. I think in terms of getting back to our long-term targets which would be high single digits growth rate in terms of the revenue and associated lives in the Medicare Advantage really reflects our momentum and such no obstacle whatsoever from my perspective in terms of achieving that over the longer term. As we entered this year we had the effect of some exits of counties. We didn't open up any new counties or any new markets this year, but as we cleared to that January cycle and look ahead to the future, don't see any reason why we couldn't get back to our and won't get back to our long-term averages.",0.4940711,0.519
CI-2017-Q4-2018-02-01,89,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Josh, it's Eric. I'll start with the first part of your question, just be clear, yes, any impact from the minimum MRL, rebates and such are included in the $150 million. The amount is small in terms of a portion to that given the profile of our book of business and such, but that is included in the 150. I'll ask David to comment on the other item.",0.4782609,0.392
CI-2017-Q4-2018-02-01,90,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Josh, good morning. Two comments specific in general. Specific to your question, think about as today as we operate before we get the HealthSpring. We're able to operate and deliver quite good services for employer clients through on-site clinic management and coordination, on-site health coaches, management and coordination, in select instances, on-site pharmacy management coordination, so think about that is one retail point of interaction that we do on a highly integrated basis.",1.0217645,0.7
CI-2017-Q4-2018-02-01,91,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Secondly to your HealthSpring question, HealthSpring model, as you recall, there are different footprints and different geographies, we can go as broad as the Cigna owned medical group in Arizona to owning bricks and mortar real estate in Tennessee and having independent physicians rotate through that and everywhere in between. I think more broadly stepping back as it relates to retail footprint, our strategic view is that virtual vertical integration is a preferred approach versus wholesale vertical integration on a hardened basis.",0.6195103,0.0
CI-2017-Q4-2018-02-01,92,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","So what we mean by that is we are through virtual vertical integration, we're able to drive improved alignment, choice and transparency where we aggressively embrace technology to expand access and choice and where we partner to create a more open framework to expand choice and impact through affordability and personalization. So, again, we have a variety of footprints, but we really prefer and are driving aggressively the vertical integration through a virtual mechanism to get that alignment, the impact, the choice and embrace technology.",0.7815779,0.599
CI-2017-Q4-2018-02-01,95,Question,2018-02-01,4,2017,Ralph Giacobbe,Credit Suisse,"Thanks. Good morning. First, just want to ask about the $18 in EPS in 2021, obviously some of that tax reform, but just looking on a CAGR basis it suggested about 12.5% growth. And if I look at the $16 number was closer to 11%. So, just wanted to sort of bridge that in terms way you expects sort of faster underlying growth beyond tax reform from where we were not that long ago on you threw out the $16 number? Thanks.",0.527939,0.934
CI-2017-Q4-2018-02-01,96,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Yes, Ralph, when we discuss the $16 number at our Investor Day, obviously we walked through a pretty methodical framing of that. So, stepping back we're quite pleased to be able to put that forth the framing of the four growth platforms and the very attractive growth profile of each of those platforms led by strong retention, further relationship expansion and net new business adds.",0.7516518,0.967
CI-2017-Q4-2018-02-01,97,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","To your question, what's net new? I'd ask you to think about two things, right. The underlying strength of our platform, we ended 2017 ahead of our strategic glide path period. We delivered an EPS growth rate of 29%. We're able to step into 2018 with an outlook as Eric articulated to grow our EPS by 19% to 23% before reserve development or any additional capital deployment. So point one is the organic fundamentals ended the year stronger which gives us more leverage power stepping into 2018. Second, is the impact of tax reform and our belief in terms of the combination of both of those enable us to increase the outlook from a very attractive $16 to even more attractive $18.",0.770307,0.944
CI-2017-Q4-2018-02-01,98,Question,2018-02-01,4,2017,Ralph Giacobbe,Credit Suisse,"Okay. That's helpful. And just the follow-up, has there been any push back on ASO fees from existing customer just on the fee itself. And then as you look across your book it sort of the average trend that you mention sort of below the 3% level. Do you see differences in trends between large nationals that may not be willing to adopt some your medical management approaches versus the smaller select and mid markets that maybe more willing to adopt your approach? Thanks.",0.1632801,0.84
CI-2017-Q4-2018-02-01,99,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Ralph, first relative to ASO fees, as you may recall from prior conversation we typically don't look at an employer relationship as a fee-only relationship. Our entire approach with our employer clients at all levels. So from select through middle market, through national is to look at the portfolio of services that best suit their strategy, their change agenda and have the highest opportunity for impact vis--vis some of the integrated offerings I made comment on -- before my prepared remarks. And then get an economic relationship with them that work in a quite transparent basis.",0.6478818,0.836
CI-2017-Q4-2018-02-01,100,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","So we've long since moved from micromanagement of the fee environment and candidly I would view the fee environment as a smaller part of the overall conversation. To your broader question relative to medical cost trend and the like. The positive [Indiscernible] it transcend the portfolio, right, as you recall ASO aided by further shared returns encompasses over 90% of all of our relationships. So that positive medical trend performance is indicative of the entire portfolio and the performance of the portfolio and what tends to drive it to such a powerful level is the alignment with the employer and transparency, highly innovative clinical programs and engagement incentive-based programs and then increasing leverage of the collaborative accountable care relationships that we're able to deliver for the benefit of our clients.",0.7897396,0.978
CI-2017-Q4-2018-02-01,101,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Ralph, it's Eric, one other point on what David said there and as David noted in his prepared remarks this morning, the effectiveness of the integration of the specialty model helps to drive even more effectiveness in terms of trends. So as we have highly integrated offerings in the smaller end of the market I generally see even the better results than the bottles that are little more a la carte or fragmented.",0.3302192,0.751
CI-2017-Q4-2018-02-01,105,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Matt, it's David. First nice job trying to displace Zach from the call queue; and Zach will get back to you as quickly as we can. Matt, I think just part of your question and I appreciate the way you framed it. I mean, at the end of the day we have talked for quite some time, while the industry as a whole for example may step back and we have a narrative around more stabilized or more muted medical cost trend. We as a company been very consistent, it is still unsustainable. So as I illustrated in the prepared remarks for example, a 1000 life employer experiencing illustratively our medical cost trend versus the industry average is a multimillion dollar savings and we believe we need to do even better.",0.780412,0.852
CI-2017-Q4-2018-02-01,106,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","So, when you look at the size and impact of medical cost trend growth being an industry average of six or seven or our industry-leading trend of below 3% this year, employers will rightfully continue to push for more value from their sizable investment and increasingly they see this disinvestment as a strategic investment and we'll manage it as a strategic investment to help them run their business more effectively.",0.4780412,0.88
CI-2017-Q4-2018-02-01,107,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Over time we think that creates more opportunity versus less for us, because we seek to be at an integrated partner for the services standpoint providing the services that deliver the value. As you know our industry is capital-intensive, as well as relatively low margin, single-digit margin, so this is not going to get solved with extracting a couple points of margin out of the equation. The solution here is helping to keep people healthier in the first place, to avoid health risk, health consumption, lowering the health risk for the 25% of Americans that are medium and high risk will be chronic or acute in two years of those risk don't go mitigated and getting the best possible evidence-based care compliance for those dealing with chronic condition and then optimizing care delivery for those confronting acute conditions.",1.0777303,0.939
CI-2017-Q4-2018-02-01,108,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","That's how the sustainability of the system is driven and employers flexing their muscle and becoming more vocal in terms of driving and being more demanding around that we actually view as a net positive, because we think the employer market is a positive aggregation of individuals and a way to get strategic alignment. So to recap, we should not view that an industry with stable medical cost trend at 5%, 6%, 7% is sustainable. We're proud of the fact that we delivered half of that. We need to do better and you do better by engagement, alignment and driving health improvement and getting the best possible quality of care when care is consumed.",0.8219977,0.986
CI-2017-Q4-2018-02-01,111,Question,2018-02-01,4,2017,Justin Lake,,"Thanks. Good morning. Just handful of number of questions here from me. First on the 2021 numbers change, sounds like to the great extent this is the improvement in taxes and some improved business momentum. On the tax side you're looking out for years and obviously assuming that a lot of this is sustainable. Can you walk us through kind of your thought process on sustainability of higher effective net income margins as you go through kind of competitive iteration over a few years?",1.1618993,0.969
CI-2017-Q4-2018-02-01,112,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Justin, its David. Good morning. I guess couple of thoughts. First to reinforce, the $16 starting point was based on strong fundamental sustained organic growth for franchise and then effective capital deployment. Yielding is as you would recall, a very attractive result. The step up these two items, I don't want to walk away from the stronger results we deliver in 2017, put us ahead of us to glide path and give us leverage going forward.",0.3886514,0.952
CI-2017-Q4-2018-02-01,113,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Specific to the taxes, as you know in the U.S. we're predominately a service-based business that has higher transparency versus not, as Eric articulated earlier there's relatively de minimis impact of the taxes on my minimum MLRs and the like, so we have more flexibility or choice with which to deploy it. For 2018 we made a very disciplined assessment of how to invest if you will those assets for sustained growth on a go forward basis looking at our customers, our clients, our community, our coworkers and our shareholders. And we're quite confident that it's a long way -- as we have continued innovation and effective execution we'll be able to both deliver the value for clients and customers as well as realize a fair return for shareholders. So we see a lot of opportunities as we look for between 2018, 2019 and 2021.",0.025651,0.975
CI-2017-Q4-2018-02-01,114,Question,2018-02-01,4,2017,Justin Lake,,"Great. And then, on the two things; one, Disability and Life, 7.5%, 8% margins is where you were before the issues kind of occur there. By my estimate it doesn't look like you got back to your 7.5% to 8% margin that you used to do there with the guidance. Is there some reason for that? And is the true? And then on membership growth can you just give us some color on where the segments beyond Medicare Advantage ASO versus commercial risk versus experience rated, where you expect that membership to come? Thanks a lot.",1.0646453,0.911
CI-2017-Q4-2018-02-01,115,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Justin, it's Eric. As it relates to the Disability and Life, we think the guidance we've provided is attractive and align with our long-term strategic targets. So again we think that business is performing in line with the strategic targets that we set for it over the long-term. As it relates to membership growth we would note a couple of things that's tying up comments David made in his prepared remarks, first of all, continued really strong momentum in the select segment in the middle market segments in particular we would see a growth there and across the insured versus ASO split again, we'd expect growth across each one of the funding arrangements as we go into 2018.",0.3614804,0.935
CI-2017-Q4-2018-02-01,119,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Zach, it's Eric. Nothing specific I would call out in terms of things that we're seeing that would - I would point to you. I think its more just coming off of the low trend that we delivered in the course of the of 2017. In particular we had very favorable pharmacy trend in the course 2017. We finished 2017 with pharmacy trend that essentially zero. We wouldn't expect that to be the rate going forward, but again, we pull those pieces together overall and nothing I would point to in terms of specifically higher utilization.",0.4520302,0.165
CI-2017-Q4-2018-02-01,122,Question,2018-02-01,4,2017,Kevin Fischbeck,Bank of America / Merrill Lynch,"Great. Thanks. If you go back to one of deal with Anthem growth, how you outlined about 7 billion of kind of capital available for deployment [Indiscernible] if you wanted to do M&A. Where do we stand in those numbers now? And then, I guess you mentioned that there was foreign tax, one-time tax in a quarter. So that mean, we repatriate in cash in 2018?",0.2194986,0.874
CI-2017-Q4-2018-02-01,123,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"It's Eric. Couple of parts to that question there. First of all, as it relates to the seven to 14 items, so we issued the $7 billion to $14 billion range at the time of the Anthem break just to help provide some framing. At that time the $7 billion end of the range represented capital available for deployment that we had on the balance sheet, plus the impact of the break fee, plus the additional leverage capacity that we had to return to more normal range. The upper end of that range represented what we could do if we took additional leverage and pursued a strategic M&A transaction.",0.3715415,0.402
CI-2017-Q4-2018-02-01,124,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now, as I noted in my prepared remarks, we expect to have your $2.8 billion or so available in 2018 plus still significant balance sheet capacity. So, again, the overall framework that we described in terms of the $7 billion to $14 billion continues to apply, will continue to be disciplined in terms of our approach on deployment and such overall.",0.0653971,0.402
CI-2017-Q4-2018-02-01,125,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"On the second part of your question, could you just repeat the specifics, I want to make sure I'm answering it appropriately.",0.1961912,0.382
CI-2017-Q4-2018-02-01,126,Question,2018-02-01,4,2017,Kevin Fischbeck,Bank of America / Merrill Lynch,I think I thought somewhere in your prepared remarks you indicated that you were -- it was like a one-time tax on foreign earnings as part of tax reform. And I wasn't sure if that meant that you were repatriating cash in 2018 or are you saying cash in 2018 is the question. And if so how much of that is that $2.8 billion.,0.5763231,0.691
CI-2017-Q4-2018-02-01,127,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes, the specific item there that we talked about in the terms of the tax associated with the foreign earnings is the repatriation portion of the recently reformed tax law. We are not anticipating significant repatriation and the tax law hasn't really changed our plans in terms of how we bring dollars back. We generally have used overseas capital to support the growth outside the United States and we continue to do so.",0.2669781,0.848
CI-2017-Q4-2018-02-01,132,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Christine its Eric, I'll start with the trend item and then ask David to comment on the Medicare Advantage pieces. So, the trend, the trend statistics we talk about on this call represent our U.S. commercial employer paid claim trends across all of our book of business.",1.1710384,0.25
CI-2017-Q4-2018-02-01,133,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"And, again, just as a reminder given that over 85% of our customer lives are self-funded, this statistic represents the amount that our clients are spending per customer per month year-over-year. There's no other adjustment or anything in terms of how we calculate that trend.",0.02659,-0.296
CI-2017-Q4-2018-02-01,134,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now, the difference between that paid trend or what you might call in a loud trend, the loud trend will help to include the effective cost borne by the individual customer in terms of deductibles and copays etcetera.",0.5407833,0.7
CI-2017-Q4-2018-02-01,135,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Given that we tend to have high customer retention from period-to-period our clients generally have pretty stable benefits from period-to-period that we haven't seen much difference between paid or allowed trends. But if you look at that allowed basis that includes the effect of car-sharing and such for 2017, our trend actually would have been even a little bit lower yet than the paid trends that I talked about in my prepared remarks. David, if you want to tackle the Medicare Advantage question.",0.1994251,0.851
CI-2017-Q4-2018-02-01,136,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Hey, Christine relative to Medicare Advantage in Medicare Growth, we continue to see it is an attractive opportunity to immediate long-term for us. I would ask you to think about it in a couple of ways. First relative to further accelerating organic growth, as Eric indicated, we view 2018 as a transition year. As we step into 2019 and beyond, we believe significant opportunity to open new markets and adjacent counties.",0.2522347,0.938
CI-2017-Q4-2018-02-01,137,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director",We are aided by the fact that we have a deep collaborative accountable care relationships in multiple states in multiple markets that are highly attractive for us for growth. Those relationships are focused on commercial today and many of those collaborative partners are excited to open up new Medicare Advantage relationships with us.,0.6626506,0.932
CI-2017-Q4-2018-02-01,138,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","So, we see the organic new market entry opportunities for 2019 and beyond is very attractive and in addition as you'll recall, we continue to have Medicare and seniors footprint growth as one of our M&A priority. So, it's one of our five M&A priorities. So, we see both opportunities through both organic expansion as well as inorganic expansion to generate sustained growth there.",0.4469491,0.929
CI-2017-Q4-2018-02-01,141,Question,2018-02-01,4,2017,Steve Tanal,Goldman Sachs,"Thanks for taking the question. I just wanted to circle up on tax reform, may close the loop on this. The $150 million of reinvestment sounds like an after-tax figure, and just using the tax rate, I guess, the pretax amount is maybe closer to $200 million. I just wanted to confirm that the way tax announced yesterday are sort of $45 million of that amount? And maybe get some color on specifics of where the rest will be reinvested. And then just finally, tying up some comments earlier around sustainability of medical cost trend generally, when do you see deflation if the - we continue down this path?",1.3626984,0.697
CI-2017-Q4-2018-02-01,142,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Steve, good morning, it's David. I'll address the taxes, and I'll ask Eric to talk about the medical cost trend and your interesting twist on it with deflation. Specifically, relative to investments, you've framed it correctly, we're talking about after-tax numbers, what are the implication, etcetera, but we're talking about a meaningful investment back into multiple key constituency group. So, you articulated rightfully, significant amount of investments back into our coworkers.",0.8756316,0.788
CI-2017-Q4-2018-02-01,143,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","And the next part that I'd ask you to think about is, furthering investments back in the company relative to innovation and innovative capabilities. We have had a long sustainable track record of designing and bringing new solutions and capabilities to market. We're going to take this opportunity to even further accelerate that in 2018, so a meaningful portion of the $150 million will make its way there.",1.0314808,0.909
CI-2017-Q4-2018-02-01,144,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","And then third category we referenced is, returning it back to the marketplace beyond that, so opportunities relative to furthering our community initiatives through our foundation and the like. Taken as a whole, that equates to approximately the 25% in aggregate of the impact that we talked about, making up the $150 million. Eric, if you share your thoughts relative to medical trend?",0.1900505,0.794
CI-2017-Q4-2018-02-01,145,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes, Steve, on the medical trend. I think a couple of points that I want to make sure land here. First of all, our trend results reflect the power of the incentive line and the power of our integrated model. And again, we're really proud of the result that we generated there. But as David said before, there is more work to be done. Not to -- to be able to predict the day or time that we hit the -- a point of deflation but there's more work to be done and we think there's quite a bit more we could tackle with the integrated model that we bring to the market.",0.5720446,0.681
CI-2017-Q4-2018-02-01,149,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Gary it's Eric. That plan into numbered the exact kind of tax rates by segment, but what I encourage you to think about the things in the following way. So, within the Global Health Care and Group Life and Disability business, the largest share of those businesses are here in the U.S. and that's where the bulk of our businesses, so you would expect to see the biggest impact there. And those businesses the impacted by U.S. tax reform.",0.40424,0.911
CI-2017-Q4-2018-02-01,150,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,The Global Supplemental Benefits business has a net tax headwind year-on-year that some of our non-U.S. jurisdictions have actually increased income tax rates so just a slight increase in terms of Global Supplemental Benefits business.,1.0574919,0.834
CI-2017-Q4-2018-02-01,151,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"And then within corporate and other operations, there's a tax rate favorability, but earnings headwind reflecting that segment where operating had a loss in total. So, those would be that piece that I would point you too.",0.5749192,-0.45
CI-2017-Q4-2018-02-01,153,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Gary, year-on-year, there's two things that point there both tax-related. First of all is the effect of the lower tax rate in 2018 and the second is the absence of some tax favorability that we had in 2017. So, some tax-related items, so it's separate from the income tax rate that we talked about earlier in the year in 2017. We don't expect those to return next year.",0.0039526,-0.296
CI-2017-Q4-2018-02-01,160,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Ana, it's David. So, multiple different questions, and let me try to address a couple of themes and invite Eric to add to it. I'm not sure we're going to be able to address every complexity referencing your question.",1.0532452,-0.093
CI-2017-Q4-2018-02-01,161,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","In the first question, I think about it in a couple of ways, right? As indicated before, this is an example of three large impactful voices, essentially suggesting that there's an opportunity to do more and they're going to lean in aggressively to enable more to be done whether it's through technological leverage, whether it's through insight and data, whether it's through insight and data, whether it's through a variety of items. But each one of those entities, essentially are ASO-serviced.",1.1333074,0.128
CI-2017-Q4-2018-02-01,162,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","So, if they're ASO-serviced, they're bearing their own risk and they're going to elevate the demands both for the parties they do business with as well as for their coworkers who are engaging in the overall equation.",0.4135251,0.625
CI-2017-Q4-2018-02-01,163,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","To your inference, I think there's opportunity and transparency, there's further opportunity in alignment, there's further opportunity in simplifying the complex. That's all on strategy from our point of view and we believe we have an opportunity to add value in every one of those areas. But it also means that the consumer and the employer need to more aggressively embrace change along the way. Net-net, we see of all of it as a positive.",0.9191605,0.945
CI-2017-Q4-2018-02-01,164,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","On your last point, I don't know. I don't know relative to the inference, relative to the consolidation and not for profits cost implications, et cetera. I would put into face of that two forces that are indisputable right now. One, you made reference to yourself, which is a relentless increase drive for transparency and demonstrable value delivery.",0.7162845,0.36
CI-2017-Q4-2018-02-01,165,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","And second, reword alignment relative to value-based care. I think those forces are indisputable and will confront any level of change and configuration of the supply chain or otherwise to push for more demonstrable value delivery and then elevation and transparency across care and quality. Eric, anything to add?",0.5608239,0.812
CI-2017-Q4-2018-02-01,166,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Ana, it's Eric. Just one other thing I would add relative to your comment about buy downs and such. I think one of the things I've noted -- and I've actually noted in the -- my response to Christine's question about paid versus allowed trend is actually, our allowed trend would have been a little bit lower that's because in 2017 versus 2016, our employers paid a little bit higher percentage of the cost than the employees. So, it's actually the opposite of cost shift in terms of 2017 versus 2016.",0.2809917,-0.232
CI-2017-Q4-2018-02-01,167,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I think what's most important, rather than just shift between how much the employer pays versus how much they employee pays is the power of getting incentives aligned with appropriate and well-designed plans to help reduce the overall cost burden of the programs and such overall. So making sure that the smart way design benefit plan helps to bring the cost down for both parties rather than just doing kind of cost shifting as the mechanism for employers to move things.",0.177147,0.941
CI-2017-Q4-2018-02-01,171,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Chris, its Eric. I'll start with a couple of comments there for you. So first of all, within the Global Supplemental Benefits business, we're really pleased with the year that we delivered in that segment. That point of three macro drivers in terms of the result that we generated in the course of 2017.",0.0150916,0.7
CI-2017-Q4-2018-02-01,172,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"First of all, we've had - continue to have favorable experience relative to our initial expectations. We've had continued growth in the business, we've been -- continue to be very disciplined in terms of the expense leverage and the expense management that we've delivered there.",0.7466762,0.691
CI-2017-Q4-2018-02-01,173,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Additionally, at the beginning of 2017, based on where the spot rates were at the time, we had anticipated the potential for some potential foreign exchange headwind, and that has actually turned into a headwind for us. So, those are all pulled together in terms of drivers of our results in 2017.",0.1282788,0.0
CI-2017-Q4-2018-02-01,174,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now, looking forward, the things I would point to in terms of drivers there, we do assume that there would be a bit of normalization in terms of that claim experience as we look ahead to 2018, one.",0.7035573,0.0
CI-2017-Q4-2018-02-01,175,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Two, we, as I noted on the tax rate question from a prior caller, we do expect a little bit higher tax rate on that segment going forward. And then as it relates to foreign exchange or FX, no particular headwind or tailwind we'd call out at this point.",0.3657923,-0.296
CI-2017-Q4-2018-02-01,179,Answer,2018-02-01,4,2017,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Sarah, its Eric. As it relates to interest rates, so our guidance and our outlook assume our macro case, which does reflect a bit of rising interest rate. But I note that the impact of interest rates has to play out over a number of years. We tend to be buy and hold investors and as a result, any changes up or down in interest rates outplay themselves out through the P&L over a pretty long period of time.",0.3715415,0.951
CI-2017-Q4-2018-02-01,183,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Yes, it's David. Our review has been and continues to be that over time, states will continue to modify their approach to populations both as defined today, but defining on a go-forward basis, additional sub-segments of the population and then seek the vendors, carriers or partners that can give them the best value relative to the populations.",0.7671978,0.895
CI-2017-Q4-2018-02-01,184,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","As you articulate today, we're not a large player in any of those spaces. But over time, we see that marketplace change as a potential future opportunity for growth and we will leverage both organic capabilities and opportunistically, inorganic activity relative to that. But we think the marketplace is going to evolve over time and this presents an additional possible long-term growth opportunity for us as the marketplace changes.",0.8460941,0.893
CI-2017-Q4-2018-02-01,190,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Yes, packed a lot in there. So, maybe quickly and simply, we see further margin expansion opportunity period relative to the line of business over time both driven by disciplined performance in the MOR range as well as expense leverage that you articulated. So, we'll opportunity to further expand the margin over time.",1.3272445,0.893
CI-2017-Q4-2018-02-01,191,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Second, your articulation of the growth profile in terms of the immediate timeframe is right. That was deliberate in terms of our positioning of those market places, and it further validates or reinforces that where we have highly aligned value based physician relationships, the performance and the value return to customers, beneficiaries and physicians is quite strong, but we don't -- the value proposition is a bit less strong.",0.9032258,0.95
CI-2017-Q4-2018-02-01,192,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","As I mentioned in prior remarks, we're delighted with the fact that we now have multiple markets with quite mature, highly performing collaborative where we have demand from those physician groups or integrated hospital systems to aggressively enter the M&A marketplace over time. So, it's a good reinforcement and learning relative to the value having the aligned physician relationship and the proven performance, as opposed to starting that build from scratch.",0.8367664,0.847
CI-2017-Q4-2018-02-01,193,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Lastly, relative to STARS, we were in 2018, about 60% from a four STAR+PLUS plan with all of our mature markets by one performing where we expected it today. For 2019, we are optimistic that we will get recognition to the proper positioning of our products and our capabilities. Our Net Promoter Score and [Indiscernible] outcomes continue to be quite strong and we have multiple leverage and tools to work with CMS to ensure they were properly positioned for 2018. So we are looking forward to the 2019 selling season.",0.5821998,0.883
CI-2017-Q4-2018-02-01,197,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","So Michael two points, you are correct. First stepping back we are - we view partnering with others as a critical capability. In fact you might recall from a investor day dialogue being the undisputed partner of choices and have borne strategic comparative to continue to drive the right value for our customers and clients and as we go forward. That relationship we entered into the CVS down in Florida was an innovation that both parties wanted to do to try to drive improved outcomes. We don't have any discernable deliberate differentiated outcomes to point to at this point in time, but it's indicative of our test and learn approach, our collaboration and are willing historically multiple partners, so you could view that is indicative of both today and in the future which would be to have multiple partnership arrangements up in running today.",0.957637,0.579
CI-2017-Q4-2018-02-01,198,Answer,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to the PBM, as Eric articulated we delivered a pharmacy trend in 2017 potentially zero with high clinical outcomes and continue to grow that business. So our proprietary owned PBM continues to perform quite well, back to partnership we have an orientation round, willingness and ability to partner with others to increase value for the benefit of our customers and clients and I think its a spectacular example of smart, well aligned partnership capabilities and being able to deliver better value for customers and clients is indicative of high clinical quality outcomes growing the platform and zero medical cost trend. So we view partnership as mission critical on a go-forward basis and a lot of bright spots to point to over the recent past.",1.1651768,0.973
CI-2017-Q4-2018-02-01,200,Closing,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Thank you everyone. Let me just move to wrap up our call with a few headlines. First, overall we delivered very strong result in 2017 with key performance across all of our priority growth platforms. Commercial employer, U.S. Senior, Global Supplemental Benefits and Group Disability & Life led by delivery of continued industry leading medical cost trend.",0.998834,0.883
CI-2017-Q4-2018-02-01,201,Closing,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","In addition, in 2017 Cigna grew to serve more than 95 million customer relationship worldwide. Relative to overall expectations for 2018, we will continue to create differentiated value for our customers and clients and as a result for your shareholders through consistent focus on delivering affordability and personalization as well as partnering with healthcare professionals to ensure our customers receive the highest quality healthcare.",0.7920715,0.802
CI-2017-Q4-2018-02-01,202,Closing,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director","Each of our four growth platforms remains well positioned for sustained growth, in addition we have an exceptionally strong ongoing capital position. We expect to deliver revenue growht inline with our long term objective of high single digit growth rates and we have an outlook for 2018 that anticipates a 19% to 23% EPS growth rate over 2017 all of which gives us confidence to increase our long term EPS target from $16 per share to $18 per share by 2021.",1.0104936,0.972
CI-2017-Q4-2018-02-01,203,Closing,2018-02-01,4,2017,David Michael Cordani,"President, Chief Executive Officer & Director",We thank you for joining our call today and look forward to further conversations.,1.5790906,0.361
CI-2019-Q3-2019-10-31,11,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks, Will. Good morning, everyone. And thank you for joining our call. Today I will highlight Cigna's strong third quarter financial results, which reflect continued momentum across our businesses including strong earnings growth in our Health Services business.",0.2215313,0.958
CI-2019-Q3-2019-10-31,12,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","I will highlight our diverse business portfolio and unique capabilities position us to deliver sustained growth in 2019 and over the long-term. As we continue to serve the needs of employers, health plans, government clients an individual customer.",0.6929654,0.612
CI-2019-Q3-2019-10-31,13,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","I will also share initial thoughts and how we will drive strong growth in 2020 as we remain on-track to deliver our 2021 EPS target of $20 to $21 per share and cash flow from operations of at least $8.5 billion. Turning to our third-quarter results. We again delivered strong performance across our businesses, lead by Health Services and Integrated Medical.",0.5538282,0.912
CI-2019-Q3-2019-10-31,14,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Cigna consolidated adjusted revenue for the quarter was $35.8 billion and we grew earnings to $1.7 million. These results reflect strong retention and continued expansion of customer relationships and significant ongoing operating cash flow generation, which fueled our strategic capital deployment.",0.8398756,0.625
CI-2019-Q3-2019-10-31,15,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","In our Health Services segment, we again delivered significant customer and revenue growth and as expected attractive year-over-year earnings growth for the quarter. Our performance in Integrated Medical is highlighted by customer growth, the expansion of relationships and ongoing differentiated medical cost management.",0.2747765,0.889
CI-2019-Q3-2019-10-31,16,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Our third-quarter results give us confidence that we will achieve our increased 2019 outlook for revenue, earnings and EPS with expected EPS growth of 18% to 20% over Cigna's strong 2018 performance. As our result continue to demonstrate our unique configuration of assets enables us to meet the diverse needs of the marketplace, which in turn positions us to deliver strong, sustained financial performance for shareholders.",0.4741547,0.936
CI-2019-Q3-2019-10-31,17,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","When you consider today's marketplace needs, we continue to confront an affordability challenge in healthcare environment where far too often outcomes are suboptimal. Too frequently individuals experience issues such as overdiagnosis, inconsistent care coordination and avoidable hospital readmissions just to name a few examples. All of this result in higher costs and missed opportunities for health improvement.",0.6319471,0.735
CI-2019-Q3-2019-10-31,18,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","At Cigna we have broad capabilities needed to address these issues and to make the overall healthcare experience a better and more seamless one for those we serve. Our combination of assets brings together the best in medical, pharmacy and behavioral health. To ensure high-quality coordinated care is delivered when and where our customers needed, weather at work at home on the go.",0.5717062,0.927
CI-2019-Q3-2019-10-31,19,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director",To our capabilities and actions were able to keep healthy people healthy. We address risk factors for healthy risk and we coordinate the needed care for chronically ill individuals. All of this positions us to drive affordability and better predictability one customer and one patient at a time.,0.4974738,0.802
CI-2019-Q3-2019-10-31,20,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Because our approach resonates so well in the marketplace were able to generate attractive sustained long-term performance, including attractive operating cash flows. This result in significant financial flexibility which is a key strategic asset that supports continued strong performance and long-term growth in a highly disruptive environment.",0.797124,0.959
CI-2019-Q3-2019-10-31,21,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Our sustained financial performance is also fueled by our four growth platforms, Health Services commercial employer, government and international. We are able to drive attractive growth across each of these businesses by effectively leveraging our collective capabilities and coordinating our service offerings to meet the needs of those we serve around the world.",0.5009716,0.875
CI-2019-Q3-2019-10-31,22,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","For example in Health Services, we consistently demonstrate deep expertise in coordinated pharmacy services and unique innovations in clinical programs resulting in a leading pharmacy trend performance for the benefit of our employer, health plan and government clients.",0.8989506,0.459
CI-2019-Q3-2019-10-31,23,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Collectively, these continue to drive exceptional customer and client satisfaction, resulting in a projected retention rate of 97% for 2020, and the addition of new business, resulting in, for example, organic prescription growth, which we project will be between 25 million and 35 million in 2020.",0.5087447,0.671
CI-2019-Q3-2019-10-31,24,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","In our commercial employer business we continue to drive organic customer growth for the 10 th consecutive year best amongst our peers. This includes capitalizing on the meaningful head room for growth in our select and middle market segments, which comprise approximately 65% of the addressable U.S. commercial employer market.",0.3354061,0.893
CI-2019-Q3-2019-10-31,25,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director",It need to increase our focus on delivering innovative commercial solutions that address whole person health needs for employers in the United States and abroad. With medical pharmacy and behavioral solutions that we delivered a fully integrated way.,1.1301982,0.856
CI-2019-Q3-2019-10-31,26,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director",We are also very well positioned for accelerated growth in our U.S. government business. We are excited with the outstanding value proposition we have in Medicare Advantage today and how we are positioned going into 2020.,1.1690634,0.93
CI-2019-Q3-2019-10-31,27,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director",Including excellent stars ratings with 77% of our customers in four star plus plan for next year and that will increase to 85% in 2021. VD MPS measures averaging approximately 70 across all our markets. And our ability to leverage aligned value-based physician arrangements to provide a well coordinated care experience for our customers. Together all these fuels our geographic and product expansion plans for 2020 and gives us confidence we will deliver Medicare Advantage customer growth of at least 10% in 2020.,0.6094054,0.961
CI-2019-Q3-2019-10-31,28,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director",Now relative to our combination with express scripts. We continue to make very good progress here. In 2019 this includes the effective integration of a medical client into our credo specialty pharmacy capability which is largely complete and will be finalized by the end of 2019. And the addition of Express Scripts high-performing home delivery pharmacy to our Cigna network.,0.7333852,0.855
CI-2019-Q3-2019-10-31,29,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","We have also made Safeguard RX, RationalMed and Health Connect 360 capabilities available for medical customers, further positioning us to increase choice and access, reduce costs and help to further avoid gaps in care and ensure customers get the clinical support they need when and how they want it.",0.4897007,0.922
CI-2019-Q3-2019-10-31,30,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","As we previously discussed, we also launched several new innovative capabilities available to commercial and health plan clients. These include our patient's insurance program where coordinated capabilities enabled us to engineer the supply chain giving our customers access to insulin for $25 co-pay per month.",0.720171,0.7
CI-2019-Q3-2019-10-31,31,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And/or embark benefit protection program, which brings together the best of our combined capabilities to build a pathway to better affordable care for potentially life-changing gene therapies. As we brought together businesses, we have continued to deliver strong results, accelerated by the synergies over combination. Reflecting this performance, we have - we have now increased a revenue and earnings outlook for the third consecutive quarter this year.",1.0042752,0.957
CI-2019-Q3-2019-10-31,32,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Now turning your attention briefly to our initial outlook for 2020, we expect attractive EPS growth next year, and remain on-track to deliver on our 2021 EPS goal of $20 to $21 per share. Our 2019 outlook represents 18% to 20% EPS growth with a midpoint of $16.90 per share.",0.2448504,0.889
CI-2019-Q3-2019-10-31,33,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","As we step into 2020, I call out a few headwinds from nonrecurring items, including first the absence of prior year reserve development, second the absence of a tax matter that we favorably settled in second quarter of 2019 and finally, the return of the health insurance tax. These three items represent a $0.50 headwind as we step into 2020 giving us an adjusted jump off point of $16.40 at the midpoint.",0.7042363,0.625
CI-2019-Q3-2019-10-31,34,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","For 2020, we expect to grow earnings per share 10% to 13% over this amount, in-line with our long-term EPS growth expectation. This growth will be driven by sustained organic growth across our well-positioned growth platforms, favorable impact of deleveraging and further administrative expense synergies.",0.998834,0.929
CI-2019-Q3-2019-10-31,35,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","All-in we are positioned for sustained attractive earnings growth for 2020, and remain on-track to achieve our strategic goal of $20 to $21 EPS of 2021. In addition, our strong operating momentum and capital light framework will continue to drive attractive cash flow and enhance our strategic and financial flexibility over the intermediate and long-term.",0.6156238,0.92
CI-2019-Q3-2019-10-31,36,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Now to ramp up, Cigna delivered strong third quarter financial results, with continued momentum across our businesses, including earnings growth for Health Services and Integrated Medical business. Strong retention and expansion of customer relationships and significant ongoing operating cash flow generation and capital deployment.",0.5060241,0.875
CI-2019-Q3-2019-10-31,37,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Collectively our third quarter results give us confidence we will achieve our increased 2019 revenue and earnings outlook representing and 18% to 20% EPS growth rate over Cigna's strong 2018 performance. Our integration of Express Scripts is tracking well and we are delivering a number of meaningful benefits for our customers, patients, clients and shareholders.",0.3455111,0.949
CI-2019-Q3-2019-10-31,38,Remarks,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","For 2021 we remain on-track to deliver $20 to $21, EPS and cash flow from operations of at least $8.5 billion. We remain committed to delivering 10% to 13% average annual EPS growth over the long-term.",0.872911,0.572
CI-2019-Q3-2019-10-31,40,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Thanks, David. Good morning, everyone. In my remarks today, I will review key aspects of Cigna third quarter results and discuss our updated outlook for the full-year.",0.2914121,0.7
CI-2019-Q3-2019-10-31,41,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Key consolidated financial highlights for third quarter 2019 include adjusted revenues of $35.8 billion, earnings of $1.7 billion after tax, and earnings per share of $4.54 reflecting continued strong execution across each of our businesses, with particular strength and momentum in both Health Services and Integrated Medical.",0.0337765,0.827
CI-2019-Q3-2019-10-31,42,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Third quarter results also included strong cash flow from operations, driven by continued strong execution across our businesses. Regarding our segments, I will first comment on Health Services third quarter adjusted revenues were $25 billion and pre-tax earnings were $1.4 billion.",0.5080848,0.765
CI-2019-Q3-2019-10-31,43,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Results for third quarter reflect organic growth with the addition of 492,000 pharmacy customers in the quarter and 2.4 million customers on a year-to-date basis, strong volumes with 312 million adjusted pharmacy script fulfilled in the quarter, continued growth in specialty pharmacy and the effective execution of supply chain initiatives. Overall, Health Services performed very well in the third quarter. As expected, Health Services earnings in the quarter grew relative to Express Scripts third quarter 2018 earnings on a comparable basis.",0.4937118,0.941
CI-2019-Q3-2019-10-31,44,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"As you heard from David the fundamentals of this business are strong, we are delivering innovative solutions like Embark and the patient assurance program for the benefit of customers and clients and we continue to hit our key milestones as we progress with our integration priorities.",0.3686669,0.949
CI-2019-Q3-2019-10-31,45,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our Integrated Medical segment, third quarter revenues grew 12% to $9 billion driven by customer growth premium growth reflecting underlying cost trends and the inclusion of the Express Scripts Medicare Part D business.",0.0682716,0.637
CI-2019-Q3-2019-10-31,46,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We ended the third quarter with 17.1 million global medical customers, an organic increase of 212,000 lives over third quarter 2018, led by growth in our select and middle market segments, partially offset by lower national account enrollment. Third quarter earnings grew to $953 million reflecting strong medical and specialty contributions and continued effective medical cost management, all while continuing to invest to drive future growth.",0.7258354,0.893
CI-2019-Q3-2019-10-31,47,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our Medical Care Ratio or MCR, our third quarter MCR of 80.5% reflects strong underlying fundamentals, including continued effective medical cost performance. Compared with third quarter 2018, our MCR increased as expected due to the price in effect of the suspension of the health insurance tax, the higher MCR in our individual business and the effect on medical costs of one additional week day in the third quarter.",0.7398491,0.893
CI-2019-Q3-2019-10-31,48,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,Third quarter 2019 Integrated Medical earnings benefited from $8 million pre-tax of favorable net prior year reserve development compared to $18 million in the third quarter of 2018. Overall Cigna's Integrated Medical segment delivered strong results in the third quarter.,0.5864175,0.751
CI-2019-Q3-2019-10-31,49,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our international markets business, revenues grew to $1.4 billion representing 9% growth over third quarter 2018 on a currency-adjusted basis third quarter earnings were $194 million, reflecting continued business growth and operational efficiency, partially offset by unfavorable foreign currency impacts.",0.3154869,0.772
CI-2019-Q3-2019-10-31,50,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our group disability and other operation segment, third quarter revenues were $1.3 billion, third quarter earnings for this segment were $143 million driven by solid performance in both disability and in life.",0.8178225,0.153
CI-2019-Q3-2019-10-31,51,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our corporate segment, the third quarter 2018 loss was $442 million, primarily driven by $409 million of interest costs. Overall, Cigna's third quarter results reflect continued strong revenue and earnings growth, led by our Health Services and Integrated Medical businesses.",0.7700323,0.765
CI-2019-Q3-2019-10-31,52,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I will now discuss our updated outlook for 2019. For full-year 2019, we now expect consolidated adjusted revenues of approximately $138 billion. This represents an increase to our prior outlook of $1.5 billion at the midpoint, reflecting higher contributions from our Health Services business.",0.3208768,0.318
CI-2019-Q3-2019-10-31,53,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We now expect full-year consolidated adjusted income from operations to be in the range of $6.38 billion to $6.46 billion or $16.80 to $17.00 per share this represents an increase of $0.10 to $0.20 per share over our prior expectations and represents a growth in the range of 18% to 20% over 2018. For 2019, we now project a consolidated adjusted tax rate of approximately 23%.",0.3467481,0.807
CI-2019-Q3-2019-10-31,54,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I will now discuss our to our 2019 outlook for the Health Services and Integrated Medical segments. For our Health Services business, we now expect full-year pre-tax earnings in the range of $5.075 billion to $5.175 billion.",0.1185771,0.0
CI-2019-Q3-2019-10-31,55,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Consistent with this outlook, we expect a continued ramp and sequential earnings for this business driven by normal seasonality as well as previously communicated factors including the run rate impact of supply chain initiatives completed in the first half of 2019. Continued strong performance in specialty pharmacy and the realization of administrative expense synergies associated with the Cigna Express Scripts combination.",0.4128638,0.66
CI-2019-Q3-2019-10-31,56,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For 2019, we now expect adjusted pharmacy script of approximately 1.22 billion scripts, which is the midpoint of our previously communicated range. Additionally for Health Services, we now project 2020 retention rate of 97%, demonstrating that our innovative pharmacy solutions continue to resonate in the marketplace and enable us to deliver greater value for those we serve.",0.7599713,0.818
CI-2019-Q3-2019-10-31,57,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"This strong retention fuels our expectation for organic scripts growth of $25 million to $35 million adjusted pharmacy scripts in 2020. For our Integrated Medical business, we now expect full-year earnings in the range of $3.8 billion to $3.85 billion. This outlook reflects strength and growth in our businesses driven by deepening customer relationships, industry leading medical cost trend performance and well managed administrative expenses.",0.6133669,0.915
CI-2019-Q3-2019-10-31,58,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Key assumptions reflected in our Integrated Medical earnings outlook for 2019 include the following; Regarding global medical customers, we continue to expect 2019 growth of approximately 200,000 customers. Our guidance reflects continued growth in select and middle market, partially offset by a decline in national accounts.",0.6945742,0.637
CI-2019-Q3-2019-10-31,59,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to medical costs for our U.S. commercial employer book of business, we continue to expect full-year 2019 medical cost trend to be in the range of 3.5% to 4.5%. We now expect the 2019 medical care ratio to be in the range of 80.8% to 81.2% and narrowing of the range from our prior expectations reflecting ongoing disciplined medical cost management.",0.4372979,0.494
CI-2019-Q3-2019-10-31,60,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"All-in, we continue to see strong outcomes from our clinical, consumer and physician engagement model. We also continue to expect solid contributions from our international markets, group disability and other businesses, as we continue to innovate in the marketplace and deliver differentiated value for our customers.",0.4588573,0.91
CI-2019-Q3-2019-10-31,61,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"All-in for 2019 we now expect consolidated adjusted income from operations of $6.38 billion to $6.46 billion or $16.80 to $17.00 per share, this represents 18% to 20% growth over 2018. I would also remind you that our outlook continues to exclude the impact of future share repurchases and any additional prior year reserve development. Our updated outlook reflects the strong performance we are delivering in 2019 and we remain confident in our ability to achieve our 2021 earnings per share target of $20 to $21 per share.",0.2720086,0.946
CI-2019-Q3-2019-10-31,62,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now moving to our 2019 capital management position and outlook. As previously communicated, we have a near-term focus on accelerated debt repayment and have deployed $3.7 billion through the end of third quarter to repay debt. We remain on-track to return our debt to capitalization ratio to the upper '30s by the end of 2020.",0.0503054,-0.758
CI-2019-Q3-2019-10-31,63,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Our long-term capital priorities remain as follows: First, reinvesting back into our businesses for innovation and growth. Second strategic M&A on a targeted basis and third, returning capital to shareholders, primarily through share repurchase.",0.0111391,0.751
CI-2019-Q3-2019-10-31,64,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Consistent with these priorities in the third quarter, we deployed $450 million to repay debt and we repurchased 4.2 million shares of stock for $676 million. Additionally, in October, we repurchased approximately 1.5 million shares for $236 million. Our debt to capitalization ratio was 46.4% as of September 30, 2019, down from 50.9% as of December 31, 2018.",0.785124,-0.153
CI-2019-Q3-2019-10-31,65,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For 2019, we now project cash flow from operations of greater than $8 billion and this year, we continue to expect to deploy approximately $4.2 billion to debt repayment. We now expect to have capacity for $2 billion of share repurchases in 2019, an increase of $500 million from our previously stated capacity.",0.096299,0.542
CI-2019-Q3-2019-10-31,66,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Through the end of October, we had already deployed $1.8 billion of that total. Our balance sheet and cash flow from operations outlook remains strong as our capital efficient businesses continue to deliver attractive margins and returns on capital.",0.6492993,0.84
CI-2019-Q3-2019-10-31,67,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now to recap, our third quarter consolidated results reflect continued strong execution and focus on creating differentiated value for our stakeholders. We are well positioned to achieve the attractive financial targets we have established for 2019 and we maintain strong visibility toward our 2021 targets of $20 to $21 of earnings per share and greater than $8.5 billion in cash flow from operations.",0.3941789,0.958
CI-2019-Q3-2019-10-31,68,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Further, our clear strategic focus strong fundamentals across our businesses and outstanding financial flexibility, gives us continued confidence in our long-term targets for growth in revenue, earnings and EPS.",0.3269853,0.953
CI-2019-Q3-2019-10-31,69,Remarks,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"With that, I will turn it over to the operator for the Q&A portion of the call.",1.716493,0.0
CI-2019-Q3-2019-10-31,72,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes Josh, it is Eric. Just to start we provided some growth rates and expectations back at our Investor Day earlier this year. The international businesses. Overall, we would expect to grow in the 8% to 10% top line and a little bit better than that bottom line on a sustained basis. So 9% to 11% earnings across that portfolio.",0.4071146,0.828
CI-2019-Q3-2019-10-31,73,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,So we think it is a really attractive set of capabilities and there are markets where we are well positioned to operate in and good connectivity between the international businesses back to our U.S. businesses so an important part of the portfolio overall.,0.5918074,0.851
CI-2019-Q3-2019-10-31,74,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"In total, we continue to see good visibility to driving an enterprise growth rate 6% to 8%, both at the top line and bottom line. So the international markets business is actually faster growing part of the portfolio and an important one for us to build on. David, maybe you can add some other comments.",0.5292849,0.832
CI-2019-Q3-2019-10-31,75,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Josh, I appreciate the way you frame the question. As it relates to the second part of your question, the synergies. A couple of things I would ask you to think about, One is, as you know, the vast majority of employer clients we serve our multinational, even the smallest of employers tend to have a multinational footprint within the global mobile population as we think about it.",0.7403809,0.402
CI-2019-Q3-2019-10-31,76,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","A significant portion of their individual care still takes place in the United States, whether it is returning to the United States for care or needing high advanced care where people travel in United States and then within that a significant portion of the overall care equation ties not only to medical care but pharmaceutical care, so we see that leverage piece of the equation.",1.0275942,0.957
CI-2019-Q3-2019-10-31,77,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Secondly, overtime, we continue to see demand outside the United States with our employer clients of all our pharmacy solutions, the same dialog exists around whole person specifically around stress and depression and coordinated care programs.",0.2491255,-0.077
CI-2019-Q3-2019-10-31,78,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And then lastly, when you think about the global supplemental benefit business while it might be surprising, some of the informatics we have innovated in the United States around AI predictive indicators, predictive modeling, some of the seeds of that originated from outside the United States where we used the logic in the capabilities.",1.4038088,0.866
CI-2019-Q3-2019-10-31,79,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","But for our sales process, we took some of that framework in to the United States to leverage in the individual business. So we still continue to see both the attractive growth as Eric articulated and synergies, whether it is a multinational needs, the care delivery or a lot of the Informatics and insights going forward.",0.9976681,0.889
CI-2019-Q3-2019-10-31,81,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Josh, I would use the word they are an important part of our portfolio. They are a growing part of our portfolio and they contribute meaningfully to the organization.",0.6416634,0.361
CI-2019-Q3-2019-10-31,85,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Gary, it is Eric. As you recall we provided a roll forward of the full-year of Health Services earnings back at our Investor Day and kind of on that basis, the way I would have you think about it would be for the first half of 2019, earnings were down in the mid-single digits on a comparable basis for the first half of 2018.",0.3923823,0.0
CI-2019-Q3-2019-10-31,86,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"After you make all of the adjustments for re-segmentation and the like, and for the back half of 2019 we expect the earnings to be up in the mid to high single-digits on a comparable basis. But, so if you pull those pieces together and that gets to the result that we have consistently guided to for the segment overall, over the course of the year in which we tightening that this earnings release to $5.075 billion to $5.175 billion.",0.7409271,0.361
CI-2019-Q3-2019-10-31,92,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning Scott, it is David. I think as we have had the conversation in the past around the regulatory framework tied around PBM or pharmacy more broadly, bring it back to the main point which is affordability the market is speaking better value and a big part of better value is more affordability. We expect to continue to see an evolving regulatory environment, but equally or more important, a more accelerated evolving innovation environment and that is what we are driving towards.",0.8010105,0.913
CI-2019-Q3-2019-10-31,93,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So we are pleased that we have continued to deliver an outstanding pharmacy trend, clinical results, et cetera. We are driving innovations that orients around affordability like the patient assurance program that I represented where we kind of lift the financial burden and create predictability for insulin dependent diabetics at $25 for 30 day supply and then new innovations like Embark to step into the high cost gene therapies in the like.",0.7504858,0.936
CI-2019-Q3-2019-10-31,94,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director",So I would bring the conversation back to affordability and it is something that we continue to drive and use innovation toward and we will continue to engage constructively with regulatory bodies around how innovation can to drive better value from a societal standpoint.,0.6078508,0.898
CI-2019-Q3-2019-10-31,97,Question,2019-10-31,3,2019,Justin Lake,,"Thanks, good morning wanted to ask about health care services going into 2020. So I appreciate the color on the second half ramp and on the PBM side and you previously said the ramp is being caused by more kind of mid-year changes in contracting, in manufacture rebate negotiation and things like that. So would appear to set up is pretty easy comps going into 2020 meaning you only got about a half-year benefit from those typical negotiations, and I think you have said previously you are going back to a 1.1 convention there. So theoretically you should get normal growth in 2020 on the PBM plus by the annualization of what you did in the back half of this year. Is that a reasonable way to think about it, such that second, that 2020 growth is kind of above typical because of that. Thanks.",0.5177346,0.983
CI-2019-Q3-2019-10-31,98,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Justin, good morning. I appreciate the question, a lot of moving parts. Let me start qualitatively and see if Eric wants' to add additionally to the point. First big picture as Eric noted, we are quite pleased with the results we are delivering in 2020 in-line with our expectations an important inflection point for the third quarter as expected. Secondly, as we noted in prepared remarks very attractive growth outlook for next year.",0.8515352,0.948
CI-2019-Q3-2019-10-31,99,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Now to the core of your question. Multiple moving parts next year, big picture, earnings will grow next year, scripts will grow next year, revenue will grow next year. The pattern will more normalize as you articulated, because your reference is correct.",0.9246016,0.0
CI-2019-Q3-2019-10-31,100,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Our supply chain activities were more front end loaded from actions and therefore a back end loaded this year from contributions, next year that will smooth out. I would ask you to consider a few additional items as well as we move forward through the business cycle our synergies will continue to ramp.",0.6288379,0.273
CI-2019-Q3-2019-10-31,101,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","As we move forward through our business cycle as well, the stranded overhead will ramp down where our objective is to have all the stranded overhead removed by the end of 2012. Resulting in zero stranded overhead as we step into 2021.",1.0275942,0.273
CI-2019-Q3-2019-10-31,102,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So I would ask you to think about those moving parts. The big picture comparator you are using I think is right, but you need to add those additional moving parts of ramping synergies and then ultimately removing all the stranded overhead by the end of 2020.",1.1045472,0.0
CI-2019-Q3-2019-10-31,103,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Justin, it is Eric. Just one other thing I would add. I would note that we expect that the fourth quarter of 2019 will be the final period where we will report transitioning client as that transition and client activity that activity will wrap up this year. So as we get into 2020 it will just be the Health Services segment that will reflect the dynamics, David just described.",0.4707151,0.273
CI-2019-Q3-2019-10-31,107,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, I appreciate the question. First, as we get through the end of the fiscal year and step through the fourth quarter call, we will look forward to providing additional color relative to 2020, but we are excited with the strength of this year and the ability to have such a strong outlook for next year.",0.092499,0.956
CI-2019-Q3-2019-10-31,108,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Specific to your question, consistently, we do not factor in two items to our forward-looking guidance or projections. First and foremost is what you articulate unless we indicate otherwise, we do not project capital deployment on a go-forward basis, and we will roll and provide that to you from that standpoint.",0.457054,0.0
CI-2019-Q3-2019-10-31,109,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","I'm going to ask Eric, to give you a little color on how the cash flow and the capital deployment that we walk through at Investor Day is oriented around 2019, 2020 and then 2021. Secondly, to remind you we also do not project prior year reserve development as part of our outlook from that standpoint.",0.8876798,0.0
CI-2019-Q3-2019-10-31,110,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So your logic is correct, those two items would be excluded from anything we articulate on a forward-looking basis and we true that up quarter-to-quarter. Eric, maybe a little color on the cash flow and the capital deployment.",1.2312476,0.103
CI-2019-Q3-2019-10-31,111,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Charles, it is Eric. We provided some detail back at our Investor Day in terms of the cash flow from operations we expected in 2019, 2020 and 2021. And I would say, we have increased our view on 2019 as I noted in my prepared remarks. 2020 view remains generally consistent, we expect to generate about $7 billion of cash from operations.",0.6730147,0.459
CI-2019-Q3-2019-10-31,112,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"The bulk of that will go to deleveraging, as I noted again in my prepared remarks that is our top capital deployment priority. We will have some capacity for repurchase and we will provide more color on that as we get into the year.",0.5055695,0.402
CI-2019-Q3-2019-10-31,116,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Hey, good morning. It is David, your recollection from our Investor Day is correct. Our intermediate to long-term outlook is 10% to 15% customer growth for that business portfolio and at Investor Day we noted as the transition you are going 2020 we expected it to be at the lower end of that range.",0.4846483,0.511
CI-2019-Q3-2019-10-31,117,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","As I noted in my prepared remarks, we expect at least 10% growth. To the first part of your question, we are quite pleased in terms of the positioning of our offerings in our key markets, both our core offerings meaning individual HMO offerings as well as our new offerings are individual PPO offerings as it relates to the benefit design in the overall price point positioning.",1.0870579,0.896
CI-2019-Q3-2019-10-31,118,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Secondly market feedback has been quite positive and third while early, early volume indicators are positive and tracking well from that standpoint. On a final note, as I referenced in my prepared remarks that is also aided by a really strong stars positioning this year and we have visibility to even a further step up from 77% which will carry into 2020, to 85% greater than four in 2021.",0.8414302,0.951
CI-2019-Q3-2019-10-31,119,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Differentiated NPS of about 70 on average across our business portfolio, and then our physician relationships that our value based. Specific to Medicaid, as you know from prior conversations, we have historically had a lower level priority on that versus other growth platforms.",0.8099495,0.422
CI-2019-Q3-2019-10-31,120,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","We continue to believe that over time, as states grapple with both the clinical burden and the health challenges as well as affordability challenges Medicaid programs will continue to evolve. our state sponsored programs will continue to evolve and be sub-segmented in terms of either value based on risk-based high comprehensive programs and we see that as an attractive intermediate term opportunity for the organization, none of that is factored into our current outlook, that is an additional growth platform opportunity for us as we look to the future.",0.7811893,0.923
CI-2019-Q3-2019-10-31,124,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Steve. Good morning. It is David, let me start and I will ask Eric to add. First, we are quite pleased. I think the headline is we are quite pleased with both the positioning, the ongoing innovation, strength of our Credo asset.",0.9109988,0.948
CI-2019-Q3-2019-10-31,125,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And just stepping back, putting it into context that business is a trusted pharmacy business as specialty care providers, specialty pharmaceutical manufacturers look to an organization that has the experience of coordinating the complex care and services that are necessary. The clinical programs up to and including 600 home health care professionals that visit our patients and help to coordinate the care and services.",0.8037311,0.956
CI-2019-Q3-2019-10-31,126,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And lastly, as you may recall from prior conversations that organization is broken down in excess of 15 subspecialty organizations given the uniqueness of what is there. The growth profile is generated from obviously additional script volume for our - we will call it more captive business but also just organic growth that exists outside of our captive business.",1.1045472,0.485
CI-2019-Q3-2019-10-31,127,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Whether it is ESI captive, or Cigna captive business, which is a validation of the quality of services. Additional therapies are coming in-line as well and I will ask Eric to provide a little bit more color on what is driving the growth.",0.4586086,0.572
CI-2019-Q3-2019-10-31,128,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Maybe just a couple of things I would note Steve, I think that there is growth in terms of the business dynamics David just described as well as all our role in helping to manage our customers and clients costs and we get rewarded for the effective job that we do there as well.",0.1897233,0.937
CI-2019-Q3-2019-10-31,129,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Specifically there have been a different drug launches, both in terms of new therapies that have come into the year this year that drive that and this just increasing use of therapies that we provide through credo and alike, so that is been a bit of the driver. And then on top of that is new alternatives like generics for some of the specialty therapies or biosimilars come online, there will be more opportunity for the credo capabilities in the future as well.",0.770751,0.817
CI-2019-Q3-2019-10-31,133,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Hey Whit it is Eric. Express Scripts announced an initiative back in 2017 aimed at reducing costs and improving efficiency in light of the transition clients and like. That should have continued, and have managed along with our integration and that is working to drive the organization broadly to the improved levels of effectiveness and efficiency.",0.4240029,0.908
CI-2019-Q3-2019-10-31,134,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"It is been managed in conjunction with our ongoing integration work and so it is again it does continue largely on-track in terms of the major milestones that Express Scripts had outlined to make sure that the costs to support the ongoing business, we are consistent with the expectations and at a really competitive level.",0.2274524,0.718
CI-2019-Q3-2019-10-31,136,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Totally separate, it is probably a bit too extreme of a separation, but we do think of EBI as separate from the synergies that are deal related. And so both of those are working to drive costs out of the organization and get us to a really competitive effective and efficient operation.",0.7797341,0.895
CI-2019-Q3-2019-10-31,139,Question,2019-10-31,3,2019,Ralph Giacobbe,Credit Suisse,"Thanks, good morning. Just quickly want to go back to the guidance commentary. You are using the 16/40 jumps off point at midpoint of 10% to 13% growth would put us in sort of the $18 to $30 range, I guess, is that a general framework. I know you want to put a spot estimate on it and that is before PYD which I think this year is running just under $0.20 and before any share repos. I just want to clarify those things. And then obviously you have delivered upside to the baseline from when you first put out the $20 to $21 EPS goal for 2021, you noted that range still holds. But is it fair to expect any bias to the upside or a higher end at this point or is it just too early to make that call? Thanks.",0.0293904,0.936
CI-2019-Q3-2019-10-31,140,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning. It is David to the first part of your question, big picture, you have it right, the 16/40, we remain committed to the 10% to 13% and your math kind of squares that range from that standpoint and for your comments excludes prior year reserve development, as we always would and/or capital deployment.",0.0804508,0.612
CI-2019-Q3-2019-10-31,141,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","To the second part of your question, I appreciate your optimism, come back, first and foremost. We are delighted in such a dynamic environment to have put that goal and objective out, which is a significant compounded EPS over a long period of time. Think of jumping out of 2017 after tax reform from an 2018 forward of 2015 mid teens CAGAR over a multi-year period of time. We are delighted with that.",0.9113875,0.945
CI-2019-Q3-2019-10-31,142,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","I appreciate your notion relative to the range. We will look forward to further updates as we go forward and as Eric and I both noted the visibility we have and the commitment we have to deliver on that $20 to $21. And at least $8.5 billion of cash flow from operations, we are delighted with it at this point in time.",1.0641275,0.823
CI-2019-Q3-2019-10-31,143,Question,2019-10-31,3,2019,Ralph Giacobbe,Credit Suisse,"Okay, fair enough. Thank you very much",0.6201016,0.691
CI-2019-Q3-2019-10-31,145,Question,2019-10-31,3,2019,Kevin Fischbeck,Bank of America / Merrill Lynch,"Great, thanks. I wanted to talk a little bit about the 2020 guidance. I guess the 10% to 13% number in-line with your long-term growth, but I guess when we think about 2020 there is transitioning costs kind of winding down that could add a 1% or 2%. There is the synergies kind of ramping up, which could add 1% or 2% and so the capital deployment kind of seems like a normal year as far as the full-year benefit of what you have done in the year before. So is there a reason to think that the core growth in 2020 might be a little bit lower than average for some reason, I guess just trying to figure out why it is only kind of 13 with standard costs and synergies ramping?",0.2300836,0.929
CI-2019-Q3-2019-10-31,146,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Kevin, its David. Pick up on your last phraseology only 13, but appreciate the tone of your question in the framing. So let me step back, if you think about our commitment to our shareholders and we walk through comprehensively at Investor Day the framework. The 10% to 13% essentially orients around 6% to 8% from the organic operations and 4% to 5% from effective capital deployment.",0.7481539,0.902
CI-2019-Q3-2019-10-31,147,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","If you think about that implied guidance direction that we provided, we are providing the same direction, which means that there is an underlying organic performance of 6$ to 8% within our expectations in the 4% to 5% from capital deployment, given that we have chosen to deploy our capital to effectuate the transformative transaction that 4% to 5% contribution largely comes through the effect of capturing synergies step up next year and the effects of deleveraging, through is some rounding relative to the share repurchase from that standpoint.",0.8422075,0.296
CI-2019-Q3-2019-10-31,148,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","It is the initial range and direction we are providing and we will look forward to providing additional context as we step through the fourth quarter call. So I think your logic stream is right by attaching the capital deployment. But again, ask you to think about that for 2018 as being driven by the effects of the deleveraging and the effects of the synergy capture, which are a direct result of prior capital deployment. Net, net we are in-line with our long-term sustained results and we will have a full-year track record of delivering that level or greater from that standpoint.",1.0050525,0.361
CI-2019-Q3-2019-10-31,149,Question,2019-10-31,3,2019,Kevin Fischbeck,Bank of America / Merrill Lynch,"Okay, great, thanks.",1.0888579,0.836
CI-2019-Q3-2019-10-31,152,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Ricky its Eric. So, on the transition in clients on the transition. We would expect that to ramp up at the end of the year at this point. So you heard me correctly that the fourth quarter will be the last period that we would expect to report that as a separate item. So we would expect the transition out to be wrapped up at the end of the year here.",0.1437298,0.0
CI-2019-Q3-2019-10-31,153,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"As it relates to the transition in and moving to the Express platform, really no update here in terms of the specifics. Much earlier this year, we announced that we had reached an agreement on the transition agreement associated with the services that they were fulfilling for the Cigna pharmacy that transition began in July.",0.1864894,0.649
CI-2019-Q3-2019-10-31,154,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,David noted in his prepared remarks are underway now. We would expect that the full-annualized benefit of that being on the Express platform will come through by the end of 2020. But we haven't broken out any further detail in terms of the specific cadence there.,0.1519943,0.202
CI-2019-Q3-2019-10-31,156,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Ricky. Nothing I would call out unusual there. I think it would be just the normal kind of waiting pace of claims cost and how they come in. Overall, we tightened the range for the full-year, we had a good track record here and driving to a really attractive loss ratios, so again nothing that I would call out is anything beyond the normal items that could drive variability up or down in the in the quarter.",0.3302192,0.545
CI-2019-Q3-2019-10-31,159,Question,2019-10-31,3,2019,Steve Tanal,Goldman Sachs,"Morning, guys, thanks for the color. Covered a lot of ground but I guess I just want to clarify the discussion around the 2020 outlook. So does it exclude future capital deployment specifically thinking about any additional debt pay down in 2020? I think the ratable portion of the two year deleveraging for the Investor Day, that is about $0.30, so is that sort of specifically in the numbers you shared this morning. And then wanted to also just confirm the step up in synergies, is that still kind of consistent with the initial outlook, I think you guys laid out like $273 million pre-tax step up back in May of 2018. So is that being contemplated as well fully?",0.3907407,0.633
CI-2019-Q3-2019-10-31,160,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Steve, it is Eric. A couple of different dynamics there. So first of all just to be clear, the figures David talked about for 2020 excludes any future share repurchase, but includes the other operations that we would expect in terms of the effect of what we have done this year, the rate and pace of our deleveraging, et cetera, but it excludes any future share repurchase or any other acquisitions or things along those lines on that base. So that is the dynamic.",0.3057851,0.846
CI-2019-Q3-2019-10-31,161,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"In terms of the second part of your question. On the synergy components broadly we are on-track for the synergy path that we have talked about, the $600 million that we have outlined over the course of the first four years, we continue to execute against that and continue to see those as reasonable markers in terms of the gold that we will achieve, the rate and pace of investments and such will always vary as we manage the business, but again at the macro level Steve would be on-track for that.",0.9543658,0.0
CI-2019-Q3-2019-10-31,165,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Lance, it is David, good morning. So within the integrated medical business as I noted my prepared remarks, 2018 was our 10 th consecutive year of organic growth. The growth as you articulate you referenced one of the driving forces there, sustain attractive growth in the select segment, we continue to see sustained attractive growth in the middle market segment for overall portfolio.",1.1721726,0.958
CI-2019-Q3-2019-10-31,166,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Stepping in 2020, we would expect that to continue. The mixes of funding mechanisms as you know, but just to remind the audience, we continue to offer a diverse portfolio of funding options to our clients and we see variability in any given point in time in terms of the clients opt for more guaranteed cost, more shared funding or shared returns or more ASO or ASO stop loss and we see that Flex overtime.",0.6117373,0.325
CI-2019-Q3-2019-10-31,167,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director",In 2018 we saw a bit more of the guaranteed cost of phenomenon play through and we are very comfortable with that also to remind you that our overall earnings profile per customer is similar between guaranteed cost and self-funded because of the nature of our portfolio of businesses from that standpoint.,0.0443063,0.718
CI-2019-Q3-2019-10-31,168,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So stay tuned for more for 2020. I think the headline is continued growth, continued trends in the select segment, continued strength in the middle market segment.",0.9623008,0.7
CI-2019-Q3-2019-10-31,172,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Dave, it is Eric, I will start. As it relates to the growth over the balance of the year, couple of things I would note. First we are up over 200,000 customers now versus where we were at the end of third quarter 2018. So to accomplish our full-year goal, we just need to keep the same pace as what we delivered in 2018.",0.9529285,0.689
CI-2019-Q3-2019-10-31,173,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"As you might know, in the Select segment, the lower end of the middle market segment that is really a year round selling cycle. I mean, so we would expect opportunity to drive to and through our goal over the course of the fourth quarter here, just by executing in the same way that we have over the last number of years. So I think about that as having good visibility in terms of trajectory and such there.",0.5425799,0.586
CI-2019-Q3-2019-10-31,174,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"David, I don't know if you want to provide some additional commentary more broadly on the selling seasons.",1.1491197,0.077
CI-2019-Q3-2019-10-31,175,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","To your thought process, first you are correct. Retention remained strong across the portfolio for 2019. We saw a little lower performance within our national commercial employer segment. Think about those as commercial employers a 5,000 or more employees that are multistate and a little low performance at the higher end of the middle market range. So the largest within the middle market, in aggregate still continue to grow.",1.1045472,0.15
CI-2019-Q3-2019-10-31,176,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Also remind you that as we get to those largest clients, they tend to be the less penetrated or a lower level of specialty penetration in terms of the profile, as such you see, even though the medical customer growth came down a tad this year, earnings strength remains from that standpoint. And then we should expect that same trend to continue into 2020, we expect 2020 to be another strong retention year, strong growth in the select segment in the core of the middle market with varied performance at the highest end where there is thinner penetration.",1.1294209,0.92
CI-2019-Q3-2019-10-31,180,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Matthew good morning its David. At the broader sense, consistent a prior comment. Employers are seeking two fundamental needs, improved affordability to create the balance and sustainability of the programs that generates improved health and productivity present to you as an engagement of the co-workers. So they are working with all the levers to drive that.",0.8301593,0.922
CI-2019-Q3-2019-10-31,181,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","To a statement you made and I think a little bit more broadly from CDHP, it depends on where the employer is in their cost-sharing arrangement, but for some employers they have concluded that they pushed, I would say to the outer limits of cost sharing and some employers are actually stepping back from that a little changing their contribution strategies by wage level to try to get the alignment with the employees as a percent of the discretionary income as opposed to a flat percentage.",1.3233579,0.572
CI-2019-Q3-2019-10-31,182,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Third, I would suggest that employers are much more actively engaged in programs around what we call whole person health putting the mind, body together taking depression stress management behavioral services and driving them more integrated in because the data would show that there high corollary to not only medical issues, but productivity present here and then overall sustainability from that standpoint. And then open to more innovation relative to care delivery mechanism.",0.6917995,0.826
CI-2019-Q3-2019-10-31,183,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So the interest in virtual care delivery to get more personalization efficiency and affordability, as well as extending the care equation, whether it is through the employer of the home or otherwise, those trends continue. So, you are theme is on absolutely, but it varies by employer and it varies by lever they are seeking to push and our portfolio of assets lines up very well to that need set.",0.6634279,0.855
CI-2019-Q3-2019-10-31,187,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","George, good morning, it is David. First and foremost, broadly speaking, we continue to be very pleased with the pharmacy trend or the overall result we are delivering for our clients and customers and continue to build off the strength there both in the core pharmacy operations as well as a very important in specialty pharmacy operations.",0.6241741,0.91
CI-2019-Q3-2019-10-31,188,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director",At this point we are not providing detailed guidance as it relates to underlying pricing trend or brand trend or otherwise from that standpoint. We will challenge ourselves to provide additional visibility as we get into the fourth quarter call in more detail outlook from that standpoint.,1.2491255,0.077
CI-2019-Q3-2019-10-31,189,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","But I think the most important part of the answer is that we are confident we are going to grow our health services portfolio, revenue, scripts and earnings next year. We feel very positive about our ability to deliver differentiated trend, clinical performance and service results next year and manage the dynamics of the inflationary environment and the mix of inflationary environment between generic brand and specialty pharmaceuticals. And we will look forward to trying to provide more guidance as we step into 2020.",1.0217645,0.912
CI-2019-Q3-2019-10-31,192,Question,2019-10-31,3,2019,Frank Morgan,RBC Capital Markets,"Good morning. Most of my questions have been answered. So these will be very random just the first one. Any color on the upcoming post-trial brief hearing on the break-up fee. I think that is it for some time in November. Maybe the date there and any expectations there, any commentary around the Texas Medicaid results that came out yesterday, and I think those are my two random questions. Thanks.",0.4687827,0.7
CI-2019-Q3-2019-10-31,193,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","It is David, I will take granular question. One, on litigation and I will ask Eric to take out random question number two on Medicaid. Specifically your dates are correct, the final trial is slated for later in the month of November.",0.1982122,-0.128
CI-2019-Q3-2019-10-31,194,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","We continue to feel very strongly about our case and look forward to a successful resolution from that outcome and to remind you we have nothing factored into our capital outlook relative to our recovery of that break fee. Eric, I will ask you to address Medicaid",0.6078508,0.735
CI-2019-Q3-2019-10-31,195,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes Frank it is Eric. On Texas Medicaid, just a couple of things to put out there for you. First of all, you are correct, we received notice earlier this week that our role in that contract will wind down next year. Just to put it in context, it represents about $900 million of revenue, but really a de-minims contribution to earnings.",0.9982034,0.214
CI-2019-Q3-2019-10-31,196,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"The timeframe in 2020 means I will have order of magnitude maybe a $300 million earnings decline year-on-year and less than a penny. I'm sorry, $300 million of revenue decline in the year and like less than a penny of earnings per share. So very immaterial.",0.5346748,0.527
CI-2019-Q3-2019-10-31,197,Answer,2019-10-31,3,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We are reviewing our options related to the potential to protest and haven't made a decision on that at this point, but very manageable under the scheme of things overall.",0.4178944,-0.128
CI-2019-Q3-2019-10-31,200,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Thank you. Just to briefly wrap up our call, I would like to highlight some key points for today. We are very pleased with our third quarter results, which reflects continued momentum across our businesses, including earnings growth for Health Services and Integrated Medical business and strong retention of expansion of our customer relationships, as well as significant ongoing operating cash flow generation and capital deployment.",0.4096386,0.955
CI-2019-Q3-2019-10-31,201,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Relative to our combination with Express Scripts, we continue to make very good progress and we are delivering a number of meaningful benefits for our customers, patients, clients and shareholders. Looking ahead to our initial outlook for 2020, we expect attractive EPS growth next year and expect to grow earnings per share 10% to 13% in-line with our long-term EPS growth expectations.",0.4162456,0.963
CI-2019-Q3-2019-10-31,202,Answer,2019-10-31,3,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And for 2021, we remain on-track to deliver our $20, $21 EPS goal as well as cash flow from operations of at least $8.5 billion. We thank you for joining our call today and look forward to our future discussions.",0.2491255,0.557
CI-2020-Q4-2021-02-04,9,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Thank you, Alexis. Good morning everyone, and thank you for joining us on our call today. When we met a year ago, the challenges from COVID-19 were just beginning to fully emerge around the globe. With the arrival of vaccines, 2021 is likely to be a year of transition, as communities and businesses seek to turn the page. I am very proud of the ways in which our 70,000-plus colleagues led, and continue to lead through this difficult time for customers, our clients, our providers, our partners, and our communities. Starting last spring, we were amongst the first to waive out-of-pocket costs COVID-19 testing as well as treatment. Our Evernorth business quickly leveraged our supply chain expertise to ensure a consistent prescription drug supply and delivery during the uncertain times.",0.8402643,0.881
CI-2020-Q4-2021-02-04,10,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","In our U.S. Medical Business, we ramped up to meet the significant increased demand for behavioral health services by growing our network, adding virtual provider partners, creating demand webcasts, treating first responders, and adding search capabilities for provider ethnicity. All over, we were deploying hundreds of millions of dollars to support our clients and partners who were hit hardest by the pandemic. In partnership with New York Life, we launched the Brave of Heart Fund to provide charitable grants for families, frontline workers, and volunteers who lost loved ones to COVID-19. And last month, our Cigna Medical Group was amongst the first non-hospital organizations in the nation to administer antibody therapy for high-risk COVID-19 patients, freeing up much needed hospital space.",0.6078508,0.962
CI-2020-Q4-2021-02-04,11,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And just a few weeks ago, we partnered with industry leaders from across the public and private sectors to ensure that people who received the vaccine had digital access to the vaccination records so they can safely return to their jobs and daily activities. As we continue to work to serve our clients, our customers, and our patients during the pandemic, we also balanced our responsibility to deliver for shareholders as well. For 2020 full-year, we grew our adjusted revenue by 14%, to $160 billion. We also delivered adjusted earnings per share of $18.45, consistent with our overall expectations, which included the ongoing elevated cost of COVID-19-related services.",0.4453945,0.854
CI-2020-Q4-2021-02-04,12,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Today, I'm going to talk about how our strategic actions we took in 2020 position each of our businesses to navigate what we expect will be another very dynamic year, one that will require us again to balance the very needs of all of our stakeholders. I'll also tell you about our growth framework and how our execution of it will drive our success throughout this challenging environment and beyond. Following my comments, Brian Evanko will share more details about our 2020 financial results and our 2021 outlook, and then we'll take your questions.",0.1943257,0.9
CI-2020-Q4-2021-02-04,13,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","At Cigna, we've been in a journey, an important one over the past two years to significantly accelerate our strategic path. During the 2020, we completed the integration of our combination with Express Scripts, and delivered on our integration priorities, including revenue growth, cash flow generation, de-leveraging targets, strong client retention, high levels of coworker retention, and working to keep our vision top of mind with innovations and improved affordability, predictability, and simplicity delivered to the market. In addition, we delivered another important milestone of our strategic journey by launching Evernorth, our health services platform, which has meaningfully grown our strategic partnerships and is bringing innovative solutions to the market already.",0.3606685,0.952
CI-2020-Q4-2021-02-04,14,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","We also made a series of leadership changes to align our capabilities and further operationalize our strategy, reinforcing our talent depth, and our commitment to continue to grow and develop our team. And based on the capital and cash flow strength of our company, we are demonstrating the ability to have [an and] [Ph] orientation to our capital deployment strategy. This means we're able to reinvest in our business for ongoing growth, and pay a meaningful quarterly dividend, and deployed substantial capital to share repurchase, and target and pursue strategic M&A. At the same time, we continue to execute effectively across each of our businesses by delivering value to our clients and customers or patients.",0.1138749,0.967
CI-2020-Q4-2021-02-04,15,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","In Evernorth, our 2020 adjusted revenue increased 20% driven by ongoing strong retention, the completion of Cigna volumes, and organic growth, including our partnership with Prime Therapeutics. In U.S. Commercial, our relentless support of our customers, and our employee clients and partners throughout the pandemic led to strong client retention levels again in 2020, along with better-than-expected in-group strength, building a solid foundation that we will carry into 2021. In U.S. Government, we grew our Medicare Advantage customer base by 18%, exceeding our annual growth target of 10% to 15%. And we expanded our geographic and product footprint to now be making market offerings in 20% of all available Medicare Advantage bio markets.",0.5371162,0.971
CI-2020-Q4-2021-02-04,16,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","In addition, 88% of Medicare Advantage and prescription drug paying customers in 2021 are in four-star plus rated plans, with our national weighted average of four-and-a-half stars, the highest amongst our national competitors. And in our International business, despite navigating the challenges of the ongoing pandemic in multiple countries, we delivered full-year adjusted earnings growth of 18% fueled by our strong partnerships.",0.6338904,0.77
CI-2020-Q4-2021-02-04,17,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Related to Group Disability and Life, which we sold to New York Life, on December 31, I am proud of the way in which our team worked to deliver in a very challenging environment, fueled by the pandemic, for the benefit of our clients and customers. As a result of the pandemic, it created a significant reduction in our earnings contribution for our business last year. However, we remain focused on serving our clients and customers.",0.3649436,0.908
CI-2020-Q4-2021-02-04,18,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Throughout 2021, we expect the macro environment to remain dynamic, which presents both challenges and opportunities for us. Among the challenges, we expect COVID-19 and the rollout of the vaccine to continue to tax an already overburdened healthcare system. And we expect intensified and much needed focus on health disparities to continue as well. At the same time, we also see opportunities. They include greater recognition of the importance of the employer-sponsored market with companies playing even more critical role in ensuring the wellbeing of their employees by offering comprehensive medical, pharmacy, and behavioral services.",0.5382822,0.941
CI-2020-Q4-2021-02-04,19,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","There were also a number of accelerating trends that will further drive fundamental changes in healthcare. For example, pharmacological innovations are quickly becoming the future of healthcare driven in part by the continued rise in specialty pharmaceuticals, gene therapies, and the evolution of the biosimilars. There is also a greater recognition and acceptance of the link between mental health and physical health. And we see care access rapidly changing as a result of consumer behavior and technology and data innovation leading to growing use of virtual visits and coordinated home-based care all aided by advancements in remote monitoring as well. Against this backdrop, the progress we achieved in 2020 along with the strength of our capabilities that gives us confidence that we will deliver at least $20 of adjusted earnings per share in 2021 even in the face of COVID-19 headwinds primarily in the form of elevated medical costs.",0.2036533,0.98
CI-2020-Q4-2021-02-04,20,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Our ability to achieve these levels of continued long-term success starts with growth framework which is three fundamental building blocks. First, we delivered differentiated value in the form of affordable, predictable, simple solutions for our clients, customers, and patients. This drives our ability to retain, further deepen, and grow our business platforms. Second, we work to partner and innovate. This enables us to rapidly bring new solutions to the market that creates even more value for our clients and customers. And it also fuels our third priority, the expansion of our addressable markets which we achieve by growing our geographic footprint further, by moving it to underpenetrated markets through service coordination, and through addition of new solutions that gives us the opportunity to sell to new buyer groups.",0.0353673,0.974
CI-2020-Q4-2021-02-04,21,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Taken together, these building blocks provide us with multiple levers to continue to achieve differentiated and sustained growth not only in 2021, but over the long-term. In Evernorth, this means bringing an expanded set of solutions to our existing health plan, commercial and government clients by leveraging the strength of our pharmacy, care management, health intelligence, and benefit management capabilities.",0.1010494,0.965
CI-2020-Q4-2021-02-04,22,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","In U.S. healthcare, this means continue outstanding retention along with further deepening relationships and target new business adds. In U.S. government, it means delivering at our goal of accelerated customer growth of 10 to 15% in Medicare Advantage. It also means continue to expand our geographic footprint in the individual exchange market where, for example, in 2021 we will be offered in 220 counties. This is a more than 50% year-over-year increase. And in International, it means continuing to grow as we deliver differentiated value for our globally mobile customers as well as our supplemental health solution customer. We look forward to delving more deeply into our growth strategy with you at our Investor Day which is slated for March 8th.",0.0085503,0.962
CI-2020-Q4-2021-02-04,23,Remarks,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So, now to summarize, I am very proud of my colleagues in our company for delivering for our customers, patients, clients, partners, and shareholders in an extraordinary year by maintaining a relentless focus on delivering on our commitments and leading through a rapidly changing landscape. Our performance is a testament to the resilience of our organization and our ability to thrive and deliver differentiated results in the most challenging of environments. We delivered strong revenue, earnings, and cash flow results in 2020. In 2021, we expect to deliver at least $20 of adjusted earnings per share. And we will continue to drive attractive operating cash flow which fuels our ability to return value to our shareholders through a meaningful quarterly dividend and through ongoing share repurchase as well targeted M&A. Overall, we have confidence that we'll achieve our 2021 outlook and our long-term growth objectives.",0.4364555,0.983
CI-2020-Q4-2021-02-04,25,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"Thanks, David. Good morning everyone. First if we look back at 2020, I am very proud of the actions we have taken in the company to meet the needs of our customers, clients, provider partners, communities, and coworkers while also delivering on our commitment to our shareholders. And as we enter 2021, we remain focused on delivering differentiated value and driving growth across our businesses. My remarks today, I'll review Cigna's 2020 results including the ongoing impact of COVID-19 on our business and provide our outlook for 2021.",0.1761531,0.955
CI-2020-Q4-2021-02-04,26,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"The consolidated financial highlights for 2020 include adjusted revenue of $160 billion, adjusted earnings of $6.8 billion after-tax, adjusted earnings per share of $18.45 and operating cash flows of $10.4 billion. These results reflect strong execution across our businesses through an unprecedented environment.",0.3091266,0.671
CI-2020-Q4-2021-02-04,27,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"Regarding our segments, I'll first comment on Evernorth. Fourth quarter 2020 adjusted revenues grew to $30.5 billion and adjusted pretax earnings grew to $1.6 billion. Evernorth strong results reflect organic growth with outstanding client retention and new partnerships, effective execution of supply chain initiatives, and continued strong performance in Accredo, our industry leading specialty pharmacy.",0.0917566,0.946
CI-2020-Q4-2021-02-04,28,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"During the quarter, we fulfilled $388 million adjusted pharmacy scripts, a 19% increase for our fourth quarter 2019. Overall, Evernorth delivered a strong fourth quarter as we completed our integration efforts and we entered 2021 with good momentum.",0.638371,0.883
CI-2020-Q4-2021-02-04,29,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"Turning to U.S. Medical, fourth quarter adjusted revenues were $9.7 billion and adjusted pretax earnings were $328 million. These results reflect COVID-19 related impacts and the return of the health insurance tax. COVID-19 related impacts in the quarter include the direct costs of COVID-19 testing and treatment, the costs of actions we have taken to support customers, providers and co-workers and decreased specialty contributions partially offset by a reduction in non-COVID utilization.",0.1123651,0.402
CI-2020-Q4-2021-02-04,30,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"As we progressed through the fourth quarter, we experienced an increase in direct COVID-19 costs for testing and treatment as incidence rates spiked across the country. While we also saw increased levels of care deferral for non-COVID costs during the latter part of the quarter, the direct COVID-19 costs outweighed the impact of lower non-COVID costs.",0.2001963,0.66
CI-2020-Q4-2021-02-04,31,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"Turning to membership, we ended the year with 16.7 million total medical customers. This represents less than a 0.5% declined sequentially excluding the loss of a 240,000 life claims as expected due to an acquisition, as our book of business remains resilient.",0.0098135,-0.318
CI-2020-Q4-2021-02-04,32,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"We finished the year with 18% Medicare advantage customer growth and delivered mid single-digit growth in the Select and International segments, despite a challenged economic backdrop. Overall results for Cigna's U.S. Medical segment reflects strong fundamentals and the impact of the increase in direct COVID-19 costs as we progressed through the fourth quarter.",0.2468106,0.902
CI-2020-Q4-2021-02-04,33,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"In our international markets business, fourth quarter adjusted revenues were $1.5 billion and adjusted pretax earnings were $91 million, reflecting the costs of actions taken to support customers and coworkers and investments in the business for future growth.",0.3493621,0.649
CI-2020-Q4-2021-02-04,34,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"For our Group Disability and Other Operations segment, fourth quarter adjusted revenues were $1.3 billion. Fourth quarter adjusted pretax earnings for this segment were $11 million, reflecting elevated life claims related to the pandemic and unfavorable disability claims. As previously noted, we completed the sale of the Group Disability and Life Business to New York Life on December 31, 2020.",0.483317,0.0
CI-2020-Q4-2021-02-04,35,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"For our Corporate segment, the fourth quarter adjusted loss of $381 million reflects lower interest expenses due to lower levels of outstanding debt. Overall Cigna's 2020 results reflects focused execution across each of our businesses through a dynamic environment, as we continue to meet the needs of those we serve, while delivering strong financial results.",0.407262,0.807
CI-2020-Q4-2021-02-04,36,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"As we turned to 2021, we have entered the year with strength and momentum driven by our strategic actions in 2020, which David detail. And we expect the environment in 2021 to continue to be dynamic presenting both challenges and opportunities for our business.",0.6015702,0.827
CI-2020-Q4-2021-02-04,37,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,Before going to our detailed outlook with the sale of our Group Disability and Life Business contributions from group should be removed for the purposes of year-over-year comparisons.,0.62316,0.0
CI-2020-Q4-2021-02-04,38,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"With that for full-year 2021, we expect consolidated adjusted revenues of at least $165 billion representing growth of approximately $10 billion after adjusting for 2020 group revenues. We expect full-year 2021 consolidated adjusted income from operations to be at least $6.95 billion, or at least $20 per share. This is inclusive of an expected COVID-19 related headwind of approximately $1.25 per share. In 2021, we expect elevated medical costs including the impact of direct COVID-19 related costs and more normalized non-COVID utilization. And we expect impact the gradual economic recovery on our customer base in 2021.",0.4631992,0.718
CI-2020-Q4-2021-02-04,39,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"Given these COVID-19 dynamics, we expect the primary impact to be in our U.S. medical business. Further, we expect the COVID-19 headwind to be more concentrated in the first quarter of the year, and so we would expect the cadence of earnings per share in 2021 to be more weighted to the final three quarters of the year. Specifically, we expect approximately 20% to 22% of 2021 earnings per share to emerge in the first quarter of the year.",0.1005888,0.671
CI-2020-Q4-2021-02-04,40,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"For 2021, we projected expense ratio in the range of 7.5% to 8%, and a consolidated adjusted tax rate in the range of 22.5% to 23.5%. I'll now discuss our 2021 outlook for our segments. In Evernorth, we expect full-year 2021 adjusted earnings of at least $5.6 billion. This represents year-over-year growth of at least 4%. In Evernorth, we expect the 2021 quarterly earnings cadence to be directionally in line with 2020. For 2021, we expect adjusted pharmacy scripts of at least $1.55 billion scripts. And we see significant opportunity to bring new innovative solutions to market through Evernorth, with less than 15% of our Evernorth revenues derived from Cigna's U.S. medical business, we have a significant external customer and client base, and we expect to continue to track the growth through existing and new Evernorth relationships.",0.0912659,0.922
CI-2020-Q4-2021-02-04,41,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"For U.S. Medical, we expect full-year 2021 adjusted earnings of at least $3.8 billion. This outlook reflects focused execution in our businesses driven by organic customer growth, deepening of customer relationships and disciplined expense management. This outlook also includes the projected impact of COVID-19.",0.5961727,0.637
CI-2020-Q4-2021-02-04,42,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"As I said earlier, the COVID-19 headwind primarily impacts our U.S. medical business with the greatest impact in the earlier part of 2021. Key assumptions reflected in our U.S. medical earnings outlook for 2021 include the following. Regarding total medical customers, we expect 2021 growth of at least 325,000 customers. This includes continued organic growth throughout the year in our commercial business led by the select and middle-market segments, partially offset by lower national accounts enrollment.",0.0691855,0.802
CI-2020-Q4-2021-02-04,43,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"We also expect Medicare advantage customer growth in our target average annual growth range of 10% to 15%, and we expect growth in our individual ACA business, which will be largely offset by our exit of our legacy non-ACA individual market offerings. We expect the 2021 medical care ratio to be in the range of 81% to 82% reflecting the impacts in 2021 of elevated medical costs including the impact of direct COVID-19 related costs and more normalized non-COVID utilization, the repeal of the health insurance tax effective for 2021, and continued focus execution and delivery of strong clinical quality across our U.S. commercial and government businesses.",0.0299313,0.955
CI-2020-Q4-2021-02-04,44,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"We also expect continued contributions from international markets. As we continue to deliver differentiated solutions that improve the health, wellbeing and peace of mind of those reserves in our global markets. Regarding interest expense, we expect costs of approximately $1.3 billion pre-tax in 2021. All in for full-year 2021, we expect consolidated adjusted income from operations of at least $6.95 billion or at least $20 per share. Overall, these expected results reflect the differentiated value, strength and strategic positioning of our businesses, as we deliver growth while navigating the headwind associated with COVID-19.",0.0147203,0.961
CI-2020-Q4-2021-02-04,45,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"Now, turning to our capital management position and outlook, we expect our businesses to continue to drive exceptional cash flow with strong returns on capital, even as we continue reinvesting to support long-term growth and innovation. In 2020, we deployed $4.7 billion to repay debt and we repurchased 21.9 million shares of stock for $4.1 billion. We ended 2020 with the debt to capitalization ratio of 39.5% and improvement of 570 basis points over year-end 2019 as we met our de-leveraging targets of a debt to capitalization ratio of less than 40%.",0.0206084,0.836
CI-2020-Q4-2021-02-04,46,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"Now, framing our capital outlook for 2021, we entered 2021 with $2.5 billion of deployable capital from our strong cash flow generation in 2020, and the remaining proceeds of the Group sale, net of the expected debt repayment we announced on deal close. For 2021, we expect at least $7.5 billion of cash flow from operations, reflecting the strong capital efficiency of our well-performing businesses. Combined, this gives us at least $10 billion to deploy in 2021, and positions us well to execute against our 2021 capital deployment priorities.",0.1653582,0.827
CI-2020-Q4-2021-02-04,47,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"First, we expect approximately $1 billion in tax payments and expenditures resulting from the Group sale. We also expect to deploy approximately $1 billion to capital expenditures primarily focused on technology to drive future growth. We expect to deploy approximately $1.4 billion to shareholder dividends, in line with our January quarterly dividend announcement. And we expect to largely deploy the remaining $6.6 billion for share repurchase and strategic M&A. Year-to-date, as of February 3, 2021, we have already repurchased 4.2 million shares for $906 million. For the purpose of the planning and 2021 earnings per share guidance, our outlook reflects the deployment of the vast majority of the $6.6 billion to share repurchase.",0.1368989,0.9
CI-2020-Q4-2021-02-04,48,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"Regarding M&A, we look for opportunities that are both strategically and financially attractive. And we would evaluate a given opportunity on its merits. Our balance sheet and cash flow outlook remains strong, benefiting from our highly efficient service-based orientation that drives strategic flexibility, strong margins, and attractive returns on capital.",0.5004907,0.975
CI-2020-Q4-2021-02-04,49,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"So to recap, our full-year 2020 consolidated results reflect strong execution led by our Evernorth segment. We enter 2021 with momentum. And we are confident in our ability to deliver our full-year 2021 earnings outlook. Further, we strategically positioned our businesses to leverage our growth framework, and to be service-based and capital light. This positioning drives significant financial strength and flexibility, and gives us continued confidence in our long-term growth targets.",0.0186457,0.971
CI-2020-Q4-2021-02-04,50,Remarks,2021-02-04,4,2020,Brian C. Evanko,CFO,"With that, we'll turn it over to the operator for the Q&A portion of our call.",2.2473013,0.0
CI-2020-Q4-2021-02-04,52,Question,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Hi, good morning. Appreciate the details. I just want to go back to sort of thinking about the COVID headwinds this year. And I know '22 is a far way away, but from this distance should we be thinking about $20.00 plus $1.25, and then putting your long-term growth rate on that. Is there any reason not to sort of generally be thinking about that as the setup for 2022?",0.1643995,0.874
CI-2020-Q4-2021-02-04,53,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Gary, good morning, it's David. As Brian noted, we estimate the $1.25 for 2021. Big picture, we think you should view it as transient or removable. I'd caution you from, at this early stage, penciling all of it as an immediate return in 2022. But to be very clear, we do believe it is removable or recoverable from that standpoint through a variety of forces. One, obviously the effectiveness and the ramping of the vaccine that will transpire from that standpoint; two, further evolution of both programs and services, as well as treatments and therapies relative to dealing with COVID, and then third, ultimately, if necessary, pricing actions activities. So big picture, agree with your conclusion. We'd just caution you not to harden it fully 100% into a 2022 number yet.",0.8981733,0.44
CI-2020-Q4-2021-02-04,57,Answer,2021-02-04,4,2020,Brian C. Evanko,CFO,"Good morning, Kevin, it's Brian. So just a few kind of framing comments, and then I'll get to the core of your question. Throughout 2020, as the pandemic emerged, we certainly did witness an inverse relationship between COVID-19 claims and deferred care. And if you step back all the way to the second quarter of 2020, the impact to care deferrals more than outweighed the direct costs associated with COVID-19 claims for testing and treatment across both our commercial and Medicare businesses. During the third quarter, these factors approximately offset one another, meaning the cost to COVID claims approximately offset the effective care deferrals.",0.1236506,0.953
CI-2020-Q4-2021-02-04,58,Answer,2021-02-04,4,2020,Brian C. Evanko,CFO,"In the fourth quarter specifically, as the back half of the quarter emerged, we started to see the cost of COVID-19 claims for both testing and treatment start to exceed the benefits we were seeing from increased care deferral activity. And so we ended the quarter with performance of medical costs in aggregate that was modestly above our seasonal baseline. That effect was consistent across both the commercial and the Medicare book-to-business. Although I would note that the commercial care deferrals were lower than the Medicare care deferrals that we saw in the fourth quarter. So that's the way I would encourage you to think about it. And as we roll that forward into 2021, our guidance contemplates the respective books-to-business in the $1.25 headwind.",0.498528,0.361
CI-2020-Q4-2021-02-04,61,Answer,2021-02-04,4,2020,Brian C. Evanko,CFO,"Morning, Matt. This is Brian. So yes, you have that right. For the fourth quarter we did see the direct cost of COVID-19 testing and treatment exceed the benefits of care deferral for the quarter in aggregate, with the back half of the quarter where the acceleration really occurred. I would note though that the fourth quarter also saw elevated care deferral relative to the third quarter in Medicare. And again, as we roll that forward stepping into 2021, we assume that the first portion of the year there will be elevated medical cost experienced in our book of business across U.S. Medical. And then as the year unfolds that will gradually dissipate toward the back half of the year.",0.1054956,0.077
CI-2020-Q4-2021-02-04,65,Answer,2021-02-04,4,2020,Brian C. Evanko,CFO,[Technical difficulty],1.8792934,0.361
CI-2020-Q4-2021-02-04,67,Question,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks. Good morning. Last year, you had talked about a potential opportunity to go back to customers and maybe take some risk off the table for them for 2021. I'm not sure if that program resonated or not and whether that had any impact on the guidance. And maybe if there are considerations around your stop loss book specifically for this year that we need to consider in terms of what's baked into the guidance. Thanks.",0.4815391,0.886
CI-2020-Q4-2021-02-04,68,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Ralph, good morning. It's David. I think what you're reflecting back on is, as the pandemic, the breath and magnitude of it began to take hold and become obvious, we made the decision as an organization that we would seek to return all the favorable economics that were manifested because of COVID disruption to clients, customers, patients, our provider partners, and our coworkers. So you're reflecting back to that. We did take proactive action throughout the course of the year to work with clients, that's a client-by-client set of actions depending on the client's position, desire, funding mechanisms, et cetera, to both return value in absolute sense, and in some cases restructure programs with an eye toward 2021.",1.542946,-0.228
CI-2020-Q4-2021-02-04,72,Question,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Great, thanks for the question. And maybe just on Evernorth and the guidance. If I look at this $5.6 billion of operating profit expectation, it doesn't seem like it bakes in too much underlying growth, if I'm thinking about this right. So I just wanted to talk through some of the pieces. And if you account for the expected benefit from the Anthem overhead costs rolling off, some of the incremental deal synergies, the Prime Scripts, just want to make sure I'm thinking about the underlying business there correctly, and what you guys are assuming the kind of organic underlying growth could be in this business for '21?",0.4380101,0.905
CI-2020-Q4-2021-02-04,73,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning. It's David. So let me start, I'll ask Brian to add some additional specificity. Stepping back relative to the Evernorth platform, we're delighted. We're really pleased with the performance, the growth that is being realized because of the value that's being delivered to our clients. Our commercial clients, our helpline clients, our government clients, from that standpoint. Two is, to put a pin in it, this is specifically relative to transit overhead, we were able to more rapidly accelerate the extraction of this transit overhead largely because of executing our efficiency initiatives, but also the significant growth. So this transit overhead extraction was more accelerated from its initiation in 2019 through 2020.",0.2273611,0.958
CI-2020-Q4-2021-02-04,75,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Brian, some adds?",1.0722892,0.827
CI-2020-Q4-2021-02-04,81,Answer,2021-02-04,4,2020,Brian C. Evanko,CFO,"Morning, George. It's Brian. So I appreciate the question, and the nature of the way you structured it. I'm going to approach it maybe a little bit differently, but hopefully this will get at what you're looking for here. As we do mention the $1.25, I would encourage you to think about it in three broad categories. The first one being the impact of elevated COVID-19 testing, treatment, and vaccination costs, as well as some of the pressure we anticipate in our revenue, for example, in our Medicare business. I would size that at about half of the $1.25. In fact, as it relates to the 2021 effect on our U.S. Medical book. And you'll see that primarily in the medical care ratio, or the MCR.",0.1825319,-0.542
CI-2020-Q4-2021-02-04,83,Question,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Okay, maybe as a quick follow-up, is there any impact expected to the Evernorth segment?",0.170618,0.0
CI-2020-Q4-2021-02-04,84,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director",The Evernorth impact is quite modest. I would characterize it's immaterial relative to the size of that business.,0.1208706,0.707
CI-2020-Q4-2021-02-04,88,Question,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks. Hi, everybody. Just to ask about Evernorth, two aspects there, one with now enhanced capital for deployment. It seems like part of the story for Evernorth is diversifying the service offering beyond the pharmacy benefit focus that it currently has. Can you comment on how quickly and you think you can diversify and maybe update us on the areas that you're thinking about adding to the capability there and then just base it on Evernorth, there was some talk last year that the PBM selling season, people were renewing for a year because of the pandemic. And do you expect the selling season to have more RFPs than normal this year? Or is it sort of a normal RFP season from what you're seeing so far?",0.0497474,0.961
CI-2020-Q4-2021-02-04,89,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","A.J. good morning, it's David. Relative to your first question, the platforms that we're operating within Evernorth and again, we'll walk through it in some good detail at our Investor Day, there are four platforms within that portfolio are well performing pharmacy services, our care management or benefit management or health intelligence platforms that are functioning, operating, delivering significant value today, and each one of which we'll continue to be invested in first and foremost, organically.",0.2568986,0.67
CI-2020-Q4-2021-02-04,90,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Brian referenced the CapEx deployment that we have within our portfolio and Evernorth is a part user of that $1 billion CapEx. Secondly, through partnerships, the way we work to partner in different ways, shapes and forms and thirdly, potentially, through M&A from that standpoint. But the platforms we have we feel quite good about as an illustration in terms of the M&A capabilities we've talked about expanding our ability to serve customers, where they are, and where they seek to be served, whether that's expanded virtual platforms, expanded in-home capabilities, et cetera through that lens.",0.0264283,0.783
CI-2020-Q4-2021-02-04,94,Question,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Hi, good morning. I'm hoping to hear David how central and important telemedicine is to Cigna and Cigna's strategy, thinking about how are you baking that into product design? How are you thinking about extended higher reimbursement deferral of patient copay, and does like remote passive digital monitoring of high risk patients fold into that picture, I'd just love to hear you talk about how central that is and how much say Cigna is pushing that as opposed to waiting on customers to pull that from you?",0.441508,0.974
CI-2020-Q4-2021-02-04,95,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So, good morning. It's interesting the way you ended in terms of push pull. We've talked before around our orientation is being we think about ourself as a consultative solution provider. So I pause a little bit on the push side of the equation, but stepping back, your framing I think is quite healthy. As I noted in my prepared remarks, we see the change in which care will be accessed and coordinated is one of the three defining trends over the decade in front of us. And we see significant opportunity to be clear.",0.5783133,0.955
CI-2020-Q4-2021-02-04,96,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So let me agree, we see significant opportunity to deliver more value, more choice, more simplicity, with appropriate coordination back to customers and patients through effective use of virtual programs. This is well beyond telemedicine, it's well beyond Urgent Care triaging. There's longitudinal nature that is attached to that, it is aided by remote monitoring, it is aided by a coordinated system to make that longitudinal delivery work. We see this transcending from healthcare through behavioral health to coordinated health care and behavioral health services from that standpoint, and we see it as a significant opportunity. I'd also note that, we've been mindful in terms of the positioning of the corporation whereby we see that as not only a significant opportunity in the market, but for us, because we've sought not be positioned in, we'll call it bricks and mortar delivery or fixed delivery infrastructure, but having the flexibility of the variable delivery infrastructure that is aided for clients.",0.9634668,0.936
CI-2020-Q4-2021-02-04,100,Question,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director",Thanks. Can you hear me this time?,0.8981733,0.402
CI-2020-Q4-2021-02-04,101,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Yes, we can, Justin.",0.8422075,0.636
CI-2020-Q4-2021-02-04,103,Answer,2021-02-04,4,2020,Brian C. Evanko,CFO,"Good morning, Justin. It's Brian. I'll take the first part of your question, then, David will comment on the individual exchange part. In terms of the Evernorth business really pleased with the revenue performance that we drove in 2020, and your comment about the relationship to the earnings, couple of things I would keep in mind there. One is the relationship that came out with Prime Therapeutics, effective April 1st, and that became expanded on January 1, 2021. When we onboard any new clients, there's a level of startup cost associated with that, as we think about bringing on new headcount to make sure that we're ramped-up for the volumes that will come. So we had a little bit of expense related to the startup associated with our relationship with Prime Therapeutics in 2020.",0.205103,0.784
CI-2020-Q4-2021-02-04,104,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Additionally, the Cigna U.S. medical insourcing, which is now complete, brought revenue, but deminimis earnings contribution in 2020 to Evernorth. So those are really the two dynamics that caused a little bit of the revenue versus earnings growth difference that you think, David anything you want to call out relative to the individual business?",0.5204042,0.84
CI-2020-Q4-2021-02-04,105,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Sure, Justin, good morning, relative to the business. First, we're pleased with the performance that we're stepping into 2021 with rolls to that portfolio. As I noted in our prepared remarks, we're expanding to counties, we're participating in by about 50%. Brian did also note that we're exiting the non-ACA portion of that business.",0.5285659,0.0
CI-2020-Q4-2021-02-04,106,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to margins, Justin, I would remind you, we were early to note that a couple of years ago, we thought that that portfolio of businesses nationally was earning margins above a sustainable margin threshold and we said targets have to revert to a sustainable marketing threshold. And in fact, the MCR we posted this year, we indicate it would show some impact of the margins, more normalizing and that indeed to take place. As it relates to the 2021 and beyond positioning, we think that our margin targets are sustainable, given our provider relationships and our service proposition and we look to grow that portfolio.",0.2137583,0.361
CI-2020-Q4-2021-02-04,108,Question,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Great, thanks. Good morning. So if you think about the commercial membership, like you mentioned you expect continued organic growth throughout the year in overall commercial membership. Curious if we can read into that maybe that Cigna is perhaps already troughed on the quarterly progression of commercial enrollment as it relates to COVID impact, economic impact etcetera. And then just within that with national accounts expect that to be down a little bit, any sense on when we may see the trough on that, whether it's early in the year or late in a year in 2021. Thanks.",0.4842596,0.913
CI-2020-Q4-2021-02-04,109,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning. It's David. I think you've identified several important features there. So, as it relates to commercial customers for 2021, as we expected to step into 2021 with about the number of customers we would end 2020 with, as relates to the years pattern. I'd ask you to think about it as follows. First, we expect the ongoing COVID impact to disenrollment to continue to have pressure on customers throughout the first-half of 2000, our customer number-- throughout the first-half of 2021. Second, as typically takes place in the national accounts segment, there are some non-COVID related disenrollment that happens historically in that business because most of the selling takes place during the first portion of the year. Offsetting that is continued growth and strength in the Select segment that has a very active selling season throughout the course of the year as well as some known middle market and new business ads that will take place during the middle portion of the year.",0.5382822,0.973
CI-2020-Q4-2021-02-04,116,Question,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director",Good morning.,0.8523125,0.981
CI-2020-Q4-2021-02-04,117,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So, relative to the ACO strategy, I think that's a broad definition of what the market calls value-based relationships and you're correct, we had an early start and a lot of passion and drive and therefore strategic direction relative to it. I would start with the end and that is the Medicare advantage book in general has a higher penetration of a comprehensive nature of value-based care relationships per customer that we serve versus commercial. So and you probably see that in other ways, you look at the marketplace, the primary care physicians integrated, multi-specialty physician groups, et cetera, tend to adapt many internalize value based care, more comprehensively for Medicare advantage given the population's health needs and the opportunity to deliver really significant value. The exciting and piece of it is we've been working now for a decade to prove that thesis in the commercial space.",0.8799067,0.997
CI-2020-Q4-2021-02-04,123,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, Charles. This is Brian. So in terms of the first part of your question there, dimensioning the test versus the treatment, we have gone through extensive modeling as you might imagine to project what we think is going to transpire in 2021, which led us to $1.25 COVID impact that described earlier. And as I went through to a previous question, we expect about half of that to come through in the form of elevated claim cost and/or revenue pressure in our U.S. Medical MCR book. So I am not going to split apart each of the different components in that for you. But just rest assured we've got a variety of projections that underlie that. So, David, maybe you want to comment on the effects of some other components?",0.4912553,0.951
CI-2020-Q4-2021-02-04,127,Question,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Yes, good morning, Brian and David. So let me just pull up a little on the strategic capital deployment, and if you could just talk to maybe two dimensions on that? Appreciate your earlier comments. As you were talking about bricks and mortar being of less interest and specifying of the areas in virtual home and remote monitoring et cetera that were of interest, maybe you can just call out the distinction? Maybe I am putting too emphasis on physician practice as being bricks and mortar and excluding them as an area of focus. And then similarly if it's in Evernorth, will be more focused on providing these services to employers and health plans? Or, how much of the focus is providing these services to risk bearing primary care or other value based care sorts of companies? Thank you.",0.5864749,0.619
CI-2020-Q4-2021-02-04,128,Answer,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Hey, Lance. Good morning. It's David. I'll start with the latter portion of your question first. So, as we evolve our capabilities both the present states, but evolve our capabilities, you should think about in general all that happens within Evernorth. It happens within Evernorth as it relates to a platform of services to serve health plans, to serve corporate clients, to serve governmental agencies, and to offer services to, as you articulated, risk bearing or performance based healthcare delivery systems. And you should think about Cigna's U.S. Medical portfolio as a consumer of those services. Now clearly an important development partner, but a consumer of those services as another client of Evernorth. As it relates to the first portion of your question, I think your basic framing of it is right. And so, if just reiterate it and step it up a notch, our view is that the U.S. is not in need of more physical proximity and physical plant to serve the population in general, especially in urban and suburban areas. We obviously have additional need states relative to rural areas in that standpoint.",0.3136417,0.99
CI-2020-Q4-2021-02-04,133,Answer,2021-02-04,4,2020,Brian C. Evanko,CFO,"Good morning, Scott. It's Brian. A few components to your question there, and just broadly the way I would encourage you to think about it is, we're on a multi-year growth turning for this business, right? And we're a year or two of our geographic and product expansion with the expectation of 10% to 15% annual growth. Really happy with the 18% growth we put up in '20. AND well on track to achieve 10% to 15% and '21. The margin profile tends to vary for a few different reasons. One is when we go into a new market, there tends to be a build-up in terms of investments, in people, in marketing before the customers start to come in. Two is when we rate a new customer, typically there's a bit of a ramp relative to profitability from a durational standpoint due to the risk adjustment coding, which you've appropriately called out. Thirdly, due to the unique nature of 2020 and the COVID-19 headwinds that we faced, the results of lower utilization, right? So as a result of that, we were not able to get all of the risk adjustment codes that we would in a normal year, if you will. We factored all that in due to 2021 outlook, the $1.25 earnings per share headwinds that we've called out here. A component to that is associated with Medicare advantage and it's associated with lower revenue that we would have otherwise anticipated having. So, as you kind of step forward as David said in the beginning 2022 and thereafter, we expect some of that will work itself out. And we're not going to give you exact 2022 guidance here today, that's the way I would encourage you to think about the margin profile.",1.5554465,0.586
CI-2020-Q4-2021-02-04,136,Closing,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Thank you. So just to wrap up, I'd like to highlight a few key points from today's discussion. First, I'm very proud of the way in which our colleagues supported the needs of our stakeholders throughout this pandemic, while also ensuring that we delivered on our shareholder commitment. We delivered solid 2020 financial results, including revenue and EPS growth and outstanding free cash flow. And our strong 2020 performance and the strength of our businesses give us confidence that we will achieve continued attractive growth in 2021 and beyond driven by a significant increase in revenue, ongoing profit growth, and very attractive cash flow performance.",0.0019433,0.791
CI-2020-Q4-2021-02-04,137,Closing,2021-02-04,4,2020,David Michael Cordani,"President, Chief Executive Officer & Director","We thank you for joining our call today, and we look forward to going into more depth with you around our growth plans at our Investor Day, which is slated for March 8. Have a good day.",1.3571706,0.077
CI-2021-Q2-2021-08-05,9,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks, Alexis and thank you for everyone for joining us on today's call. So I'm going to spend a few minutes talking about the current environment and the forces that are shaping it, the strength in durable nature of our model that enables us to capitalize on opportunities and continue to grow even in the most disruptive conditions and how the strength and durability is fueling our short and long-term success. Then Brian will share more details about our second quarter results, as well as our outlook for the rest of the year. And we'll take your questions.",0.5958026,0.957
CI-2021-Q2-2021-08-05,10,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So, let's jump in. During the quarter, we delivered adjusted revenue of $43 billion and adjusted EPS of $5.24 per share, all what we could do to drive balanced capital deployment as we execute on M&A, share repurchase and our quarterly dividend plan. We achieved these results in a fluid and challenging environment.",1.2199767,0.612
CI-2021-Q2-2021-08-05,11,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","As we continue to execute our strategy, we are confident in our ability to navigate these dynamic conditions. Our portfolio with three growth platforms enables us to create value for our clients and customers and drive sustained business growth.",0.5332297,0.941
CI-2021-Q2-2021-08-05,12,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","During the quarter, the strength of our Evernorth business was clearly a standout. We are seeing high demand for health services programs, and we continue to invest in broadening our service offerings, as well as our reach. Our sustained success validates our ability to be a trusted partner of choice for customers and clients, as they manage many of the most challenging aspects of healthcare today.",0.0015546,0.958
CI-2021-Q2-2021-08-05,13,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","We do this by leveraging our portfolio. That includes pharmacy solutions, benefit management solutions, care solutions, and intelligence solutions. Evernorth is helping to improve access to care, keep costs down and deliver better outcomes, as we serve our clients, patients, and customers. And another quarter of Evernorth strong revenue and earnings growth reinforces that our customers and clients value these capabilities.",0.7835212,0.984
CI-2021-Q2-2021-08-05,14,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","In Cigna Medical, we did see elevated medical cost pressure in the quarter, as costs associated with direct COVID-19 care and the broader ramp-up of utilization levels exceeded our projections. Within this challenging environment, we continue to take proactive steps to ensure our customers have access to the care they need. This includes the elevated mental health services needed during these unprecedented times, as well as continued to work with our customers and patients to help navigate them to optimal sites of care.",1.9891178,0.963
CI-2021-Q2-2021-08-05,15,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","During the quarter, we achieved customer growth in Cigna Medical, in both our U.S. Commercial and Government business. And we continue to be on track for medical customer growth of at least 350,000 customers in 2021. Brian will share additional perspective on our results and outlook and his comments. Overall, our performance, which is strong through the first half of the year, reflects the resiliency of our business and the balanced profile within our organization.",3.127089,0.866
CI-2021-Q2-2021-08-05,16,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","With our focus on driving performance during the remainder of the year, it's imperative that we understand and account for the challenges our customers and clients will face, as well as the continued evolution of the healthcare landscape. At a macro level, the environment is marked by ongoing uncertainty for business, governments, communities around the world. For example, COVID vaccination levels have brought welcome relief to millions, given only about half of the U.S. is fully vaccinated, and that percentage is much lower for the world's population.",1.7668092,0.599
CI-2021-Q2-2021-08-05,17,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","With the spread of the more contagious Delta variant, COVID infections and hospitalizations are on the rise in some regions, bringing renewed attention to travel restrictions and mask mandates. We see the economic recovery, while positive, has let uneven and varied amongst industries, as companies continue to cope with supply chain disruption, emerging inflationary pressure and various issues impacting the workforce.",0.1084337,-0.42
CI-2021-Q2-2021-08-05,18,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","More broadly from a health perspective, federal and state policy makers continue to be actively engaged. And as we've previously discussed, we continue to see three primary forces of change shaping the healthcare landscape today and into the future. Specifically, pharmacological innovation, including specialty pharmaceuticals, gene therapies, evolved oncology medications, vaccines and acceleration in biosimilars.",0.5437233,0.765
CI-2021-Q2-2021-08-05,19,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Second, the recognition of the link between mental health and physical health continues to grow, especially accelerated in this COVID environment. And third, the rise of virtual care and other alternative access to care models are rapidly changing. Together, these macro dynamics are profoundly influencing buying behaviors and service innovation in healthcare.",0.4667703,0.878
CI-2021-Q2-2021-08-05,20,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Now, with respect to clients, we are seeing a renewed commitment of employer clients to providing healthcare benefits vital to helping them to both attract and retain talent, as well as increased productivity by maintaining a healthy workforce. This includes, for example, adopting alternative side of care programs and access programs.",1.1321415,0.975
CI-2021-Q2-2021-08-05,21,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","We see an intensified need for affordability across all of our clients, including pharmacy services, as demand surges for high price, breakthrough drug therapies. We see a desire for more concentrated solution based services, as many clients are confronting the convergence of social, physical, and mental health issues in ways they have not experienced before.",0.3066459,0.49
CI-2021-Q2-2021-08-05,22,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","With respect to the individual customers and patients utilizing our service, we see that they're increasingly valuing their employee-based service models. They're benefiting from support services that help them tend to their emotional wellbeing. And they have growing demand for coordination of care, both in COVID and non-COVID events.",0.516129,0.931
CI-2021-Q2-2021-08-05,23,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Against this backdrop, we are delivering differentiated value for the benefit of our customers and clients with our capabilities that address their emerging and evolving needs. For example, we have had a strong focus on providing virtual services, broadening networks, as well as coordinated clinical programs.",0.4679363,0.869
CI-2021-Q2-2021-08-05,24,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","In our pharmacy solutions, we've been answering the call for greater affordability, as we continue to see the emergence of new and expensive pharmacological advancements. Evernorth's recent expansion of our industry first comprehensive weight management program illustrates the benefit of a more coordinated approach. Patients can now receive treatment with Wegovy, a promising new therapy for obesity and other weight management medications. And now with MDLIVE fully operational within our Evernorth business, MDLIVE physicians along with other Evernorth clinicians are available to help patients.",0.2895453,0.912
CI-2021-Q2-2021-08-05,25,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","This program expansion also includes personalized support services from health coaches, peer support groups, and curated digital apps. This weight management effort is the latest addition to our Evernote suite of SafeguardRX programs. As we're impacting 2020, patients enrolled in SafeguardRX to save more than $6 billion in aggregate.",0.7788574,0.823
CI-2021-Q2-2021-08-05,26,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","In Evernorth care solutions, we've experienced an increase in demand for our behavioral health solutions from customers and clients as well. In the past year and a half, it has brought heightened stress and other personal challenges, and we see many more people reaching out for help and services. Clients now more broadly understand that someone with a chronic condition is more likely to have a mental health or substance abuse related illness and individuals are feeling the additional mental and physical challenges associated with the pandemic. With our market leading behavioral health capabilities, we are driving more value to our Evernorth and Cigna medical clients and customers by providing the tools and services they need to address their mental wellbeing and deliver better, sustained long-term outcomes.",2.3913719,0.851
CI-2021-Q2-2021-08-05,27,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Within our Cigna medical platform in U.S. Commercial, we are working closely with our employer clients to provide our integrated suite of solutions, designed to make their workforce healthier and more productive. We know that employees receiving health and wellbeing benefits through their employers are less likely to miss work because of poor health. Our recent study shows a significant impact of the 70 fewer percent days missed over a year.",3.136028,-0.137
CI-2021-Q2-2021-08-05,28,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","With our integrated approach, we strive to bring the right mix of solutions that reduce the workforce challenges many of our clients are facing and helping to support them to engage and retain their employees. And affordability is remained the primary focus across our entire portfolio, as it is in Cigna medical.",1.1853867,0.807
CI-2021-Q2-2021-08-05,29,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director",Our clients continue to manage through an incredibly dynamic environment for their business and is becoming even more important that they can count on us with greater affordability for the healthcare programs. New and expensive pharmacological advancements are predominant contributor to this challenge. And we have been a leader here putting these treatments in the hands of those who need them at a more affordable price.,0.6148465,0.782
CI-2021-Q2-2021-08-05,30,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","For example, Remicade is treatment for chronic conditions, such as Crohn's disease or rheumatoid arthritis, while life changing can also impose significant financial burdens. One year of Remicade infusion costs about $30,000 on average, and as much as $70,000, depending on site of care. We recently launched a Cigna pharmacy program that shares prescription drug savings directly with patients who switched from Remicade to one of the approved biosimilars.",0.5192382,0.7
CI-2021-Q2-2021-08-05,31,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","More than 20% of eligible patients in consultation with their provider have already switched to lower cost preferred alternative medications. This program has an immediate benefit to clients who save at least 10% of the cost of the drug. And we've taken a leadership position here by supporting our patients with a $500 incentive. This is a great example of aligning interest. Over the longer term, we can drive even greater impact as biosimilars become a more prevalent part in the United States as helping us further improve affordability",0.5709289,0.977
CI-2021-Q2-2021-08-05,32,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And in Cigna medical, we're actively working toward improving affordability by ensuring that our customers continue to have the access to the care they need and optimize their long-term health. For example, in Arizona, we conducted a highly targeted outreach program to our customers who are high risk due to chronic condition, yet who have not been vaccinated. The initial results are encouraging, and we're seeing positive increase in vaccination rates amongst these targeted individuals. We are now taking the learnings from that pilot into other locations across the United States, with a particular focus on increasing vaccination rates amongst those in most need.",0.3280218,0.975
CI-2021-Q2-2021-08-05,33,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","This broad range of examples illustrates how our comprehensive and strategic approach to helping our clients and customers address their most pressing health needs help us going forward. And in this dynamic environment, we will continue to expand the services we offer our clients and customers, and therefore, we see many more opportunities to create value for both our clients and customers, and as a result for your shareholders.",0.8507579,0.951
CI-2021-Q2-2021-08-05,34,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","It is clear that the strength of our medical and pharmacy offerings combined with our strategic agility has enabled us to continue to capture growth, even in the most dynamic environment by delivering differentiated value, by partnering and relentlessly innovating, and by expanding our addressable markets, as we broaden our reach to new geographies and through the introduction of a broader suite of solutions.",0.170618,0.926
CI-2021-Q2-2021-08-05,35,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","When you combine this compelling growth potential, along with our significant operating cash flow generated by our service-based capital light model, we have confidence in our ability to meet our long-term targets by achieving differentiated results, which include average annual revenue growth of 6% to 8%, average annual EPS growth of 10% to 13% and continued to pay an attractive dividends, all while producing cumulative operating cash flow of approximately $50 billion through 2025. Relative to 2021, we remain committed to delivering full year EPS of at least $20.20.",0.5946366,0.958
CI-2021-Q2-2021-08-05,36,Remarks,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Now to briefly summarize. First, we recognize in an environment like this it's so challenging, we know that growth doesn't come easily. It has to be earned each and every day. Second, we have a proven track record of delivering differentiated value, innovating and partnering and smartly expanding our addressable market to fuel sustained long-term growth, even in disrupted environment. And our company has attractive sustainable growth opportunities across our three well position growth platforms, and importantly the strategic and capital flexibility to take advantage of opportunities.",0.5926934,0.986
CI-2021-Q2-2021-08-05,38,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Thanks David. Good morning, everyone. Today, I'll review key aspects of Cigna second quarter results, including the ongoing impact of COVID-19 on our business. And I'll discuss our updated outlook for the full year.",0.7752699,0.7
CI-2021-Q2-2021-08-05,39,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,Key consolidated financial highlights for second quarter of 2021 include adjusted revenue growth of 10% to $43.1 billion; adjusted earnings of $1.8 billion after tax; and adjusted earnings per share of $5.24. Results in the second quarter reflects strong top line growth with solid contributions across our businesses.,1.1619235,0.902
CI-2021-Q2-2021-08-05,40,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Before I go into segment specific results, I'd like to spend a couple of minutes addressing the medical cost environment we are experiencing. Let me be clear. Our second quarter results and our full year outlook have been adversely impacted by elevated claim costs compared to our prior expectations.",0.781158,0.511
CI-2021-Q2-2021-08-05,41,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Despite this pressure, our diversified portfolio of businesses and multiple earnings levers drove second quarter adjusted earnings that exceeded our expectations at the enterprise level. Specifically within the second quarter, ongoing direct COVID-19 costs were above our expectations and non-COVID utilization returned more rapidly than we anticipated.",0.1084396,-0.296
CI-2021-Q2-2021-08-05,42,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"During my comments today and in our Q&A, David and I will use the term baseline to refer to 2019 or pre-pandemic claim costs that will be trended forward for two years to 2021, to provide you with an estimate for what 2021 claim costs would have been in the absence of COVID-19.",0.2600589,0.0
CI-2021-Q2-2021-08-05,43,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"The return of non-COVID utilization has varied by both geography and customer group. For example, we saw the following within the second quarter: In U.S. Commercial, non-COVID costs were back to baseline level; while in Medicare Advantage, non-COVID costs accelerated from first quarter levels, but remain slightly below baseline for the second quarter. We expect to continue seeing elevated claim costs compared to our original expectations for the balance of 2021 within U.S. Medical.",0.4519136,0.535
CI-2021-Q2-2021-08-05,44,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"However, the strength of our diversified portfolio of businesses and our multiple earnings levers, give us the confidence to reaffirm our full year EPS outlook of at least $20.20. Additionally, as we look forward to 2022, while we recognize the dynamic environment in which we operate, we expect another year of attractive growth driven by all three of our growth platforms.",0.0834151,0.945
CI-2021-Q2-2021-08-05,45,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Now, I'd like to turn to our segment level results and then provide an update on the details of our outlook, as well as our capital positioning. Regarding our segments. I'll first comment on Evernorth. Second quarter 2021 adjusted revenues grew 14% to $32.6 billion, and adjusted pre-tax earnings grew 13% to $1.4 billion compared to the second quarter of 2020. Evernorth's strong results in the quarter were driven by ongoing organic growth, driving both top and bottom line contributions and continued progress on a range of affordability initiatives for the benefit for our customers and clients.",0.6344455,0.944
CI-2021-Q2-2021-08-05,46,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"In the quarter, we also continued to make significant investments to support our ongoing growth, including our virtual care platform and technology capabilities. Our adjusted pharmacy script volume was $410 million during the quarter, a 13% increase over second quarter 2020, driven by strong organic growth, as well as the impact of vaccine volumes in the quarter. Overall, Evernorth delivered another strong quarter, continuing to create differentiated value for clients and customers, while driving better-than-expected top and bottom line contribution to the enterprise.",0.3797841,0.978
CI-2021-Q2-2021-08-05,47,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Turning to U.S. Medical. Second quarter adjusted revenues were $10.5 billion and adjusted pretext earnings were $1 billion. Overall, our second quarter U.S. Medical earnings reflected the impact of elevated claim costs, offset by favorability from operating expenses, non-recurring items and net investment income.",0.3493621,0.0
CI-2021-Q2-2021-08-05,48,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Regarding our medical costs. We entered the second quarter expecting a continued decline in COVID-related claim costs and a gradual return in broader care consumption patterns toward more normalized levels. While these directional patterns did transpire, as I noted earlier, both direct COVID-19 costs and broader utilization levels were above our expectations for the second quarter. Direct COVID-19 costs were highest in April, decreasing throughout the second quarter, while non-COVID costs approximated baseline levels for the quarter.",0.0696762,0.494
CI-2021-Q2-2021-08-05,49,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Both U.S. Commercial and U.S. Government total medical costs reflecting the combined impact of direct COVID-19 and non-COVID costs were above baseline for the quarter, with U.S. Commercial further above baseline as those customers returned to utilize the healthcare system at a slightly higher level.",1.1560353,0.0
CI-2021-Q2-2021-08-05,50,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Given these developments, the second quarter medical care ratio was above our expectation. We now expect that the level of non-COVID costs we incurred toward the end of the second quarter will persist for the balance of the year. This coupled with the ongoing direct COVID-19 related costs we expect to incur has led us to raise our guidance for the full year 2021 medical care ratio.",0.1084396,0.751
CI-2021-Q2-2021-08-05,51,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Turning to membership. We ended the quarter with 17 million total medical customers, an increase of 249,000 customers sequentially. The customer growth in the quarter was largely driven by new wins in middle market and growth in the individual business through the extended special enrollment periods, supported by continued strong retention across our portfolio. All-in. for U.S. Medical, we continue driving customer growth and expanding services, while remaining focused on delivering value and supporting our customers and clients in the dynamic environment.",0.015211,0.983
CI-2021-Q2-2021-08-05,52,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"In our International markets business, second quarter adjusted revenues were $1.6 billion and adjusted pre-tax earnings were $234 million. These results were approximately in line with our expectations. Corporate and other operations delivered a second quarter adjusted loss of $331 million.",0.5544652,-0.318
CI-2021-Q2-2021-08-05,53,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Overall, we continue to deliver value for all of our stakeholders with strong growth, reflecting contributions across our businesses, led by outperformance in Evernote, the diversified portfolio of Cigna businesses and the multiple avenues to create an ultimately capture value has allowed us to continue meeting our enterprise commitments despite ongoing uncertainties in the marketplace.",0.1226693,0.924
CI-2021-Q2-2021-08-05,54,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Now turning to our updated outlook for full year 2021. We are reaffirming our adjusted earnings per share guidance for full year 2021 of at least $20.20. Before I walked through the outlook by segment, I'd like to frame the key drivers underlying this outlook. The updated components include an increase in expected earnings from Evernorth, a decrease in expected earnings from U.S. Medical driven by a higher medical care ratio, a more favorable outlook for operating expenses, and other contributions that are net favorable for the year.",1.2850834,0.943
CI-2021-Q2-2021-08-05,55,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Additionally, we now expect full year 2021 consolidated adjusted revenues of at least $170 billion, representing growth of at least 9% from 2020, when excluding the divestiture of our group disability and life business.",0.0544652,0.382
CI-2021-Q2-2021-08-05,56,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Within our outlook, we now expect a full year COVID-19 related headwind of approximately $2.50 per share, primarily impacting our U.S. Medical business. This includes approximately 80% related to impacts on the medical care ratio and approximately 20% related to lower customer volumes due to economy driven enrollment dynamics. Finally, we now expect an adjusted SG&A ratio of approximately 7.5%, an improvement relative to our prior outlook.",0.1241413,0.807
CI-2021-Q2-2021-08-05,57,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"I'll now discuss our 2021 outlook for our segments. For Evernorth, we now expect full year 2021 adjusted earnings of at least $5.8 billion, representing growth of at least 8% over 2020, reflecting the significant value we create for our customers and clients. For U.S. Medical, we now expect full year 2021 adjusted earnings of at least $3.5 billion. Underlying this updated outlook, we now expect the 2021 medical care ratio to be in the range of 83% to 84%, driven by our updated medical cost expectations for the second half of 2021 as I previously discussed. Regarding total medical customers, we continue to expect 2021 growth of at least 350,000 customers.",1.5520118,0.914
CI-2021-Q2-2021-08-05,58,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"All-in, for full year 2021, we continue to expect adjusted earnings per share of at least $20.20, with the underlying drivers being an increase in expected earnings from Evernorth, a decrease in expected earnings from U.S. Medical driven by a higher medical care ratio, a more favorable outlook for operating expenses and other contributions that are net favorable for the year.",0.0073602,0.926
CI-2021-Q2-2021-08-05,59,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Now moving to our 2021 capital management position and outlook. We expect our businesses to continue to drive strong cash flows and returns on capital, even as we continue reinvesting to support long-term growth and innovation. I would highlight that we had some timing related items, which impacted cash flow from operations during the second quarter. For full year 2021, we continue to expect at least $7.5 billion of cash flow from operations, reflecting the strong capital efficiency of our well-performing businesses.",0.0029441,0.955
CI-2021-Q2-2021-08-05,60,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Year-to-date, as of August 4th, 2021, we have repurchased about 18 million shares for about $4.1 billion. And we now expect full year 2021 weighted average shares of 344 million to 345 million shares. On July 28th, we declared a $1 per share dividend payable on September 23rd to shareholders of record as of September 8th.",0.1560353,0.778
CI-2021-Q2-2021-08-05,61,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Our balance sheet and cash flow outlook remains strong, benefiting from our highly efficient service-based orientation that drives strategic flexibility, strong margins, and attractive returns on capital.",0.2845927,0.932
CI-2021-Q2-2021-08-05,62,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"So now to recap. Results in the second quarter reflects strong top line growth with contributions across our businesses. Additionally, we acknowledged that the environment remains fluid as evidenced by the impact of elevated medical costs in the second quarter and on our outlook for the remainder of the year.",0.4106968,0.772
CI-2021-Q2-2021-08-05,63,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"Even with this additional pressure, our diversified portfolio and multiple earnings levers have positioned us to achieve our outlook for full year 2021, all while continuing to support our customers, clients, and coworkers. We continue to expect 2021 full year adjusted earnings of at least $20.20 per share and have continued confidence in delivering our long-term EPS growth rate that will average 10% to 13% per year.",0.0834151,0.823
CI-2021-Q2-2021-08-05,64,Remarks,2021-08-05,2,2021,Brian C. Evanko,CFO,"With that, we'll turn it over to the operator for the Q&A portion of the call.",1.0068695,0.0
CI-2021-Q2-2021-08-05,68,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"Good morning A.J. It's Brian. So, a few different questions in there. I'll try to give you the overall picture. So, as I said my prepared comments there, we now anticipate about a $2.50 earnings per share headwind in 2021 associated with COVID and of that approximately 80% impacts to medical care ratio, and approximately 20% is related to enrollment levels being depressed here in 2021.",0.9931305,-0.296
CI-2021-Q2-2021-08-05,69,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"Focusing on the $2 per share COVID-related headwind, that's impacting the medical care ratio, there's a few components underlying that. So, one would be the impact of Medicare Advantage risk adjuster revenue headwinds here in 2021. The other component of it is the level of total cost of care that we're experiencing in 2021 compared to our prior expectations, which includes both COVID direct costs. And it also includes non-COVID costs that returned earlier than we anticipated during the year here. And so, I wouldn't necessarily parse the two-thirds, one-third, the way that you did, but rather look at the total cost picture, be more elevated in comparison to what we had previously expected.",0.0058881,0.494
CI-2021-Q2-2021-08-05,70,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"COVID costs were highest for us in the first quarter. Within the second quarter, they were higher in April than they were in May and June. And we expect for the balance of the year that COVID costs will run at a lower level than they did in the first half of the year. So, that's what's embedded in our outlook. And as I said, the non-COVID utilization, we're anticipating to run at approximately baseline levels for the back half of the year. That plus the COVID costs we expect to incur leads us to all-in cost levels at slightly above our baseline for the back half of 2021.",0.3287537,0.577
CI-2021-Q2-2021-08-05,71,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"As it relates to what we expect to unwind heading into 2022, again, if you parse apart the components of that $2 I was just making reference to, the Medicare Advantage risk adjuster headwind, we expect to fully recover in 2022. So, between our bid strategies and the operational activities we're seeing, we have a full confidence that we'll fully recover that component.",1.5672228,0.586
CI-2021-Q2-2021-08-05,72,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"The components related to total cost of care, we expect to recover a portion of that in 2022. And so, a portion of that will come through pricing actions. A portion of that will come through clinical management activities and a portion of that we expect to be a little bit of natural abatement in aggravated costs between 2021 and 2022. So, we're currently estimating that about half of that $2 per share headwind will come back in 2022 in the form of incremental earnings. So, think about $1 of the $2.50 EPS headwind returning into the P&L in 2002.",0.0569185,0.361
CI-2021-Q2-2021-08-05,75,Question,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks. Good morning. Just staying on that topic. I think last quarter you had also suggested that, growth would be at or above the high-end in 2022. I think off that 2020 baseline, I guess, is that still the case? So the way to think about it is sort of at or above the high-end, and then add back that dollar that you just said Brian? Thanks.",0.5126312,0.926
CI-2021-Q2-2021-08-05,76,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Ralph, good morning. It's David. So, as we think about 2022, clearly, early to give you a detailed guidance, but let me try to walk through the moving parts as we think about 2022. Underlying our outlook will be strong base earnings growth, contributions from ongoing capital deployment, and the recovery of some of the headwind that Brian articulated. There'll be an offset to that. Partially offsetting that will be, the lack of some of the non-run-ratable items we're realizing in our 2021, at least $20.20 EPS outlook. So when you take it all together, we expect 2022 will be another strong year for us.",0.2005441,0.361
CI-2021-Q2-2021-08-05,77,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","As relates to growth rates, the way I ask you to think about that is, first off, I take at least $20.20. When we adjust that for the non-renewable items, we would expect to grow at the high-end of our 10% to 13% range. Another way of thinking about it, if you take at least $20.20 outlook for 2020, we would expect to grow at least 10% on that. So, a net new item, that was the non-run-ratable items that we'll have in 2022, but an attractive growth rate on either parameter, as we expect to have another strong year for 2022.",0.9280995,0.791
CI-2021-Q2-2021-08-05,79,Question,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Yes. Thank you. I was hoping you could maybe just talk a little bit about the individual business, which has been volatile for some companies and the extent to which you saw that and how much that may or may not be contributing to headwinds you are seeing?",0.2180334,0.823
CI-2021-Q2-2021-08-05,80,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Matthew, good morning. It's David. From the individual business portfolio, as you know, we've been active in that marketplace since its inception. And after a few years of test and learn and the marketplace stabilizing itself, we sought and began to more systematically expand our growth and that carries into the current year.",0.4978624,0.527
CI-2021-Q2-2021-08-05,81,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","As relates to the performance in the current year, we have some attractive growth in that business, both underlying fundamental growth, as well as growth contribution from the SEP period. And as it relates to the core of your question on performance, I'd asked you to think about the underlying -- what we're seeing the underlying performance of that book of business is similar to the trends and impact that Brian articulated before. So, we see an uptick in utilization within that book of business, more approximating from a non-COVID standpoint, baseline activity with some additional utilization on the COVID side of the equation. And lastly, our early look at the SEP, special enrollment period, additional lives, those lives are performing similar to other special enrollment period lives we've observed before. So, some of the MLR that we're seeing across our broader portfolio is showing through in the individual business, but not up proportion in either way from the overall behavior of that book.",0.686747,0.361
CI-2021-Q2-2021-08-05,86,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"Good morning, Justin. This is Brian. I'll start and then David to pile on here. So, on the first part of your question there, if I misspoke, I apologize. For the second quarter our non-COVID utilization or commercial was essentially at baseline, that plus the direct COVID-19 related costs we incurred put the total cost picture above baseline, but the non-COVID utilization was at baseline. For the back half of the year within our commercial business, we're expecting that non-COVID utilization will continue to run at baseline and we will incur direct COVID-19 related costs, but at a lower level than what we saw in the first half of the year. So, hopefully that clarifies a bit the commentary around commercial and the assumptions on the back half.",0.3253189,0.077
CI-2021-Q2-2021-08-05,87,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Relative to the non-recurring items that you asked about, you can think about those as largely being SG&A oriented, with the bulk of it being associated with litigation from prior years where we had some favorable developments in the quarter, that allowed us to recognize some gains there. So, boxing that just directionally, you should think of it as about $150 million after tax. So think of it in the range of $0.45, $0.50 earnings per share in terms of the favorable benefit that we've seen here in 2021.",0.5270113,0.744
CI-2021-Q2-2021-08-05,89,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Sure. So, Justin, crosswalk again. First from prior dialogue, as you recall, we would have talked about base earnings, capital deployment, and a recovery of COVID headwind as contributor to our 2022 expectations for ourselves. And that remains, the base performance, the capital deployment and recovery of COVID headwind. As Brian articulated with the COVID headwind, that opportunity is a little greater now for 2022 than it was a quarter of ago from that perspective. The net new item is what Brian walked through, which are the non-reoccurring items. And he gave you approximate order of magnitude.",0.3175282,0.552
CI-2021-Q2-2021-08-05,90,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So, again, to repeat to the specific part of your question, we believe today, if you take the at least $20.20 that we will deliver for this year, our growth rate will be at least 10%. We believe if you take the -- at least $20.20 and adjusted for those non-reoccurring items, that we referenced -- that Brian just referenced, the growth rate will approximate 13% or so. So, those are the moving parts relative to our expectations for 2022 on either convention another year for strong, attractive balance performance.",0.6770307,-0.55
CI-2021-Q2-2021-08-05,92,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","No. It includes, Justin, the dollar. So, let's come back -- and previously we would have talked about baseline earnings, capital deployment and the recovery of the headwind. That's what took us to the high-end of the range versus within the range. It currently -- the expectation includes that, but the dollar is somewhat offset by the lack of the non-run-ratable items next year. So, on an all-in basis, we'll grow in the 10% to 13% range, depending on the convention you use, either the $20.20, we will grow at least 10% all-in, or if you look at it, excluding the non-recurring items, that Brian just articulated, about $0.50 we will grow at about 13% all-in.",1.3365721,0.941
CI-2021-Q2-2021-08-05,94,Question,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Great. Thanks very much and good morning. David, I'm just wondered if I can ask about the PBM, was really strong in the quarter. First, can you talk about the 2022 selling season and how that plays into the outlook that that you're talking about right now?",0.2922658,0.869
CI-2021-Q2-2021-08-05,95,Question,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And then secondly, can you tell us that the number of vaccines that are included in that, that script count, just want to get a better idea of what you're seeing on overall script count, including vaccines?",0.5946366,0.982
CI-2021-Q2-2021-08-05,96,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, Lisa. I'll talk about the growth outlook in the environment and then I'll ask Brian to come back in and talk about the script count, specifically the vaccine. First, we're very pleased with the performance of the Evernorth portfolio. The durable nature of that and an environment of disruption provides some diversification within the portfolio and the service delivery for our clients, health plan clients, corporate clients, government clients remains quite strong.",0.9032258,0.0
CI-2021-Q2-2021-08-05,97,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to the underlying growth rate, our growth in 2021 outstanding for that portfolio and we'll continue to see expected growth for 2022. As we discussed previously, we've known for some time that we have lack of renewal of two health plan clients. So, we knew that, and even with that, we will grow again in 2022 at an attractive rate. We also recognize that given our strong performance, we've been able to maintain appropriate pricing discipline, as we looked at the 2022 environment. So, take it as a whole, an active dynamic year for 2022. We'd expect another strong year of retention, even acknowledging those health plan clients in the mid-90s. And we would expect strong underlying growth of the Evernorth portfolio.",0.6750874,0.535
CI-2021-Q2-2021-08-05,98,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Brian, I'll ask you to talk about the vaccine volumes within our scripts for the quarter.",0.0928877,0.818
CI-2021-Q2-2021-08-05,99,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"Sure. Morning, Lisa. So, in the second quarter, we fulfilled 9 million of vaccine related scripts. So, out of the 410 million adjusted scripts that we fulfilled in the quarter, about 9 million of those were associated with a vaccine, obviously that's not something to run rate, given we would not expect that level to persist for the balance of the year, but 2%, 3% of the total script volume.",0.2306183,0.361
CI-2021-Q2-2021-08-05,102,Question,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks. Good morning, everybody. So, I guess, just back on the medical cost for a moment, just curious if you have any additional color on the medical costs ran versus baseline by cost category, for example, inpatient, outpatient, pharmacy, et cetera. And some MCO have called up, behavioral health and also diagnostic and lab work as cost categories that are trending above baseline. I'm curious if you're seeing those same trends as well. Thanks.",1.4613292,0.0
CI-2021-Q2-2021-08-05,103,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning. It's David. Let me provide a little overview and I'll ask Brian to provide some specifics of what we're seeing in terms of some of the specific categories of utilization. You did call out an important category we've unequivocally seen, and I noted in my prepared comments, the mental health or behavioral and substance abuse category is growing. We see more individuals needing and utilizing those services, and appropriately needing and utilizing those services given the environment and our portfolio is really well-positioned to provide that level of support necessary. And we believe that it's not only appropriate required. It will provide some intermediate and long-term benefit to those individuals, obviously to clients, as well as to ourselves on a sustainable basis.",0.3241353,0.0
CI-2021-Q2-2021-08-05,104,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Beyond that, we've seen an uptick in -- from prior levels and uptick in both inpatient and outpatient surgeries in the non-COVID category. And as Brian articulated, that categories more broadly approximated baseline levels, and we've assumed that we'll remain at that for the second half of the year.",0.6369996,0.966
CI-2021-Q2-2021-08-05,105,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director",I'll ask Brian to give you a little bit more color in terms of some of the insights we're seeing in terms of the more detailed utilization patterns.,0.5592693,0.842
CI-2021-Q2-2021-08-05,106,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"Yeah. Sure, David and good morning, Steve. So, just to reiterate David's point, surgeries in particular were a hotspot for us, both in terms of inpatient, outpatient activity in the quarter. We also saw overall outpatient and professional utilization pick up pretty meaningfully in the quarter. Emergency room utilization, radiology remained below baseline in the quarter and kind of within these different categories, there was also some state of service shift, which is a good thing over time. We saw inpatient shift outpatient, particularly for some lower acuity procedures. And we saw some of the emergency room utilization shift, urgent care centers and physician offices, which we view as a good thing from the standpoint of optimizing, like to care.",0.2134446,0.8
CI-2021-Q2-2021-08-05,107,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"On your point about behavioral health, a metric that I'll share with you just relative to prior to the pandemic. Within our U.S. Commercial book, in 2019 about 8% of our customers were utilizing behavioral health services. And as you know, we have an industry-leading capability in this space. This year, that number is going to be up almost 40%. So, we're going to have nearly 11% of our customers this year, utilizing behavioral health services, which we think is a good thing for the long-term. It's putting a little bit of pressure on the P&L this year, but we believe it's a good thing for the long-term, and our recent acquisition of MDLIVE offers us the opportunity to further synergize that given the demand for virtual behavioral health has grown meaningfully over the course of the pandemic.",4.4774289,0.361
CI-2021-Q2-2021-08-05,110,Question,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hi. Thanks. Good morning. I'm interested if you can just break down the 20% of the COVID headwind that's from the lower customer volumes, maybe a little more insight into that in terms of some of the key customer segments for you in terms of where you're seeing more of that drag.",0.9673533,0.166
CI-2021-Q2-2021-08-05,111,Question,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And then, also just want to -- just confirm on the $4 billion revenue raised. If you can also just break that down by segments. It feels like Evernorth is probably the bulk of that growth, but just want to confirm that in terms of the segment, the breakdown of the $4 billion of revenue heads. Thanks.",1.9102215,0.0
CI-2021-Q2-2021-08-05,112,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, Scott. It's David. Let me speak to the headwind and I'll Brian speak to the revenue raise. If I understand your question correctly, you're coming out the portion of the headwind that is non-MCR related. And broadly, we see the impact of the pandemic on employment levels within the commercial population broadly. We had previously called that out as a headwind. We previously called that as a headwind that we believed would return as a favorable tailwind over time. We're taking the posture right now that given the current employment environment, that headwind will more likely persist or set otherwise that's the baseline with which to grow off of. We'll continue to grow no doubt, but that's the baseline to grow off of as we observed the marketplace and the overall employment levels beginning to move forward, but more slowly than anticipated in a variety of sectors.",1.0003887,0.0
CI-2021-Q2-2021-08-05,113,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So, view it as disenrollment and/or aggregate employment levels, and the requisite level of changing those employment levels, having and flowing at a slower rate, given the prolonged pandemic.",0.7858531,0.927
CI-2021-Q2-2021-08-05,115,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"Sure. Morning, Scott. So, relative to the revenue outlook, obviously we're very pleased with the aggregate growth for the company this year. Of the $4 billion, you should think of the lion's share of that being driven by Evernorth. So think of it as roughly 75-25 with the other segments and in totality Evernorth is on track for a year where both revenue and earnings will grow above well -- above our long-term average annual expectation 4% to 6%. So, we're really pleased with the performance of that business.",0.9568204,0.911
CI-2021-Q2-2021-08-05,118,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Good morning, Kevin. It's Brian. So, appreciate the question. If you think about how the second quarter unfolded, I think this is instructive for how we think about the back half of the year and into 2022. So, April, we saw the highest level of COVID costs. As I said earlier, those tracked downward pretty meaningfully in May, in June and the total cost of care when you combine the COVID and non-COVID costs together in the months of May and June is more in line with what we're expecting for the back half of 2021 and as we step into 2022. So, for those reasons, based on the more emergent data, we feel better about the next 18 months as compared to the first four months of the year where we had particularly elevated costs in our book.",0.4687136,0.742
CI-2021-Q2-2021-08-05,120,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Yeah. Good morning, Kevin. The only item I would add is, as we think about our book of business, approximately two-thirds of our risk business is yet to be priced for 2022. So, as you know, it's not all -- that portfolio of our business is not all one, one or front end loaded from that standpoint. So, we have the opportunity be appropriately responsive as the marketplace changes, but the underlying assumptions that Brian articulated in the medical cost pattern are the most important part of it.",0.3431792,-0.511
CI-2021-Q2-2021-08-05,121,Question,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","But I guess you're saying that you got back to normal faster in Q2 than your original guidance, assumed you would get back to normal sort of price. So, again, that feels to be like the trajectory is higher. Why would it get higher and then level off, I guess, in the back half of the year?",0.889623,-0.392
CI-2021-Q2-2021-08-05,122,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Sure. The underlying question comes back to, as Brian broke up -- broke out the portions of it. We essentially are looking at an environment in the second half of the year where the medical cost environment will be slightly above baseline. And the pieces of that are that the non-COVID or the -- call, traditional parts of medical costs approximately baseline in the commercial portfolio and above and beyond that there's some additional load for COVID.",1.2071512,0.586
CI-2021-Q2-2021-08-05,123,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So, one would have to believe that either A, the non-COVID costs are going to run above baseline for some reason that they haven't to date when we look at the way we built up the policy for baseline and/or that the additional COVID costs that we're saying are additive to that, will be materially greater, right? So, we acknowledge it's the fluid environment beyond a shadow of a doubt, but we believe that the estimate we've made for the step-up in aggregate for the rest of the year to run slightly above baseline, is an appropriate assessment based upon the pattern we saw in the end of the first quarter and the way in which the second quarter was evolved and developed and as I noted that we have about two-thirds of the risk business yet to be priced for 2022.",0.3276331,0.361
CI-2021-Q2-2021-08-05,127,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"Good morning, Josh. This is Brian. So, a few different components there, the question. Big picture compared to our expectations, I would encourage you to think about the three books of business, meaning the commercial risk, the individual exchange, and the Medicare Advantage, as all being approximately off by the same amount compared to our expectations in terms of total claim costs.",1.4779195,0.881
CI-2021-Q2-2021-08-05,128,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"So, I'd start there in terms of, we are not seeing one being really disproportionately impacted relative to our prior expectations. They're all off by, call it, that 200 basis points or so that changed in our MCR guide. The Medicare Advantage business though in 2021 is further weighed down by the risk adjustment revenue headwinds. So, you should view the margins on the Medicare Advantage business as being particularly low relative to what our long-term expectations are. And as we step into 2022, we would expect margin expansion on each of those books of business off of what we're experiencing here in 2021.",0.4793916,0.361
CI-2021-Q2-2021-08-05,129,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"As it relates to the risk adjuster headwind, that's a component of the $2 per share headwind. We haven't specifically sized that. It's certainly a less than half of that. I would note, we recently received our mid-year settlement from CMS, which was favorable to our expectations, which gives us a further confidence in our ability to fully recover that headwind in 2022.",1.4906771,0.843
CI-2021-Q2-2021-08-05,132,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"Sure. Good morning. Our longer term targets are consistent, and we remain committed to them. And to remind everybody, it's our attractive revenue growth rate of 6% to 8%, our EPS growth rate of 10% to 13% with the dividend above and beyond that. And our outlook of operating cash flow generation from current year to 2025 of approximately $50 billion. Those numbers are on average over a prolonged period of time. And as we've identified at Investor Day as well, as you look back over the last decade, we have a track record of delivering against those targets and objectives.",1.1148184,0.985
CI-2021-Q2-2021-08-05,134,Question,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Yeah. Good morning, guys. I have a question on strategic capital deployment. And if you could just talk through a little bit of long-term, like five years out or so, what do you think is the mix of businesses you're expecting thinking of kind of employer managed care, government managed care, PBM and other services? And as you're out looking at things and contemplating that, what's the landscape like as far as attractiveness of opportunities, just availability of targets and the like. And within that value-based care, home care, Medicaid, are there any new views on categories that you'd be interested in?",0.0909444,0.967
CI-2021-Q2-2021-08-05,135,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Lance, good morning. It's David. Appreciate the forward-looking orientation relative to that. To answer your question, we got a ground back into our portfolio. The three platforms we have, which we feel very positively about, the services based platform within Evernorth, the U.S. Medical platform, both Commercial and Government, and then our International platform. We see attractive growth opportunities organically and inorganically in all three as we look to the future. Specifically, you start -- your real thoughtful question in terms of kind of apportionment five years out. We don't have a rigid target five years out that we want X percent in category A or Y percent in category Z. But however, we do see an environment where the services portion of our portfolio will continue to grow at an accelerated rate.",0.8041197,0.994
CI-2021-Q2-2021-08-05,136,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","We see the right to win, the ability to create value and our strategic position there for the multiple client segments we're able to serve there as being quite attractive, and you should expect this to continue to grow our pharmacy, our care, our benefits and our intelligence capability to be able to bring to bear against that.",0.0594637,0.361
CI-2021-Q2-2021-08-05,137,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Secondly, we've continued to call out U.S. Government as an attractive growth segment and that will transpire both organically and inorganically, as opportunities present themselves. And thirdly, we continue to see targeted opportunities in our International portfolio as attractive growth opportunities. On a final note, you articulated examples of home care, otherwise, et cetera, I won't call out any one precise example. But I'll step back and remind you, as we've talked about it, we see what we call alternative sites of care. So, virtual -- longitudinal virtual, polychronic, home care, coordinated home care as attractive additional growth opportunities within our service portfolio, and we continue to extend ourselves and expand ourselves within that space. So, multiple strategic alternatives. Second, strong platforms to build off of. Third, the capital flexibility to be able to grow in multiple attractive markets that you appropriately called out. Thanks.",0.2677808,0.751
CI-2021-Q2-2021-08-05,141,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"Good morning, Ricky. It's Brian. I'll take the acuity portion of the question and David to tackle the government component. So, big picture, we're not yet seeing signs of any meaningfully higher acuity amongst our customer base. Part of that due to the focus we've had on preventive care, as you indicated in your question, as well as appropriate behavioral health utilization as we talked about earlier. There are a variety of metrics that we use to track this.",0.1947988,0.077
CI-2021-Q2-2021-08-05,142,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And just one really specific one I'll give you, we track within our commercial book of business when we have new cancer diagnosis, how many of them are at a metastatic stage when they're first diagnosed. And so, prior to the pandemic, if you look at the top five cancer types, we saw 38% to 39% of these in a metastatic stage when they presented to us. In 2021, we're in that same range, 38% to 39%. So, that's an indicator that we track one of many that suggests we do not yet have those signs of acuity spikes. And as I said earlier, we're also seeing a site of service shifts in the book of business, which is a mitigant over time to the potential for a QE coming back into the book.",1.1068791,0.962
CI-2021-Q2-2021-08-05,144,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Sure, Ricky. Good morning. The short answer is we see expansion opportunities in both the U.S. Medical side of the equation, as well as in the Evernorth services side. So, more specifically, within the U.S. Medical portfolio organically, we see and are continuing to deliver and pursue additional growth opportunities for both our Medicare Advantage portfolio in existing geographies as well as, as we've discussed before, our continued expansion of those geographies and leveraging our broader product portfolio and platform, as well as in our exchange portfolio as we continue to expand our individual exchange portfolio, which we view as more government business versus not.",0.397979,0.361
CI-2021-Q2-2021-08-05,145,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","On the services side, you referenced pharmacy unequivocally, but expanded beyond pharmacy to care and benefit management services, as well as intelligent services. For example, as we look to continue to serve our expanding portfolio of health plan clients, they have diverse portfolios that they serve, commercial obviously, Medicare, Medicaid, exchange and otherwise. That's an important part of our growth chassis as we go forward with dedicated resources. And then ultimately, direct to government contractor relationships as well. So, we see attractive growth opportunities in the government space, both off of the health plan side of the business in the Cigna medical portfolio, as well as in the services side of the business through Evernorth.",0.762534,0.361
CI-2021-Q2-2021-08-05,148,Question,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hey, I'm going to ask about a happy topic, because you guys have been beaten up this morning, and I want you to end on a happy note. The -- if we go back particular time period, 12, 18, 24 months, obviously, the PBM side of Evernorth has done a lot better than I think anybody expected. Can you kind of point to the top one, two or three reasons why that is?",0.0163234,0.94
CI-2021-Q2-2021-08-05,149,Question,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And then secondly, if we think about the profit model of the PBM, how has that shifted away from kind of adjudication straight dollars and toward things like mail order and kind of backward fees into pharma that presumably might be a bit more sticky than some of the ways of making money? Thanks.",0.5658764,0.827
CI-2021-Q2-2021-08-05,150,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Sure. Good morning, John. It's David. I'll start relative to your question. And I appreciate the tone, but candidly, I don't feel beaten up. These are dynamic and challenging times. And we're proud of the fact that our portfolio, our diverse portfolio can perform in this environment and importantly, deliver for our clients, our customers and patients, while we deliver our responsibilities from a shareholder perspective. But I appreciate the tone of your question.",1.0174893,0.918
CI-2021-Q2-2021-08-05,151,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Now, specifically, as you go back in time, when we brought this portfolio together in terms of the companies, we viewed obviously that we had an opportunity to bring in a leading PBM portfolio of services, but it was broader than that. Secondly, we viewed, as we talk about now, that pharmacological innovation was a big part of the future of healthcare. And the acceleration of innovation is what we're seeing today through a whole variety of things, gene therapy, specialty, medications evolving, biosimilars, et cetera.",0.890789,0.836
CI-2021-Q2-2021-08-05,152,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And hence, if you're going to be helping individuals with their overall healthcare needs, being a leader in pharmacy services is mission-critical. We also saw the opportunity to expand that portfolio through a broader services platform, which we did through Evernorth, and then continue to feed that broader services platform for health plan clients, for corporate clients, for our government clients, et cetera. And as we've noted -- both Brian and I have noted, we're very pleased with the performance within the portfolio and the service we're delivering. And importantly, we continue to invest in that portfolio at an accelerating rate relative to expanding products, services, capabilities, as well as our reach.",0.7108434,0.318
CI-2021-Q2-2021-08-05,153,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Now as it relates to the profit model, the primary mechanisms would articulate for you to think about is back to the time you referenced, we acknowledge that the financing models were going to change, and we didn't resist that. We offer choice. We offer choice in terms of how purchasers or clients want to finance their offering. And we've evolved, for example, with a higher percentage of pass-through arrangements for clients in the PBM services from well less than 50% to 50% to well greater than 50% over three cycles. And we've been able to evolve our service based capabilities and our value creation capabilities for the benefit of clients. Secondly, we continue to press for more aligned relationships with pharmaceutical manufacturers on the clinical outcomes, not just the consumptions. We know that broadly in the industry is value based programs, but think about them as aligned programs.",0.7924602,0.963
CI-2021-Q2-2021-08-05,154,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And then lastly, as the biosimilars start to evolve at a more rapid rate, the positioning of our company to have the clinical depth, the coordination of clinical services, the manufacturer relationships and importantly, the medical physician relationships are mission-critical. And as I use the Remicade example, all those come to bear, because it's a patient-by-patient decision made with a practicing physician relative to the choices and alternatives.",1.3365721,0.44
CI-2021-Q2-2021-08-05,155,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","So, again, I appreciate your question. We're pleased with the performance, but maybe even more importantly than that underlying your question, we're delighted with the strategic position that the platform gives us right now to continue to drive growth and create value going forward.",0.3925379,0.361
CI-2021-Q2-2021-08-05,158,Question,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Hi. Good morning. Thanks for taking my question. So, David, if I go back to your growth construct and think about a $20.20 minus the one-timers and grow that by 13%, it would seem that the dollar recovery for next year represents maybe 40% of that growth next year. Can you talk about the factors that you see at this point that would be limiting on your core business apart from the dollar. So, it looks like that would be mid to high single digit growth including capital deployment. And so, that would obviously be below your trend line. What are the factors limiting the core business apart from the dollar? Thank you.",0.0753984,0.859
CI-2021-Q2-2021-08-05,159,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Dave, good morning. So, again, it's early for the detailed 2022 guidance, but taking the spirit of your question, it ultimately is going to come down to two things. Rate and pace of evolution of the cost environment -- medical cost environment, and rate and pace of our investment portfolio decisions within the organization positioning us for the future. We have a track record of sustained investment in the organization for long-term growth. We have -- as Brian articulated earlier, we have multiple growth and profit levers, and we'll seek to make trade-offs within that and ensure that we seek to deliver an attractive, sustainable result. So, I think those are the two major points I'd ask you to think about.",0.585309,0.707
CI-2021-Q2-2021-08-05,160,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","I talked about the growth rate in framework of at least. So, we weren't providing guidance to pencil a number rather how we're thinking about the growth platforms and trajectory. And there's nothing in our underlying business portfolio today. I'll leave you with, there's nothing in our underlying business portfolio today that suggests that the organic underlying growth of our earnings will be demonstrably different unless we determine we're going to make a trade-off in terms of rate and pace of investment within the portfolio or there's an exogenous impact for the industry on the cost side of the equation. We're just trying to frame the at least growth rates off of what we know now mid-year.",0.5697629,0.361
CI-2021-Q2-2021-08-05,165,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"Good morning, Steve. It's Brian. So, I would encourage you to think of the year in two halves, one half and two half. So, the first half, we ran at 83.6% MCR, and we're modeling the back half to perform at approximately that same level if you use the mid-point of our guidance. So, rather than looking at quarter-by-quarter, because there's quite a bit of variability that's transpired in the different months.",0.3851816,-0.527
CI-2021-Q2-2021-08-05,166,Answer,2021-08-05,2,2021,Brian C. Evanko,CFO,"But big picture, the first half of the year, we ran a few points above baseline in total when you combine the effect of COVID and non-COVID utilization together. For the back half of the year, we're projecting to run slightly above the baseline in totality and that's comprised of non-COVID utilization running approximately at baseline, plus COVID utilization on top of that.",0.3851816,0.361
CI-2021-Q2-2021-08-05,167,Answer,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","To your question on how does that pattern relative to what we saw in the first half? You should think of the direct COVID-19 related costs as being the highest in the first quarter, lower in the second quarter and we're modeling slightly lower than that for the back half of the year on direct COVID-19 related costs. So, those pieces get you to that overall expectation of slightly above baseline for the back half of the year, and that essentially offsets the seasonality we would typically see in the MCR pattern for our book of business.",1.1422464,0.964
CI-2021-Q2-2021-08-05,169,Closing,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","Sure. I'll be brief. I want to thank everybody for joining our call. And I just want to reinforce two points. First, I'm appreciative and proud of our more than 70,000 coworkers and their dedication to working to change our customers' lives for the better every day. They continue to rise to the challenges in the moment by helping our clients, our customers, our patients, working with our partners and in our communities to drive positive change.",0.1542946,0.66
CI-2021-Q2-2021-08-05,170,Closing,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","And second, we continue to demonstrate the resiliency of our business and our well-positioned three portfolios, and the strength of our strategic framework, given our results and our outlook.",1.0645161,0.077
CI-2021-Q2-2021-08-05,171,Closing,2021-08-05,2,2021,David Michael Cordani,"President, Chief Executive Officer & Director","With that, I ask you to have a good day, and we look forward to our future conversations. Thank you.",0.2483482,
CI-2020-Q2-2020-07-30,9,Remarks,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks, Will, and good morning, everyone. Thank you for joining our call today. The current environment that we all live in and work in is more dynamic, more unsettled, and more complex than any time in recent history, and Cigna's mission to improve the health, wellbeing, and peace of mind of those we serve has never been more important, and it continues to guide the actions as we move forward. In recent weeks and months, we have taken decisive steps to support employers who are the driving force of a thriving economy to withstand and emerge from the COVID-19 pandemic, and to support our communities, customers, and patients, including our efforts to combat systemic racism, which we view as a critical health issue as a well.",0.5592693,0.911
CI-2020-Q2-2020-07-30,10,Remarks,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Today, I'll offer several recent examples of how we continue to differentiate ourselves in the marketplace and with our key stakeholders by delivering on our promises and working to make healthcare more affordable, predictable, and simple by creating innovative solutions to solve for healthcare's most complex challenges and by partnering with our clients, some of whom are viewed as competitors, but who we see as strategic partners capable of extending our reach to making even greater impact for customers around the globe. We view all of this with the goal of maintaining and improving the health and vibrancy of our clients, communities, and customers. I will also give you an update on our financial results that we delivered for the quarter, and how these results provide a further testament to the strength of our businesses and the value we create for our customers and clients, as well as a few comments on our growth path forward, and then, I will conclude with a brief update on our outlook before turning the call over to Eric.",0.4135251,0.985
CI-2020-Q2-2020-07-30,11,Remarks,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Cigna's longstanding commitment to our clients, communities, and customers is fundamental to who we are as a global health service company, and it has been critical in shaping our ongoing response to COVID-19 crisis. This response begins with our more than 70,000 colleagues around the globe, who worked tirelessly and with great empathy throughout this pandemic. They wake up each and every day with the sole focus to serve the needs of our customers, patients, and clients around the globe, and I am proud to be teamed up with such a talented group of co-workers, and I thank them for what they do to positively impact millions of lives each and every day.",0.3913719,0.912
CI-2020-Q2-2020-07-30,12,Remarks,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Nowhere is their commitment more evident than in their deep support of our employer clients; large, small, public, private. These businesses have always been critical to a robust economy, and today more than ever companies will play an essential role in serving individuals, reenergizing their communities and returning economies around the world to economic vibrancy. From the outset of the COVID-19 crisis, Cigna's leverage of breadth of solution, strength of our team, and a consultative approach in our broad data and analytical capabilities to support our employer clients and their employees in numerous ways from taking rapid and decisive steps to eliminate cost as a barrier to testing and treatment, to expanding to access to care, to helping them safely work to return their employees to worksites, most recently, for example, with the launch of our COVID-19 high risk dashboard.",0.7761368,0.95
CI-2020-Q2-2020-07-30,13,Remarks,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","This new suite of innovative analytical tools combines the power of data, predictive models, and clinical expertise to help clients project how COVID-19 might impact the health and safety of their employee populations, and to model forward impacts of different pandemic scenarios going forward. For example, the dashboard compiles and analyzes COVID-19 case data on the health of that client-specific employees at national, state, and county levels, giving them essential insights to guide their decision-making for bringing employees back to work safely. In cases, where employers see concerning trends in the reports, Cigna is prepared to help them take action. For instance, through routes like COVID-19 testing and triage services delivered from on our Cigna onsite health solutions.",0.8764089,0.963
CI-2020-Q2-2020-07-30,14,Remarks,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Our COVID-19 high risk taskforce represents just one powerful example of how Cigna is helping employers navigate the complexities of the pandemic, and serves as a reinforcement of why employers rank Cigna highest amongst its competitors for driving healthcare quality and value as reported in a recent study conducted by The Leapfrog Group, an independent national organization representing employers.",2.1916051,0.649
CI-2020-Q2-2020-07-30,15,Remarks,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Turning to our support of communities where we live, work, and play each and every day, our commitment is reflected in our efforts to increase understanding of the impacts of, and to drive positive changes to combat systemic racism, and only is systemic racism an issue of human rights, we also view it as a critical health issue, contributing to well-documented disparities in health treatment and outcomes that disproportionately impact communities of color. Two weeks ago, we launched our new five-year initiative, our building equity and equality program, which commits a mix of local community grants, scholarship funds, and employee volunteer hours to continue to drive Cigna's efforts to eliminate racism, bias, and health and economic disparities for people of color. This new initiative is another important part of Cigna's ongoing commitment to partner with our communities and government leaders to effect positive sustainable change, and we will continue to expand and evolve our engagement programs going forward.",1.0839487,0.84
CI-2020-Q2-2020-07-30,16,Remarks,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","All of Cigna's efforts to partner with our clients and communities is ultimately rooted in our mission to improve the health wellbeing and peace of mind of those we serve, specifically focused on customers and patients. Today, more than ever, they are looking for us to make healthcare more affordable, predictable and simple. We continue to introduce new innovative programs and solutions designed to deliver on this promise. For example, our Customer Protection Program, which safeguards our customers from unexpected costs from COVID-19 through surprise or balance bills from out-of-network providers.",0.8258842,0.957
CI-2020-Q2-2020-07-30,17,Remarks,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","In addition, our pharmacy solutions leverage existing and newly-created tools to put resources and medicines and treatments in the hands of those who need the most. For example, we help Americans who lose their prescription coverage from recent job loss to secure their medications at affordable predictable prices through our Express Scripts Parachute Pharmacy Program. Further, as demonstrated by our most recent drug term report, we also delivered affordability and predictability to our health service customers and clients, who in 2019, experienced an overall rate of increase of drug spending of just 2.3%, a result that is in line with the Consumer Price Index, and important to note, more than one-third of our commercial plans experienced a decrease in overall spending in 2019. Taken altogether these examples I've shared with you today are reflective of how Cigna is and will continue to deliver on our promises, create innovative solutions, and partner effectively to further reach and drive impact.",0.4088613,0.949
CI-2020-Q2-2020-07-30,18,Remarks,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Now turning briefly to our results, we once again delivered strong financial performance in this quarter, and we remain on track to complete our integration and reach our deleveraging objectives by year-end. Our consolidated revenue is $39.2 billion, and after tax earnings of $2.2 billion reflect continued strong execution of our strategy and the fundamental strength of our four well-positioned diversified growth platforms. In particular, the continued strong performance of our Health Service segment demonstrates the range of services and value we provide to diverse health plan, employer, federal and state government clients.",0.4298484,0.953
CI-2020-Q2-2020-07-30,19,Remarks,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Our Integrated Medical segment results reflect lower consumption of medical services, as individuals have deferred some services during the COVID-19 pandemic. Additionally, integrated medical customers continue to track much better than the national unemployment figures, as many employers have maintained benefits through this disruptive time, and importantly, because our client mix is less weighted to industries that have been most impacted by COVID-19. As our employer clients have continued to support their employees' health and wellness needs, we've provided hundreds of millions of dollars in assistance to our employer clients, both through direct financial support and by leveraging our flexibility of our full suite of funding alternatives, all of which are already reflected in our second quarter results. I would also note that our self-funded medical clients have directly benefited from well in excess of $2 billion of reduced spending this year. Overall, I'm pleased that by maintaining the strength and health of our franchise, we've effectively balanced and responded to the needs of our stakeholders in this challenging environment.",0.7450447,0.968
CI-2020-Q2-2020-07-30,20,Remarks,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Now, to bring my comments to a close, the current environment we live in and work in is highly dynamic, unsettled and complex, and as I noted, more than any time in recent history. Cigna's strong second quarter results reflected continued strong execution of our strategy and the underlying strength of our four well-positioned diverse growth platforms. We have confidence that we will continue to effectively support our clients, communities, customers and patients, all while working to deliver on our EPS and revenue outlook for 2020, as well as our 2021 EPS target of $20 to $21 per share. This is driven by our sustained culture of innovation in our organization, the value we deliver to the marketplace each and every day, and aided by the financial strength and flexibility of our franchise.",0.6750874,0.987
CI-2020-Q2-2020-07-30,22,Remarks,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Thanks, David, and good morning, everyone. First, we've recognized that the current environment is even more dynamic, disrupted and complex than usual as we navigate the ongoing COVID-19 pandemic, and I'm proud of the many ways that Cigna has responded as we drive to be the champions for affordable, predictable, and simple health care. Today, I will review key aspects of Cigna's second quarter results, including the impact of COVID-19 on our business and discuss our outlook for the full-year.",1.2364355,0.955
CI-2020-Q2-2020-07-30,23,Remarks,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Regarding our second quarter consolidated results a few key financial highlights include adjusted revenue of $39.2 billion, adjusted earnings of $2.2 billion after tax, adjusted earnings per share of $5.81, and continued strong operating cash flow of $3.3 billion. Within the second quarter, we continue to execute on the fundamentals of our businesses as we deliver value for customers and clients.",0.6802012,0.785
CI-2020-Q2-2020-07-30,24,Remarks,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Regarding our segments, I'll first comment on health services. Second quarter adjusted revenues grew 22% to $29 billion, and adjusted pre-tax earnings grew 7% to $1.2 billion. These results were driven by growth and customer event script volumes, favorable impacts from supply chain initiatives, strong specialty performance as our leading Accredo's specialty pharmacies proactively work with patients with complex and chronic conditions to maintain continuity of care for their medications, partly offset by an increase in operating expenses to support growth. We fulfilled $364 million adjusted pharmacy scripts in the second quarter of 2020, an increase of 24% over a second quarter 2019, driven by the in-sourcing of integrated medical script volumes and strong organic growth, partially offset by somewhat lower retail network scripts related to acute needs due to the COVID-19 pandemic. Overall, health services delivered another strong quarter as we continue to deliver value for our customers and clients.",0.744161,0.986
CI-2020-Q2-2020-07-30,25,Remarks,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our Integrated Medical Segment, second quarter adjusted revenues were $9 billion and adjusted pre-tax earnings were $1.5 billion. In the quarter, we experienced significantly lower utilization of medical services in both commercial and government as individual deferred care due to the pandemic. By month compared to baseline expectations, utilization was 30% to 35% lower in April, 20% to 25% lower in May, and closer to normal in June at approximately 0% to 5% lower. We also experienced strong customer retention as our clients' maintained coverage for furloughed employees and our commercial book of business less weighted to the most economically impacted industries.",0.5289256,-0.077
CI-2020-Q2-2020-07-30,26,Remarks,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"In response to the pandemic and the tremendous burden is placing on those reserve, we are financially supporting our customers and clients. There are a series of actions including early on waiving all cost sharing for COVID-19 testing and treatment and for Medicare Advantage and individual and family plans additionally, waiving cost sharing for in office and telehealth visits for primary care, specialty care, and behavioral health.",0.8124326,0.919
CI-2020-Q2-2020-07-30,27,Remarks,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Additionally, we've provided premium relief programs for clients and financial assistance programs to support providers. All in our results for the quarter include approximately $270 million of charges related to these initiatives. It's also important to note that we serve 85% of Cigna's U.S. commercial customers through self-funded arrangements. And as such, our medical cost performance is highly aligned with our clients, who have seen savings well in excess of $2 billion year-to-date related to deferred medical costs.",1.9859863,0.765
CI-2020-Q2-2020-07-30,28,Remarks,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our international markets business, second quarter adjusted revenues were $1.4 billion and adjusted pre-tax earnings were $319 million, reflecting deferred medical utilization primarily in our global health benefits business. Claims volumes as well as sales activities increased throughout the quarter as global economies reopened. For our Group Disability and Other Operations segment, second quarter adjusted revenues were $1.3 billion. Second quarter adjusted pre-tax earnings for the segment were $132 million, reflecting elevated life claims primarily due to the pandemic partially offset by favorable performance and disability. Overall, our businesses remained focused and delivered strong performance in the second quarter as we work to rapidly innovate to serve our customers and patients in this disruptive environment.",0.5530004,0.937
CI-2020-Q2-2020-07-30,29,Remarks,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now, looking forward to our outlook for the full-year, we continue to focus on driving strong performance across our businesses to continue to be able to improve the health wellbeing, and peace of mind of those we serve. Aided by our strong and diverse portfolio of businesses, we continue to expect full-year 2020 consolidated adjusted revenues in the range of $154 billion to $156 billion, and we continue to expect to deliver full-year adjusted earnings per share in the range of $18 to $18.60. As we look to the balance of the year, we expect medical utilization to increase. We expect additional COVID-19 treatment costs, and we expect lower enrollment as well as continued lower net investment income, due to recessionary pressures.",0.4006468,0.917
CI-2020-Q2-2020-07-30,30,Remarks,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Inside in our guidance, we considered a range of scenarios regarding the rate and pace of the return of medical utilization, as well as the rate and pace of the reopening of the U.S. and global economies and subsequent impact on employment and customer levels. Our ability to deliver in a range of scenarios, underscores the strength and diversity of our portfolio of businesses, which continue to deliver solutions directly aligned with marketplace needs. We will continue to dynamically manage our businesses, ensuring that we are delivering on the fundamentals and meeting our customer's needs, while also continuing to provide financial support to our customers and clients in a thoughtful and deliberate manner. Taken as a whole, we continue to expect full-year consolidated adjusted earnings per share in the range of $18 to $18.60.",0.3409989,0.955
CI-2020-Q2-2020-07-30,31,Remarks,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I would remind you that our financial outlook excludes the impact of future share repurchases and assumes a full-year of contributions from a group disability and life business, although, we continue to expect our divestiture of that business to close in the third quarter. Overall, these expected results are driven by strong underlying fundamentals and disciplined expense management and deployment of capital.",4.2278117,0.671
CI-2020-Q2-2020-07-30,32,Remarks,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now, moving to our 2020 capital and liquidity position and outlook, our capital efficient businesses, generate a substantial amount of cash flow, which provides us with significant capital and financial flexibility. In the second quarter, we generated $3.3 billion of cash flows from operations, due to strong fundamental as well as the timing impact of approximately $900 million of delayed tax payments permitted under the CARES Act. Through the end of second quarter, we also deployed $1.1 billion to debt repayment. And on a year-to-date basis, we have repurchased $8.3 million shares of stock for $1.5 billion. For 2020, we continue to expect greater than $7.5 billion of cash flow from operations, reflecting the strong capital efficiency of our well performing businesses. And as of June 30th, we had $1.7 billion of cash available at the parent.",0.3345311,0.972
CI-2020-Q2-2020-07-30,33,Remarks,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Finally, we remain on track to close the sale of our group disability and life business in the third quarter, generating $5.3 billion in net proceeds, which we expect to deploy the share repurchase and debt repayment in 2020. Our debt-to-capitalization ratio was 43.5% as of June 30th, an improvement of 170 basis points from December 31st of 2019, and we remain on track to return on debt-to-capitalization ratio to the upper 30s by the end of 2020. Our balance sheet and cash flow outlook remains strong benefiting from our highly efficient service-based orientation that drives strategic flexibility, strong margins and returns on capital.",0.3963349,0.93
CI-2020-Q2-2020-07-30,34,Remarks,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now to recap, through the exceptionally dynamic and disruptive environment associated with COVID-19, Cigna has remained intensely focused on delivering affordability, predictability, and simplicity for the benefit of our customers, patients, and all of our stakeholders. We're fully committed to helping create vibrant, diverse, high performing communities, whether through partnerships with our employer, health plan or government clients with our provider partners, or with our customers directly. We've delivered strong fundamental performance this year. We'll also see lower medical costs from deferred care, and we continue to provide financial support to our clients and customers. We expect our strong fundamentals across our diverse portfolio of growth businesses to enable us to manage through the various impacts of the current environment, and as such, we continue to expect 2020 full-year adjusted EPS of $18, $18.60 per share, and remain on track to deliver on our target of $20 to $21 of adjusted earnings per share in 2021.",1.1519943,0.985
CI-2020-Q2-2020-07-30,37,Question,2020-07-30,2,2020,Ralph Giacobbe,Credit Suisse,"Thanks. Thanks, good morning. I guess can you just give us a sense of your conversations with existing employer customers an appetite, if any, for sort of revisiting funding scenarios? I think in the past, you've talked about shared return models, any of that resonating, and then ASR enrollment was down slightly, but you had a more pronounced decline in fees, can you just help reconcile that, and if that's at all related to some of those changing in those funding scenarios would be helpful?",0.5870827,0.858
CI-2020-Q2-2020-07-30,38,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Ralph, good morning. It's David. I'll take the first part, and I will ask Eric to take the second part of your question. At a macro level, yes to what you stated at the first part of your question. So, a lot of dynamic interaction back and forth with employer clients is a regular part of our business, even more elevated in the current environment, a lot of proactive engagement in the change relative to maximizing value for them through using our broad array of alternative funding mechanisms, and even the intra-year conversation, given the uniqueness how this year is playing out bringing more choice to clients. So, yes, continuation of we see it as a strength and continue to see movement in the use of funding mechanisms to best align ourselves with employers, and that plays to a strength of our company.",0.6059075,0.985
CI-2020-Q2-2020-07-30,40,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes, Ralph. It's Eric. I would note two items as it relates to the fee dynamics; first and most significantly, we had a reclassification of certain revenues that we implemented actually back at the beginning of the year, so effective January 1st. That did not have an impact on the P&L, but it reduced revenues and has an exact offset in lower SG&A as well. So, that's showing up in the comparison of this year versus last year, and second, as you know, we did see some declines in self-funded enrollment, but just think that is consistent with the impact of COVID-19 and the economic environment overall.",0.7660798,0.578
CI-2020-Q2-2020-07-30,44,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes, Matt. It's Eric. I will give you a couple of perspectives here. As I noted in my prepared remarks, and we saw the decline of 30% to 35% back in April, and utilization is uptick since then. You've called out geography, and that's a really important dimension here is looking at this play out market-by-market and having the local perspective is important, and we're certainly seeing this play out different rates and phases in different geographies. As I noted also in the prepared remarks, we saw June at much closer to normal level of utilization. I'd say our early indicators for July are pretty consistent with June. So, still some impacts moving through different geographies, but at this point, we'd say July looks an awful lot like June.",0.6737334,0.825
CI-2020-Q2-2020-07-30,46,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I wouldn't call anything out on that yet, Matt. I think again, our outlook for the full-year does assume some additional utilization coming in the back-half of the year, but I think it'd be too early to say that we've seen anything like that within the second quarter.",1.1394179,0.502
CI-2020-Q2-2020-07-30,49,Question,2020-07-30,2,2020,Justin Lake,,"Thanks. Good morning. I wanted to focus on the PBM here. Specifically, two things; one, your first-half growth has been significantly ahead of at least the initial guidance for the full-year. So, by my math, it implies, you know, about 3% growth in the back-half versus about 8% growth in the first-half. So I'm just curious, I know you haven't updated in the guide, so do you expect this first-half performance to be indicative of the full-year, or not with the kind of swing factors first-half to the second-half? And then also your scripts are running kind of better than I think a lot of people would have expected, given the slowdown in scripts in the second quarter overall, so can you give us some color there, and maybe any color on kind of mail order mix in the second quarter and the kind of profitability drivers there? Thanks.",0.5194508,0.968
CI-2020-Q2-2020-07-30,50,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Hi, Justin. It's Eric. Good morning. So, on the first part of your question for the health services and kind of the pattern of the earning, we just step back, the normal pattern for this business is for income to grow throughout the year, as you know, just reflects the overall utilization patterns, and our efforts to manage the supply chain, and we think that will continue to play out throughout the course of 2020. Now I'll remind you, in 2019, the pattern was a little bit extra weighted towards the back-half of the year just given the timing of the supply chain initiatives. So, when you are comparing 2020 to 2019, you'll see that the impact of that kind of play out to the year. We think of 2020 as being more of a normal pattern this year. We think of 2019 was a little bit backend weighted. So, that'd be the biggest dynamic I'd call out as it relates to the pattern.",0.4028027,0.852
CI-2020-Q2-2020-07-30,51,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now, as it relates to the script volumes, overall, we're executing very well and very much in line with the pattern that we had expected to play itself out. As I noted back at our call a quarter-ago, we did see, or we estimated to be about five million scripts get refilled a little earlier that moved from the second quarter into the first quarter, and since that played out, and additionally we've seen nice utilization within our home delivery pharmacy. There's a lot of benefits to the mail order pharmacy and such for our customers and clients. We've seen that adoption continue to be good, but again, nothing else I'd call out in terms of major dynamics.",0.5530004,0.855
CI-2020-Q2-2020-07-30,54,Question,2020-07-30,2,2020,Kevin Fischbeck,Bank of America / Merrill Lynch,"Great, thanks. I want to ask about the commercial membership trends, I guess that you're thinking about for the back-half of the year, I appreciate that, you mentioned that furloughs has impacted as well as your customer exposure, but just maybe if you go down to both of those a little bit, have you had any conversations with clients about membership at risk from furloughs just to sign kind of size, what that might mean in the back-half of the year, and then the comment about being less exposed to the markets most impacted by COVID, are you seeing a differential in trend, or are you seeing those customers in the segments you expect to be impacted seeing larger declines in enrollment already versus the other sectors? So, any color there?",0.7810585,0.579
CI-2020-Q2-2020-07-30,55,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Kevin, good morning. It's David. So, let me try to paint the 2020 picture, and then maybe even bleed in a little bit of comments in terms of how we expect to unfold beyond that going into 2021. So, first and foremost, a significant amount of interaction with clients, always part of our consultative approach, elevated even further in the current environment and the dynamism. So, we're looking at this as best we can through a client-by-client framework. As we noted previously, a high percentage of clients have maintained benefits either through the use of the word that we talk about is furloughs or layoffs with benefit continuity taking place, and I think that's a testament to how committed employers are to the health safety and wellbeing of their employees, and the optimism they continue to hold on to return employees back to work to keep their businesses running on a go-forward basis.",0.8876798,0.974
CI-2020-Q2-2020-07-30,56,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to the second-half of the year, we expect the following: we expect to see those employees who are furloughed, or with continuity of benefits, we expect to see those furloughs dissipate or go away, and one or two things transpire either (a), no benefits for the employee and they transition to [indiscernible] or other alternatives, or (b), they return to full employment, and client-by-client, we're going through patterning of what the expectations are relative to that. Therefore, we expect to see the effect of lower levels of employment across our book continue throughout the second-half of the year, and that's fully factored into the outlook that Eric made reference to. And then finally, maybe at the most macro level, the way we're thinking about it is essentially over the next 18 months, second-half of '20 and 2021, we expect to see a slow recovery to the overall employment marketplace in the United States, and that's what's factored into our thinking, said otherwise, we expect to see pressure of through the second-half of this year and 2021 to what would otherwise be a normal course of business from a membership standpoint, and that's factored into our thinking for 2020 as well as 2021.",0.415857,0.542
CI-2020-Q2-2020-07-30,58,Question,2020-07-30,2,2020,Kevin Fischbeck,Bank of America / Merrill Lynch,"Do you have any color about the impact on the members, who are [indiscernible] impacted by COVID versus those [infected] that you don't see disrupted, any difference in trend there?",1.1083565,0.0
CI-2020-Q2-2020-07-30,59,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Kevin, stay on the line. Are you asking the question of medical trend or employment dynamic?",0.0843373,0.0
CI-2020-Q2-2020-07-30,60,Question,2020-07-30,2,2020,Kevin Fischbeck,Bank of America / Merrill Lynch,"Sorry. It's the employment dynamic. Second part of my question was, you know, are you seeing a differential in employment -- or job losses or in markets where you said that you have low exposure to those segments that are impacted by COVID, so just wanted to see if you are seeing any differential in the employment trends.",0.9807799,-0.361
CI-2020-Q2-2020-07-30,61,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","The answer to that is absolutely yes. So, as we parse our business by sector, and then employer-by-employer, there is no doubt, there are some employers that are having either de minimis impact to their employee base as a result of COVID, or there are some factors that you're seeing actually the need for more employees, given the environment. So there is no doubt that the phenomenon we're talking about is incredibly uneven or unique not just to sector, but to employers within the sector. That's why our approach is a client-by-client approach, so yes to that portion, unequivocally high variability there.",0.7388263,0.315
CI-2020-Q2-2020-07-30,65,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Ricky, good morning. So, appreciate you referencing the prepared remarks. My remarks said, of what some view is traditional competitors, we view as strategic partners. So stepping back, our philosophy has been we seek to be the undisputed partner of choice. And our view is that the ability to partner with others and work to create shared value presents an opportunity for mutual growth, which means more customers to serve in a larger impact.",0.7065682,0.961
CI-2020-Q2-2020-07-30,66,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","So, now stepping back, whether that's through an expanding portfolio of health plan clients through a health service portfolio, where we challenge ourselves to continue to bring additional innovations for the benefit of our health plan clients to help them deliver better affordability, better value and continue to grow or specifically to come to your question with Oscar. We have an exciting partnership with Oscar where we're bringing mutual capabilities to the table to bring some additional innovation to the small employer market, a marketplace that both organizations feel has been underserved as relates to benefiting from more innovative programs around health engagement, personalization, value based care, more comprehensive clinical engagement programs, and together we're going to be able to bring the best of both companies together. And at the later part of this year, we'll be opening up some additional markets where we're already quoting today, jointly, so the philosophy of the corporation is defined mutually aligned organizations where we could create leverage value together, and then pursue that and Oscar is a wonderful example of it. And actually, we had to check in with the team earlier this week, Eric and the team is working exceptionally well to get around the innovation here.",0.6012437,0.994
CI-2020-Q2-2020-07-30,68,Question,2020-07-30,2,2020,Frank Morgan,RBC Capital Markets,"Yes, just one question around the difference. Could you distinguish any difference in what you saw regarding deferrals into commercial versus the Medicare book? Thanks.",0.9427973,0.681
CI-2020-Q2-2020-07-30,69,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Frank, this is Eric. With a pattern was with similar in terms of how we progress through time, we would note we saw more of a deferral percentage in the commercial book than what we saw in the Medicare Advantage book, but again, kind of the progression month-to-month has been pretty consistent, just more significant impact in the commercial business.",0.7502695,0.853
CI-2020-Q2-2020-07-30,73,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Whit, it's David, can you repeat the first part of your question because Eric, and I didn't hear a couple of your words and we want to make sure we understand the query.",0.0808395,0.382
CI-2020-Q2-2020-07-30,75,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Great, I will ask Eric to take the first part of the question and I'll come back and take the second part of your question on Medicaid.",0.9479207,0.625
CI-2020-Q2-2020-07-30,76,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Good morning, Whit. On the leakage, as you termed it, maybe step back the -- I think the way I think about that is we have a kind of spectrum across our different customer segments. So within our Select segment, offering, really think about all of our Select segments as having a comprehensive bundle of our services, so pharmacy, behavioral, disease, and care management et cetera, all tied together with stop loss and administration or in our fully insured product, but to that point, think about the Select segment as being effectively 100% penetrated with our pharmacy offering, as you move into the middle market segment, reasonably high degree of penetration there, but you see more buyers that have smaller cart offerings are purchasing and such we've provided some statistics on this at the past and some of our past Investor Day materials, but think about, you know, a meaningful portion but not all of the middle market is having purchased an integrated offering, which then flows to the PBM, and then that same dynamic holds through in the national segment, it's even more  la carte, if you will, in terms of the pieces that are, but the I think about it more along the segment lines than I would around just kind of the funding on it is true that the insured business also carries a high degree of penetration, but I encourage you to think about it by segment",0.5249731,0.967
CI-2020-Q2-2020-07-30,77,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And Whit relative to Medicaid, we currently serve very attractive portfolio of Medicaid relationships through a health service portfolio. As a result of our diversion, high performing health plan, portfolio businesses, we see that as growing. We've grown that successfully. Notwithstanding the COVID pandemic ramifications and looking forward, we see that as a continued growing base of an opportunity for us to expand into servicing the Medicaid population, but servicing them through the health service platform.",0.8771862,0.754
CI-2020-Q2-2020-07-30,81,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes, Gary, this is Eric. So we'll take that one on a couple of different dimensions we've talked about there. First of all, stepping back, we expect a loss ratio to be somewhat elevated in the back-half of the year. Think about that as 150 to 200 basis points increase over what we previously would have expected for the second-half of the year. Not dimensioned that off a couple of things. One, we do think that there will be some deferred care utilization and the potential for higher acuity coming back in, and then, two, the ongoing effect of the programs we put in place to reduce co-payments or make care more accessible and affordable within quality drive of some additional utilization. I don't have a precise kind of identification of each of those components, but think about those as the biggest drivers for our outlets over the course of the back-half of the year. On the minimum MLR, as you know it's a three-year calculation for the minimum MLRs for the commercial business. So again, we generally speaking, do have a margin between where we are at and the minimum. Now I would know that we increased our accrual in the second quarter by $95 million, and we've got $175 million on the balance sheet for this as a provision at this point, and so it's something we watch, but would still know that there's across the board. Still a margin there before we did not see any of the impact kind of flows through the bottom-line.",0.7743442,0.681
CI-2020-Q2-2020-07-30,85,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Josh, good morning. It's David. I'd identify two; one in terms of access, two, in terms of programmatic. As it relates to access, it's indisputable that the COVID pandemic has either required caused or pushed more utilization of technology as a mechanism to access care coordinate care et cetera. You recall that our view has been for some time that we believe a meaningful amount of care can be delivered through a combination of technology, you can call it tele, you call it virtual et cetera, but it needs to be highly coordinated care, and then, further augmented by in-home care that is also aided by technology. So one, we believe that the rate and pace of adoption and acceleration of reformatting care access, utilizing technology to coordinate care and deliver care in a personalized high-quality basis. And then augmenting it with re-envisioning what could take place in the home is mission critical and accelerated by COVID, that's on strategy for us, and we are aggressively investing in and innovating in those categories off of a variety of platforms.",0.7559269,0.976
CI-2020-Q2-2020-07-30,86,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Secondly, a lot of what we talked about before. It's a little back to the future, but COVID re-highlights for all societies around the globe that as challenging as COVID is, it's exponentially more challenging for individuals who have chronic conditions or who are polychronic, so it presents another opportunity to engage with employers, with health policymakers and from a public health policy standpoint to make sure we're investing in and innovating programs with physicians and individuals to lower health risks or increase health quality for those who are chronic or polychronic because all things remaining equal, if you have a better health status, you're more likely to withstand COVID or the next generation, a decade from now and beyond, and that's an area where Cigna excels on our current state of basis in terms of what we're able to bring to bear from that standpoint, as well as with the health service portfolio, and then, putting up over that of COVID-19 highlights the mental health dimension that is, highlighted in societies around the globe, where the mental health and the physical health needs to come together to best manage overall wellbeing. So, reformatting, utilizing technology, chronic condition management and improving overall health risk and then taking mental health and the physical health together are all areas we see as being accelerated because of COVID and additional opportunities and areas that Cigna is heavily investing in.",0.5281772,0.987
CI-2020-Q2-2020-07-30,90,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Lance, good morning. It's David. I'm going to ask Eric to comment on the portion of your question specifically because of the uniqueness of the group sale, and then, I'll come back and talk about M&A priorities more broadly.",2.3082005,0.44
CI-2020-Q2-2020-07-30,91,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes, Lance, good morning. So just on the group sales specifically, so first of all, we do expect that transaction to close within the third quarter reminder, we expect $5.3 billion of after-tax proceeds once that transaction closes, so that is coming in, in the relatively near-term. As we've talked about for some time now, we've had a goal of and are committed to obtaining a debt or achieving a debt-to-capital ratio of under 40% by the end of the year. We're driving towards that, and we've committed to deploying a significant amount of the proceeds from the group transaction to share repurchase to offset the dilution, the effect of the not having the group insurance business for a portion of the year. So again, at the most macro level, those are the pieces we're navigating. We do continue to fund significant organic growth; we continue to have capital investments to advance our capabilities, but definitely, we see share repurchase as a really excellent use of capital to drive shareholder value in the near-term, and the last thing I note is just add our recent board meeting, our board increased the share repurchase authorization consistent with our expectation of closing the New York Life transaction later this quarter. And as we sit here today, we have $4.4 billion of share repurchase authority outstanding.",0.796263,0.988
CI-2020-Q2-2020-07-30,92,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","And Lance relative to the portfolio of businesses today and going forward. First to be clear, we like our portfolio in the strategic positioning and are pleased with its performance from a growth standpoint, from a service standpoint and from a capital and fiscal flexibility standpoint that portfolio is positioned to deliver sustained 6% to 8% revenue growth. As it relates to M&A priorities, we continue to remain focused on five specific M&A priorities; one, to further strategically and smartly over global footprint, second, to further enhance our U.S. seniors' capabilities, third, continue to broaden our digital and information capabilities, fourth, looking to continue to expand our care coordination capabilities, and five, as we've talked before, exploring state-based risk program capabilities as we see states who are under budgetary pressure for within their Medicaid programs, seek to further sub segment their programs and seek either high credit -- high cost complex critical programs to be able to perform on their behalf and deliver more value. So, we see opportunity going forward, but building off of a very strong base and low performing portfolio.",0.5207928,0.945
CI-2020-Q2-2020-07-30,96,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Hi, Sarah, it's Eric. Broadly, I wouldn't call out any change in terms of impact. Since again nothing that would rise to being inevitable. With respect to our reserving approaches and policies has been very consistent, because the same team and the same approach to working through those calculations for some time, it served us really pretty well so I wouldn't note anything unusual here.",0.9090909,0.839
CI-2020-Q2-2020-07-30,102,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","A.J., it's David. I'll take the selling season. I'll ask Eric to comment briefly on the year equivalent of its enrollment on the integrated medical what we're seeing on the health service portfolio. First broadly on the selling season, I appreciate you asked about multiple segments of business. Headline is well we're not guiding for 2021 yet, we will expect another year of attractive revenue growth for the franchise in 2021. For the health service portfolio that will be anchored in a third consecutive year of truly outstanding client retention, where our clients continue to reward us by staying with us and expanding the relationship because of the services we're delivering because of the continued innovation we're delivering, and because of the outstanding affordability or market trends we're delivering on their behalf.",1.5569374,0.979
CI-2020-Q2-2020-07-30,103,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Before I jump over to Integrated Medical comments on Medicare Advantage, we would expect another year of attractive customer growth within our Medicare Advantage portfolio, and I will remind you we set a strategic objective to grow Medicare Advantage customers 10% to 15%. We're tracking well to that objective in 2020. We would expect to know the year of contribution in 2021, and specific to the Integrated Medical, our visibility in 2021 is largely through the national accounts at this point in time, and to remind you we defined that as commercial employers with 5,000 or more employees. We're a multi-state, at this point in time, we expect to see that tracking to a bit higher retention rate than recent past. And while we have some new business wins, we expect the new business wins to be a little less than recent past taken as a whole, probably performing a little better as we step into 2021 off of that portfolio, and then the middle market or regional and select segments are currently in the throes of their growth trajectories as we look into 2021. Wrapping it up, we would expect again another year of very attractive and profitable revenue growth for 2021. Eric, maybe just a little color on the health services dynamic of the equivalent disenrollment?",0.923047,0.987
CI-2020-Q2-2020-07-30,104,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Thanks, David, and good morning, A.J. So, on the health services business, again within the segment, I think we've talked about in the past we've got a really diversified book of business here with customers through a variety of channels and players that are helped play on government relationships, some direct programs and the like, we've had a really strong degree of client retention and we've had a high degree of continuity in terms of enrollment within those clients as well. So note in my prepared remarks, we did have a bit of a dip of retail acute scripts, especially earlier in the quarter, but that'd be really the only thing I would call out is particularly impactful. Overall, the enrollment levels within our clients and within our health plan clients have held up quite nicely.",0.6410349,0.918
CI-2020-Q2-2020-07-30,107,Question,2020-07-30,2,2020,Stephen Tanal,Goldman Sachs,"Hey good morning, guys. Thanks for the question. Maybe just one really quick follow-up on strategic M&A, and then an actual question, so I just want to understand what would you say we should expect with respect to the size of any future deals you might choose to do, and your willingness to do another large deal just following up on that question earlier, and I also just wanted to get your latest thoughts, obviously in the executive order last Friday order HHS to put out the rebate rule again, but it was conditioned on being able to demonstrate no increase in premium or really any kind of cost any payers, which looks pretty unlikely given the CBO scoring the first time around, but just given the prospect, I guess it'd be helpful if you could just remind us how to think about that rule and its potential effect on the economics of the PBM business and Medicare? That'd be helpful. Thank you.",1.9560669,0.974
CI-2020-Q2-2020-07-30,108,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Sure, good morning. It's David. I'll take both questions. On the first question as I noted before, we're really pleased with the configuration of our business portfolio today and its performance. I'm not going to comment on size of assets. We've been quite disciplined over a long period of time relative to strategic alignment and financial alignment relative to assets we would pursue. And it would be inappropriate to say that there's an asset of the certain type or size from that standpoint that we would limit ourselves to. Specific to the executive order, stepping back; first, at the more macro level, we share the administration's objectives to further improve affordability of prescription drugs. There's no doubt about that and concrete examples, including we were the first to step into the need to reformat the diabetes and insulin environment with a patient insurance program that caps cost at $25 for 30-day supply. It truly creates affordable, simple, predictable, or embark program that focuses on high cost specialty drugs, or recent launch of our Parachute program for workers who've been displaced. So we will continue to drive innovation, and our clients are benefiting from that relative to our market leading trends. Specific to the rebate rule, your overall framing I think is right. Specifically, we do believe the rebate rule, if implemented in its current configuration would have a material effect on Cigna. It focuses on the government programs and as you know as designed today, the government run programs required and are facilitated by full pass-through, fully transparent rebate economic to start with. They were designed in the pricing scheme as indicated by government rules that we all comply with as an industry. The result of this rebate rule change is designed will result in increasing cost all seniors as an example, and thereby decreasing cost for some depending on their point-in-time drug utilization, and the rule is written today would create a conflict in terms of what would transpire around that, but from a Cigna perspective, we do not see that as having an impact on our book of business and overall performance even if the rebate rule was implemented.",0.7909056,0.878
CI-2020-Q2-2020-07-30,112,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes, Bob. It's Eric. Good morning. So with respect Prime, we announced the collaboration with Prime last December. We worked quite diligently over the end of the year and through the first quarter to get ready for that when we began servicing that collaboration on April 1st. It's really performed very well and very much consistent with our expectations both in terms of services provided, timing and the volumes and the like such to getting up to a great start. We are delighted to have the relationship there.",0.5289256,0.972
CI-2020-Q2-2020-07-30,113,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"In terms of specialty, I appreciate you calling out Accredo. Accredo continues to be industry leading capability here, and it does continue to drive growth as we see more and more specialty products and as more and more clinical needs the clients those we serve or both of those things drive an additional growth within Accredo. So again, continued strong growth there as well and that's a real bright spot even in the strong health services results.",0.5609055,0.967
CI-2020-Q2-2020-07-30,117,Answer,2020-07-30,2,2020,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Yes, Chuck, it's Eric. I will start here. With respect to international if you noted it was a strong result year-to-date. And the segment overall continues to perform really well. We've got as I think you know two platforms within the international business. A global health benefits platform that serves employers and a more individually oriented platform that serves both kind of health and supplemental needs and such. With the employer book of business, I would say globally the dynamics were pretty similar to the dynamics that we talked about in our Integrated Medical segment. So, we saw a deferral, less utilization earlier in the quarter. Some of that's come back over the balance of the quarter. We continue to expect to see a slower recovery in terms of employment levels and the like within this business, but I think of it is having a lot of parallels with the U.S. medical business. On individual business, I think here we saw disruption back in first quarter even in terms of both sales and in terms of claims experience and such. Really seen a lot of that come back in Asia, and our Asian market is already and very much kind of back to normal in a lot of our individually oriented businesses at this point. So again, looking forward from here, we would see a continued strong performance in a business, continued growth trajectory from a growth perspective.",0.9716134,0.961
CI-2020-Q2-2020-07-30,119,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Just add in the learning category, as we are learning in the United States, state-by-state, we are seeing around the globe the imperative of being flexible as the pandemic ebbs and flows from that standpoint from community standpoint from health access standpoint, from the academic standpoint, from the employer standpoint, and secondly, we have seen consistently around the globe a more aggressive adoption of as I referenced before technologically-enabled health access solutions, even in environments where they previously were at a really low adoption rate, less desire to go to physical proximity to access care, if it could be delivered through technology, and we see an elevation of that those services being utilized around the globe. We think that trend will continue.",0.8573649,0.773
CI-2020-Q2-2020-07-30,122,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","Thanks. Just briefly wrap up, I want to first and foremost again acknowledge and thank Cigna's more than 70,000 colleagues around the globe who worked tirelessly with great empathy throughout this pandemic to serve the needs of our customers, our patients, work within our communities, and support our clients around the world. At Cigna, our mission to improve health wellbeing and peace of mind of those we serve has never been more important, and that continues to guide our actions, and will as we go forward. In recent weeks and months, we've taken decisive actions to support our employers who we believe are the driving force to a thriving economy to withstand and emerge from the COVID-19 pandemic, as well as to support the communities and customers we work and serve in each and every day, including our efforts to combat systemic racism, which we also view as a critical health issue.",1.060241,0.949
CI-2020-Q2-2020-07-30,123,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","From a results perspective, we once again delivered strong financial performance this quarter, and we remain on track to complete our integration and reach our de-leveraging objectives by the end of this year. We continue to expand and innovative programs and services to support our clients, our customers, our patients, and our communities, and we are on track to deliver our revenue and EPS outlook for 2020, as well as our 2021 EPS target of $20 to $21 per share.",0.8904003,0.927
CI-2020-Q2-2020-07-30,124,Answer,2020-07-30,2,2020,David Michael Cordani,"President, Chief Executive Officer & Director","With that, I thank you for joining our call today, and we look forward to future discussions.",0.1403031,0.361
CI-2019-Q1-2019-05-02,11,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Today, I'm going to highlight Cigna's strong financial results in our first quarter as a combined company with Express Scripts driven by growth, innovation and focused execution across our businesses. I'll then address how Cigna is creating differentiated value in an ever changing landscape as we remain on the path to deliver attractive growth in 2019 and beyond. I'll also update you on how our team is advancing our integration priorities before turning the call over to Eric for a more detailed overview of our financial results.",0.0606296,0.967
CI-2019-Q1-2019-05-02,12,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","I'll begin with our strong first quarter performance which included exceptional service delivery to our customer's, patients and clients, strong retention levels, expansion and deepening of our customer, patient and client relationships, and innovation and growth across our portfolio of businesses.",1.3758259,0.896
CI-2019-Q1-2019-05-02,13,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director",I'll provide just a few examples of our momentum. In Health Services we added $1.7 million new pharmacy customers since the start of the year. We drove 9% organic medical customer growth in the select segment year-over-year reflecting the value of the differentiated fully integrated solutions we bring to that marketplace.,0.2996502,0.717
CI-2019-Q1-2019-05-02,14,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Within our integrated medical business, we further deepened our customer relationships by adding approximately 800,000 behavioral and approximately 600,000 in dental. In addition, Cigna continues to deliver outstanding medical and pharmacy cost trend across our commercial, government and health service businesses.",0.143801,0.612
CI-2019-Q1-2019-05-02,15,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director",This momentum has helped to fuel a great start to 2019. Cigna's consolidated adjusted revenue was $33.4 billion and we grew after tax earnings by 48% to $1.5 billion.,1.5149631,0.625
CI-2019-Q1-2019-05-02,16,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Within our business segments, Integrated Medical delivered a 13% increase in revenue with very strong earnings growth of 16%, and Health Services delivered significant growth in both revenue and earnings.",1.9961135,0.909
CI-2019-Q1-2019-05-02,17,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Our other business segments also made solid contributions, as we generated very strong cash flows in the first quarter, while deploying significant capital to both debt repayment and share repurchase. Collectively, our first quarter results demonstrate Cigna's strong performance and momentum and give us confidence we will achieve our increased outlook for revenue, earnings and EPS in 2019.",0.0419743,0.929
CI-2019-Q1-2019-05-02,18,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Looking beyond our strong first quarter results, we recognize that our company operates in a dynamic environment and that customers and patients need even greater value from the health care system. As more stakeholders seek to improve sustainability, we continue engaging with our regulatory client provider and community partners.",0.2141469,0.954
CI-2019-Q1-2019-05-02,19,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Our goal in doing this is to better identify and implement proven solutions that improve affordability, choice and predictability, all while accelerating innovation. This path to sustainability is strengthened by our combination with Express Scripts leveraging our broad services, depth of informatics and healthcare partnerships all to accelerate innovation and the value for those we serve.",0.329965,0.942
CI-2019-Q1-2019-05-02,20,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Let me provide two recent examples of how Cigna has already leveraged our combination to deliver additional innovations for our customers, patients and clients. The first relates to diabetes. Approximately 24 million Americans are diagnosed with diabetes and about 6 million of them are insulin dependent. To many of these individuals, who struggle to afford their insulin. In fact a recent yield study found that one in four insulin dependent individuals with diabetes cut back on their use of insulin because of cost. We view that as unacceptable and given the importance of the issue, it was when we decided to tackle immediately.",0.4337349,-0.599
CI-2019-Q1-2019-05-02,21,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","We launched our patient assurance program last month, which addresses the need for greater affordability and increases access to insulin for people diabetes. By ensuring our eligible customers pay no more than $25 for a 30 day supply of insulin. This is a major innovation for people with diabetes, some of whom have to pay hundreds of dollars they can't afford for the 30 day supply. Together, we harnessed our combined strength and accelerated the introduction of this new solution for our customers and patients. Our combination created the opportunity for us to deliver this solution to the marketplace faster than either Cigna or Express Scripts could have achieved independently.",0.2685581,0.949
CI-2019-Q1-2019-05-02,22,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","The second example of how we're innovating revolves around improving today's fragmented health care system, which is too frequently marked by episodic uncoordinated care. To help address this, Express Scripts recently launched Health Connect 360, an outcome based approach to delivering highly personalized clinical support for our clients and patients. The capability comprehensively connects health plans, providers, pharmacists and other clinical partners to ensure each person gets the clinical care support they need when and how they want it.",0.5196269,0.973
CI-2019-Q1-2019-05-02,23,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","With Health Connect 360, we're able to dramatically expand value based care programs as well benefiting customers, patients, clients and those health care professionals who are creating the most value today.",0.7042363,0.941
CI-2019-Q1-2019-05-02,24,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","The platform works by integrating otherwise unconnected data to our care insights hub which provides more comprehensive care programs that lead to better health and greater affordability for our patients and clients. The result is personalized and effective coordination without duplication or confusion. We've already rolled out Health Connect 360 in successful pilot programs covering approximately 500,000 customers and patients. We're receiving significant client interest for implementation later this year and into 2020.",1.178391,0.977
CI-2019-Q1-2019-05-02,25,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","These examples highlight how Cigna is using the full breadth of our capabilities to address the most pressing challenges in healthcare. Fueled by our clear strategic direction to maximize the value we create for our customers, patients and clients, our highly engaged 74000 co-workers, our four well positioned growth platforms, the breadth and depth of our actionable data and analytics which give us the tools to holistically understand and address our customer patient needs, and our strong cash flow which gives us meaningful financial flexibility and strategic optionality.",1.0520793,0.971
CI-2019-Q1-2019-05-02,26,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Relative to Express Scripts integration activities, we're making very good progress. Specifically we're executing well against each of our five integration priorities which include first and foremost, delivering on our commitments to provide outstanding service to our customers, patients and clients in 2019, and as we look to 2020.",0.0101049,0.917
CI-2019-Q1-2019-05-02,27,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","In the first quarter, our customer net promoter score across our commercial business saw significant improvement year-over-year. In our health service business specifically, we continue to earn the trust of our clients as validated by the outlook introduced this morning for 96% to 98% retention for 2020.",0.0695686,0.84
CI-2019-Q1-2019-05-02,28,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director",The second priority is maintaining high level of talent engagement retention. We are encouraged by our early progress with engagement retention levels which are above our already strong pre combination levels.,0.813836,0.947
CI-2019-Q1-2019-05-02,29,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Third is realizing shareholder synergies from administrative costs and other efficiencies. We are on track with our targets. Fourth, delivering medical and pharmacy cost savings. We are well into our program and we are on track to deliver meaningful savings. And fifth, is keeping our vision top of mind as we collaborate to drive accelerate innovation.",0.5413914,0.886
CI-2019-Q1-2019-05-02,30,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","All in, we are pleased with our progress to-date and we look forward to providing you with additional insights on our integration progress at our upcoming Investor Day.",0.6828605,0.818
CI-2019-Q1-2019-05-02,31,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Now to conclude, Cigna delivered strong first quarter financial results which reflect momentum across our businesses in our first full quarter as a combined company including continued customer, growth and deepening of relationships and health services, as well as integrated medical business and strong medical and pharmacy costs results.",2.3738826,0.883
CI-2019-Q1-2019-05-02,32,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","In the quarter we generated strong cash flows and deployed significant capital to both debt repayment and share repurchase. Our first quarter results reflect Cigna's strong performance momentum and give us confidence we will achieve our increased outlook for revenue, earnings an EPS in 2019.",0.0058298,0.91
CI-2019-Q1-2019-05-02,33,Remarks,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Looking ahead, I am very confident and excited about our path forward and we remain on track to achieve our 2021 EPS target of $20 to $21 per share.",0.3835989,0.81
CI-2019-Q1-2019-05-02,36,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"In my remarks today, I will review key aspects of Cigna's first quarter results and discuss our updated outlook for the full year. Key consolidated financial highlights for first quarter 2019 include adjusted revenues of $33.4 billion, earnings of $1.5 billion after tax, earnings per share of $3.90 and continued strong operating cash flow. These results reflect the underlying strength of our business and the value we deliver to our customers and clients.",0.4071146,0.878
CI-2019-Q1-2019-05-02,37,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Regarding our segments, I'll our first comment on health services. First quarter revenues were $22.5 billion and pre-tax earnings were $994 million. Results for first quarter reflect organic growth with the addition of 1.7 million pharmacy customers year-to-date and strong volumes with 292 million adjusted pharmacy scripts fulfilled in the quarter and strong performance in specialty pharmacy. Overall, health services delivered good results in the first quarter consistent with our expectations and reflecting continued focused execution and the first full quarter following our combination with Express Scripts.",2.1731944,0.948
CI-2019-Q1-2019-05-02,38,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our Integrated Medical segment, first quarter revenues grew 13% to $9.2 billion driven by customer growth and expansion of specialty relationships, premium growth reflecting underlying cost trends, and the inclusion of the Express Scripts Medicare Part D business.",0.3715415,0.637
CI-2019-Q1-2019-05-02,39,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We ended the first quarter with 17 million global medical customers driven by an organic increase of 224,000 lives quarter-over-quarter and 32,000 lives sequentially led by growth in our select and middle market segments. First quarter earnings grew 16% to $1.17 billion reflecting strong medical and specialty contributions and continued effective medical cost management.",0.3147682,0.883
CI-2019-Q1-2019-05-02,40,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our total medical care ratio or MCR, our first quarter MCR of 78.9% reflects continued strong medical cost performance in both our commercial and government businesses and the pricing effect of the suspension of the health insurance tax. First quarter 2019 Integrated Medical earnings benefited from $50 million dollars pre-tax of favorable nets prior year reserve development compared with $51 million pre-tax in the first quarter of 2018. Overall, Cigna's Integrated Medical segment had a very strong start to the year.",0.4125045,0.917
CI-2019-Q1-2019-05-02,41,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to our international markets business, revenues increased to $1.4 billion and first quarter earnings were $206 million reflecting business growth partially offset by unfavorable foreign currency movements and spending to strengthen our capabilities to further long term growth.",0.6381603,0.823
CI-2019-Q1-2019-05-02,42,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our group disability and other operations segment, first quarter revenues were $1.3 billion. First quarter earnings for this segment were $84 million with unfavorable disability claims partially offset by strong performance from our life business.",0.8235717,0.511
CI-2019-Q1-2019-05-02,43,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For our corporate segment, the first quarter 2019 loss was $490 million primarily driven by $449 million of interest costs. Overall, Cigna's quarter results reflect strong earnings, revenue and customer growth led by our Health Services and Integrated Medical businesses.",1.3862738,0.765
CI-2019-Q1-2019-05-02,44,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I will now discuss our outlook for 2019. As we've completed our first full quarter as a combined organization, we are proud of the focus and results we have delivered for our customers and clients. Looking ahead, we have considerable momentum as we continue to innovate to deliver affordability and predictability for our customers, and clients across our portfolio of businesses.",0.5077255,0.743
CI-2019-Q1-2019-05-02,45,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For full year 2019, we now expect consolidated adjusted revenues in the range of $132.5 to $134.5 billion. This represents an increase to our prior outlook of $1 billion reflecting growth in our customers in specialty pharmacy contributions.",0.1818182,0.599
CI-2019-Q1-2019-05-02,46,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,We now expect full year consolidated adjusted income from operations to be $6.24 billion to $6.4 billion or $16.25 to $16.65 per share. This represents an increase of $0.15 to $0.25 per share over our prior expectations and represents growth in the range of 14% to 17% over 2018.,1.5745598,0.807
CI-2019-Q1-2019-05-02,47,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Regarding the cadence of earnings per share this year, we now expect 45% to 46% of our earnings in the first half of the year. This now includes the $50 million of favorable prior year reserve development recognized in the first quarter which is not contemplated in our original outlook.",0.02659,0.765
CI-2019-Q1-2019-05-02,48,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"For 2019, we continue to project an expense ratio in the range of 10% to 10.5% which reflects ongoing efficiencies and administrative expense synergies in line with our previous estimate of $112 million pre-tax. I would also note that our full year expense ratio expectation contemplates a higher ratio over the balance of 2019 than the first quarter result due to the timing of planned spending. For 2019, we continue to project a consolidated adjusted tax rate in the range of 23.5% to 24.5%.",1.4067553,0.382
CI-2019-Q1-2019-05-02,49,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I'll now discuss our 2019 outlook for the health services and integrated medical segments. For health services business, we continue to expect full year pre-tax earnings in the range of $5.05 billion to $5.2 billion. We continue to expect adjusted pharmacy scripts in the range of 1.17 billion to 1.19 billion scripts. I would note that this range includes all script volumes associated with Cigna's May order and specialty pharmacy operations. In addition to scripts associated with the acquired Express Scripts business.",0.6762487,0.0
CI-2019-Q1-2019-05-02,50,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Our 2019 guidance range is consistent with Express Scripts previous expectation of 2% to 3% growth in core adjusted pharmacy scripts. Our guidance does not include Cigna pharmacy script volumes we expect to transition from OptumRx. And consistent with all of our key performance metrics for the segment, this guidance range does not include pharmacy script volumes associated with transitioning clients.",1.1879267,0.382
CI-2019-Q1-2019-05-02,51,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We now expect full year Integrated Medical earnings in the range of $3.7 billion to $3.8 billion. This outlook reflects strength and growth in our businesses driven by continued benefits from organic customer growth, deepening of customer relationships, and strong medical cost performance.",0.312253,0.923
CI-2019-Q1-2019-05-02,52,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Fee assumptions reflected in our Integrated Medical earnings outlook for 2019 include the following; regarding global medical customers, we continue to expect 2019 growth in the range of 300,000 to 400,000 customers.",0.6999641,0.382
CI-2019-Q1-2019-05-02,53,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Turning to medical costs, for our U.S. commercial employer book of business, we continue to expect full year 2019 medical cost trend to be in the range of 3.5% to 4.5%. And we continue to expect the 2019 medical care ratio to be in the range of 80.5% to 81.5%.",0.028746,0.494
CI-2019-Q1-2019-05-02,54,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"We also expect strong growth and contributions from our international markets, group disability and other businesses as they continue to deliver more personalized and affordable solutions for the benefit of those we serve.",0.5019763,0.863
CI-2019-Q1-2019-05-02,55,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"All in, for full year 2019, we now expect consolidated adjusted income from operations of $6.24 billion to $6.4 billion or $16.25 to $16.65 per share. This represents 14% to 17% growth over 2018.",0.3956162,0.586
CI-2019-Q1-2019-05-02,56,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I'd also remind you that our outlook continues to exclude the impact of future share repurchases and any additional prior year reserved development. Overall, our updated outlook reflects the strong fundamentals of our four differentiated growth platforms accelerated by our combination with Express Scripts.",0.5713259,0.735
CI-2019-Q1-2019-05-02,57,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Our 2019 outlook, is also consistent with our multi-year growth expectations and reinforces our confidence and our ability to achieve our 2021 earnings per share target of $20 to $21 per share.",0.2062522,0.891
CI-2019-Q1-2019-05-02,58,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,Now moving to our 2019 capital management position and outlook. Our subsidiaries remain well capitalized and we expect them to continue to drive exceptional free cash flow with strong returns and capital even as we continue reinvesting to support long-term growth and innovation.,1.7750629,0.939
CI-2019-Q1-2019-05-02,59,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"As previously communicated, our top capital deployment priority is accelerating debt repayment with the objective of returning our debt to capitalization ratio to the upper 30s by the end of 2020.",0.2256558,-0.494
CI-2019-Q1-2019-05-02,60,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Additionally, while we reduce leverage over the next two years, we expect to also have capacity for additional capital deployment. Our capital priorities are as follows; first, continuing to reinvest back into our businesses to drive further innovation and growth. Second, strategic M&A on a targeted basis. And third, returning capital to shareholders, primarily through share repurchase.",3.2928494,0.751
CI-2019-Q1-2019-05-02,61,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Consistent with these priorities in the first quarter, we deployed $1.9 billion to repay debt and we repurchased 2.5 million shares of stock for $462 million. Additionally in April of 2019, we repurchased approximately 600,000 for $94 million.",0.229249,-0.077
CI-2019-Q1-2019-05-02,62,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Our debt to capitalization ratio was 48.8% as of March 31, down from 50.9% as of December 31 of 2018. For 2019, we continue to project capital available for deployment of approximately $6.2 billion. In the year, we continue to expect to deploy approximately $4.2 billion to debt repayment and approximately $800 million to capital expenditures. Our balance sheet and free cash flow outlook remain strong benefiting from our highly efficient service based orientation drive strategic flexibility, strong margins and returns on capital.",1.3039885,0.886
CI-2019-Q1-2019-05-02,63,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Now to recap, our first quarter consolidated results reflect focused execution and strong delivery of results across our diversified portfolio of global businesses and give us momentum as we continue throughout the year. The fundamentals of our business are strong and sustainable and we are well-positioned to achieve the attractive financial targets we've established for 2019 to 2021. We are confident in our ability to achieve our full year 2019 earnings outlook and continue to have a good line of sight toward our $20 to $21 earnings per share target for 2021.",0.1031261,0.967
CI-2019-Q1-2019-05-02,64,Remarks,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,And with that we'll turn it over to the operator for the Q&A portion of the call.,0.4218469,0.0
CI-2019-Q1-2019-05-02,66,Question,2019-05-02,1,2019,Kevin Fischbeck,Bank of America / Merrill Lynch,"I just want to get a little bit more color on the drivers behind the guidance range. Because it looks like on the Healthcare Integrated Medical business, you've raised guidance essentially by the favorable development in the quarter. In fact 0 to 50 versus -- 0 to 40 versus, a 50 million favorite development number. Wasn't sure if there's anything else kind of going on underneath that number. And then for the full year though the EPS numbers raised by a little bit more than the favorable development. So just try to understand that -- that's a share repo or are there any other kind of moving parts underneath that?",0.0518106,0.944
CI-2019-Q1-2019-05-02,67,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"On the raise, I think you've got the headlines right there. Raising the Integrated Medical segment by essentially the amount of the prior year development that we have reported in the first quarter at the low end of our range. That translates through into the metrics for the enterprise.",0.4750269,-0.273
CI-2019-Q1-2019-05-02,68,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,Really no other pieces to call noticed earlier in the year but I feel good about our start to the year. In terms of the full year number then it just reflects the strength of the results as well as the updated share count.,0.5828243,0.923
CI-2019-Q1-2019-05-02,72,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Let me start with just framing how the transition is going and a little color on the marketplace. And then ask Eric to talk a little bit about the specific metrics in the earnings results et cetera. First at the macro level, we're really pleased with the performance. It's in line with our expectations and it's quite strong.",0.0722892,0.777
CI-2019-Q1-2019-05-02,73,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Secondly, as I noted in my prepared comments. We're well into our integration plan and the focus execution within the integration plan. The teams are working well together. Most importantly putting the customer client patience service relationships front and center and ensuring that, there's not only no disruption there's continued elevation in terms of just strong performance there from that standpoint.",0.1900505,0.934
CI-2019-Q1-2019-05-02,74,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And then we're quite proud of some of the already targeted innovations we've been able to bring to the marketplace. As relates to kind of hopping over the current results, I'll hand back to Eric in a moment.",0.4593859,0.765
CI-2019-Q1-2019-05-02,75,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","We're delighted with the be able to talk about another outstanding year of client retention, it's a combination of the commercial and health plan clients, obviously coming to bear with a 96% to 98% retention demonstrating the value proposition is resonating very well in terms of that strong service delivery outstanding clinical performance, medical cost, pharmacy cost performance from that standpoint and then within the background we're winning new business as well.",0.5312864,0.976
CI-2019-Q1-2019-05-02,76,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","We'll look forward to providing a more comprehensive update on the outlook for 2020 and beyond and Investor Day but retention is strong, new business results are strong, so we're pleased with the traction there. I'll ask Eric to talk a little bit about the puts and takes within the segment redefinition in the performance, but again, it's in line with our expectations we're delighted with that. Eric?",0.1053245,0.965
CI-2019-Q1-2019-05-02,77,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"The major headlines here, the resegmentation impacts we've had a couple of moving pieces when compared to prior Express Scripts dynamics. The headline overall is the result was consistent with our expectations.",0.3438735,0.273
CI-2019-Q1-2019-05-02,78,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"As you noted, the Part D business is now part of the Integrated Medical segment, the legacy Cigna home delivery operations are part of the Health Services segment as some of the primary moving pieces versus prior period.",0.096299,0.0
CI-2019-Q1-2019-05-02,79,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Additionally, there are minor items as we've just conformed different practices across the organizations and such but again the headlines would be the Health Services business performed right in line with our expectation. And I'd know it actually were particularly pleased with the strength in the Accredo and the specialty businesses overall.",1.2364355,0.862
CI-2019-Q1-2019-05-02,81,Question,2019-05-02,1,2019,Justin Lake,,"Just first, wanted to follow up on the A.J's question on the PBM. Can you give us a little more color on the resegmentation on the PBM side. I mean, its clear you had a great quarter on the - look the year-over-year growth on the integrated medical side was very strong but when I look at the PBM and all I can do is match it up to what Express Scripts did last year but it actually looks like it was probably down year-over-year when I add into Cigna mail order.",0.5858124,0.866
CI-2019-Q1-2019-05-02,82,Question,2019-05-02,1,2019,Justin Lake,,"So I am just wondering if you give us some more color to help us model this thing going forward in terms of what the moving parts are that might have transition back and forth between those two businesses or maybe stated another way, was there actually growth at Express Scripts you know the Health Services business year-over-year?",0.6026888,0.677
CI-2019-Q1-2019-05-02,83,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,We just had to drill on that a little bit further than. We talked about in my prior answer to A.J's question. The couple biggest items that move this part of resegmentation but it also note there's normal differences in terms of just timing of different generic launches and things along those lines in any one quarter on.,0.7445203,0.0
CI-2019-Q1-2019-05-02,84,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Two, from an accounting policies of perspective and such as we've looked at the EVI initiatives that Express Scripts had previously announced. A number of the costs that previously would have been below the line at Express Scripts things were including and just the ongoing operating expenses, so there's a little bit of a difference in terms of the expense level that we're driving through in the segment metric versus prior Express Scripts items.",0.3284226,0.077
CI-2019-Q1-2019-05-02,85,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"And there are other kind of minor items in terms of the timing of different expenses and things along those lines. So again, when you pull kind of all of those pieces out and look at the full year guidance, we continue to be on track for a nice growth for that business and again overall consistent with our expectations for the quarter as well.",0.0873158,0.758
CI-2019-Q1-2019-05-02,86,Question,2019-05-02,1,2019,Justin Lake,,"And then just a quick follow up on a membership line. Your membership was fairly flat year-over-year. I know you're still or I should say sequentially I know you are still expecting year-over-year growth. Can you give us a little color on where that growth is going to come from through the year and specifically on the stop loss side, it was the first quarter that you guys hadn't seen a double-digit stop loss premium growth in the -- my history of covering the company.",1.1089817,-0.052
CI-2019-Q1-2019-05-02,87,Question,2019-05-02,1,2019,Justin Lake,,"So I was curious just with everyone talking more about these product, these similar products in terms of stable premium whatever you want to call them. I'm curious if you're seeing the impact of competition there what you're seeing in the market. Thanks.",0.5283181,0.861
CI-2019-Q1-2019-05-02,88,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","First from a growth standpoint at a macro level, we're really pleased with the growth trajectory we have stepping into 2019 and our ability to increase our revenue outlook by $1 billion here in the first quarter.",0.6284493,0.9
CI-2019-Q1-2019-05-02,89,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Stepping back specific to the book of business performance and the core of your question, we elevated the focus on retention as a critical priority in 2018 as we look to 2019, noting the pendency of our combination and we're pleased with the exceptional retention performance we had across the totality of our business, the integrated medical as well as health services as previously discussed.",0.2044306,0.402
CI-2019-Q1-2019-05-02,90,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Secondly, further intensified the focus relative to deepening the relationships and I noted in my prepared remarks significant success there in terms of 800,000 additional behavior relationships, 600,000 additional dental relationships in addition to that 1.7 million additional pharmacy relationships.",0.1076564,0.751
CI-2019-Q1-2019-05-02,91,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","As we look to the remainder 2019, we expect to see strong retention continue, further deepening continue, as well as very importantly additional new medical integrated business, especially in the second half of the year as the underlying strong performance and power of the Select Segment in the middle market business perform throughout the course of the year. So taken as a whole, we're pleased with the start to the result, our intense focus on retention and deepening paid off and we see a good outlook relative to integrated growth.",0.0446949,0.958
CI-2019-Q1-2019-05-02,92,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","As relates to stop loss, no change in traction or pass. I think we pivoted maybe to a high single-digit number 9% approaching 10% and we just see continued traction. And I would just highlight, it's the integrated nature and coordinated nature of our programs that are resonating. Not having a product or not having our product on the shelf that integrated nature is performing very well and we're excited about the outlook for 2019.",0.1099883,0.201
CI-2019-Q1-2019-05-02,95,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"I'll start you on the rates we are estimate is that it'll be about 2.35% for us, which is a results consistent with how we've been thinking about it. We're in the course of finalizing our bids over the next few weeks here and we'll walk through that market-by-market basis as we typically do. Let David comment on the expansion path.",0.2371542,0.0
CI-2019-Q1-2019-05-02,96,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Specific to MA, macro we continue to see it as a very attractive growth marketplace. We're pleased to be back in the market growing in 2019 with our very focused local individual HMO portfolio and expect to see growth throughout the course of the year. To the core of your question as we look to 2020 and beyond, we expect to see accelerated growth begin to fuel that by market expansion to your point. We have a meaningful amount of demand for new market expansion with our collaborative partners and that work is well underway.",0.4508356,0.965
CI-2019-Q1-2019-05-02,97,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Secondly, continued in-market growth off of our very focused individual HMO portfolio of solutions and third, I'm expanding our portfolio of offerings to individual PPO offerings. So net-net, we're excited about the growth outlook for that portfolio of businesses with or without the half movement on the core fundamentals of our medical cost performance.",0.263117,0.887
CI-2019-Q1-2019-05-02,98,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Our collaborative accountable care relationships having an access to 75% of our lives in four Star Plus programs. Having a corporate star rating of four and a half stars for new market entre and having the signal whitespace as relates to the individual PPO marketplace, we're excited about the growth outlook there.",1.1620676,0.802
CI-2019-Q1-2019-05-02,101,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","The way I would think about 2020 as it relates to the Health Service business and the client portfolio, essentially think about the health plan portion that portfolios complete. And think about the commercial portion of that portfolios completing. So there could be some variability in the number`. We feel really good about the 96% and 98%, proud of the organization's performance in terms of delivery of our service promise. So I did break the book out through that portfolio.",0.0147688,0.822
CI-2019-Q1-2019-05-02,102,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","A bit longer conversation than we could have on the phone call relative to the value proposition. But in a nutshell, first and foremost, think about the core aspect of our value proposition and market message as staying intact, which is a very consultative client-oriented approach to putting together the solution suite that best works for our clients, one at a time understanding their culture, their strategy, to help burden their population, their readiness to change and the opportunity for us to drive incentive based programs and collaborative each programs with them.",0.3968131,0.953
CI-2019-Q1-2019-05-02,103,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director",The add to it is further strengthened in a significant way relative to tremendous breath and flexibility of pharmacy solution and market defining solutions as relates to specialty pharmacy from that standpoint.,0.1678974,0.84
CI-2019-Q1-2019-05-02,104,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to the Health Services value proposition, the same core proposition exists, that expanded with a broader set of tools and programs that could be offered to commercial clients as well as health plan clients, who want to broaden services and the rate and pace of that is being ramped up as we go forward.",0.255344,0.586
CI-2019-Q1-2019-05-02,105,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So core same, client focus, value creation engagement-oriented, enhancements on the capabilities as we come forward. But it is one client at a time which we deem to be a very significant strategic advantage as opposed to pushing product that we oriented around designing customized solutions on a modular basis for the benefit of our clients and customers and evolving those over time with them across the portfolio. You can expect to feel more of that at our Investor Day. As we bring it to life, not only in words but with some demonstrations of some of the capabilities behind our programs.",0.5631558,0.698
CI-2019-Q1-2019-05-02,107,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"On the disability piece, we flagged back at the fourth quarter that there is some pressure on the disability line and favorability in the life insurance business. That continued in January, but actually has normalized in February and March. So, not want to mention here but think of it as small in the context of enterprise certainly. And in February and March we're back to what we call normal and targeted levels of performance.",0.1239669,0.19
CI-2019-Q1-2019-05-02,110,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So first I'm stepping back. As you know, we've continued to prioritize segments outside of traditional Medicaid as our targeted growth segments in the marketplace. You'll also note that one of our inorganic priorities that we have highlighted in the past correlate around state based risk or performance based programs is we believe that we're going to see accelerated innovation at the state level to take portions of the population and look at a highly integrated clinical offerings that are risk based and performance based. We see that as attractive over time.",0.3579479,0.599
CI-2019-Q1-2019-05-02,111,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Two is as you reference, within our health service portfolio today, we serve Medicaid providers and we serve them well. In fact, recent meaningful wins in the Medicaid specialty space relative to servicing them from a pharmacy, specialty pharmacy and expanding over time of the Evercore platform of services.",0.6793626,0.796
CI-2019-Q1-2019-05-02,112,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And then lastly, in terms of using the best of the both, we see this as a growth opportunity again for the collective franchise over time. Some of the capabilities we have today the point two, to the last part of your question.",0.3280218,0.863
CI-2019-Q1-2019-05-02,113,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","One, we're quite successful in terms of servicing the dual eligible population today and the core part of the proposition that drives out or our value base highly engaged physician programs that take the whole person orientation and the continuity of care from the physician's office to home healthcare coordination through social services and the like. And we could coordinate through the long term care dimension. We obviously enter that through the Medicare charity today.",0.2059852,0.965
CI-2019-Q1-2019-05-02,114,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director",Secondly he is through a credo as you think about the specialty pharmacy capability for prior conversations are at home fulfillment capability is quite powerful. And we essentially have a new credo clinician within an hour's drive of 85% of all Americans. So the ability to go into the home with expanded services beyond specialty of services is quite important from that standpoint.,0.4636611,0.776
CI-2019-Q1-2019-05-02,115,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director",So those are just illustrations of some of the capabilities we have today. Net-net on a targeted basis we see it as a growth opportunity in both platforms today and over time we see it as a potential additional growth platform as the marketplace evolves.,1.3773805,0.791
CI-2019-Q1-2019-05-02,118,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Steven it's David. Just big picture as we've discussed in the past. Looking at the call it the deflationary environment more broadly, relative to pharmacy Express Scripts as early to identify that. And continue to make sure they were evolving the products programs and services with those clients as well as manufacturers and recognition to that to Express Scripts as well as Cigna. We're early and deeply committed to a low total cost proposition balancing obviously appropriate clinical quality.",0.4255733,0.674
CI-2019-Q1-2019-05-02,119,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And so long as you're aligned with your partners, a decelerating environment is actually a net positive across the board although sometimes it may put a little pressure on the traditional measures of revenue for the corporation. So taken as a whole we see that having the broad portfolio of services, the broad portfolio of funding mechanisms and accelerated alignment with both our manufacturing partners as well as our clients via they health client or commercial clients. Is actually a strength to be able to moderate our approach relative to a decelerating or accelerating trend environment. As we focus on delivering a total low cost outcome, that obviously is fueled by tremendous clinical and service quality.",0.7613681,0.709
CI-2019-Q1-2019-05-02,122,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director",In my prepared remarks I comment that on the five specific priorities that we have - we're clear for our organization as a whole. Within days after our successful closure of the combination and we remain focused on those. So that guide you back in terms of what we're seeking to accomplish. Most importantly sustained outstanding phenomenal service delivery to our clients and customers to ensure that there is no perception or reality of disruption getting in the way of delivering on our promise. And our MPS outlook and our retention outlook reinforced that.,0.2059852,0.963
CI-2019-Q1-2019-05-02,123,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director",Secondly throughout the course of this year and into next year we have milestones internally as we're continuing to step up leverage of the phenomenal Express assets for the benefit of the legacy Cigna clients. Early on specialty assets and that's taking place in line with our targets and expectations throughout the course of this year. And then further leverage of the Express core PBM capability for the benefit of our clients. Prior comments that transition takes place throughout 2019 and into 2020 and will be completed by the end of 2020. So a very planned full and targeted approach relative to that.,0.0470268,0.813
CI-2019-Q1-2019-05-02,124,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","On a final note something is less talked about our clinical teams are deep at work with our Evercore Partners accelerating, innovation of products programs and services. Now that capability is in-house and there's just tremendous excitement not just for the benefit of our so called integrated portfolio, but for additional products programs and services for our health plan clients and service based commercial clients.",0.1430237,0.599
CI-2019-Q1-2019-05-02,125,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So the five priorities remain, we're well on track, leverage of the Express Script specialty and pharmacy capability is well underway, the broader of pharmacy will be completed by the end of 2020, specialty being accelerated right now and Evercore program development well underway.",0.5744267,0.649
CI-2019-Q1-2019-05-02,127,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director",Matthew very important and appreciate it. So stepping back to put in context as you in the marketplace very well know we have a long history of owning operating and innovating are PBM. In terms of the history of Cigna with service partners and modularly successfully managing those service partner relationships over a long period of time while successfully growing our book of business and delivering outstanding results for the benefit of our clients and customers.,0.272056,0.966
CI-2019-Q1-2019-05-02,128,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","That same approach is being taken to this integration and coordination activity. Secondly, we're taking a very disciplined and paced and planned full approach to transitioning from some service partners like our great work with Optum today to Express Scripts over a very disciplined timeframe that will last between 2019 and 2020. I'm not a hurried approach. So no there is not one moment in time or one platform transition. It's very orderly and modular in fashion and we'll leverage our proven track record of managing that way for the last half a dozen years.",1.1780023,0.626
CI-2019-Q1-2019-05-02,130,Question,2019-05-02,1,2019,Stephen Tanal,Goldman Sachs,I guess given the re-segmentation it's making a bit challenging to kind of compare the underlying results but helpful commentary around sort of seems like everything tracking in line with expectations. So I just kind of wanted to better understand a couple of high level points is the deal still expected to be double-digit accretive in year one. And how would you frame the cadence of that accretion clearly express as a different seasonal earnings pattern and your synergy is ramping.,0.8054393,0.935
CI-2019-Q1-2019-05-02,131,Question,2019-05-02,1,2019,Stephen Tanal,Goldman Sachs,So I'm just trying to make sure we understand that dynamic and maybe in the process get your thoughts on the cadence of the medical customer growth over the balance of the year. And the sense as well for why the upper bound of Integrated Medical segment pre-tax earnings guidance did not increase by sort of the full amount of the PPD in the quarter?,0.6294082,0.768
CI-2019-Q1-2019-05-02,132,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Steve it's Eric, I'll start and then have David add some additional commentary as well so just stepping back. So we talked about when we announced the transaction over a year ago, now our expectation that the combination would be teams accretive in the first full year of operation just to give the color there. Now a lot's happened over the course of the last year plus. We ended up finishing with quite a bit stronger results in 2018 than we anticipated at the time. One, that raise the jump off point.",0.5932447,0.61
CI-2019-Q1-2019-05-02,133,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"Two, as we've noted in terms of our initial guidance issuance for the year and such in particular, we had some strong performance in our individual book of business that we didn't believe to be sustainable. We're still performing in line with our targets and expectations, but a step down from 2018 into 2019 and so that's a factor as well. When you adjust for those things, Steve broadly the expectations in terms of income being generated from the various components of Express Scripts that most of which are health services business and the pieces in Integrated Medical and such are in line with where we were expected them to be for the year.",0.134028,0.586
CI-2019-Q1-2019-05-02,134,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"And so again the acquisition case from that perspective are pulled so again those are the pieces. And then on the last part of your question on the prior year development, really we brought up the bottom end of our range by the amount of the prior year development. Again just note it's early in the year and that's why we have a range in terms of the variability of outcome over the balance of the year.",0.5246137,0.0
CI-2019-Q1-2019-05-02,135,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And Steve first and foremost kudos to you to fit, five or six questions into one quite efficient from that standpoint just to recap a couple of pieces. Big picture I think to the core of your question. Our results demonstrate that we're on track to deliver our commitment to $20 to $21 of EPS in 2021. Second, the raise in the first quarter this year early in the year, but the raise has our EPS growth in the mid teens plus for 2019 off as Eric reference and outstanding 2018. And lastly just reinforcing all along the way with tremendous free cash flow production which underlies the kind of quality of the results that we're able to post so we feel great about the results here.",0.2335795,0.98
CI-2019-Q1-2019-05-02,137,Question,2019-05-02,1,2019,Ralph Giacobbe,Credit Suisse,Just wanted to go to the enrolment figures looks like ASO was flat to slightly down. And I know there's the employer segments that we needed that consider there 49.38 but the risk of this was also up. So anything to kind of call out that's either happening in the market and or so your positioning and then just you mentioned the national account losses maybe any details there. And the opportunity with the larger employer base now with Express. And when you think maybe you could see that perhaps start to show better growth? Thanks.,0.2347605,0.788
CI-2019-Q1-2019-05-02,138,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","A couple points, first again to set the stage relative to growth. And as indicated previously really pleased with the growth trajectory we're stepping into 2019 with the revenue health the ability to increase our revenue outlook by $1 billion this early in the year we're quite pleased with that. Secondly, we had an intensified focus in 2018 with our eye toward 2019 on retention acknowledging dependency of the transaction and the potential perceived disruption as well as further deepening results. So we look at growth more holistically than a singular measure of medical customer growth although I'll come to that which is a quite important measure.",0.534007,0.964
CI-2019-Q1-2019-05-02,139,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And as noted we grew our specialty license further deepened relationships quite attractively. As it relates to the Integrated Medical customer growth we feel good about our outlook for the full year. As I noted we will expect to see continued strong performance in trajectory of the select in the middle market portfolio throughout the residual part of the year specifically, the second half of the year. July tends to be an important July 1 is an important month for that portfolio September 1 is an important month for that portfolio and that portfolio will perform well.",0.1329188,0.95
CI-2019-Q1-2019-05-02,140,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","We had a little lighter retention rate in national accounts for 1/1/2019. Last year we had a bit stronger this year we had a little lighter. There's your way of sowing and so within the context of that. But again we further deepened relationships with the specialty portfolio. On a final note as a combined corporation, we'll be looking again more holistically at those larger account relationships deciding whether or not we're best positioned to have an expanded services relationship with those clients and or an integrated relationship or a combination of both.",0.2145356,-0.195
CI-2019-Q1-2019-05-02,141,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director",So you'll see again the revenue growth be contributed through both segments not just one segment on a go forward basis again taken as a whole we feel really good about the result for 2019.,1.2856588,0.7
CI-2019-Q1-2019-05-02,144,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Ana it's David it was a bit hard to hear you with the background noise but I think I got the core of your question. The simple answer to the last part of your question is, no. We do not see a change in performance relative to the competitive landscape. It has been, is and will continue to be a competitive environment. We need to deliver outstanding value and we need to continue to innovate. Specifically, as I noted in my prepared remarks Select segment had an outstanding performance in the first quarter of this year and we'll have another strong year this year.",0.2806063,0.981
CI-2019-Q1-2019-05-02,145,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","I remind you that that strike zone is expanded from 50 to 250 to 50 to 500 and we're successfully selling both our core ASO Stop Loss offering as well as guarantee costs as we offer choice in the marketplace and our full integrated as opposed to a bundled offering but a full integrated offering continues to resonate very well in that portfolio for us as we go forward. Specifically to the larger account portfolio, national either signals definition of that 5000 or more employees commercial and multi-state. It's a smaller strike zone than many of our competitors defined.",0.2110377,0.115
CI-2019-Q1-2019-05-02,149,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","So, as we noted that's an example of the power of the combination and can accelerate innovations that puts the customer front and center or patient and then looks at their specific needs on affordability and predictability.",0.6513797,0.0
CI-2019-Q1-2019-05-02,150,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director",We're able to essentially and we don't go through all the details. It's about time as well as a competitive differentiator. We're able to rapidly reengineer relationships and alignment very importantly with a pharmaceutical manufacturer partners to again put that customer patient front and center and provide that level of predictability. And we just couldn't be more pleased with that client feedback early on is extremely positive and we would expect adoption of that to ramp pretty meaningfully over time.,0.1383599,0.94
CI-2019-Q1-2019-05-02,151,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","To the core of your question as well which I appreciate. There is a platform within there for other disease or health burden states that our team is aggressively focused on right now. So exciting opportunities to give more peace of mind, predictability and customer a patient derived view of affordability to the marketplace and we stepped into diabetes and insulin specifically because of the size of the population and the needs set to be able to address this. But that platform could be leveraged further.",0.2942091,0.907
CI-2019-Q1-2019-05-02,154,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Let me put this in a couple of blocks. First and foremost, our passionate view is that client retention when you deal with the affordability and the transparency that exists in all of our products and programs today is a direct correlation of the clients view of the value we are delivering to them day-in, day-out. Regrown back to the Health Services portfolio, the commercial pharmacy trend for 2018 was 0.4%, a phenomenal result, not perfection of phenomenal results with strong service delivery and additional proven innovations as we go forward. That's what enables us to deliver that retention.",0.2215313,0.637
CI-2019-Q1-2019-05-02,155,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Two, to your margin question, the margin levels are in line with our expectations. This puts and takes they're aligned with our expectations, they're strong, they're shareholder friendly and we need to get the right balance in terms of alignment with our clients, our customers, our patients as well as from a shareholder return but they're aligned with our expectations.",0.0520793,0.586
CI-2019-Q1-2019-05-02,156,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","There will be puts and takes and levers on a go forward basis and we see more transparency as an opportunity to drive more of alignment. We see alignment as a strategic advantage. It's something we embrace, because alignment allows us to accelerate innovation and that allows us to drive lower total costs and higher total quality and a go forward basis.",0.3731053,0.758
CI-2019-Q1-2019-05-02,157,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And we've been able to prove as an organization that delivering that type of value allows you to get a fair sustainable margin and that's what we're on track for. So whether it be spread pricing, a change in posture on rebates or otherwise, those are movements in sub components of the portfolio. The total cost, total value proposition is to work and we've proven the ability to innovate to make sure we're able to get a fair sustainable shareholder return through margin and we're excited about that because we have the ability to lead in that changing marketplace as opposed to resist it.",0.178391,0.958
CI-2019-Q1-2019-05-02,160,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","I appreciate the questions. As you might expect we're not going to tell you what the slope of our pricing curve or approach in the marketplace is, big picture though stepping back, we're pleased with the performance, pleased with the financial results, pleased with the positioning of their client-by-client decisions that are made because everything we do in our company is oriented around one client at a time, strategic alignment and sustained innovation going forward and the coexistence of the new business growth with the outstanding retention and the deepening of the relationships reinforces that. So we're pleased with the positioning and the discipline you would expect us to have from a new business standpoint continues in the organization.",0.2747765,0.97
CI-2019-Q1-2019-05-02,161,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","As it relates to your second point, there is appetite no doubt for dimensions of or examples of deepening alignment guarantees or otherwise and we have the capabilities within the portfolio to be able to do that. Again that's one client at a time.",0.7182277,-0.572
CI-2019-Q1-2019-05-02,162,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","And it all comes back to alignments with your partner, making sure we put the programs in place financing or otherwise and then we perform and we have a track record and knock on wood of the performance and the alignment, but there's not a one size fits all guarantee program that we're putting in the marketplace, it's a client-by-client side of relationships and again we see that as an advantage for us both in the integrated portfolio as well as in the services portfolio as we go forward. Again something we embrace and we're driving for the change in.",0.1305869,0.882
CI-2019-Q1-2019-05-02,166,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"So a couple of different dimensions to that question there. But the first and foremost year-over-year, I'd encourage you on a particular quarter there. There are a number of different moving pieces, so there wouldn't want you to just one adjustment and then you'd have comparability as I mentioned in my prior answer several different dimensions between resegmentation which is normal, timing quarter-to-quarter types of items in that of the conformance of various policies and that just make quarter-over-quarter difficult. The punch line though on the full year in line with our expectations performing well and we'll expect to deliver growth and touch there.",0.3693856,0.748
CI-2019-Q1-2019-05-02,167,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"The second part of your question in terms of the $200 million stranded costs that we identified, that's a function of a couple of things. We haven't provided a specific quarter-by-quarter guidance. But think of as the - as the transition in clients as Anthem works through their migration, and the volumes come out. That will increase things but we'll be working to rightsize our expense base so again those will be working to offset each other over the balance of the year.",0.2565577,0.166
CI-2019-Q1-2019-05-02,168,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,And then last but not least in terms of just the other items in terms of the sequencing of earnings over the year the note in my prepared remarks continue to expect 45% to 46% of the enterprise's income in the first half of the year. Think about across the segments Integrated Medical tends to be more front end loaded so higher income in the beginning part of the year and that tapers down over the year as customers reach their deductibles and things along those lines. Health services business tends to have the other dynamic where the income builds throughout the course of the year and I think you'll see that in the Express Scripts historic result.,0.4010061,0.71
CI-2019-Q1-2019-05-02,169,Answer,2019-05-02,1,2019,Eric P. Palmer,Chief Financial Officer & Executive Vice President,"On top of that this year we've got the additional effect of the synergies will build throughout the course of the year and will have the effect of as we work with the deleveraging interest costs will decline throughout the year. So that probably even further puts the income towards the back half of the year than ""a normal year"" all to be an equal.",0.1336687,0.586
CI-2019-Q1-2019-05-02,171,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","Thank you. Just wrap up our call. I'd like to highlight some key points from today's discussion. Cigna delivered strong financial results in our first quarter as a combined company with Express Scripts, driven by growth, innovation and focus execution across our businesses relative to our Express Scripts integration activities, we're making very good progress and executing well against each of our five integration priorities. Collectively our first quarter results demonstrate Cigna's strong performance and momentum and gives us confidence we will achieve our increased outlook for revenue, earnings and EPS in 2019.",0.9957248,0.983
CI-2019-Q1-2019-05-02,172,Answer,2019-05-02,1,2019,David Michael Cordani,"President, Chief Executive Officer & Director","We remain on track to achieve our 2021 EPA target of $20, $21 per share and we look forward to going into this deeper with you as well as our long term growth strategy at our Investor Day later this month. Thank you for joining our call today. And we look forward to our future discussions.",0.839487,0.813
